Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Norman G, Goh EL, Dumville JC, Shi C, Liu Z, Chiverton L, Stankiewicz M, Reid A

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
TABLE OF CONTENTS

HEADER ........................................................................................................................................................................... 1
ABSTRACT ........................................................................................................................................................................... 1
PLAIN LANGUAGE SUMMARY ........................................................................................................................................ 2
SUMMARY OF FINDINGS .............................................................................................................................................. 4
BACKGROUND ............................................................................................................................................................. 7
OBJECTIVES ............................................................................................................................................................... 8
METHODS ................................................................................................................................................................. 8
RESULTS ...................................................................................................................................................................... 12
Figure 1. ........................................................................................................................................................................... 13
Figure 2. ........................................................................................................................................................................... 17
Figure 3. ......................................................................................................................................................................... 18
Figure 4. ......................................................................................................................................................................... 20
Figure 5. ......................................................................................................................................................................... 21
DISCUSSION ............................................................................................................................................................. 23
AUTHORS’ CONCLUSIONS ...................................................................................................................................... 26
ACKNOWLEDGEMENTS ........................................................................................................................................ 27
REFERENCES ........................................................................................................................................................... 28
CHARACTERISTICS OF STUDIES .......................................................................................................................... 43
DATA AND ANALYSES ............................................................................................................................................. 205
Analysis 1.1. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 1: Mortality ........... 206
Analysis 1.2. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 2: Surgical site infection ... 207
Analysis 1.3. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 3: SSI grouped by contamination class .............................................................. 209
Analysis 1.4. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 4: SSI (superficial) ....... 210
Analysis 1.5. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 5: SSI (deep) ............ 211
Analysis 1.6. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 6: Dehiscence .......... 212
Analysis 1.7. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 7: Reoperation .......... 213
Analysis 1.8. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 8: Readmission ........... 213
Analysis 1.9. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 9: Seroma ............... 214
Analysis 1.10. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 10: Haematoma ....... 214
Analysis 1.11. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 11: Skin blisters ....... 214
ADDITIONAL TABLES ............................................................................................................................................... 215
APPENDICES ............................................................................................................................................................ 241
WHAT’S NEW ............................................................................................................................................................. 257
HISTORY ...................................................................................................................................................................... 257
CONTRIBUTIONS OF AUTHORS .............................................................................................................................. 257
DECLARATIONS OF INTEREST ................................................................................................................................. 258
SOURCES OF SUPPORT ....................................................................................................................................... 258
DIFFERENCES BETWEEN PROTOCOL AND REVIEW .............................................................................................. 259
INDEX TERMS .......................................................................................................................................................... 261
Negative pressure wound therapy for surgical wounds healing by primary closure

Gill Norman¹, En Lin Goh², Jo C Dumville¹, Chunhu Shi³, Zhenmi Liu³, Laura Chiverton⁴, Monica Stankiewicz⁵, Adam Reid⁶

¹Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK. ²Oxford Trauma, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, UK. ³West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China. ⁴NIHR Clinical Research Facility, Great Ormond Street Hospital, London, UK. ⁵Cherside Community Health Centre, Community and Oral Health Directorate, Brisbane, Australia. ⁶School of Biological Sciences, Faculty of Biology, Medicine & Health, Manchester, UK

Contact address: Gill Norman, gill.norman@manchester.ac.uk.

Editorial group: Cochrane Wounds Group.


Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background
Indications for the use of negative pressure wound therapy (NPWT) are broad and include prophylaxis for surgical site infections (SSIs). Existing evidence for the effectiveness of NPWT on postoperative wounds healing by primary closure remains uncertain.

Objectives
To assess the effects of NPWT for preventing SSI in wounds healing through primary closure, and to assess the cost-effectiveness of NPWT in wounds healing through primary closure.

Search methods
In June 2019, we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries and references of included studies, systematic reviews and health technology reports. There were no restrictions on language, publication date or study setting.

Selection criteria
We included trials if they allocated participants to treatment randomly and compared NPWT with any other type of wound dressing, or compared one type of NPWT with another type of NPWT.

Data collection and analysis
At least two review authors independently assessed trials using predetermined inclusion criteria. We carried out data extraction, assessment using the Cochrane 'Risk of bias' tool, and quality assessment according to Grading of Recommendations, Assessment, Development and Evaluations methodology.

Main results
In this third update, we added 15 new randomised controlled trials (RCTs) and three new economic studies, resulting in a total of 44 RCTs (7447 included participants) and five economic studies. Studies evaluated NPWT in the context of a wide range of surgeries including...
Orthopaedic, obstetric, vascular and general procedures. Economic studies assessed NPWT in orthopaedic, obstetric and general surgical settings. All studies compared NPWT with standard dressings. Most studies had unclear or high risk of bias for at least one key domain.

**Primary outcomes**

Four studies (2107 participants) reported mortality. There is low-certainty evidence (downgraded twice for imprecision) showing no clear difference in the risk of death after surgery for people treated with NPWT (2.3%) compared with standard dressings (2.7%) (risk ratio (RR) 0.86; 95% confidence interval (CI) 0.50 to 1.47; $I^2 = 0$%). Thirty-nine studies reported SSI; 31 of these (6204 participants), were included in meta-analysis. There is moderate-certainty evidence (downgraded once for risk of bias) that NPWT probably results in fewer SSI (8.8% of participants) than treatment with standard dressings (13.0% of participants) after surgery; RR 0.66 (95% CI 0.55 to 0.80; $I^2 = 23$%). Eighteen studies reported dehiscence; 14 of these (3809 participants) were included in meta-analysis. There is low-certainty evidence (downgraded once for risk of bias and once for imprecision) showing no clear difference in the risk of dehiscence after surgery for NPWT (5.3% of participants) compared with standard dressings (6.2% of participants) (RR 0.88, 95% CI 0.69 to 1.13; $I^2 = 0$%).

**Secondary outcomes**

There is low-certainty evidence showing no clear difference between NPWT and standard treatment for the outcomes of reoperation and incidence of seroma. For reoperation, the RR was 1.04 (95% CI 0.78 to 1.41; $I^2 = 13$%; 12 trials; 3523 participants); for seroma, the RR was 0.72 (95% CI 0.50 to 1.05; $I^2 = 0$%; seven trials; 729 participants). The effect of NPWT on occurrence of haematoma or skin blisters is uncertain (very-low-certainty evidence); for haematoma, the RR was 0.67 (95% CI 0.28 to 1.59; $I^2 = 0$%; nine trials; 1202 participants) and for blisters the RR was 2.64 (95% CI 0.65 to 10.68; $I^2 = 69$%; seven trials; 796 participants). The overall effect of NPWT on pain is uncertain (very-low-certainty evidence from seven trials [2218 participants] which reported disparate measures of pain); but moderate-certainty evidence suggests there is probably little difference between the groups in pain after three or six months following surgery for lower limb fracture (one trial, 1549 participants). There is also moderate-certainty evidence for women undergoing caesarean sections (one trial, 876 participants) and people having surgery for lower limb fractures (one trial, 1549 participants) that there is probably little difference in quality of life scores at 30 days or 3 or 6 months, respectively.

**Cost-effectiveness**

Five economic studies, based wholly or partially on trials included in our review, assessed the cost-effectiveness of NPWT compared with standard care. They considered NPWT in four indications: caesarean sections in obese women; surgery for lower limb fracture; knee/hip arthroplasty and coronary artery bypass graft surgery. They calculated quality-adjusted life-years for treatment groups and produced estimates of the treatments’ relative cost-effectiveness. The reporting quality was good but the grade of the evidence varied from moderate to very low. There is moderate-certainty evidence that NPWT in surgery for lower limb fracture was not cost-effective at any threshold of willingness-to-pay and that NPWT is probably cost-effective in obese women undergoing caesarean section. Other studies found low or very low-certainty evidence indicating that NPWT may be cost-effective for the indications assessed.

**Authors’ conclusions**

People experiencing primary wound closure of their surgical wound and treated prophylactically with NPWT following surgery probably experience fewer SSI than people treated with standard dressings (moderate-certainty evidence). There is no clear difference in number of deaths or wound dehiscence between people treated with NPWT and standard dressings (low-certainty evidence). There are also no clear differences in secondary outcomes where all evidence was low or very low-certainty. In caesarean section in obese women and surgery for lower limb fracture, there is probably little difference in quality of life scores (moderate-certainty evidence). Most evidence on pain is very low-certainty, but there is probably no difference in pain between NPWT and standard dressings after surgery for lower limb fracture (moderate-certainty evidence). Assessments of cost-effectiveness of NPWT produced differing results in different indications. There is a large number of ongoing studies, the results of which may change the findings of this review. Decisions about use of NPWT should take into account surgical indication and setting and consider evidence for all outcomes.

**Plain Language Summary**

Negative pressure wound therapy for surgical wounds healing by primary closure

**What is the aim of this review?**

The aim of this Cochrane Review was to find out if negative pressure wound therapy (NPWT) has an effect on complications including infections in surgical wounds which are healing by primary closure (where the edges have been brought together, usually by using stitches or staples) and to assess its cost-effectiveness. We collected and analysed all relevant studies to answer this question and found 44 studies analysing NPWT and surgical site complications, and five studies analysing cost-effectiveness. This is a new update of a Cochrane review which was last updated in March 2019.

**Key messages**
NPWT probably reduces the incidence of surgical site infection (SSI) in surgical wounds healing by primary closure – this is moderate-certainty evidence and new studies could change this finding. It is not clear what effect NPWT has on reopening of the wound (“dehiscence”) and risk of death - this is low-certainty evidence. Results for other complications also show no clear difference with NPWT treatment. NPWT is probably cost-effective for caesarean section wounds in obese women and probably not cost-effective for fracture surgery wounds. Evidence for the cost-effectiveness of NPWT in other surgical wounds is less certain.

What was studied in the review?

A potential complication of surgery is the development of SSI which can occur at the site of a surgical incision. The incidence of SSI can be as high as 40%, with an increased infection risk linked with age, diet, weight, diabetes, heart disease and cancer. An SSI can cause pain and discomfort, as well as increasing a person’s length of hospital stay and cost of treatment. Dehiscing (separation of wound edges) may occur if a wound fails to heal. Wound infection and weight can increase the risk of dehiscence.

NPWT is a sealed wound dressing attached to a vacuum pump which sucks fluid away from the wound. This may assist with wound healing and reduce risk of infection.

There has been a large number of new studies over the last decade as NPWT is increasingly being assessed for different surgical wound types. We assessed the effect of NPWT on risk of death, SSI and dehiscence.

What are the main results of the review?

We found 44 studies analysing NPWT and surgical site complications and five studies analysing cost-effectiveness of NPWT. A total of 7447 participants have been included in the review. A wide variety of surgeries are included such as knee and hip operations, caesarean sections, operations for broken bones and abdominal surgeries. Most participants were enrolled in North America, Europe or Australasia.

NPWT was compared with a standard dressing (e.g. gauze) in all 44 studies. A variety of NPWT systems was used. Only four studies reported risk of death; little difference was shown between NPWT and standard dressing and the evidence is low certainty. We pooled the SSI results of 31 studies; NPWT probably reduces the risk of SSI compared with standard dressings (moderate-certainty evidence). Fourteen studies which reported on dehiscence were combined; the low-certainty evidence suggests no clear difference between NPWT and standard care.

In the cost-effectiveness analysis, two studies looked at women with caesarean sections, one looked at people with lower limb fractures, one at knee and hip surgeries, and one at heart surgery. All these studies used clinical information from studies included in this review. There is moderate-certainty evidence that NPWT is probably cost-effective for caesarean section wounds in obese women and probably not cost-effective for fracture surgery wounds. Evidence for the cost-effectiveness of NPWT in other surgical wounds is low or very low-certainty.

How up to date is this review?

We searched for studies that had been published up to June 2019.
### Summary of findings 1. Negative pressure wound therapy compared with standard dressing for surgical wounds healing by primary closure

**Patient or population:** adult patients with surgical wounds healing by primary closure  
**Setting:** general surgical, orthopaedic or obstetric wards in acute care hospitals  
**Intervention:** negative pressure wound therapy (NPWT)  
**Comparison:** standard dressing

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Anticipated absolute effects* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of participants (studies)</th>
<th>Certainty of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Mortality (proportion of participants dying in each group at follow-up of between 30 days and six months)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study population</td>
<td>23 per 1000</td>
<td>5 fewer deaths per 1000 people (13 fewer to 9 more)</td>
<td>RR 0.86 (0.50 to 1.47)</td>
<td>2107 (4 studies)</td>
<td>⊕⊕⊝⊕</td>
</tr>
</tbody>
</table>

**Surgical site infection (proportion of participants in each group with SSI; follow-up of 30 days except where other time points specified as primary outcome measure in study)** | | | | | |
| Study population | 130 per 1000 | 43 fewer SSI per 1000 people (58 fewer to 26 fewer) | RR 0.66 (0.55 to 0.80) | 6204 (31 studies) | ⊕⊕⊕⊕ | NPWT probably decreases the incidence of surgical site infection compared with a standard dressing. Risk of bias in various domains affecting half the participants reduces the certainty of the evidence to moderate. |

**Dehiscence (proportion of participants in each group with wound dehiscence; follow-up of 30 days except where other time points specified as primary outcome measure in study)** | | | | | |
| Study population | 62 per 1000 | 9 fewer dehiscence per 1000 people (19 fewer to 8 more) | RR 0.88 (0.69 to 1.13) | 3809 (14 studies) | ⊕⊕⊕ | There is no clear difference in dehiscence between people treated with NPWT and standard dressings. |

| Study population | RR 1.04 (0.78 to 1.41) | 3523 (12 studies) | | | |
### Reoperation (proportion of participants in each group requiring reoperation for reasons related to wound; follow-up of 30 days except where other time points specified as primary outcome measure in study)

| Study population | 72 per 1000 | 3 more reoperations per 1000 people (16 fewer to 29 more) | Low

There is no clear difference in reoperation between people treated with NPWT and standard dressings.

### Seroma (proportion of participants in each group with seroma; follow-up of 30 days except where other time points specified as primary outcome measure in study)

| Study population | 104 per 1000 | 29 fewer seroma per 1000 people (52 fewer to 5 more) | Low

There is no clear difference in the incidence of seroma between people treated with NPWT and standard dressings.

### Haematoma (proportion of participants in each group with haematoma; follow-up of 30 days except where other time points specified as primary outcome measure in study)

| Study population | 23 per 1000 | 7 fewer haematoma (16 fewer to 14 more) | Very low

It is uncertain if the incidence of haematoma is increased or decreased when NPWT is compared with a standard dressing.

### Skin blisters (proportion of participants in each group with at least one skin blister; follow-up of 30 days except where other time points specified as primary outcome measure in study)

| Study population | 48 per 1000 | 78 more blistering cases per 1000 people (17 fewer to 461 more) | Very low

It is uncertain if there is a higher risk of developing skin blisters when NPWT is compared with a standard dressing.

---

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: confidence interval; NPWT: negative pressure wound therapy; RR: risk ratio

**GRADE Working Group grades of evidence**

**High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect.

**Moderate certainty:** We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.

**Low certainty:** Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
**Very low certainty:** We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.

1. Downgraded twice for very serious imprecision resulting from very low event rates which produced wide confidence intervals.
2. Downgraded once for high risk of bias in various domains, affecting approximately 50% of participants.
3. Downgraded once for high risk of bias in various domains and once for imprecision.
4. Downgraded twice for very serious imprecision.
5. Downgraded once for high risk of bias in various domains and twice for very serious imprecision.
6. Downgraded once for high risk of bias in various domains, once for imprecision and once for inconsistency.
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Description of the condition

An estimated 4511 operations per 100,000 population are carried out annually worldwide, equating to one operation per year for every 22 people (Lancet Commission on Global Surgery 2015). This figure is higher in high-income countries. For example, in Australia in 2013/14, there were approximately 2.4 million surgical procedures in a population of 23.4 million, or around one operation each year for every 10 people (ABS 2014). One of the complications of surgery is surgical site infection (SSI), which is an infection that occurs at the site of a surgical incision or in an organ space within 30 days of the surgery. The overall incidence of SSI is 1.9% (Berrios-Torres 2017), but it may be as high as 40% in some populations (Maehara 2017). As well as causing pain and discomfort for the patient, SSI increases the length of hospital stay and the cost of treatment (De Lissvoy 2009).

Surgical wounds generally heal by primary closure during which the wound edges are brought together so that they are adjacent to each other. Wound closure is usually assisted by the use of sutures (stitches), staples, adhesive tape, or glue (Coulthard 2010), and healing begins within hours of closure (Rodero 2010). Some types of surgical wounds, such as sternal wounds, are more difficult to heal due to their anatomical position or an increased likelihood of infection (Toeg 2017); so too are surgical wounds in patients with certain types of underlying characteristics such as advanced age or medical conditions including malnutrition, uncontrolled diabetes, cardiovascular disease, compromised immunity, and morbid obesity (Baronski 2008; Waisbren 2010; Winfield 2016).

Failure of a wound to heal may also be the result of dehiscence (separation of the wound edges). Reasons for dehiscence are either technical, such as sutures breaking, cutting through tissue or knots slipping, or inadequate splinting (Baronski 2008), or patient-related factors such as wound infection and obesity (Sandy-Hodggets 2015). Chronic obstructive pulmonary disease is a major risk factor for dehiscence in sternal surgery (Olbrecht 2006). The most serious complication of dehiscence is wound evisceration, where the wound separates completely, exposing the underlying organs. Where evisceration occurs, the mortality rate in the postoperative period may be as high as 45% (Kenig 2012).

Description of the intervention

Negative pressure wound therapy (NPWT) has been used to treat wounds since the late 1990s (Fleischmann 1997; Morykwas 1997). Negative pressure wound therapy has been recommended for a diverse range of lesions including open abdominal wounds (Stevens 2009), open fractures (Stannard 2009), burn wounds (Kantak 2016), pressure ulcers (Mandal 2007), post-traumatic wounds (Kanakaris 2007), diabetic foot ulcers (Eneroth 2008), split-thickness skin grafts (Blume 2010), sternal wounds (Sjogren 2011), and after clean surgery in obese patients (Dragu 2011). Negative pressure wound therapy is increasingly being used prophylactically on closed incisional wounds to prevent surgical site complications (De Vries 2016; Webster 2014), as well as being used on wounds healing by secondary intention (left open to heal from the bottom up) such as chronic or infected wounds (Dumville 2015).

Negative pressure wound therapy consists of a closed, sealed system that applies negative pressure (suction) to the wound surface. The wound is covered or packed with an open-cell foam or gauze dressing and sealed with an occlusive drape. Intermittent or continuous suction is maintained by connecting suction tubes from the wound dressing to a vacuum pump and liquid waste collector. Standard negative pressure rates range from −50 mmHg to −125 mmHg (Ubbink 2008; Vikatmaa 2008). The longest-established device is the vacuum-assisted closure (VAC) system (KCI, San Antonio, Texas) (Morykwas 1997). However, alternatives have been developed and are being used (Visser 2017). Portable versions of the device have been introduced for use in community settings (Hurd 2014; Ousey 2014). An emerging advance has been the addition of ‘instillations’ of sterile water, saline, antiseptics, or antibiotics to VAC therapy, as in new negative pressure wound therapy with instillation (NPWTi) systems such as V.A.C. VeraFlo Therapy (KCI, San Antonio, Texas) (Gabriel 2014; Gupta 2016).

How the intervention might work

In humans, the wound-healing process is regarded as occurring in three consecutive and overlapping stages, namely: inflammation, new tissue formation, and remodelling (Gurtner 2008). The precise way in which NPWT may aid in this process is unclear. Experimental evidence suggests that NPWT may assist wound healing by increasing local blood flow and the production of granulation tissue (Xia 2014), and may encourage other changes to the microenvironment of the wound by reducing bacterial contamination, oedema, and exudate (Banwell 2003). Other mechanisms for healing have been investigated using animal models. For example, an increase in fibrocytes (stem cells involved in wound healing) was demonstrated in an NPWT-treated group of diabetic rats compared with a control group (Chen 2017). Expressions of vascular endothelial growth factor receptors, which are involved in healing, were also seen to increase when NPWT was compared with a control group of rabbits (Tanaka 2016). One of the basic theoretical principles underpinning the development of NPWT is that it increases perfusion or blood flow. However, this was challenged in an experimental study using healthy volunteers that showed that local blood flow decreased as suction pressure increased (Kairinos 2009), while a study in closed incisional wounds in a porcine model (Malmssjö 2014) found little impact on wound perfusion with any tested system, and some slight decreases in blood flow in superficial tissue. In closed incisions healing by primary intention, NPWT also delivers a sealed environment, preventing or reducing bacterial entry to the wound, while removing blood and exudate from the wound. A systematic review of laboratory studies in both acute and chronic wound models (Glass 2014) suggests that NPWT shifts the cytokine profile to being less inflammatory, but that, although there may be differences in mechanisms between acute and chronic wounds, in both cases wound healing is promoted through changes in the expression of multiple enzymes such as the matrix metallo-proteinases. There are multiple probable mediators of a possible effect of NPWT on wound healing in closed surgical incisions and these are not yet fully understood.

Why it is important to do this review

Surgical wounds that become infected and/or that fail to heal may cause considerable distress to patients and impact negatively on the physical, social, emotional, and economic aspects of their lives (Andersson 2010). Investigations into interventions to avoid wound breakdown are therefore important. Negative pressure wound therapy was approved by the US Food and Drug Administration.
Since the introduction of NPWT, there has been an explosion of publications (over 2600 in the last 10 years), which have been influential in changing practice. Along with an increase in primary studies and other non-research publications, there has been a concomitant increase in the number of systematic reviews (Hyldig 2016; Ingargiola 2013; Karlakki 2013; Ubbink 2008; Vikatmaa 2008; Willy 2017). Many of these reviews have included non-randomised controlled trials; have considered both acute and chronic wounds; and, as with the primary studies, many have received industry sponsorship (Kairinos 2014). In addition, concerns have been raised about the premature termination of studies (Gregor 2008). It is therefore unsurprising that some recent reviews have concluded that the evidence for the effectiveness of NPWT remains uncertain (Hyldig 2016; Webster 2014; WHO 2016). None of the reviews published to date have included formal cost-effectiveness studies. NPWT is a rapidly expanding therapy with widening indications for its use, so new trials continue to emerge. Consequently, an updated systematic review was required to summarise the current evidence for the effect of NPWT on the healing of surgical wounds by primary closure.

A glossary of main terms is given in Appendix 1.

**OBJECTIVES**

To assess the effects of NPWT for preventing surgical site infection in wounds healing through primary closure, and to assess the cost-effectiveness of NPWT in wounds healing through primary closure.

**METHODS**

**Criteria for considering studies for this review**

**Types of studies**

For changes to this section since the protocol (Webster 2011) and previous versions of the review (Webster 2014; Webster 2019), please see Differences between protocol and review.

We included published or unpublished randomised controlled trials (RCTs) or cluster RCTs that evaluated the effects of NPWT on surgical wounds healing by primary closure. We excluded crossover trials and quasi-randomised studies where, for example, treatment allocation was made through alternation or by date of birth.

We also included comparative full and partial economic evaluations conducted within the framework of eligible RCTs (i.e. cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses, and cost analyses).

**Types of participants**

We included trials involving people of any age and in any care setting that assessed the use of NPWT for uninfected surgical wounds healing by primary closure in all intervention groups. We excluded trials where NPWT was used as a dressing following a skin graft (including split-skin grafts and full-skin grafts); flap closure surgery; skin graft donor sites; or surgery involving harvesting veins following flap elevation. We also excluded wounds that could not be closed immediately due to damaged tissue (e.g. in severe trauma), infection, or chronicity (wounds healing by delayed primary intention or secondary intention).

**Types of interventions**

The primary intervention was NPWT for closed surgical incisions delivered by any mode, or simple closed-system suction drainage; continuously or intermittently over any time period and at any pressure. The comparison interventions were any standard dressing (e.g. gauze) or any advanced dressing (e.g. hydrogels, alginates, hydrocolloids); or comparisons between different negative pressure devices. The use of a particular negative pressure system, device or protocol (e.g. different pressures) had to be the only systematic difference between the intervention groups.

**Types of outcome measures**

**Primary outcomes**

- Mortality (all cause)
- Surgical site infection (superficial, deep or organ space)
- Dehiscence

**Secondary outcomes**

- Reoperation
- Readmission to hospital within 30 days for a wound-related complication
- Seroma, expressed as the proportion of participants in each group with seroma
- Haematoma, expressed as the proportion of participants in each group with haematoma
- Skin blisters, expressed as the proportion of participants in each group with blisters
- Pain (measured by any valid pain assessment instrument)
- Quality of life (measured by any valid assessment instrument and including utility scores representing health-related quality of life)
- Incremental cost-effectiveness ratio (ICER) or other measure of relative cost-effectiveness

We accepted study authors’ definitions of SSI, dehiscence and wound-related complications requiring reoperation. We anticipated that outcomes would be reported at 30 days but accepted any duration of follow-up unless otherwise specified. Where data were reported at multiple durations of follow-up we used data at 30 days or equivalent time point unless another duration was specified as the primary measure in the study.
Search methods for identification of studies

In June 2019, we searched the Cochrane Wounds Specialised Register; the Cochrane Central Register of Controlled Trials (CENTRAL); Ovid MEDLINE (including In-Process & Other Non-Indexed Citations); Ovid Embase and EBSCO CINAHL Plus. We also searched clinical trials registries for ongoing and unpublished studies, and scanned reference lists of relevant included studies as well as reviews, meta-analyses and health technology reports to identify additional studies. There were no restrictions with respect to language, date of publication or study setting.

Electronic searches

We searched the following electronic databases to identify reports of relevant clinical trials and cost effectiveness studies:

- the Cochrane Wounds Specialised Register (searched 20 June 2019);
- the Cochrane Central Register of Controlled Trials (CENTRAL; 2019, Issue 5) in the Cochrane Library (searched 20 June 2019);
- Ovid MEDLINE including In-Process & Other Non-Indexed Citations (1946 to 20 June 2019);
- Ovid Embase (1974 to 20 June 2019);
- EBSCO CINAHL Plus (Cumulative Index to Nursing and Allied Health Literature; 1937 to 20 June 2019).

We searched the NHS (National Health Service) Economic Evaluation Database (NHS EED; 2015, Issue 2) for the previous version of this review (Webster 2019). As NHS EED has not been updated since 2015 we did not search it for this update.

The search strategies for the Cochrane Wounds Specialised Register, CENTRAL, Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus can be found in Appendix 2. We combined the Ovid MEDLINE search with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision) (Lefebvre 2019). We combined the Embase search with the Ovid Embase filter developed by the UK Cochrane Centre (Lefebvre 2019). We combined the CINAHL Plus searches with the trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN 2019). There were no restrictions with respect to language, date of publication or study setting. We combined Ovid MEDLINE, Ovid Embase and EBSCO CINAHL Plus searches with filters developed by the Centre for Reviews and Dissemination for the identification of economic studies (CRD 2013).

We also searched the following clinical trials registries:

- ClinicalTrials.gov (www.clinicaltrials.gov) (searched 26 June 2019);

Search strategies for clinical trial registries can be found in Appendix 2. Details of the search strategies used for the previous version of the review are given in Webster 2019.

Searching other resources

We checked the citation lists of papers identified by the above strategies for further reports of eligible studies. We contacted corresponding authors of identified studies where key information was missing or unclear. In the first version of this review, we contacted the manufacturers and distributors of devices used to deliver NPWT, such as vacuum-assisted (VAC) closure (KC1, San Antonio, Texas); SNAp Wound Care System Dressing (Spiracur Inc, Sunnyvale, California); Venturi Avanti and Venturi Compact (Talley Group, Romsey, UK); and RENASYS EZ (Smith & Nephew, Hull, UK). We did not contact manufacturers or distributors for this update.

Data collection and analysis

We carried out data collection and analysis according to the methods stated in the published protocol (Webster 2011), which were based on the Cochrane Handbook for Systematic Reviews of Interventions (Li 2019). Changes from the protocol or previous published versions of the review are documented in Differences between protocol and review.

Two authors on the previous version of this review were authors of some of the papers included in the review. To prevent any form of bias, neither of them were involved in extracting data or assessing quality for any of the studies in which they were investigators.

Selection of studies

Two review authors independently reviewed titles and abstracts identified by the search. We retrieved full reports of all potentially relevant trials for further assessment of eligibility based on the inclusion criteria. We settled differences of opinion by consensus. There was no blinding of study authorship.

Data extraction and management

Two review authors independently extracted the following data using a predesigned checklist:

- methods (number of participants eligible and randomised, adequacy of randomisation, allocation concealment, blinding, completeness of follow-up);
- participant characteristics and exclusions;
- type of surgery;
- setting;
- study dates;
- interventions;
- number of participants per group;
- prospective registration on a clinical trials registry;
- information about ethics approval, consent, and conflict of interest;
- source of funding;
- economic data (healthcare costs);
- outcomes.

For cost-effectiveness studies, we additionally extracted data relating to study design, analytical approach, sources of effectiveness and cost data, perspective, utility valuation, measures of benefit, and analysis of uncertainty.

Any discrepancies were resolved through discussion. One review author entered data into the Review Manager 5 software (Review Manager 2014); and a second author checked the data for accuracy. Where necessary, we attempted to contact study authors of the original reports for clarification. When more than one publication
Arose from a study, we extracted data from all relevant publications but did not duplicate data.

**Assessment of risk of bias in included studies**

Two review authors independently assessed the eligible trials for risk of bias using the Cochrane tool for assessing risk of bias (Li 2019). This tool addresses six specific domains, namely sequence generation, allocation concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias (see Appendix 3 for details of the criteria on which our judgements were based). We assessed blinding and completeness of outcome data for each outcome separately. We completed a ‘Risk of bias’ table for each eligible study. Any disagreements between review authors were resolved by consensus. We contacted investigators of included trials to resolve any ambiguities. Assessment of risk of bias is presented as a ‘Risk of bias’ summary figure, which shows all the judgements in a cross-tabulation of study by entry.

We reported bias, and more generally study limitations within economic evaluations, using the checklist from the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) (Husereau 2013), and used the scoring system reported by Hope 2017 to assess the overall quality of each study, expressed as a percentage. Specifically, we allocated 1 point for each item that was fully met, 1/2 point if the item was partially met, and 0 for each item that was not met. We summed the total score and calculated a percentage (total score/total number of items less any non-applicable (N/A) item). We classified the quality of a report as follows: 85% or higher as excellent; 70% to 84% as very good quality; 55% to 70% as good quality; and below 55% as poor quality.

**Measures of treatment effect**

For individual trials, we extracted the numbers with an event for each treatment group and used them to calculate the risk ratio (RR) with its 95% confidence interval (CI). For statistically significant effects, we planned to calculate the number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) from the risk difference. However, based on the quality of the data and lack of evidence of effect for most outcomes, we decided not to conduct these calculations. For continuous outcomes, we extracted the mean and standard deviation (SD) and calculated the mean difference (MD) or, if the scale of measurement differed across trials, the standardised mean difference (SMD), each with its 95% CI. For economic studies, we focused on measures of relative cost-effectiveness such as the incremental cost-effectiveness ratio (ICER) as reported in the primary study.

**Unit of analysis issues**

If included studies had randomised at the participant level and measured outcomes at the wound level, we planned to treat the participant as the unit of analysis when the number of wounds assessed appeared equal to the number of participants (e.g. one wound per person). Where studies randomised wounds or body parts as opposed to individuals and there were multiple wounds per participant, and we were unable to obtain further information from trialists, we did not include them in the meta-analysis but instead presented narrative summaries of the results in Appendix 4. We also included studies with split-body designs, where patients undergoing bilateral procedures were enrolled and one wound was randomised to one treatment and the other to the alternative treatment. These approaches are similar to the ‘split-mouth’ approach (Lesaffre 2009). These studies should be analysed using paired data which reflects the reduced variation in evaluating different treatments on the same person. However, it was unclear whether such an analysis had been undertaken. We have noted this lack of clarity in the ‘Risk of bias’ assessment and in the notes in the Characteristics of included studies table. These studies were analysed separately from the parallel group trials and the results are presented in Appendix 4.

In some cases, trials enrolled a mixture of participants undergoing unilateral and bilateral procedures and it was not possible to separate the paired and unpaired data. We noted the results of these trials but did not analyse them further; results are presented in Appendix 4.

**Dealing with missing data**

Where it appeared that data had been excluded from the analyses, we attempted to contact authors for these missing data. If data remained missing despite our best efforts to obtain them, we conducted an available-case analysis, based on the numbers of participants for whom outcome data were known. No imputations were made. We did not conduct planned best-case and worst-case analyses, nor did we calculate SDs from standard errors (SE) (Li 2019).

**Assessment of heterogeneity**

Assessment of heterogeneity can be a complex, multifaceted process. Firstly, we considered clinical and methodological heterogeneity, that is, the degree to which the included studies varied in terms of participant, intervention, outcome, and characteristics such as length of follow-up. This assessment of clinical and methodological heterogeneity was supplemented by information regarding statistical heterogeneity, assessed using the Chi² test (we considered a significance level of P < 0.10 to indicate statistically significant heterogeneity) in conjunction with the I² statistic (Higgins 2003). The I² examines the percentage of total variation across RCTs that is due to heterogeneity rather than chance (Higgins 2003). In general, I² values of 40% or less may not be important (Higgins 2003), while values of more than 75% or more indicate considerable heterogeneity (Deeks 2011). However, these figures are only a guide, and it has been recognised that statistical tests and metrics may miss important heterogeneity. Thus, while these were assessed, the overall assessment of heterogeneity assessed these measures in combination with the methodological and clinical assessment of heterogeneity. Where there was evidence of high heterogeneity we attempted to explore this further; see Data synthesis for details on how we handled potential heterogeneity in the data analyses.

**Assessment of reporting biases**

We assessed selective outcome reporting for each trial as part of our appraisal of risk of bias. In addition, as a large number of trials were included in the meta-analysis for one of our primary outcomes (surgical site infection), we also assessed publication bias using a funnel plot (Li 2019). We note the particular risk of outcome reporting bias for a post hoc exploration which we undertook of
superficial and deep SSI and its implications for the certainty of the data.

Data synthesis

Where studies were clinically similar and outcome measurements comparable, we pooled results using a random-effects model and reported the pooled estimate together with its 95% CI. Where statistical synthesis of data from more than one study was not possible or considered inappropriate, we conducted a narrative review of eligible studies.

We were unable to pre-specify the amount of clinical, methodological, and statistical heterogeneity in the included studies, thus we used a random-effects approach for meta-analysis. Conducting meta-analyses with a fixed-effect model in the presence of even minor heterogeneity may provide overly narrow CIs. We would only have used a fixed-effect approach when clinical and methodological heterogeneity was assessed as minimal, and the assumption that a single underlying treatment effect was being estimated held. Chi² and I² were used to quantify heterogeneity but were not used to guide the choice of a model for meta-analysis. We would have exercised caution when meta-analysed data were at risk of small-study effects because, in such a case, use of a random-effects model may be unsuitable. In this case, or where there were other reasons to question the selection of a fixed-effect or random-effects model, we planned to assess the impact of the approach using sensitivity analyses to compare results from alternate models, but this was not implemented (Thompson 1999).

We presented data using forest plots wherever possible. For dichotomous outcomes, we presented the summary estimate as an RR with 95% CI. Where continuous outcomes were measured, we presented an MD with 95% CI; we planned to pool SMD estimates wherever studies measured the same outcome using different methods.

Economic analyses

We have presented a tabulated analysis of the identified economic data in accordance with current guidance on the use of economics methods in the preparation of Cochrane Reviews (Shemilt 2019). We classified the economic evaluation according to the framework described by Husereau and colleagues (Husereau 2013). We tabulated the main characteristics and results of the identified economic evaluation studies and augmented these with a narrative description. The methods used are discussed, and the key results of the studies compared. We assessed the quality of the studies using the CHEERS checklist (Husereau 2013).

We expected the results of cost-effectiveness studies to vary according to the particular circumstances of each study. For example, the comparator treatment, such as standard care, may differ for different types of wounds and in different settings. Our analysis placed the results of the economic studies in context and entailed a discussion of scenarios that were likely to lead to the most cost-effective use of the therapy, as well as the least cost-effective use.

We intended to capture and report all substantial costs that were observed to differ between participants administered NPWT and participants administered standard care as part of the economic analysis. However, we did not treat cost or resource use as an outcome in itself but as a component of cost-effectiveness. We therefore used the currency and price year together with the principal sources of resource costings in each original study. The primary trial outcome (adverse events) is relevant to the economic analysis as it may indicate a difference in the number of hospital bed days and specialist time required and a possible improvement in quality of life of the participant.

We examined information on the change in health-related quality of life via utilities measured by a multi-attribute utility instrument (MAUI) or other approaches (such as the time trade-off, standard gamble) where possible. These data are ideally reported in trials for both the group treated with NPWT and a control group receiving the comparator wound care. We assessed the utility data for comparability and representativeness considering issues such as the types of wounds included, the patient populations, timing of the baseline point and follow-up collection, the MAUI used, and the algorithm for scoring the MAUI. We planned to discuss the potential impact on health-related quality of life attributable to the intervention as part of the analysis. As with cost and resource use data, we treated utility data as a component of cost-effectiveness. If differences were observed in the rates of adverse events, wound infections, and complications resulting from the treatment of the wound, we planned to discuss the economic implications as part of the economic analysis.

Subgroup analysis and investigation of heterogeneity

Investigations of heterogeneity were not required as inconsistency was low for all outcomes, nor did we consider any population, intervention, or comparator subanalyses to be appropriate. We had originally planned a range of subgroup analyses in the protocol for this review, including type of setting, type of device, type of surgery, and type of comparison dressing. Based on the current interest in NPWT as a treatment for wounds healing by primary intention, and given the available data, we have conducted one of these suggested analyses: a subgroup analysis for different types of surgery defined in line with broad clinical grouping. We have also presented the data subgrouped by types of surgery based on contamination class. The decision to define surgery in two ways was a post hoc decision resulting in an exploratory analysis and, as with all subgroup analysis, the results should be interpreted with caution.

Subgroup analyses by type of surgery have been conducted for SSI - the primary outcome for which sufficient studies were available. For the outcome of dehiscence, we have grouped the studies in the analysis by their broad clinical grouping but have not implemented the subgroup analysis as there were too few studies in some groups.

For the outcome of SSI, we also performed an exploratory post hoc analysis in which we looked at studies which reported separate data for superficial SSIs and for deeper infections (classified as “deep” or “deep and organ space” SSIs), or which only reported either superficial or deep infection. Where infections were reported using the Szilagyi classification, we considered Szilagyi class I or II to be superficial and class III to be deep infections.

Sensitivity analysis

We performed a sensitivity analysis on the primary outcomes of SSI and dehiscence to assess the influence of removing studies classified as being at high risk of bias from the meta-analysis. We excluded studies that were assessed as having high or unclear risk of bias in the key domains of adequate generation of the
randomisation sequence, adequate allocation concealment, and blinding of outcome assessor.

'Summary of findings' tables and GRADE assessment of the certainty of the evidence

We have presented the main outcomes of the review in a 'Summary of findings' (SoF) table. This table presents key information concerning the quality of the evidence, the magnitude of the effects of the interventions examined, and the sum of available data for the main outcomes (Schünemann 2019a). 'Summary of findings' tables also include an overall grading of the evidence related to each of the primary outcomes, using the GRADE approach. The GRADE approach defines the certainty of a body of evidence as the extent to which one can be confident that an estimate of effect or association is close to the true quantity of specific interest. The quality of a body of evidence involves consideration of within-trial risk of bias, directness of evidence, heterogeneity, precision of effect estimates, and risk of publication bias (Schünemann 2019b). We planned to create a separate SoF table for each comparison evaluated. We have presented the following outcomes in the SoF table for the comparison of NPWT with standard care:

- incidence of mortality;
- incidence of surgical site infection;
- incidence of dehiscence;
- Incidence of reoperation;
- incidence of seroma;
- incidence of haematoma;
- incidence of skin blisters.

For other outcomes, we conducted a GRADE assessment and presented these assessments in a narrative format within the Results section but did not present them in separate 'Summary of findings' tables. We based the GRADE assessment of cost-effectiveness evidence on the RCT evidence on which the evaluation was based.

RESULTS

Description of studies

See Characteristics of included studies; Characteristics of excluded studies; Characteristics of studies awaiting classification; Characteristics of ongoing studies. Outcome data for intervention studies are given in Table 1 and Table 2; economic data are summarised in Table 3.

Results of the search

We searched for both intervention studies and economic evaluations. The results of these searches are reported separately below, and summarised in Figure 1. Over the lifetime of the review, we have now assessed a total of 1872 records from electronic searches as abstracts for intervention studies with 659 screened at full-text stage, although many of these were clinical trial registry records. For economic evaluation studies, we have assessed 387 records as abstracts and ten as full texts.
Figure 1. Study flow diagram.

1737 previously assessed records
452 new intervention records
and 80 new economic records
identified through database and clinical trial registry searching
Total 2250

2268 records

1240 records previously excluded
346 records newly excluded
Total 1586

2355 (after 13 duplicates from this update removed)

418 records excluded as reviews for reference screening or clearly not relevant clinical trial registry records etc.

3 studies awaiting classification
89 ongoing studies (92 records)
40 studies (46 records) excluded, with reasons (16 newly excluded)

487 records previously assessed
Interventions search

For this third update, we identified 452 unique new interventions records through our electronic search including the search of trial registry platforms. We retrieved 179 publications for inspection including full texts, abstracts, trial registry records and references identified from citation checking. From these, 14 new intervention studies reported in 16 records were eligible for inclusion in the review; three were reported in abstract form only. We also identified one other new included study (Galiano 2018) and two new excluded studies (Krishnamoorthy 2012; Stannard 2006) plus additional records for previously identified trials (total of nine records) through reference checking and cross-referencing of trial database records. The previous update included 30 intervention studies, one of which we have now excluded (Frazee 2018) because it did not assess an eligible comparison.
This update therefore includes 44 intervention studies reported in 58 records, of which 15 studies are newly identified (Bobkiewicz 2018; Galiano 2018; Giannini 2018; Giannini 2018; Bobkiewicz 2018; Bobkiewicz 2018; Bobkiewicz 2018; Bobkiewicz 2018; Javed 2018; Keeney 2019; Kwong 2018; Martin 2019; Murphy 2019; Newman 2019; Schmid 2018; Shim 2018; WHIST 2019a; Whitby 2018) and 29 were previously included (Chaboyer 2014; Crist 2014; Crist 2017; DiMuzio 2017; Engelhardt 2016; Gillespie 2015; Gunatilake 2017; Howell 2011; Hussamy 2017; Karlakki 2016; Kunczewitch 2017; Lee 2017a; Lee 2017b; Leon 2018; Lozano-Balderas 2017; Manoharan 2016; Masden 2012; Nordmeyer 2016; O’Leary 2017; Pauser 2016; Pachowsky 2012; Pleger 2018; Ruhstaller 2017; Sabat 2016; Shen 2017; Stannard 2012; Tanaydin 2018; Tuuli 2017; Witt-Majchrzak 2015). Ten of these studies were reported in abstract form only. We are grateful to the authors of the WHIST 2019a study for extensive personal communication which enabled the study to be included in this version of the review.

Economic analysis search

Electronic searches for previous versions of the review yielded 307 references and yielded two included studies (Heard 2017; Nherera 2017). For this update, we identified a further 80 publications; two of which were retrieved for full-text examination; both of these were included (Hyldig 2019b; Nherera 2018). We also included the WHIST study (WHIST 2019b) which was identified through the intervention searches and personal communication with the authors, bringing the number of included economic evaluations to five. All of these studies were based on RCTs included in the intervention review (Chaboyer 2014; Hyldig 2019b; Karlakki 2016; WHIST 2019a; Witt-Majchrzak 2015).

Included studies

Types of participants

In this update, we included 15 additional intervention studies enrolling 4470 participants (Bobkiewicz 2018; Galiano 2018; Giannini 2018; Bobkiewicz 2018; Bobkiewicz 2018; Bobkiewicz 2018; Javed 2018; Keeney 2019; Kwong 2018; Martin 2019; Murphy 2019; Newman 2019; Schmid 2018; Shim 2018; WHIST 2019a; Whitby 2018). The review now includes 7447 participants. The newly identified studies were larger than those in previous versions of the review, including in particular, the WHIST 2019a trial in fractures (1548 participants) and the Hyldig 2019a study in women having caesarean sections (876 participants). Sample sizes now range from 19 to 1548 participants and half of trials (22/44) included at least 100 participants.

Participants had a wide range of surgical procedures, including obstetric, orthopaedic, vascular and general surgeries:

- Seven studies enrolled women undergoing caesarean section (Chaboyer 2014; Gunatilake 2017; Hussamy 2017; Hyldig 2019a; Ruhstaller 2017; Tuuli 2017; Whitby 2018).
- Seven studies enrolled people having peripheral vascular procedures (DiMuzio 2017; Engelhardt 2016; Gombert 2018; Kwong 2018; Lee 2017b; Pleger 2018; Sabat 2016).
- Seven studies enrolled people undergoing abdominal procedures (Bobkiewicz 2018; Kunczewitch 2017; Leon 2016; Lozano-Balderas 2017; Murphy 2019; O’Leary 2017; Shen 2017).
- Six studies enrolled people undergoing surgery for limb fracture (Crist 2014; Crist 2017; Nordmeyer 2016; Pauser 2016; Stannard 2012; WHIST 2019a).
- Two studies enrolled people undergoing cardiac surgery (Lee 2017a; Witt-Majchrzak 2015).
- Two studies enrolled people undergoing hepatopancreaticobiliary procedures (Javed 2018; Martin 2019).
- In two studies participants were undergoing breast surgery Galiano 2018; Tanaydin 2018).
- One study (Masden 2012) included mixed wound types.
- One study (Shim 2018) enrolled people requiring surgery for hand injuries.
- One study (Schmid 2018) enrolled people having inguinal lymph node dissection.

Most studies were conducted in North America (21 studies), Europe (16 studies) or Australasia (three studies); Israel and South Korea were also represented and two studies did not report where they were conducted.

Types of interventions

Most studies used one of a small number of commercially available NPWT systems:

- Seven studies used the vacuum-assisted closure (VAC) negative pressure device (KCI, San Antonio, Texas), set to ~125 mmHg (Crist 2014; Crist 2017; Howell 2011; Lozano-Balderas 2017; Masden 2012; Stannard 2012; Whitby 2018).
- Thirteen studies used the PICO system (Smith & Nephew, Hull, UK) (Chaboyer 2014; Galiano 2018; Giannini 2018; Gillespie 2015; Hyldig 2019a; Keeney 2019; Karlakki 2016; Martin 2019; Nordmeyer 2016; O’Leary 2017; Tanaydin 2018; Tuuli 2017; Witt-Majchrzak 2015).
- Sixteen studies used the PREVENA system (KCI, San Antonio, Texas) (DiMuzio 2017; Engelhardt 2016; Gombert 2018; Gunatilake 2017; Javed 2018; Kwong 2018; Lee 2017a; Lee 2017b; Manoharan 2016; Murphy 2019; Newman 2019; Pachowsky 2012; Pauser 2016; Pleger 2018; Ruhstaller 2017; Sabat 2016).
- A minority of studies did not specify the device but described it in varying degrees of detail (Bobkiewicz 2018; Hussamy 2017; Kunczewitch 2017; Leon 2016; Schmid 2018; Shen 2017; WHIST 2019a).
- One study (Shim 2018) used Curavac (CGBio, Seongnam-si, Gyeonggido, Korea).

Comparators were mostly described as standard care, standard dressings, usual care or conventional dressings, care or therapy. Where specified, dressings were most commonly described as gauze or nonadherent or containing these components. A small number of studies reported using dressings with specific properties such as silver or iodine-impregnated dressings and some reported the use of steri-strips in some or all wounds.

Types of economic assessments

All of the five included economic studies used clinical effectiveness data, in particular data on SSIs, from RCTs included in this review to assess measures of cost-effectiveness; several also derived resource use and cost data from the trial data but other sources were also used to inform estimates of cost-effectiveness.
Two obstetric surgery studies looked at use of NPWT in women undergoing caesarean section (Heard 2017; Hyldig 2019b); these were based on the RCTs of Chaboyer 2014 and Hyldig 2019a, respectively. Heard 2017 used the perspective of the Australian public healthcare provider with resources priced in AUD (Australian dollars) at 2014 values; while Hyldig 2019b used a Danish healthcare perspective; resource costs in Euro were reported after transformation from Danish Krona at 2015 values.

Two orthopaedic surgery studies were also identified. The WHIST 2019b study was undertaken alongside the WHIST 2019a RCT in people having surgery for lower limb fractures. Nherera 2017 looked at NPWT in people having knee and hip arthroplasties and was based on Karlakki 2016. Both studies were undertaken in a UK context with an NHS perspective and resources priced in pounds sterling (GBP) at 2017/18 and 2015/16 values, respectively. WHIST 2019b also used an NHS and personal social services (PSS) (including indirect costs) perspective.

Finally, an assessment in general surgery, Nherera 2018, looked at people having coronary artery bypass graft (CABG) surgery and was based on Witt-Majchrzak 2015. A German Statutory Health Insurance payer perspective was employed and resource costs were priced in Euro.

All studies used resource costs and clinical outcome data to assess the quality-adjusted life year gained (QALY). A QALY is a generic measure of disease burden including both the quality and the quantity of life lived (NICE 2013; NICE 2018), and can be used in combination with cost data to assess the value for money of medical interventions (NICE 2013). One QALY equates to one year in perfect health and a year of less than perfect health is worth less than one, while death is considered to be worth zero (Heard 2017). The estimated incremental cost-effectiveness ratio (ICER) considers the mean cost per QALY. Some studies used the ICER(s), together with their 95% credible intervals (CI) to calculate the probability of NPWT being cost-effective at particular “willingness-to-pay” thresholds.

Excluded studies

The previous update of this review excluded a total of 24 studies (for reasons see Characteristics of excluded studies). For this update, we excluded one previously included study (Frazee 2018) which we determined did not assess an eligible comparison. We identified and excluded 15 new studies for the following reasons: ineligible population (Costa 2018; Joos 2015; Muller-Sloof 2018; Sinha 2016; Stannard 2006; Zotes 2015); ineligible intervention (Bi 2017; Erne 2018; Walker 2018); ineligible study design (Athanasiou 2018; Chang 2018; Fleming 2018; Svensson-Bjork 2018; ineligible comparison (e.g. NPWT was not the only difference between groups) (Krischnamoorthy 2012; Trofa 2019). This brought the total number of excluded studies to 40. Two of these were identified through reference checking and cross-referencing of trial records (Stannard 2006; Krischnamoorthy 2012). We also identified additional references for a number of already excluded studies.

Ongoing studies

Screening by two review authors identified a total of 89 ongoing studies, primarily from the trial registry search; this number incorporates 28 newly identified studies and several published protocols identified from the main database search. Some studies listed as ongoing in the previous version of the review have now been identified as published studies and moved to included or excluded studies, as appropriate. For this new update, we identified five published protocols (Gillespie 2016; Jorgensen 2018; Masters 2018; Mihaljevic 2015; Sandy-Hodgetts 2017) in addition to the two we had previously included (Nguyen 2017; SUNRRISE 2017). We also identified a number of trial registry records which we have judged to represent ongoing potentially relevant studies. We were able to link some previously listed trial records to included or excluded studies or to published protocols so the total number of ongoing studies is now 89 (the previous version of the review contained 77). Two trials were recorded as terminated without sufficient data for analysis; we did not include these records.

Studies awaiting classification

There are three studies awaiting classification pending author contact, one of which was newly identified for this update (Nagata 2018) and two of which were included in the previous review (NCT00654641; NCT00724750). Some studies listed as pending classification in the previous version of the review have now been identified as published studies and moved to included, excluded or ongoing studies, as appropriate.

Risk of bias in included studies

Given that we anticipated unclear or high risks of performance bias in all studies due to the nature of the intervention (Appendix 3), we regarded the domains of sequence generation, allocation concealment and detection bias as having key importance: eight studies (Chaboyer 2014; Giannini 2018; Gillespie 2015; Gombert 2018; Masden 2012; Murphy 2019; Tanaydin 2018; WHIST 2019a) were at low risk of bias for all three of these domains. Conversely, twelve studies were at high risk for one or more of these (Galiano 2018; Gunatilake 2017; Karlakki 2016; Kwon 2018; Lozano-Balderas 2017; Manoharan 2016; O’Leary 2017; Schmid 2018; Shen 2017; Shim 2018; Whibey 2018; Witt-Majchrzak 2015). The remaining 24 studies were at unclear risk of bias for one or more of these domains.

We included a number of studies reported only in abstract form; these had multiple domains at unclear risk of bias because of the constraints of the form in which they were published. Three studies were planned interim analyses (Martin 2019; Sabat 2016; Schmid 2018). A number of studies used designs which either mixed paired and unpaired data (for example, by recruiting participants with a mixture of unilateral and bilateral wounds and randomising them differently) or simply used different units of randomisation and analysis (Howell 2011; Kwon 2018; Pleger 2018; Sabat 2016; Stannard 2012). Four studies employed split-person designs and it was not clear whether the paired data had been taken into account in the analysis (Galiano 2018; Manoharan 2016; Schmid 2018; Tanaydin 2018). These studies were all considered to have a high or unclear risk of bias for the domain of other sources of bias, depending on the reporting of the study and whether other considerations were present.

See Figure 2 and Figure 3 for the ‘Risk of bias’ summary; details of the risk of bias judgements for each domain and their rationales for each study are given in Characteristics of included studies. Risk of bias, or more specifically study quality, for the economic studies is shown in Table 4.

Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.

- Random sequence generation (selection bias)
- Allocation concealment (selection bias)
- Blinding of participants and personnel (performance bias): All outcomes
- Blinding of outcome assessment (detection bias): All outcomes
- Incomplete outcome data (attrition bias): All outcomes
- Selective reporting (reporting bias)
- Other bias

Low risk of bias | Unclear risk of bias | High risk of bias
Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias): All outcomes</th>
<th>Blinding of outcome assessment (detection bias): All outcomes</th>
<th>Incomplete outcome data (attrition bias): All outcomes</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobkiewicz 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Chaboyer 2014</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Crist 2014</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Crist 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>DiMuzio 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Engelhardt 2016</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Galiano 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Giannini 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Gunatilake 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Heard 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Howell 2011</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Hyldig 2019b</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Javed 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Kunczewitch 2017</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Kwon 2018</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Lee 2017a</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ] [ ]</td>
<td>[ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ]</td>
<td>[ ] [ ] [ ] [ ] [ ]</td>
</tr>
</tbody>
</table>
Figure 3. (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
<th>11</th>
<th>12</th>
<th>13</th>
<th>14</th>
<th>15</th>
<th>16</th>
<th>17</th>
<th>18</th>
<th>19</th>
<th>20</th>
<th>21</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lee 2017a</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leon 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lozano-Balderas 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manoharan 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Martin 2019</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masden 2012</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Murphy 2019</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nherera 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nherera 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nordmeyer 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O’Leary 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pachowsky 2012</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pauser 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleger 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruhstaller 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabat 2016</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Schmid 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stannard 2012</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanaydin 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHIST 2019b</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzac 2015</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Risk of bias in economic studies**

We used the CHEERS checklist, Husereau 2013, to assess the quality of the reports of the five included economic studies (Heard 2017; Hyldig 2019b; Nherera 2017; Nherera 2018; WHIST 2019b). All studies scored >80% on the checklist, indicating very good reporting quality. Additionally, data for the Nherera 2017 study and the Nherera 2018 were drawn from the Karlakki 2016 and Witt-Majchrzac 2015 trials, which were at high risk for detection bias. The two items that were least well addressed were ‘Measurement and valuation of preference based outcomes’ and ‘Choice of model’. The full assessments for each study are shown in Table 4.

The lead author in the Nherera 2017 and Nherera 2018 studies was an employee of Smith & Nephew, which manufactures the intervention product used in the studies.

**Effects of interventions**

See: Summary of findings 1 Negative pressure wound therapy compared with standard dressing for surgical wounds healing by primary closure.

See Summary of findings 1 for the main comparison: NPWT compared with standard dressing for surgical wounds healing by primary closure. Studies which reported a relevant outcome but which could not be included in the pooled analysis because of methodological or reporting issues are noted and reported fully in Appendix 4. As random-effects analyses were used throughout, each pooled result presented is an average effect, rather than a common effect and should be interpreted as such.

**Comparison 1: NPWT compared with standard dressing (44 trials, 7447 participants)**

All of the studies for this comparison compared a negative pressure device with a standard dressing. The included surgery types were diverse: study devices varied by manufacturer, and standard dressings differed based on individual hospital preference.

**Primary outcomes**

Primary outcome data are summarised in Table 1.

**Mortality (follow-up period 30 days to 90 days or unspecified)**

Four studies (2107 participants) reported mortality, these data were pooled. There may be little difference in mortality between...
people treated with NPWT (25/1074 (2.3%)) and those treated with standard dressings (28/1033 (2.7%)). The RR was 0.86 (95% CI 0.50 to 1.47; $I^2 = 0\%$) (Analysis 1.1). This was low-certainty evidence downgraded twice for very serious imprecision due to small numbers of events which produced wide confidence intervals which include the possibility of both harm and benefit as well as no effect. Using mortality data recorded at 3 months instead of 6 months in the largest trial (WHIST 2019a, with data for 1456 participants) made little difference to the pooled effect estimate (RR 0.76, 95% CI 0.42 to 1.39; $I^2 = 0\%$).

**Surgical site infection (follow-up period 30 days to 12 months or unspecified)**

Thirty-nine studies (6917 participants) reported this outcome. We pooled incident SSI data from 31 studies (6204 participants). The evidence showed that NPWT probably reduces the incidence of SSI in participants treated with NPWT: 273/3115 (8.8%) compared with standard dressing 402/3089 (13.0%); RR 0.66 (95% CI 0.55 to 0.80; $I^2 = 23\%$) (Analysis 1.2). This is moderate-certainty evidence downgraded once for high risk of bias in domains other than performance bias; half the studies with approximately 50% of the analysis weight were at high risk of bias in one or more domains (excluding performance bias). We assessed this analysis for evidence of publication bias but there was no clear evidence of this despite some asymmetry in the funnel plot (Figure 4); we judged that the effect estimate was unlikely to have been substantively influenced by this.

**Figure 4. Funnel plot of comparison: 1 Negative pressure wound therapy versus standard dressing, outcome: 1.2 Surgical site infection.**
**Sensitivity analyses**

We applied a prespecified sensitivity analysis which included only the six studies (2229 participants) which reported SSI and were judged to be at low risk of bias in the key domains of randomisation, allocation concealment and blinding of outcome assessment. This produced a less clear estimate of the effect of NPWT (RR 0.75, 95% CI 0.56 to 1.00; I² = 29%) based on 119/1135 (10.4%) SSI in NPWT groups compared with 148/1094 (13.5%) in standard dressing groups. However, the evidence remains moderate certainty, downgraded once for imprecision. A post hoc analysis which included studies with no domain at high risk of bias (except performance bias) found a result very similar to the main analysis even though there were many fewer participants (16 studies; 3282 participants; RR 0.71; 95% CI 0.57 to 0.88; I² = 0%) based on 128/1664 (7.7%) SSI in NPWT groups compared with 177/1618 (10.9%) in standard dressing groups. We ran this analysis to explore the impact of removing all studies with any domain at high risk of bias but retaining those where risk of bias in key domains was unclear; this is a common approach to sensitivity analysis in Cochrane reviews. A formal GRADE assessment for a post hoc analysis is not appropriate but this result, together with the prespecified analysis suggests that the result of the main analysis is likely to be robust to known high risk of bias in the studies contributing data.

The results of the primary analysis and the two sensitivity analyses (exploratory and a priori) are shown in Figure 5: as can be seen, the lower bound of the 95% CI appears unaltered by reductions in both numbers of participants and events and risks of bias. The estimate of effect shows limited sensitivity but the upper bound of the 95% CI moves towards the line of no effect as numbers of participants decrease and uncertainties around key risks of bias also decrease. This suggests that the widening of the confidence intervals is not simply a consequence of increasing imprecision but reflects a tendency for studies which are not known to be free from key biases to produce larger estimates of effect. It may also reflect the greater influence in the analysis of the low risk of bias WHIST trial which only assessed deep SSI.

**Figure 5. Effect estimates for SSI: primary analysis and sensitivity analyses**

![Figure 5](image)

**Subgroup analyses**

Of the prespecified subgroup analyses, we were only able to conduct the comparison based on different types of surgery: conducted in two different ways type of surgery (e.g. treatment of limb fractures; caesarean sections etc.) and contamination class. The results of these analyses are shown in Analysis 1.2 and Analysis 1.3. There was no clear evidence of a difference between the subgroups based on type of surgery (I² for subgroup differences = 44.3% and P associated with X² for subgroup differences = 0.08)) or between subgroups based on contamination classes (I² for subgroup differences = 38.3% and P associated with X² for subgroup differences = 0.18). The type of SSI assessed is not independent of the surgical indication (e.g. some fracture surgery studies focus on deep SSI) and we consider this below.

**Types of SSI**

In this update, we also looked at studies which reported separate data for superficial SSIs and for deeper infections (classed as deep or deep and organ space SSIs), or which only reported either superficial or deep infections. This is an exploratory analysis as we did not pre specify that we would assess the classes of infection identified separately. This analysis includes studies which reported more detailed information about the outcome of SSI or which specified that they would only include SSIs which were superficial or deep. For these analyses to be considered reliable, we would need to obtain this level of detail from all the included studies; this is very low-certainty evidence but these results suggest that we might usefully explore uncertainty as to whether NPWT acts equally for all types of SSI.

Superficial SSI: eighteen studies reported SSIs which were identified as being superficial. Where studies reported Szilagyi classification, we considered Szilagyi class I or II SSIs to be superficial. Fifteen of these (2783 participants) contributed data to a pooled estimate of effect. The RR was 0.58 (0.42 to 0.79); I² = 41% (Analysis 1.4).

Deep SSI: twenty studies reported SSIs which were identified as being deep. Where studies reported deep and organ-space SSIs separately, we combined these for this analysis. Where studies reported Szilagyi classification, we considered Szilagyi class III SSIs to be deep. Seventeen studies (4279 participants) contributed data to a pooled estimate of effect. The RR was 0.94 (0.71 to 1.25; I² = 0%) (Analysis 1.5).

**Summary of findings for SSI**

There is moderate-certainty evidence from a large number of participants across a range of surgical indications that NPWT following surgery probably results in a lower risk of SSI compared with standard dressings. This evidence was downgraded once due to risks of bias in various domains. In a sensitivity analysis which only included the six trials with low risk of bias in key domains (approximately one-third of the total participants), the evidence remains moderate certainty but shows a less clear difference between NPWT and standard dressings; this evidence was downgraded once due to imprecision.

**Dehiscence (follow-up period 30 days to an average of 113 days or unspecified)**

Eighteen studies reported dehiscence. We combined results from 14 studies (3809 participants) that compared NPWT with standard dressings. Low-certainty evidence suggests that there is no clear
difference in dehiscence between NPWT (102/1920 (5.3%)) and standard dressings (117/1889 (6.2%)) (RR 0.88; 95% CI 0.69 to 1.13; I² = 0%) (Analysis 1.6). The evidence was downgraded once for risk of bias and once for imprecision as the number of events was relatively low (219) despite the large number of participants; and the 95% CI included both benefit and harm as well as no effect.

Sensitivity and subgroup analyses

We applied a prespecified sensitivity analysis which included only the three studies (1552 participants) which reported dehiscence and were judged to be at low risk of bias in the key domains of randomisation, allocation concealment and blinding of outcome assessment. This did not substantially change the estimate of the effect of NPWT (RR 0.79, 95% CI 0.29 to 2.18; I² = 37%) based on 19/793 (2.4%) dehiscences in NPWT groups compared with 19/759 (2.5%) in standard dressing groups. The evidence remains low certainty as it is downgraded twice for very serious imprecision.

We have presented the analysis with studies arranged according to the type of surgery undertaken for information only; the number of studies in the analysis meant that some subgroups are represented by a single study and we have not undertaken any analysis of the effect of subgroups.

Summary of findings for dehiscence

Low-certainty evidence suggests no clear difference in dehiscence between participants treated with NPWT and those treated with standard dressings following surgery.

Secondary outcomes

Secondary outcome data are summarised in Table 2.

Reoperation (follow-up period 30 days to an average of 113 days or unspecified)

Fourteen trials assessed reoperation. We were able to combine data from 12 of these (3523 analysed participants). The pooled RR was 1.04 (95% CI 0.78 to 1.41; I² = 13%). This was low-certainty evidence which suggests that there is no clear difference in the incidence of reoperation between NPWT compared with standard dressings. Evidence was downgraded once for high risk of bias (various domains) and once for imprecision due to low numbers of events (136 reoperations in total) producing wide confidence intervals which include the possibility of both benefit and harm as well as no effect of the intervention. The WHIST 2019a study also reported much smaller numbers of subsequent surgeries as being due to wound complications; these data are shown in Table 2.

Wound-related readmission to hospital within 30 days (follow-up period 10 days to 90 days)

Eleven trials assessed wound-related readmissions. We were able to combine data from nine of these (1591 participants). The pooled RR was 0.88 (95% CI 0.57 to 1.35; I² = 0%). This is low-certainty evidence of no clear difference, downgraded twice for imprecision; low numbers of events resulted in wide confidence intervals which include the possibility of both benefit and harm as well as no difference between the groups. (Analysis 1.8).

Seroma (follow-up period 10 days to 6 weeks)

Nine trials reported the incidence of seroma. We were able to combine data from seven of these (729 participants). The pooled RR was 0.72 (95% CI 0.50 to 1.05; I² = 0%). This is low-certainty evidence of no clear difference, downgraded twice for imprecision due to low numbers of events resulting in wide confidence intervals which include both benefit and harm as well as no effect. (Analysis 1.9).

Haematoma (follow-up period 30 days to 6 weeks)

Thirteen studies reported on haematoma. We were able to pool data from nine trials (1202 participants). The effect of NPWT on haematoma is uncertain. The pooled RR was 0.67 (95% CI 0.28 to 1.59; I² = 0%). This evidence is very low certainty, downgraded once for risk of bias and twice for very serious imprecision; the number of events was very low (25) and this resulted in wide, fragile confidence intervals which included both the possibility of benefit and harm as well as no effect. (Analysis 1.10).

Skin blisters (follow-up period 6 weeks to 12 months)

Eight studies reported on skin blistering and we were able to pool seven of these with 796 participants. It is uncertain whether there is a higher risk of developing skin blisters with NPWT compared with standard dressings (RR 2.64; 95% CI 0.65 to 10.68; I² = 69%). An eighth study (Howell 2011) had unit of analysis issues and is reported in Appendix 4; this study was stopped early due to the high rate of blistering in the NPWT group. This evidence is very low certainty, downgraded once for inconsistency, once for risk of bias and twice for imprecision (Analysis 1.11).

Pain

Seven studies (2218 participants) assessed pain, but the data could not be pooled. One (Gombert 2018) stated that pain was assessed but did not report results of the assessment. Results from two of the studies reported "no difference" in pain (O'Leary 2017; Ruhstaller 2017). Another study (Gunati 2017) reported that there were more participants in the NPWT group with reductions in incisional pain both at rest (39/46 (84.8%) versus 20/46 (43.5%); P < 0.001) and with incisional pressure (42/46 (91.3%) versus 25/46 (54.3%); P < 0.001), compared with standard care. One study (Tuuli 2017) reported a lower pain level in the NPWT group (NPWT median = 0, interquartile range (IQR) = 0 to 1; standard dressing median = 1, IQR = 0 to 3; P = 0.02). The large (1549 participants) WHIST 2019a trial also reported median and interquartile ranges for each group assessed on a visual analogue scale (VAS) at three and six months postsurgery. The figures at three months were 3.0 (IQR 1.0 to 6.0) for the NPWT group compared with 4.0 (IQR 2.0 to 5.0) in the standard dressing group. At six months, the figures for the two groups were identical. The proportions of participants with neuropathic pain were also reported. Giannini 2018 reported pain at dressing change giving the mean, median and range for each group as NPWT 2.6, 2 (1 to 6) compared with 4.8, 5 (2 to 7).

Overall, the evidence is very low certainty, downgraded twice for imprecision and once for risk of bias. However, the evidence from the WHIST 2019a trial suggests that there is probably little difference between the groups after fracture surgery when assessed at three or six months (moderate certainty).

Quality of life

Quality of life was measured using a recognised scale by five studies (Chaboyer 2014; Hylidig 2019a; Karlakki 2016; Lee 2017a; WHIST 2019a). In four cases, these estimates were then used to inform calculations of QALY in subsequent or integrated cost-effectiveness analyses. The data from Chaboyer 2014 and Karlakki 2016 were not
report although they were then used in the cost-effectiveness analyses. Another study Manoharan 2016 reported some data but did not use a validated scale; we have not analysed this further.

Lee 2017a reported EuroQol-5D (EQ-5D) scores for the NPWT group of 78 (26 participants) and 63 for the standard dressing group (17 participants). No measures of variance were reported and we could not analyse the data further.

Hyldig 2019a used the EQ-5D-5L and reported EQ-Index and EQ-VAS at 30 days together with 95% CI for each group of obese women having caesarean sections. The scoring algorithm was not reported but the Danish-specific context was considered. The mean difference in the EQ-Index was 0.00 (95% CI -0.01 to 0.01). For the EQ-VAS the mean difference was 1.00 (95% CI -1.23 to 3.23).

WHIST 2019a reported EQ-5D-3L; EQ-VAS and Disability Rating Index (DRI), each at both three and six months scored using the UK algorithm. We report the three-month data here (this is based on more participants); six-month data is detailed in Table 3. The mean and SD EQ-5D for the NPWT group was 0.5 (0.29) compared with 0.6 (0.30) in the standard dressing group giving a mean difference of -0.10 (95% CI -0.14 to -0.06). For the EQ-VAS, the results were 64.1 (22.24) compared with 64.7 (21.15) giving a mean difference of -0.60 (95% CI -3.28 to 2.08) but this difference was not sustained at six months. The results of the DRI were 51.6 (23.46) in the NPWT group compared with 51.1 (23.92) in the standard dressing group giving a mean difference of 0.50 (95% CI -2.50 to 3.50). Approximately 60% of the 1548 participants in the trial contributed to each estimate.

We have chosen not to pool the data from Hyldig 2019a and WHIST 2019a because of the very different surgical indications and time points of the assessments. This evidence is impacted on by the fact that it is not based on all the participants in WHIST but nevertheless is moderate-certainty evidence that, at relevant time points for each surgical indication, there is probably little clinically important difference in the quality of life of participants assessed by aspects of the EQ-5D.

Economic outcomes

We focus here on the relative cost-effectiveness of NPWT and standard dressings; the costs and QALY estimates which contribute to these are detailed in Table 3 and Appendix 5.

Using the CHEERS checklist (for a summary of ratings, see Table 4), we rated the overall quality of all the reports as very good, but the studies used different modelling assumptions. Results therefore depend on which resources are incorporated into the model, and on the cost-effectiveness threshold used. We note that large numbers of participants were included in the trials informing two of the analyses, providing evidence for key areas of obstetric and orthopaedic surgery. GRADE assessments were based on the RCTs which provided the clinical inputs to the assessments in all cases, and the utility data in all except one instance (costs were derived from a range of sources).

Incremental cost-effectiveness ratio (ICER)

All of the studies used QALY along with costs data to inform an estimate of relative cost-effectiveness.

In caesarean sections in obese women, Hyldig 2019b concluded that NPWT was dominant to standard dressings but did not report the base case ICERs (ICERs were reported for subgroups). Heard 2017 concluded that NPWT is probably cost-effective relative to standard care, estimating an ICER value of GBP 20.65 per QALY gained. This is moderate-certainty evidence downgraded once for imprecision.

In orthopedic surgery, the WHIST 2019b study reported a base case ICER of GBP 396,531 using an NHS/PSS perspective, other perspectives and sensitivity analyses produced higher estimates. Based on these estimated ICERs, NPWT was calculated to have a very low probability of cost-effectiveness at any willingness-to-pay threshold considered. This is high-certainty evidence assessed in terms of deep SSI; it is moderate-certainty evidence for SSI overall, downgraded once for indirectness.

Based on deterministic results, Nherera 2017 estimated that NPWT was dominant over standard dressings in hip or knee replacement surgery, as NPWT was cost-saving and improved QALYs. This was based on clinical data from the Karlakki 2016 trial from which utility estimates were also derived. This is low-certainty evidence downgraded once for imprecision and once for risk of bias.

In general surgery, in people undergoing CABG surgery, Nherera 2018 concluded that NPWT was dominant to standard dressings for both SSIs avoided and QALY gained but did not report the ICER. This was based on clinical data from the Witt-Majchczak 2015 trial; but utility estimates were derived from the published literature. This is very low-certainty evidence downgraded twice for imprecision and once for risk of bias.

DISCUSSION

Summary of main results

Wound complications

This systematic review synthesises RCT evidence on the effects of NPWT on death, SSI and dehiscence following acute surgery in which wounds are primarily closed. We added 15 additional RCTs (4470 participants) to this third update, bringing the total number of RCTs to 44 (7447 participants). This is more than double the number of participants in the previous version of the review. We have also added three cost-effectiveness studies, bringing the total to five, and the number of participants included in source trials to 2811.

With the addition of a substantial number of RCTs - and a very substantial number of participants - there is moderate-certainty evidence that NPWT probably reduces the incidence of SSI in surgical wounds healing by primary closure. Sensitivity analyses suggested that the upper bound of the confidence interval may not be robust to the effects of risk of bias in the included studies. Evidence was downgraded once for high risks of bias across various domains in trials which contributed approximately half the participants in the analysis and when only studies with low risk of bias in key domains were considered the difference between the groups was not clear. Pre-planned subgroup analyses did not show clear evidence of differential effects across different types of surgery. Exploratory analysis of reported SSI data suggested that there is scope for investigating the types of SSI for which NPWT may be most effective; exploratory analysis of available data raises the possibility that superficial SSI is reduced with little difference in deep SSI. The results of the large high quality publicly funded WHIST trial in fracture surgery which only assessed deep SSI would tend to support this.
 Whilst we found moderate-certainty evidence suggesting that, compared with standard dressings, NPWT probably results in fewer SSI, the evidence for our other primary outcomes - mortality and dehiscence - was low certainty and showed no clear differences between the groups. In the case of mortality, the evidence was downgraded twice for imprecision, as low numbers of events made for very wide confidence intervals which included the possibility of both benefit and harm as well as no effect. For dehiscence, we downgraded once for imprecision and once for risks of bias across various domains; certainty remained low in a sensitivity analysis including only trials with low risks of bias in key domains as it was then downgraded twice for imprecision.

For our secondary outcomes, we generally found no clear difference. There is low-certainty evidence that there may be little or no difference between NPWT and standard dressings for the outcomes of reoperation, readmission, and seroma. For haematoma and skin blisters, we are uncertain what the effect of NPWT is compared with standard dressings because the evidence was very low certainty. Evidence was downgraded because of imprecision due to small numbers of events and in some cases also because of risks of bias across various domains. Inconsistency was also present in the analysis of blistering. For pain, the evidence was disparate, being reported for different time points and using different measures; in many cases, it was very poorly reported. Where data were available, most studies, including the large and well-conducted WHIST trial, found little difference between the groups. This is very low-certainty evidence overall, downgraded for imprecision and risk of bias across most studies, but the evidence from WHIST is of moderate certainty. For quality of life, there is moderate-certainty evidence that there is probably little difference in EQ-5D scores between participants treated with NPWT and standard dressings at time points relevant to the surgery involved.

Economic outcomes

Five economic studies, Heard 2017; Hyldig 2019b; Nherera 2017; Nherera 2018; WHIST 2019b, based on results from five RCTs, Chaboyer 2014; Hyldig 2019a; Karlakki 2016; WHIST 2019a; Witt-Majchrzac 2015, compared the cost-effectiveness of NPWT with standard dressings. The economic evaluations used different methods and different perspectives and relied on source data from very different trials. The economic studies were well reported but our further assessment of the certainty of the evidence rests on our assessments of the trials which contributed clinical data to the models. The trials on which the economic analyses were based varied considerably. While the sample sizes of three of the studies were relatively small (80 to 220 participants) (Chaboyer 2014; Karlakki 2016; Witt-Majchrzac 2015), in two cases the trials were large; Hyldig 2019b was based on a trial in 876 women whilst WHIST 2019b used data from a trial which enrolled 1548 participants with lower limb fractures. Two studies were at low risk of bias other than performance bias (Chaboyer 2014; WHIST 2019a). In Hyldig 2019a, one domain was at unclear risk of bias and one at high risk while Karlakki 2016; and Witt-Majchrzac 2015 had multiple domains with high or unclear risks of bias. The type of SSI considered in the clinical and cost-effectiveness analyses also differed between the trials; the WHIST 2019a trial considered only deep SSI whilst all the other studies considered all types of SSI and superficial SSI predominated.

Results of the analyses based on these trials also differed. Three studies across three different surgical indications (caesarean section in obese women; joint arthroplasty and CABG) found that NPWT was a dominant strategy (Hyldig 2019b; Nherera 2017; Nherera 2018). However, Heard 2017 reported that total costs for the episode of care in caesarean section were higher with NPWT than with standard dressings and found that value for money from NPWT was relatively low. In the WHIST 2019b study, NPWT was not cost-effective in fracture surgery at any threshold of willingness-to-pay.

The measurement of costs was reasonable in all studies although different healthcare system perspectives were employed. The measurement of health states, using the SF-12 version 2 in Heard 2017, the SF-36 in Nherera 2017, and versions of the EQ-5D in Hyldig 2019b and WHIST 2019b was also reasonable. However, the approach to scoring the SF-36 in Nherera 2017, which used a non-preferred based algorithm developed in the 1990s, is questionable, especially since the SF-6D, a preference-based scoring algorithm for the SF-36 with country-specific weights for the UK (Kharroubi 2007), the USA (Craig 2013), and other countries, is available. Without using a preference-based scoring system, the gains in QALYs estimated by Nherera 2017 may have been over- or understated. In Nherera 2018, the valuations of health states were derived from published literature rather than from the trial participants.

All cost-effectiveness estimates should be interpreted in the context of the certainty of the clinical evidence base. In the case of NPWT in primary closure of surgical wounds, this is judged to be moderate or low for most outcomes with very low-certainty evidence for some outcomes which are likely to be important to patients, such as blistering of the skin and pain. The largest trial with a low overall risk of bias supported an analysis which did not find NPWT to be cost-effective while a small trial with low risks of bias supported an analysis which showed low value for NPWT. The less certain evidence from other trials supports analyses which found NPWT was cost-effective. Consequently, there is moderate-certainty evidence that NPWT is probably not cost-effective for fracture surgery, high-certainty evidence that it is not cost-effective if only deep SSI are considered, and moderate-certainty evidence that it probably is cost-effective for caesarean sections in obese women. Evidence for cost-effectiveness in arthroplasty or CABG surgery is low and very low certainty, respectively.

Overall completeness and applicability of evidence

Indications for the use of NPWT following surgery are broadening (Acosta 2017; DeCarbo 2010; Pellino 2015; Webb 2017), with a range of new systems on the market, including those designed for use on closed, clean wounds (Allen 2011; Gabriel 2014; Gupta 2016). Studies included in this review used NPWT across a wide range of surgical indications. However, the majority of the participants were undergoing a small number of procedures - orthopaedic surgery for either limb fracture or knee/hip arthroplasty and obstetric surgery (caesarean section) each represent approximately 25% of participants in the review, and peripheral vascular surgery represents almost 10% of participants. Although other procedures were represented, there is proportionally much less evidence for these.

While many trials were small (half had fewer than 100 participants), there were a number of large studies. Eight trials had more than 200 participants; three had more than 400 and one randomised over
1500 people. The three largest trials together accounted for almost 40% of the participants and were undertaken in the two areas most represented in the review: caesarean section and fracture surgery.

Because of the number of trials and the number of participants in caesarean section surgery, there are several substantial trials enrolling only women in the review and a majority of the women in these studies were obese. Since obese patients have higher rates of SSI (Althumairi 2016), these studies represent a population of particular interest. There were no studies involving children.

The magnitude of the negative pressure applied varied between trials and it is unclear whether different pressures produce different outcomes. Animal studies indicate that performance is similar across the range of pressures used in the included trials (Morykas 2001).

Another limitation in the studies was the variation in durations of follow-up, which ranged from the 10th postoperative day to 12 months after surgery. This is partly the result of the different level of follow-up appropriate to different surgical indications - for instance, the two largest trials were in lower limb fracture surgery and caesarean; longer follow-up is required for the former indication compared with the latter. However, in many cases short duration of follow-up is likely to have missed instances of SSI and other events occurring after discharge from hospital and may contribute to an under-estimation of SSI incidence in both the NPWT and standard dressing groups. Description of the criteria used for SSI diagnosis and other events also varied and was sometimes absent, meaning that the true comparability of events between trials is uncertain.

In some cases, we know that trials only assessed deep SSI. In particular, the largest study, the WHIST trial, only assessed deep SSI. Evidence from our exploratory analysis of trials reporting events which we know to be superficial or deep from the trial reports suggests that there may be a differential effect, with NPWT having a greater impact on superficial than deep infections. This would be important to explore given the proportionally greater clinical impact of deep infections.

Cost-effectiveness evidence was limited to trial-based evaluations using evidence from RCTs included in the effectiveness review. Inclusion of other relevant, high quality studies using model-based evaluations (drawing on different types of evidence) might change the cost-effectiveness evidence base. We did not, however, identify any such studies in the searches conducted for this review.

Finally, the included studies were limited, as although there was a wide geographical spread, almost all the studies were from higher income countries.

**Quality of the evidence**

The certainty of the evidence is moderate for the primary outcome of SSI but low for the primary outcomes of mortality and dehiscence. Evidence for most secondary outcomes is low or very low, due to risks of bias, small sample sizes, and wide confidence intervals that included both an effect and no effect or even a harm of the intervention. There is moderate-certainty evidence for quality of life in two indications and for pain in one indication. The evidence for cost-effectiveness is moderate certainty that NPWT is probably not cost-effective in fracture surgery and low or very low-certainty evidence that it may be cost effective in other indications.

**Limitations in study design, implementation and reporting**

We assessed risk of bias according to six domains: sequence generation, allocation concealment, blinding, selective outcome reporting, incomplete follow-up, and other potential biases. Our assessments of the risk of bias for a number of these domains found that all but three of the included studies, Chaboyer 2014; Gillespie 2015; WHIST 2019a, showed limitations in study design and implementation or reporting of these, which have been reported elsewhere in the review (Figure 3). We had particular concern, where blinding of the intervention is difficult or impossible, that there was subsequent uncertainty about allocation concealment and blinding of outcome assessment. We assumed the risk of performance bias to be unclear unless there was information to the contrary and we did not downgrade for high risk of performance bias alone. We did downgrade for high risk of bias in all other domains including detection bias where a substantial number of studies had a high risk. A number of studies used non-standard designs and it was not clear that these were adequately accounted for in the authors' analyses. Where this was the case, we did not include the studies in the meta-analyses we conducted but reported them separately; this included several studies which adopted an intra-individual (split-body) approach analogous to the 'split-mouth' design (Lesaffre 2009).

Another consideration was the involvement of industry in at least 23 (where reported) of the 44 included trials. Authors from the Karlakki 2013 trial disclosed conflicts of interest, with all benefiting from funding from the manufacturer of the NPWT device. There continues to be a concern with the issue of manufactuer sponsorship in studies of healthcare products. For example, a review of the effect of manufacturer involvement on studies of NPWT examined 24 studies where 19 had manufacturer involvement. Importantly, 18 of the 19 manufacturer-funded studies showed a positive effect for the manufacturer's product, while one was "impartial" (Kairinos 2014).

**Indirectness of evidence**

There was no indirectness, as the participants, interventions, and outcomes in the included studies were within the scope of the published review protocol. However, the evidence may not be directly relevant to children undergoing surgery. The high proportion of the participants in particular surgical indications may also be considered in assessing the relevance of the review to a particular population, although we did not find evidence of statistical differences in the effect estimates between different types of surgery.

**Unexplained heterogeneity or inconsistency of results**

Statistical heterogeneity was low for almost all of the outcomes we assessed and, although there was substantial clinical heterogeneity, subgroup analysis for the primary outcome suggests that this did not substantially impact on our results. There was also variation in aspects of clinical methods, with negative pressure devices, control dressings, length of follow-up and definition of SSI varying between studies but the low levels of statistical heterogeneity in our analyses - and visual inspection of forest plots - suggest that, with the exception of the outcome of skin blistering, these factors did not substantially impact on effect estimates. We consider that differences in study characteristics may be responsible for some of the variability which was observed, as larger trials with less risk of bias were not evenly distributed across...
surgical indications. We also consider that the type (severity) of SSI considered may be a potential source of heterogeneity, based on exploratory analyses, and that further research is required in this area. The type of SSI assessed and reported was not independent of the surgical indication evaluated and this needs to be taken into account when considering these results. Standardised methods for assessing and reporting pain in studies of NPWT are needed to improve the evidence base in this important outcome.

Imprecision of results
This update of our review included a large number of participants from newly identified trials. The confidence intervals for the primary outcome of SSI were not large but they are relatively wide in view of the number of participants now included in our analysis. Confidence intervals were wide in all of the other pooled outcomes, with most crossing 1, indicating uncertainty about whether NPWT was associated with an increase or reduction in outcomes. The imprecision was due to studies being underpowered to assess what in many cases were uncommon events. The low certainty of the evidence for most outcomes stems wholly or partly from this imprecision. However it may be that case that NPWT does have little or no effect on some of the outcomes assessed and that this is accurately reflected in confidence intervals which cross the line of no effect.

Publication bias
We feel confident that our comprehensive electronic searches, coupled with reference checking and cross-checking of trial registry searches, identified all existing, published RCTs addressing the review question, helping to limit bias in the review process. The funnel plot (Figure 4) includes all published studies that reported on SSI, but a failure to include results from any unpublished studies may have affected the plot’s relative symmetry. However, there are a large number of studies (88 ongoing trials) identified primarily through a search of the clinical trial registries. Whilst many of these are ongoing, or were scheduled to conclude only recently, there are a number which have concluded some time previously but have not yet been published or had results uploaded to the registry.

Potential biases in the review process
Clearly described procedures were followed to prevent potential bias in the review process. We conducted a careful literature search, and the methods we used were transparent and reproducible. It is possible that studies published in journals that were outside our search strategy may have been missed. We attempted to contact ten authors, but only two responded. Consequently, we may have underestimated the quality of some studies, simply because their publications did not include the information we required to assess study quality. We have already mentioned our concern about commercial funding, which may have influenced the results of our review. Three of the authors of previous versions of this review (Webster, Chaboyer, and Scuffham) were also investigators of studies included in the review (Chaboyer 2014; Gillespie 2015; Heard 2017). We were careful to ensure that the trials in which they were involved were critically appraised and that the data were extracted by others. None of the authors of this review has any conflicts of interest or associations with manufacturers of products included in the review. Differences between the published protocol, previous versions of this review (Webster 2011), and the methods used for this update have been described, and a rationale provided in the Differences between protocol and review section.

Agreements and disagreements with other studies or reviews
One early systematic review of NPWT included chronic and acute wounds and was published before seven of our included trials were undertaken (Ubbink 2008); it also included an earlier trial that we excluded from our review (Moisidis 2004), so results are not comparable. Our findings also differ from those of two other systematic reviews that evaluated the effectiveness of NPWT for incisional wounds. Important differences in the inclusion criteria account for the differences: the first review included 10 RCTs and five observational studies (Ingargiola 2013), and the second review included 33 publications, seven of which were RCTs, with the remainder consisting of a combination of non-comparative case series, comparative cohort studies, and comparative laboratory studies (Karlaakki 2013). The most recent systematic review of NPWT for closed surgical wounds included 10 trials and found a reduction in the rate of SSI and seroma in the NPWT group (Hyldig 2016). The review included one trial (Grauhan 2013), which we excluded because it was a quasi-RCT. It also included data that the author obtained from personal correspondence with the investigator of an unpublished trial, to which we had no access. More recent systematic reviews have focused on specific surgical indications (caesarean section, laparotomy) and have included non-randomised studies as well as RCTs (Sahebally 2018; Yu 2018). Although we have included many more RCTs, our conclusions are consistent with previous general reviews including RCTs; that is, that the quality of the studies may limit any firm conclusions regarding the relative effectiveness of NPWT and standard dressings while the results of further RCTs are likely to affect findings. This conclusion is consistent with evidence-based recommendations for the use of NPWT, which cover a range of applications, including NPWT for acute wounds (Krug 2011), but differs from the latest World Health Organization (WHO) guideline for the prevention of surgical site infection (WHO 2016). The WHO guideline states: “The panel suggests the use of prophylactic negative pressure wound therapy (pNPWT) in adult patients on primarily closed surgical incisions in high-risk wounds”. However, the recommendation was labelled “conditional” based on a number of issues, including low-quality evidence and the inclusion of non-RCT evidence. Finally, Willy 2017 published international multidisciplinary consensus recommendations suggesting the use of NPWT for a number of patient categories, including those at high risk of SSI. The review contained 100 studies (including RCTs, case series, editorials, cohort studies, technical reports, systematic reviews, and expert opinion), so the conclusions are highly uncertain. In addition, two employees of Acelity, NPWT device manufacturers, were involved in preparing the manuscript, and all of the authors of the review are consultants to an Acelity company (Willy 2017).

Authors’ conclusions
Implications for practice
NPWT for surgical wounds healing by primary closure probably reduces the rate of SSI compared with standard wound dressings. This conclusion is based on moderate-certainty evidence which was affected by high risk of bias in approximately half the included trials. Although there were some large, generally well-conducted studies included in the review, these were concentrated in a few surgical indications (caesarean section, fracture surgery, hip and knee arthroplasty and abdominal surgery). A concomitantly high
proportion of the participants were undergoing these procedures. Although we did not find evidence for substantial differences between the different types of surgery, this weighting should be borne in mind. There may be no or little difference in the occurrence of many important complications associated with surgical incisions, including mortality, dehiscence, reoperation, readmission to hospital and seroma (low-certainty evidence of no clear effect). The effects of NPWT on the incidence of haematoma, skin blisters and pain are uncertain. NPWT probably does not substantively alter quality of life scores following fracture surgery or caesarean section. Estimates of cost-effectiveness should be interpreted in the context of the healthcare system, the surgical indication and the uncertainty underlying the studies on which the modelling is based.

Implications for research

Use of NPWT for closed surgical incisions remains a topic of interest, with a very large number of records of ongoing studies identified in our review of clinical trials registries. In particular, a very large study of NPWT in caesarean section is underway (NCT03009110). Review updates will be required to include the data from trials as they become available. A living systematic review may be an appropriate undertaking given the rapidly increasing volume of literature and the number of currently ongoing studies, while sharing of individual participant data from studies would contribute to understanding of circumstances in which NPWT may be beneficial. If further new trials are undertaken - perhaps in surgical indications with relatively sparse data and a high incidence of SSI - the type (severity) of SSI should be recorded using recognised classifications. There is scope for research to use the data from the extant and ongoing studies to identify the types of SSI which may be most likely to be avoided if NPWT is used. Such research may also support the investigation of mechanisms which may underlie the potentially differential effects of NPWT on different types of SSI. The risk of SSI occurring varies across surgical indications and the impact of superficial and deep SSI differ both clinically and from a cost-effectiveness perspective; these factors should be considerations in further exploration of existing data and in any new primary research.

ACKNOWLEDGEMENTS

The authors would like to thank peer referees Nuala Livingstone and Ian Chetter who provided feedback on this update, and also Dirk Ubbink, Gill Worthy, Fausto Biancari, Susanne Cunliffe, Patricia Davies, Ian Schemilt, Liz McInnes and another referee who wished to remain anonymous, who provided feedback on previous versions of this review. They would also like to thank copy editors Jenny Bellorini, Elizabeth Royle and Lisa Winer for their contribution to previous versions of this review, and Anne Lethaby for copy editing this version of the review. We continue to be grateful to Joan Webster, Wendy Chaboyer and Karen Sherriff who were authors on previous versions of this review. We are especially grateful to Paul Scuffham who was also an author on previous versions of this review and has assisted with the interpretation of the economic evidence and provided comments on the review draft in this version. We are also grateful to the following people for their assistance with this update: Louise Hussey for assistance with screening and classification of ongoing studies; Jennifer Brown for assistance in screening of German language studies; Emma Connaughton for assistance with the plain language summary.

The National Health and Medical Research Council (NHMRC) provided funding for this review from its Centre of Research Excellence scheme, which funds one or more of the authors.
REFERENCES

References to studies included in this review

Bobkiewicz 2018 (published data only)

Chaboyer 2014 (published data only)

Crist 2014 (published and unpublished data)

Crist 2017 (published data only)

DiMuzio 2017 (published data only)

Engelhardt 2016 (published data only)

Galiano 2018 (published data only)


Giannini 2018 (published data only)

Gillespie 2015 (published data only)

Gombert 2018 (published data only)


Gunatilake 2017 (published data only)

Heard 2017 (published data only)


Howell 2011 (published and unpublished data)

Hussamy 2017 (published data only)

Hyldig 2019a (published data only)


Hyldig 2019b *(published data only)*


Javed 2018 *(published data only)*


Karlakki 2016 *(published data only)*


Keeney 2019 *(published data only)*


Kuncewitch 2017 *(published data only)*


Kwon 2018 *(published data only)*


Lee 2017a *(published data only)*


Lee 2017b *(published data only)*


Leon 2016 *(published data only)*


Lozano-Balderas 2017 *(published data only)*


Manoharan 2016 *(published data only)*


Martin 2019 *(published data only)*


Masden 2012 *(published data only (unpublished sought but not used))*


Murphy 2019 *(published data only)*

Chadi SA, Vogt K, Knowles S, Murphy PB, Van Koughnett JA, Brackstone M. Negative pressure wound therapy use to
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Pachowsky 2012 [published data only]

Pauser 2016 [published data only]

Pleger 2018 [published data only]

Ruhstaller 2017 [published data only]

Schmid 2018 [published data only]

Shen 2017 [published data only]

Shim 2018 [published data only]

Stannard 2012 [published data only]

Tanaydin 2018 [published data only]

Tanaydin V, Beugels J, Andriessen A, Sawor JH, Van der Hulst RRWJ. Randomized controlled study comparing...
References to studies excluded from this review

Albert 2012 (published data only)

Al-Inany 2002 (published data only)

Anderson 2014 (published data only)

Athanasiou 2018 (published data only)

Banasiewicz 2013 (published data only)

Bi 2017 (published data only)

Bondokji 2011 (published data only)

Braakenburg 2006 (published data only)

Chang 2018 (published data only)

Chiang 2017 (published data only)

**Chio 2010 (published and unpublished data)**


**Costa 2018 (published only data)**


Cook R, Thomas V, Martin R. Negative pressure dressings are no better than standard dressings for open fractures. *BMJ Open* 2019; 364:k4411.


**Dorafshar 2012 (published only data (unpublished sought but not used))**


**Eisenhardt 2012 (published only data)**


**Erne 2018 (published only data)**


**Fleming 2018 (published only data)**


**Frazeet 2018 (published only data)**


**Grauhan 2013 (published data only)**


**Hu 2009 (published data only)**


**Johannesson 2008 (published data only)**


**Joos 2015 (published data only)**


**Kim 2007 (published data only)**


**Krishnamoorthy 2012 (published data only)**


**Li 2016 (published data only)**


**Llanos 2006 (published and unpublished data)**


**Moisidis 2004 (published data only)**

**Mouës 2004** *(published data only)*


**Mouës 2007** *(published data only)*


**Muller-Sloof 2018** *(published data only)*


**Pellino 2014** *(published data only)*


**Petkar 2012** *(published data only)*


**Rahmanian-Schwarz 2012** *(published data only)*


**Sinha 2016** *(published data only)*


**Stannard 2006** *(published data only)*


**Svensson-Bjork 2018** *(published data only)*


**Trofa 2019** *(published data only)*


**Visser 2017** *(published data only)*


**Walker 2018** *(published data only)*


**Yu 2017** *(published data only)*


**Zotes 2015** *(published data only)*


**References to studies awaiting assessment**

**Nagata 2018** *(published data only)*


**NCT00654641** *(unpublished data only)*

References to ongoing studies

ACTRN12615000175572 {unpublished data only}
  . Do suction assisted negative pressure dressings reduce the incidence of surgical site infections after abdominal surgery: a randomized controlled trial. anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12615000175572 (first received 23 February 2015).

ACTRN1261800026224p {unpublished data only}

ACTRN12618001611213 {published data only}
  . Does the use of negative pressure wound therapy reduce the rate of post operative wound infection after bowel surgery. The effect of PICO dressings on surgical site infection following bowel resection: a randomised controlled trial. apps.who.int/trialsearch/Trial2.aspx?TrialID=ACTRN12618001611213 (first received 28 September 2018).

ACTRN12618002006224 {unpublished data only}

ChiCTR -IOR-15006439 {unpublished data only}

DRKS00006199 {unpublished data only}

DRKS00011033 {unpublished data only}

DRKS00015136 {unpublished data only}
  . Negative pressure wound therapy (NPWT) on closed incisions to prevent surgical site infection in HPB-surgery. apps.who.int/trialsearch/Trial2.aspx?TrialID=DRKS00015136 (first received 19 February 2019).

Gillespie 2016 {unpublished data only}

ISRCTN12702354 {unpublished data only}

ISRCTN31224450 {published data only}

ISRCTN55305726 {unpublished data only}

Jorgensen 2018 {published data only}

JPRN000030936 {unpublished data only}
  . A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporarily diverting stoma. upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000030936 (first received 22 January 2018).

KCT0004063 {unpublished data only}

Masters 2018 {published data only}

Mihaljevic 2015 {published data only}
The use of the Prevena™ incision management system on post-surgical cesarean section incisions. clinicaltrials.gov/ct2/show/NCT01450631 (first received 12 October 2011).

Prophylactic treatment of high-risk patients with cardiovascular implantable electronic devices (CIED) with continuous in-situ ultra high-dose antibiotics (CITA) under regulated negative pressure-assisted wound therapy (RNPT). clinicaltrials.gov/ct2/show/record/NCT01770067 (first received 17 January 2013).

Intervention for postpartum infections following caesarean section (APIPCS). clinicaltrials.gov/ct2/show/NCT01891006 (first received 2 July 2013).

Negative pressure wound therapy to reduce surgical site infection. clinicaltrials.gov/show/NCT01905397 (first received 23 July 2013).

PICO above incisions after vascular surgery. clinicaltrials.gov/ct2/show/NCT01913132 (first received 31 July 2013).

Negative pressure wound therapy for prevention of poststernotomy infection. clinicaltrials.gov/ct2/show/NCT02020018 (first received 24 December 2013).

Study to compare negative pressure wound therapy or standard dressings after orthopedic surgery (PICO). clinicaltrials.gov/ct2/show/NCT02064270 (first received 17 February 2014).

Prevena incisional negative pressure wound therapy in re-operative colorectal surgery. clinicaltrials.gov/ct2/show/NCT02509260 (first received 27 July 2015).

Effects of preventive negative pressure wound therapy with PICO on surgical wounds of kidney transplant patients. clinicaltrials.gov/ct2/show/NCT02558764 (first received 24 September 2015).

Prophylactic incisional care in obese women at cesarean (PICO-C). clinicaltrials.gov/ct2/show/NCT02578745 (first received 19 October 2015).

A comparative study to assess the prevention of surgical site infection (SSI’s) in revision total joint arthroplasty patients treated with single-use negative pressure wound therapy (PICO) or standard care dressings (AQUACEL Ag surgical dressing). clinicaltrials.gov/ct2/show/NCT02664168 (first received 26 January 2016).
NCT02682316 {unpublished data only}  
. Negative pressure wound therapy in post-operative incision management. clinicaltrials.gov/ct2/show/NCT02682316 (first received 15 February 2016).

NCT02790385 {unpublished data only}  

NCT02799667 {unpublished data only}  

NCT02892435 {unpublished data only}  
. Prevena incision management system vs conventional management for wound healing. clinicaltrials.gov/ct2/show/NCT02892435 (first received 8 September 2016).

NCT02901405 {unpublished data only}  
. NPWT in soft tissue sarcoma surgery. clinicaltrials.gov/ct2/show/NCT02901405 (first received 15 September 2016).

NCT02901613 {unpublished data only}  
. Prophylactic post-cesarean incisional negative-pressure wound therapy in morbidly obese patients. clinicaltrials.gov/ct2/show/NCT02901613 (first received 15 September 2016).

NCT02926924 {unpublished data only}  
. Prophylactic application of an incisional wound vac to prevent wound complications in obese spine surgery patients. clinicaltrials.gov/ct2/show/NCT02926924 (first received 6 October 2016).

NCT02954835 {unpublished data only}  

NCT02967627 {unpublished data only}  

NCT03000010 {unpublished data only}  
. Wound Vac bandage comparison after spinal fusion (VV). clinicaltrials.gov/ct2/show/NCT03000010 (first received 21 December 2016).

NCT03009110 {unpublished data only}  

NCT03010137 {unpublished data only}  

NCT03021668 {unpublished data only}  
. Comparison between wound vacuum dressing and standard closure to reduce rates of surgical site infections. clinicaltrials.gov/ct2/show/NCT03021668 (first received 16 January 2017).

NCT03061903 {unpublished data only}  

NCT03069885 {unpublished data only}  
. INPW in immediate breast reconstruction. clinicaltrials.gov/ct2/show/record/NCT03069885 (first received 3 March 2017).

NCT03082664 {unpublished data only}  
. Negative pressure wound therapy to prevent wound complications following cesarean section in high risk patients. clinicaltrials.gov/ct2/show/NCT03082664 (first received 17 March 2017).

NCT031144726 {unpublished data only}  
. RCT on NPWT for incisions following major lower-limb amputation to reduce surgical site infection. clinicaltrials.gov/ct2/show/NCT031144726 (first received 9 May 2017).

NCT03175718 {unpublished data only}  

NCT03180346 {unpublished data only}  
. A prospective, randomized, comparative study to assess the prevention of surgical site infection (SSIs) in revision total joint arthroplasty patients treated with single-use negative pressure wound therapy (PICO) or standard care dressings (AQUACEL Ag surgical dressing). clinicaltrials.gov/ct2/show/NCT03180346 (first received 8 June 2017).

NCT03250442 {unpublished data only}  
. Evaluating the outcomes for incisional application of negative pressure for nontraumatic amputations. clinicaltrials.gov/ct2/show/NCT03250442 (first received 15 August 2017).

NCT03269968 {unpublished data only}  
. Use of negative pressure wound therapy in morbidly obese women after cesarean delivery. clinicaltrials.gov/ct2/show/record/NCT03269968 (first received 1 September 2017).

NCT03274466 {unpublished data only}  

NCT03321799 {unpublished data only}  
. Comparison of negative pressure wound therapy versus conventional dressings for the prevention of wound complications after revision THA. clinicaltrials.gov/ct2/show/NCT03321799 (first received 26 October 2017).
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

NCT03345771 (unpublished data only)
- Antimicrobial barrier dressing versus closed-incision negative pressure therapy in the obese primary total joint arthroplasty. clinicaltrials.gov/ct2/show/NCT03345771 (first received 17 November 2017).

NCT03346694 (unpublished data only)
- Reducing surgical site infection rates using an alternative sternal dressing. clinicaltrials.gov/ct2/show/NCT03346694 (first received 17 November 2017).

NCT03395613 (unpublished data only)
- Negative pressure incision management system in infrainguinal vascular surgery. clinicaltrials.gov/ct2/show/NCT03395613 (first received 10 January 2018).

NCT03402945 (unpublished data only)

NCT03414762 (unpublished data only)
- PICO negative pressure wound therapy in obese women undergoing elective cesarean delivery. clinicaltrials.gov/ct2/show/NCT03414762 (first received 30 January 2018).

NCT03458663 (unpublished data only)
- Randomized trial comparing Prevena and ActiV.A.C. system to conventional care after Bascom’s cleft lift surgery. clinicaltrials.gov/ct2/show/NCT03458663 (first received 8 March 2018).

NCT03460262 (unpublished data only)

NCT03512470 (unpublished data only)
- Clinical study on the prevention of surgical wound complications for aneurysmal thoracic-abdominal aortic pathology using the "PREVENA" system (TVAC). clinicaltrials.gov/ct2/show/NCT03512470 (first received 20 April 2018).

NCT03576222 (unpublished data only)
- Preventive PICO on surgical wounds after large incisional hernia repair. clinicaltrials.gov/ct2/show/NCT03576222 (first received 9 June 2018).

NCT03632005 (unpublished data only)
- Negative pressure wound therapy vs. sterile dressing for patients undergoing thoracolumbar spine surgery. ClinicalTrials.gov/show/NCT03632005 (first received 08 August 2018).

NCT03688438 (unpublished data only)
- WoundVac in obese patients undergoing lumbar surgery. ClinicalTrials.gov/show/NCT03688438 (first received 26 September 2018).

NCT03700086 (unpublished data only)
- Efficacy of a disposable negative wound pressure device in reducing the incidence of wound infection after HPB surgery. ClinicalTrials.gov/show/NCT03700086 (first received 15 May 2018).

NCT03716687 (unpublished data only)
- Prophylactic negative pressure wound therapy for high risk laparotomy wounds. A randomized prospective clinical trial. clinicaltrials.gov/ct2/show/NCT03716687 (first received 21 October 2018).

NCT03777357 (unpublished data only)
- Evaluation of closed incision negative pressure dressing (PREVENA) to prevent lower extremity amputation wound complications. ClinicalTrials.gov/show/NCT03777357 (first received 10 December 2018).

NCT03781206 (unpublished data only)
- Negative pressure wound therapy for wound healing after stoma reversal. ClinicalTrials.gov/show/NCT03781206 (first received 13 December 2018).

NCT03816293 (unpublished data only)
- SuPress SSI - single use negative pressure wound therapy (NPWT) to reduce surgical site infections. clinicaltrials.gov/ct2/show/NCT03816293 (first received 22 January 2019).

NCT03820219 (unpublished data only)

NCT03871023 (unpublished data only)
- Prophylactic negative wound therapy in laparotomy wounds. clinicaltrials.gov/ct2/show/NCT03871023 (first received 07 March 2019).

NCT03886818 (unpublished data only)
- Efficacy of negative pressure wound therapy after total ankle arthroplasty. ClinicalTrials.gov/show/NCT03886818 (first received 20 March 2019).

NCT03900078 (unpublished data only)

NCT03905213 (unpublished data only)
- Prevention of surgical wound infection. clinicaltrials.gov/show/nct03905213 (first received 20 March 2019).

NCT03935659 (published data only)
- Negative pressure wound therapy for surgical site infection prevention in common femoral artery exposure. ClinicalTrials.gov/show/NCT03935659 (first received 25 April 2019).
NCT03948412 (unpublished data only)
  . Negative pressure wound therapy (PREVENA) versus standard dressings for incision management after renal transplant incision management with Prevena after renal transplant (IMPART) trial. clinicaltrials.gov/ct2/show/NCT03948412 (first received 05 May 2019).

Nguyen 2017 (published data only)

NL6488 (unpublished data only)

NTR6481 (unpublished data only)
  . Randomized controlled clinical trial incisional NPWT versus sterile dressings for surgical wounds after arterial vascular surgery. www.trialregister.nl/trialreg/admin/rctview.asp?TC=6481 (first received 1 June 2017).

Sandy-Hodgetts 2017 (unpublished data only)

SUNRISE 2017 (published data only)

TCTR20170331001 (unpublished data only)

Additional references

ABS 2014

Acosta 2017

Allen 2011

Althumairi 2016

Andersson 2010

Apostoli 2008
  Apostoli A, Caula C. Pain and basic functional activities in a group of patients with cutaneous wounds under V.A.C therapy in hospital setting. Professioni infermieristiche 2008; 61(3):158-64.

Banwell 2003

Baronski 2008

Berrios-Torres 2017

Blume 2010

Brazier 2004

Chen 2017

Citak 2010
  Citak M, Backhaus M, Meindl R, Muhr G, Fehmer T. Rare complication after VAC-therapy in the treatment of deep sore...
ulcers in a paraplegic patient. *Archives of Orthopaedic Trauma Surgery* 2010; 130:1511-4.

**Coulthard 2010**


**Craig 2013**


**CRD 2013**

Centre for Reviews and Dissemination. NHS EED search filters. www.crd.york.ac.uk/crddweb/s (accessed prior to 2 April 2020).

**De Lissovoy 2009**


**De Vries 2016**


**DeCarbo 2010**


**Dragu 2011**


**Drummond 2005**


**Dumville 2015**


**Enroth 2008**


**Expert Working Group 2008**


**FDA 2009a**


**FDA 2009b**


**Fleischmann 1997**


**Gabriel 2014**


**Glass 2014**


**Gregor 2008**


**Gupta 2016**


**Gurtner 2008**


**Heuser 2005**


**Hope 2017**


**Hurd 2014**

Hurd T, Trueman P, Rossington A. Use of a portable, single-use negative pressure wound therapy device in home care patients.
with low to moderately exuding wounds: a case series. Ostomy/Wound Management 2014; 60:30-6.

**Husereau 2013**


**Hyldig 2016**


**Ingargiola 2013**


**Kairinos 2009**


**Kairinos 2014**


**Kanakaris 2007**


**Kantak 2016**


**Karabacak 2016**


**Karlaekki 2013**


**Kenig 2012**


**Keskin 2008**


**Kharroubi 2007**


**Kloth 2002**

Kloth LC. 5 questions and answers about negative pressure wound therapy. *Advances in Skin and Wound Care* 2002; 15:226-9.

**Krug 2011**


**Lancet Commission on Global Surgery 2015**


**Lefebvre 2019**


**Lesaffre 2009**


**Li 2019**


**Maehara 2017**


**Malmström 2014**

Mandal 2007

Morykwas 1997

Morykwas 2001

NICE 2013

NICE 2018

Olbrecht 2006

Ousey 2014

Pellino 2015

Petzina 2010

Review Manager 2014 [Computer program]

Rodero 2010

Sahebally 2018

Sandy-Hodgetts 2015

Schünemann 2019a

Schünemann 2019b

Shemilt 2019

Shmueli 1999

SIGN 2019

Sjogren 2011

Stannard 2009
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

**Steenvoorde 2009**

**Stevens 2009**

**Tanaka 2016**

**Toeg 2017**

**Tuffaha 2015**

**Ubbink 2008**

**Vikatmaa 2008**

**Waisbren 2010**

**Webb 2017**

**WHO 2016**

**Willy 2017**

**Wilson 1986**

**Winfield 2016**

**Xia 2014**

**Yu 2018**

**References to other published versions of this review**

**Webster 2011**

**Webster 2014**

**Webster 2019**

* Indicates the major publication for the study
### Characteristics of included studies [ordered by study ID]

**Bobkiewicz 2018**

#### Study characteristics

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** Not reported
- **Follow-up period:** Not reported
- **Sample size estimate:** Not reported
- **ITT analysis:** yes, **number randomised:** 30, **number analysed:** 30
- **Funding:** Not reported
- **Preregistration:** Not reported

**Participants**
- **Location:** Poland
- **Intervention group:** 15, **control group:** 15
- **Mean age:** not reported
- **Inclusion criteria:** People undergoing surgery for stoma reversal
- **Exclusion criteria:** Not reported

**Interventions**
- **Aim/s:** to investigate the efficiency of closed incision negative pressure wound therapy (ciNPWT) portable system on the incidence rate of SSI after stoma reversal surgery
- **Group 1 (NPWT) intervention:** closed incision negative pressure wound therapy portable system changed every 3 days or earlier in case of unsealed system or absorbed entirely with wound exudate
- **Group 2 (control) intervention:** standard dressing changed every day
- **Study date/s:** Not reported

**Outcomes**
- **SSI**
- **Wound dehiscence**
- **Haematoma**

**Validity of measure/s:** Superficial SSI was defined according to definition of Centers for Disease Control and Prevention.

**Time points:** Not reported

**Notes**
- Abstract only

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
</tbody>
</table>
### Bobkiewicz 2018 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>No information provided but, for both participants and personnel, frequency of dressing changes differed systematically meaning blinding was unlikely to be successful</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>All randomised participants included in analysis for SSI</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Partial reporting of some outcomes</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Insufficient information to determine if there was additional risk of bias</td>
</tr>
</tbody>
</table>

### Chaboyer 2014

#### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study design:</strong> randomised controlled trial</td>
</tr>
<tr>
<td><strong>Study grouping:</strong> parallel</td>
</tr>
<tr>
<td><strong>Ethics and informed consent:</strong> yes</td>
</tr>
<tr>
<td><strong>Follow-up period:</strong> 6 weeks</td>
</tr>
<tr>
<td><strong>Sample size estimate:</strong> pilot study</td>
</tr>
<tr>
<td><strong>ITT analysis:</strong> yes, <strong>number randomised:</strong> 92, <strong>number analysed:</strong> 87</td>
</tr>
<tr>
<td><strong>Funding:</strong> non-industry</td>
</tr>
<tr>
<td><strong>Preregistration:</strong> yes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Location:</strong> Queensland, Australia</td>
</tr>
<tr>
<td><strong>Intervention group:</strong> n = 35, <strong>control group:</strong> n = 35</td>
</tr>
<tr>
<td><strong>Mean age: intervention group</strong> = 30.6 years (IQR 5.5), <strong>control group</strong> = 30.7 years (IQR 5.0)</td>
</tr>
<tr>
<td><strong>Inclusion criteria:</strong> booked for elective caesarean section; pre-pregnancy BMI ≥ 30; able to provide consent</td>
</tr>
<tr>
<td><strong>Exclusion criteria:</strong> women whose condition changed to require urgent caesarean section; previous participation in the trial; existing infection</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Aim/s:</strong> to assess the feasibility of a definitive RCT to test the effectiveness and safety of prophylactic NPWT in obese women after caesarean section</td>
</tr>
<tr>
<td><strong>Group 1 (NPWT) intervention:</strong> PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days or longer if drainage continued, unless soiled or dislodged.</td>
</tr>
<tr>
<td><strong>Group 2 (control) intervention:</strong> Comfeel dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days or longer if drainage continued, unless soiled or dislodged.</td>
</tr>
<tr>
<td><strong>Study date/s:</strong> July 2012 to April 2014</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>• surgical site infection</strong></td>
</tr>
</tbody>
</table>
Chaboyer 2014 (Continued)

- type of SSI
- hospital readmission
- dehiscence; blisters
- haematoma

Validity of measure/s: CDC definitions and criteria for superficial, deep, and organ/space SSI were used for the primary outcome and SF-12 for quality of life.

Time points: 1, 2, 3, and 4 weeks postsurgery

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;computer generated 1:1 ratio with blocks of randomly varying sizes&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>A centralised web-based randomised service was accessed.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>There was no information on this.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Quote &quot;a separate person ... assessed the outcome and was blinded to the allocation&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>2 women in the intervention group and 3 in the control group were lost to follow-up, but an ITT analysis was used.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol registered on ANZCTR</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>

Crist 2014

Study characteristics

Methods

Study design: randomised controlled trial
Study grouping: parallel
Ethics and informed consent: ethics approved and consent obtained
Follow-up period: 12 months
Sample size calculation: not stated
ITT analysis: available-case analysis
Funding: non-industry
Crist 2014 (Continued)

Preregistration: yes

Participants

Location: USA

Intervention group: n = 55, control group: n = 60

Mean age: intervention group = 47.2 years (SD 19.6), control group = 48.3 years (SD 20.1). Data extracted from results section of ClinicalTrials.gov (NCT00635479)

Inclusion criteria: patients that had undergone an open surgical exposure for hip, pelvis, or acetabular fracture

Exclusion criteria: none stated

Interventions

Aim/s: to determine the effectiveness of using NPWT over primarily closed surgical incisions used for open reduction and internal fixation of hip, pelvis, and acetabular fracture surgery

Group 1 (NPWT) intervention: quote "negative pressure dressing applied over the primarily closed incision steriley in the operating room. NPWT was left on for 2 days or longer if drainage continued".

Group 2 (control) intervention: quote "standard gauze dressing"; description not provided

Study date/s: not provided

Outcomes

• infection
• LOS
• total serious adverse events

Validity of measure/s: not provided

Time points: followed for 12 months

Notes

Conference abstract. Additional information provided by the investigator and from a search of ClinicalTrials.gov (NCT00635479).

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)      | Low risk           | Evidence: quote "computer randomization"
|                                                  |                    | Comment: correspondence with author                                                   |
| Allocation concealment (selection bias)          | Unclear risk       | Evidence: quote "opaque sealed envelope opened in the OR"
|                                                  |                    | Comment: correspondence with author; but unclear whether envelopes were sequentially numbered? |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk | Insufficient information                                                             |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk           | Evidence: quote "yes"
|                                                  |                    | Comment: correspondence with author                                                   |
| Incomplete outcome data (attrition bias)         | High risk          | Evidence: quote "55 patients randomised to the NPWT group and 60 patients randomised to the standard dressing group. The NPWT group included 49 patients and the gauze group included 42 patients that completed the 12 month follow-up."
|                                                  |                    | Comment: 10.9% participants in NPWT group and 30.0% of those in control group were lost to follow-up. |
Selective reporting (reporting bias)  Unclear risk  
**Comment:** protocol registered on ClinicalTrials.gov with identifier (NCT00635479). Expected outcomes were reported in the abstract, but other outcomes specified in the protocol were not reported (such as total serious adverse events). These may be included when the full trial is published.

Other bias  Unclear risk  
**Comment:** no other biases detected

### Crist 2017

#### Study characteristics

**Methods**

- **Study design:** randomised controlled trial  
- **Study grouping:** parallel  
- **Ethics and informed consent:** ethics approved and consent obtained  
- **Follow-up period:** not stated  
- **Sample size calculation:** not stated  
- **ITT analysis:** number randomised: 71, number analysed: 66  
- **Funding:** no external funding  
- **Preregistration:** not stated

**Participants**

- **Location:** USA  
- **Intervention group:** n = 33, **control group:** n = 33  
- **Mean age (range):** intervention group = 44 (19 to 87), control group = 43 (18 to 92)  
- **Inclusion criteria:** patients at least 18 years of age with an acetabular fracture that required ORIF  
- **Exclusion criteria:** less than 18 years old; pregnant; unable to provide informed consent; or if their injury could be treated nonoperatively or percutaneously

**Interventions**

- **Aim/s:** to determine if NPWT decreased the risk of deep infection when used over primarily closed surgical incisions for acetabular fracture ORIF  
- **Group 1 (NPWT) intervention:** NPWT (VAC; KCI, San Antonio, TX) over their surgically closed incision  
- **Group 2 (control) intervention:** a standard postoperative (dry gauze) dressing  
- **Study date/s:** March 2008 to September 2012

**Outcomes**

- **Validity of measure/s:** the clinical diagnosis of infection was determined from the drainage at the operative site in addition to 1 or more of the classic signs and symptoms of inflammation (redness, heat, swelling, pain). Deep infections were those that required operative debridement. Bacteriological cultures obtained at the time of operative debridement.

- **Time points:** 10 to 21 days, 6 weeks, 12 weeks, and every 6 to 8 weeks thereafter until bony union occurred

**Notes**

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Selective reporting (reporting bias)</strong></td>
<td>Unclear risk</td>
<td></td>
</tr>
</tbody>
</table>
**Comment:** protocol registered on ClinicalTrials.gov with identifier (NCT00635479). Expected outcomes were reported in the abstract, but other outcomes specified in the protocol were not reported (such as total serious adverse events). These may be included when the full trial is published.  
| **Other bias** | Unclear risk |  
**Comment:** no other biases detected  

### Crist 2017 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: &quot;we did not blind the patients and staff to treatment group.&quot; Comment: No blinding of personnel or participants</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Approximately 7% of participants were lost to follow-up; reasons for losses were not reported. No more information provided</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
</tbody>
</table>

### DiMuzio 2017

#### Study characteristics

<table>
<thead>
<tr>
<th>Method Type</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design</td>
<td>randomised controlled trial</td>
</tr>
<tr>
<td>Study grouping</td>
<td>parallel</td>
</tr>
<tr>
<td>Ethics and informed consent</td>
<td>not provided</td>
</tr>
<tr>
<td>Follow-up period</td>
<td>30 days</td>
</tr>
<tr>
<td>Sample size calculation</td>
<td>not stated</td>
</tr>
<tr>
<td>ITT analysis: number randomised: number analysed:</td>
<td>120, 120</td>
</tr>
<tr>
<td>Funding</td>
<td>not stated</td>
</tr>
<tr>
<td>Preregistration</td>
<td>not stated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Participants</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location</td>
<td>Philadelphia, USA</td>
</tr>
<tr>
<td>Intervention group (high risk): n = 59, control group (high risk): n = 60, (3 arms: low risk: n = 21)</td>
<td></td>
</tr>
<tr>
<td>Mean age</td>
<td>not provided</td>
</tr>
<tr>
<td>Inclusion criteria</td>
<td>femoral incisions closed primarily following elective vascular surgery</td>
</tr>
<tr>
<td>Exclusion criteria</td>
<td>none stated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aim/s:</td>
<td>to prospectively evaluate negative pressure therapy as a means to decrease wound complications and associated healthcare costs</td>
</tr>
<tr>
<td>Group 1 (NPWT) intervention</td>
<td>NPWT</td>
</tr>
<tr>
<td>Group 2 (control) intervention</td>
<td>standard gauze dressing</td>
</tr>
<tr>
<td>Study date/s:</td>
<td>not provided</td>
</tr>
</tbody>
</table>
DiMuzio 2017 (Continued)

Outcomes
- infection
- LOS
- reoperation
- readmission

Validity of measure/s: not provided

Time points: over 30 days

<table>
<thead>
<tr>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
</tr>
<tr>
<td>Other bias</td>
</tr>
</tbody>
</table>

Engelhardt 2016

Study characteristics

Methods
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** ethics approved and consent obtained
- **Follow-up period:** primary endpoint of the study was the occurrence of SSIs
- **Sample size calculation:** not stated
- **ITT analysis:** no number randomised: 141, number analysed: 132
- **Funding:** not stated
- **Preregistration:** not stated
Participants

Location: Germany

Intervention group (high risk): n = 64, control group (high risk): n = 68

Mean age (range): intervention group = 72 (64 to 75), control group = 70 (60 to 78)

Inclusion criteria: all consecutive patients scheduled for vascular surgery with a femoral cutdown; age > 18 years and the need for an open, nonemergency surgical procedure for peripheral arterial disease or aneurysm involving the femoral artery using a longitudinal femoral cutdown in the groin

Exclusion criteria: dementia (not capable of informed consent) and declining to participate

Interventions

Aim/s: to determine whether closed-incision negative pressure therapy is able to reduce SSI rate in the groin after vascular surgery

Group 1 (NPWT) intervention: NPWT was applied on the closed skin intraoperatively. The system is comprised of a therapy unit containing a pump with a 45-millilitre canister delivering a continuous negative pressure of 125 mmHg and a self adhesive dressing with a foam bolster that manifolds the negative pressure to the incision area. A special polyester interface layer protects the skin from direct contact with the foam bolster, while at the same time allowing delivery of negative pressure and fluid removal.

Group 2 (control) intervention: absorbent adhesive dressing

Study date/s: January 2012 and October 2014

Outcomes

• infection

Validity of measure/s: all wounds were documented with photos and classified according to the Szilagyi classification. Grade I infections only involved the skin (dermal infection); grade II extended to the subcutaneous tissue without reaching the vessels; and grade III finally involved the artery or bypass.

Time points: 5th postoperative day and 6 weeks after surgery

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Random assignment of the participants to the 2 treatment groups was performed according to an external randomisation sequence.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Sealed randomisation envelopes were provided by an external institution. On eligibility confirmation, the sequential randomisation envelope was opened, and the assignment was allocated.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Quote: “all wounds were documented by photography and classified according to the Szilagyi classification”.</td>
</tr>
<tr>
<td>Comment: unclear whether outcome assessment was blinded</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>ITT not used; 141 participants were randomised, and 132 completed the study; 9 participants (6%) did not complete follow-up due to urgent reoperation or death during follow-up.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Planned outcomes reported</td>
</tr>
</tbody>
</table>
Engelhardt 2016 (Continued)

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
<th>None detected</th>
</tr>
</thead>
</table>

Galiano 2018

**Study characteristics**

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** intra-individual (split person)
- **Ethics and informed consent:** ethics approval was first obtained at the institution of the principal investigator (R.D.G.), institutional review board at Northwestern University, Chicago, (STU00062369 - 5/22/2012), and at each of the other sites. Before entry into the study, all patients signed informed consent forms.
- **Follow-up period:** 21 days (90 days)
- **Sample size estimate:** 197 patients would be required to detect an absolute difference of 10% in the complication rate between bilateral breasts treated either with NPWT or SC dressings, assuming 20% of wounds treated with SC dressings and 10% of wounds treated with NPWT develop a healing complication (a 50% reduction) and that there were 26% discordant pairs. This is on the basis of a 2-sided McNemar’s test at the α = 5% level of significance and 80% power. The sample size was rounded up to 200.
- **ITT analysis:** yes, **number randomised:** 200, **number analysed:** 199
- **Funding:** Smith & Nephew Wound Management, Inc.
- **Preregistration:** registered under the name "A prospective, randomised, intra-patient, comparative, open, multi-centre study to evaluate the efficacy of a single-use negative pressure wound therapy (NPWT) System on the prevention of postsurgical incision healing complications in patients undergoing reduction mammaplasty," ClinicalTrials.gov identification number NCT01640366 (http://clinicaltrials.gov/show/NCT1640366)

**Participants**

- **Location:** Multi-centre across 6 sites – United States (n = 3), France (n = 1), South Africa (n = 1), Netherlands (n = 1)
- **Intervention group:** n = 199, **control group:** n = 199
- **Mean age:** 35.7 (18–65), **intervention group:** 35.7 (18–65), **control group:** 35.7 (18–65)
- **Inclusion criteria:** women aged > 18 years who had undergone elective surgery for bilateral reduction mammaplasty and having postsurgical incisions of similar length on each breast were included in the study.
- **Exclusion criteria:** presurgical – pregnancy or lactation, using steroids or other immune modulators known to affect healing, history of radiation of the breast, tattoos in the area of the incision, skin conditions such as cutis laxa that would result in poor healing or widened scars, patients with a known significant history of scar problems (i.e. hypertrophic scarring or keloids), and known allergies to product components. Postsurgical – incisions still actively bleeding and incisions > 12 inches (30 cm) maximum linear dimension

**Interventions**

- **Aim/s:** To assess the efficacy and cost-effectiveness of the Single-Use Negative Pressure Wound Therapy (NPWT) system (PICO) with regard to the reduction of postsurgical incision healing complications during the immediate postoperative treatment phase, and to assess the medium-term aesthetic appearance and quality of the resultant scar, in patients undergoing reduction mammaplasty, compared with standard care

**Group 1 (NPWT intervention):** The NPWT device was PICO (Smith & Nephew Medical Limited, Hull, United Kingdom), a portable, single-use (disposable after 7 days) NPWT system delivering -80mm Hg (nominal) negative pressure to the wound surface. Treatment commenced on day 0 and lasted up to 14 days. The pump has a 7-day lifespan, and the associated PICO NPWT dressing is left in place up to 7 days. Each PICO kit comes with 2 NPWT dressings, so, according to the needs of the individual patient and the level of exudate, dressing changes were permitted before 7 days at the investigator’s clinical judgement. Participating physicians were advised to discontinue treatment on day 14 and return patients to SC (see below) if the incision was still not closed at this time point.

**Group 2 (control intervention):** 3M STERI-Strip (3M Health Care, St. Paul, Minn.). STERI-Strips were placed along the entire axis of the incision and covered with a dry gauze dressing or nonadherent dressing. Alternatively, investigators could use a nonadherent dry dressing if STERI-Strips were not deemed appropriate by the principal investigator at that site.
Galiano 2018 (Continued)

Study date/s: 1 June 2012 to 9 April 2014

Outcomes
- SSI
- Dehiscence
- Haematoma
- Seroma

Validity of measure/s: N/R
Time points: 21 days after surgery

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote “Treatment randomization was within-patient (i.e., right or left breast) via a central Web site, <a href="http://www.SealedEnvelope.com%E2%80%9D">www.SealedEnvelope.com”</a>.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Computerised generation of randomisation sequence</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote “Treatment randomization was within-patient (i.e., right or left breast) via a central Web site, <a href="http://www.SealedEnvelope.com%E2%80%9D">www.SealedEnvelope.com”</a>.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Centralised service used for allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote &quot;Treatment could not be blinded&quot;.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: Participants and personnel could not be blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote &quot;Treatment could not be blinded&quot;.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: This was stated as a limitation for personnel and there was no information that another individual performed the outcome assessment.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Comment: Low attrition rate; only one participant was not included in the analysis</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: All prespecified outcomes reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Comment: Unclear if the analysis took account of the paired data resulting from the split-person design</td>
</tr>
</tbody>
</table>

Giannini 2018

Study characteristics

Methods
- Study design: randomised controlled trial
- Study grouping: parallel
- Ethics and informed consent: ethics approved and consent obtained
- Follow-up period: 7 days
Sample size estimate: power analysis based on 80% chance of detecting decrease in ASEPSIS score from 10 to 5

ITT analysis: per protocol analysis, number randomised: 110, number analysed: 100

Funding: Smith & Nephew

Preregistration: not reported

Participants

Location: Italy (single site)

Intervention group: 58, control group: 52

Mean age: intervention group 66.0 (8.9), control group 66.8 (11.5)

Inclusion criteria: patients aged 40–80 years old, indicated for hip or knee revision performed through the same surgical approach of primary surgery (hip: direct lateral approach, knee: medial parapatellar approach)

Exclusion criteria: patients undergoing revision surgery due to periprosthetic fracture or prosthetic joint infection, antibiotic therapy within the last month; declined to take part in the study

Interventions

Aim/s: To compare the effectiveness in wound healing of negative pressure wound therapy versus a standard dressing in patients who underwent hip or knee revision surgery

Group 1 (NPWT) intervention: single use, 80mmHg sub-atmospheric NPWT dressing (PICO, Smith & Nephew, UK) changed only if the dressing was completely saturated with fluids

Group 2 (control) intervention: a traditional povidone-iodine gauze and patch wound dressing (a sterile folded non-woven gauze swabs, Rays Spa, Italy, and Hypafix dressing retention tape, Essity Ak- tiebolag, Sweden) changed depending on the wound leakage

Study date/s: February 2013 to June 2015

Outcomes

SSI: The severity of wound infection measured by the ASEPSIS score - a quantitative scoring method using objective criteria based on wound appearance to evaluate wound infection (higher score = worse wound healing; a score > 10 = the increasing probability and severity of infection)

Pain (VAS) at dressing change

Blisters

Validity of measure/s: The reference for the ASEPSIS score was given in the study report, suggesting the ASEPSIS score is valid.

Time points: 7 days

Notes

The leading author received honoraria from Smith & Nephew and the study was financially supported by Smith & Nephew.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk           | Quote "Randomisation was performed by a web based, independent randomisation service (Sealed Envelope, UK) to ensure allocation concealment. The allocation was created using permuted blocks."
|                                           |                    | Computer-generated randomisation sequence                                               |
| Allocation concealment (selection bias)   | Low risk           | Quote "Randomisation was performed by a web based, independent randomisation service (Sealed Envelope, UK) to ensure allocation concealment. The allocation was created using permuted blocks."
|                                           |                    | Independent randomisation service used to conceal allocation                            |
\[ \text{Giannini 2018 (Continued)} \]

**Blinding of participants and personnel (performance bias)**
- All outcomes
  - Unclear risk
  - Blinding was not reported but different criteria for dressing changes would have revealed allocation to both participants and personnel.

**Blinding of outcome assessment (detection bias)**
- All outcomes
  - Low risk
  - Quote "the clinician was blinded regarding to the treatment group".
  - The clinician undertaking the wound evaluation was blinded to treatment group.

**Incomplete outcome data (attrition bias)**
- All outcomes
  - Unclear risk
  - Quote "A number of patients (n = 10) were excluded from the data analysis due to septic loosening of the prosthesis once the results of microbiological and histological examinations were obtained".
  - Comment: 8 participants in the treatment group and 2 in the control group were excluded from the analysis on this basis of the reason of septic loosening which could only be detected postoperatively. The power calculation allowed for a 20% dropout but it’s not clear how this differential removal from the analysis may have affected the results.

**Selective reporting (reporting bias)**
- Low risk
  - No evidence of selective reporting

**Other bias**
- Low risk
  - No evidence of any other source of bias

\[ \text{Gillespie 2015} \]

**Study characteristics**

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 6 weeks
- **Sample size estimate:** pilot study
- **ITT analysis:** yes, **number randomised:** 70, **number analysed:** 70
- **Funding:** non-industry
- **Preregistration:** yes

**Participants**
- **Location:** Queensland, Australia
- **Intervention group:** n = 35, **control group:** n = 35 (primary hip arthroplasty)
- **Mean age:** intervention group = 62.5 years (SD 12.4), control group = 63.8 years (SD 14.0)
- **Inclusion criteria:** undergoing elective primary total hip arthroplasty, aged >/= 18 years, able to provide informed consent and attended hospital preadmission clinic
- **Exclusion criteria:** people with an existing infection, had previously participated in the trial or were unable to speak and understand English

**Interventions**
- **Aim/s:** to assess the use of NPWT on surgical sites to prevent infections and other wound complications after elective primary arthroplasty and to determine the feasibility of conducting a larger trial
- **Group 1 (NPWT) intervention:** PICO dressing applied over the primarily closed incision by the surgeon in the operating room. On day 5 the dressing was changed to OPSITE Post-Op Visible.
**Gillespie 2015** *(Continued)*

**Group 2 (control) intervention:** Comfeel dressing reinforced with 2 absorbent dressings, and then with a self adhesive, non-woven tape, which was applied over the primarily closed incision by the surgeon in the operating room. Participants were discharged with their dressing intact.

**Study date/s:** March 2013 to May 2014

<table>
<thead>
<tr>
<th>Outcomes</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• SSI</td>
<td></td>
</tr>
<tr>
<td>• dehiscence</td>
<td></td>
</tr>
<tr>
<td>• haematoma</td>
<td></td>
</tr>
<tr>
<td>• seroma</td>
<td></td>
</tr>
<tr>
<td>• hospital readmission</td>
<td></td>
</tr>
<tr>
<td>• cost of dressings</td>
<td></td>
</tr>
</tbody>
</table>

**Validity of measure/s:** CDC definitions and criteria for superficial, deep, and organ/space SSI were used for the primary outcome.

**Time points:** 30 days and 6 weeks postsurgery

**Notes**

Investigator contacted for additional details.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “computer generated randomised schedule 1:1 ratio in randomly varying blocks was prepared by the statistician on the research team (not involved in recruitment)”.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: “on skin closure, the RNA opened the next sealed, opaque, numbered envelope”.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: &quot;Masking was not possible for those administering the intervention, and nor was it possible to mask the patients receiving it&quot;.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Quote: &quot;the independent outcome assessors as well as the data analyst were blinded to group allocation&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>An ITT analysis was used.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol pre-registered on ANZCTR</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
</tbody>
</table>

**Gombert 2018**

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study design:</strong> randomised controlled trial</td>
<td></td>
</tr>
<tr>
<td><strong>Study grouping:</strong> parallel</td>
<td></td>
</tr>
<tr>
<td><strong>Ethics and informed consent:</strong> ethics approved and consent obtained</td>
<td></td>
</tr>
</tbody>
</table>
*Gombert 2018 (Continued)*

**Follow-up period:** 30 days

**Sample size estimate:** yes, based on SSI rate expected in treatment group (3%) and difference of 0.14 between groups with 10% dropout

**ITT analysis:** no, **number randomised:** 204, **number analysed:** 188

**Funding:** Acelity, San Antonio, TX, USA.

**Preregistration:** Yes

<table>
<thead>
<tr>
<th>Participants</th>
<th>Location: Germany (two sites)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Intervention group: 98, control group: 90</td>
</tr>
</tbody>
</table>

**Mean age:** intervention group 67.9 (10.1), control group 65.2 (8.4)

**Inclusion criteria:** Vascular surgery for peripheral arterial disease involving longitudinal groin incision for vascular surgical procedures involving the arterial system of the lower extremity or the iliac arteries; a comorbidity profile including smoking (active or past history), cardiac risk factors (e.g. hypertension, coronary heart disease, or history of myocardial infarction), and metabolic disorders (e.g. diabetes, dyslipidaemia, hyperhomocysteinaemia, or chronic renal failure). Dyslipidaemia was defined as hypertriglyceridaemia (> 150 mg/dL) or hypercholesterolaemia (total cholesterol > 200 mg/dL). Chronic kidney disease was defined as glomerular filtration rate (GFR) < 60 mL/min/1.73m²

**Exclusion criteria:** Age below 18 years, pregnancy, local skin infection, simultaneous participation in another clinical trial, and immunosuppressive medication; emergency procedures. When a groin incision was performed on both sides, only one side was randomised and assessed for this study.

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Aim/s: to assess the potential benefits of cinPT application after groin incisions for vascular surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Group 1 (NPWT) intervention: closed incision negative pressure therapy (cinPT); Prevena (continuous pressure of 125 mmHg); removed 5-7 days postoperatively, after which no further wound dressings were used unless SSIs occurred</td>
</tr>
<tr>
<td></td>
<td>Group 2 (control) intervention: Cosmopore E (Hartmann, Heidenheim, Germany) was applied as the wound dressing, changed daily</td>
</tr>
</tbody>
</table>

**Study date/s:** July 2015-May 2017

| Outcomes | • SSI (7 days after the surgery)  
|          | • Pain  
|          | • Readmission  
|          | • Surgical revision (reoperation) |

**Validity of measure/s:** SSI were clinically assessed and classified using the Szilagyi classification (grades I-III)

**Time points:** 7, 15, 30 days

<table>
<thead>
<tr>
<th>Notes</th>
<th>Register: Clinicaltrials.gov NCT02395159</th>
</tr>
</thead>
</table>

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote “The randomisation sequence was computer generated using the random allocation rule, and allocation was implemented using a centralised web based system to ensure allocation concealment.”  
| | | Computer-generated randomisation sequence |
| Allocation concealment (selection bias) | Low risk | Quote “The randomisation sequence was computer generated using the random allocation rule, and allocation was implemented using a centralised web based system to ensure allocation concealment.” |

Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Centralised allocation system

Blinding of participants and personnel (performance bias) All outcomes
High risk
Quote "The nature of the therapy meant that double blinded treatment was not possible. Furthermore, blinding of the vascular surgeons was not achievable".
Personnel could not be blinded.

Blinding of outcome assessment (detection bias) All outcomes
Low risk
Quote "Until the seventh day after surgery, each wound was assessed by two physicians. From this point, the wound was assessed by at least three professionals (triple assessment). The involved wound care nurses were blinded. Furthermore, each wound was documented by photography."

Incomplete outcome data (attrition bias) All outcomes
Low risk
16 randomised participants were neither treated nor analysed; their group assignment was unclear. 6 of these did not undergo groin surgery (screening failures), 10 needed reoperation within 48 hours for occlusion of the treated vessel and were treated as dropouts. Fully documented.

Selective reporting (reporting bias) High risk
Pain data and other device-related complications did not appear to be reported despite being assessed. Trial protocol obtained

Other bias Low risk
No evidence of other sources of bias. We note that antibiotics were used in more people in the control group than in the NPWT group.

Gombert 2018

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes

Follow-up period: 42 ± 10 days

Sample size estimate: not stated

ITT analysis: yes, number randomised: 92, number analysed: 92

Funding: non-industry

Preregistration: yes

Participants

Location: Texas, USA

Intervention group: n = 46, control group: n = 46

Mean age (SD): intervention group = 30.4 (5.7), control group = 29.7 (5)

Inclusion criteria: 18 years of age with BMI 35 kg/m² at the time of delivery

Exclusion criteria: women with skin or systemic infections, chorioamnionitis (defined by maternal fever + 1 clinical criterion), critical illness, or high-risk for anaesthesia (ASA class P4, P5, or P6)

Interventions

Aim/s: to compare short-term clinical outcomes among obese pregnant women undergoing caesarean delivery who received cNPT or a standard-of-care dressing

Primary outcome/s: SSO: unanticipated local inflammation, wound infection, seroma, haematoma, dehiscence, and need for surgical or antibiotic intervention

Secondary outcome/s: not stated
Group 1 (NPWT) intervention: a sterile, "peel-and-place" multilayer dressing (wicking fabric, reticulated foam, and adhesive) was placed over participant's closed incision. The dressing's tubing was then attached to a portable negative pressure therapy unit that delivered 125 mmHg of continuous pressure to the dressing and removed exudates into a disposable canister. Duration of ciNPPT was 5 to 7 days, immediately following surgery.

Group 2 (control) intervention: Steri-Strips (3M Health Care, ½ inch, St Paul, MN), sterile gauze, and Tegaderm (3M Health Care, transparent film dressings (nonpenetrable barrier)) were applied to the closed surgical incision for at least 1 day and no longer than 2 days.

Study date/s: between 2012 and 2014

Outcomes

- postoperative SSOs: included unanticipated local inflammatory response, prolonged drainage, fluid collection, dehiscence, and surgical site intervention
- surgical interventions: included antimicrobials for SSI, surgical drainage of the incision, surgical incision packing, adjunctive negative-pressure therapy, debridement, or reoperation

Validity of measure/s: wound scoring system; surgical site assessments included the supplementary outcomes of incisional pain scores at rest and with pressure on the closed incision, as measured by the Wong–Baker Faces Scale

Time points: all participants were followed up postoperatively for 42 ± 10 days via periodic incisional assessments (postoperative days 1, 2, 6, 14, and 42).

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Study personnel obtained the next sequentially numbered, opaque randomisation envelope, which contained the randomly assigned treatment group for the participant.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Study personnel obtained the next sequentially numbered, opaque randomisation envelope, which contained the randomly assigned treatment group for the participant.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Although a standardised wound scoring system was utilised to minimise bias, the postoperative examiner was privy to the treatment group.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>An ITT analysis was used.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Planned outcomes reported. Protocol preregistered on ClinicalTrials.gov (identifier NCT01450631).</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected.</td>
</tr>
</tbody>
</table>

Cochrane Database of Systematic Reviews
Study design: Cost-effectiveness analysis. Data drawn from the Chaboyer 2014 RCT

Methods

Analytical approach: Trial-based evaluation

Effectiveness data: Data from pilot RCT (N = 87) (Chaboyer 2014). Key effectiveness inputs were SSI and quality of life (SF-12) at up to 4 weeks post-discharge in trial.

Perspective: Australian public health care provider

Utility valuations: QALYs were calculated from SF-12 data. QoL indices (utility weights) were calculated using the method of Brazier and Roberts. QALYs were estimated from the utility weights using the standard area under the curve method.

Adjustment: QALYs were adjusted for differences in baseline SF-12 indices using the regression-based adjustment of Manca, Hawkins and Sculpher.

Measure of benefit: surgical site infection avoided; QALY

Cost data: measured in AUSD; in hospital resource use data were collected by direct observation or chart audit during the trial. Included cost of intervention, nursing time for dressing changes, hospital (inpatient) care. No discount rate was applied due to the short time horizon.

Analysis of uncertainty: A nonparametric bootstrap with 1000 replications was used to construct 95% percentile method confidence intervals (CIs) for the estimates. A sensitivity analysis used only post-discharge QALYs, ignoring the period of hospitalisation (the base case analysis calculating QALYs from utility weights assumed that the change in QoL over the hospital stay was linear).

Funding: Office of Health and Medical Research, Queensland Health, the National Health and Medical Research Council Centre of Research Excellence in Nursing and a Gold Coast University Hospital Private Practice grant

Participants

Location: Obstetric unit, Australia

Intervention group: n = 46, control group: n = 46 (obese women (> 30 BMI) undergoing elective CS)

Mean age: intervention group = 30.6 years (SD 5.5), control group = 30.7 years SD 5.0

Inclusion criteria: booked for elective CS; pre-pregnancy BMI > 30; able to provide consent

Exclusion criteria: women whose condition changed to require urgent CS; previous participation in the trial; existing infection

Interventions

Aim/s: To evaluate whether NPWT is cost-effective compared with standard care in preventing surgical site infection among obese women undergoing caesarean section

Group 1 (NPWT) intervention: NPWT: PICO (Smith and Nephew) dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged (n = 44 in Heard 2017 trial)

Group 2 (Comparator) intervention: Comfeel dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged (n = 43 in a trial).

Study date/s: July 2012 to April 2014

Outcomes

For data see Heard 2017 and for clinical data see Chaboyer 2014 in additional table 1

• Surgical site infection
• Costs (AUSD)
• QALY (measure of benefit).
• ICER with 95% CI (AUSD per unit outcome) to inform probability of intervention being cost-effective
Authors' conclusions: NPWT may be cost-effective in the prophylactic treatment of surgical wounds following elective caesarean section in obese women. Larger trials could clarify the cost-effectiveness of NPWT as a prophylactic treatment for SSI. Sensitive capture of QALYs and cost offsets will be important given the high level of uncertainty around the point estimate cost-effectiveness ratio which was close to conventional thresholds.

Quality rating according to the CHEERS checklist was 83.3%.

Howell 2011

Study characteristics

Methods

- **Study design:** randomised controlled trial
- **Ethics and informed consent:** not reported
- **Sample size calculation:** yes
- **Follow-up period:** 12 months
- **ITT analysis:** all participants completed the study
- **Funding:** the study was supported by KCI, the manufacturer of the negative pressure device.

Participants

- **Location:** New York University Hospital for Joint Disorders, New York, NY, USA
- **Intervention group:** n = 24, **control group:** n = 36
- **Mean age:** not reported
- **Inclusion criteria:** patients undergoing unilateral or bilateral primary total knee arthroplasty who were obese (BMI > 30), who met criteria of increased risk for postoperative wound drainage and who were prescribed enoxaparin sodium for deep vein thrombosis prophylaxis
- **Exclusion criteria:** patient refusal to participate in the study, revision total knee replacement, prior knee surgery (except arthroscopy), and patients with documented diabetes mellitus

Interventions

- **Aim/s:** to compare the number of days to dry wound in a negative pressure dressings group compared with a static pressure dressings group
- **Intervention/s in both groups:** "all patients received three doses of peri-operative intravenous antibiotics and were maintained on subcutaneous DVT prophylaxis for 30 days after surgery".

Group 1 (NPWT) intervention: "subsequent to the closure of the surgical incision, a negative pressure dressing (VAC Therapy, Kinetic Concepts Inc., San Antonio, Texas) was applied under sterile conditions. A medical grade open cell polyurethane ether foam (pore size of 400-600 micrometers) was cut into the shape of a rectangle approximately 5 cm in width and a length sufficient to cover the entire linear wound. The knee was held in 151° of flexion, and the foam was secured over the incision by the application of a specialized adhesive drape, provided in the NPWT system. An evacuation tube with side ports was embedded within the reticulated foam, allowing negative pressure to be applied equally over the entire wound bed. The foam-evacuation tube complex attached to a programmable vacuum pump applied a −125 mmHg continuous vacuum pressure to the wound. The NPWT dressing remained in place for a 48-hour period, after which time clean, dry gauze dressings were applied and changed on daily basis until the wound was dry".

Group 2 (SPD) intervention: "patients in the control arm had their surgical wound covered in the operating room with a sterile, dry gauze dressing that was held in place with a perforated, stretchable cloth tape. This initial dressing remained in place for 48 hours after which time clean, dry gauze dressings were applied and changed on a daily basis until the wound was dry".

Outcomes

- days to dry wound
- deep wound infection
Howell 2011 (Continued)

- blister formation

**Time points:** participants followed up for 12 months postsurgery

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> not described</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td><strong>Quote:</strong> &quot;randomised with blinded envelopes to either the treatment with negative pressure wound therapy group or a control group using sterile gauze&quot;</td>
</tr>
<tr>
<td><strong>Comment:</strong> unclear if envelopes were sequentially numbered or opaque</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> insufficient information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td><strong>Evidence:</strong> not described</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td><strong>Evidence:</strong> 51 participants were randomised, and 51 completed the study.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> the prespecified clinical outcomes were presented in table 1 in the trial report, and a post hoc analysis of blister occurrence was shown in Table 2. Infection rates were reported in the results section of the trial report. We could not find a published protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>No baseline data were presented. In addition, groups contained unequal numbers, which could indicate undisclosed losses in 1 group.</td>
</tr>
</tbody>
</table>

**Hussamy 2017**

**Study characteristics**

**Methods**

- **Study design:** randomised controlled trial
- **Ethics and informed consent:** not reported
- **Sample size calculation:** yes
- **Follow-up period:** not stated
- **ITT analysis:** yes
- **Funding:** not stated

**Participants**

- **Location:** Texas, USA
- **Intervention group:** n = 222, **control group:** n = 219
- **Mean age:** not reported
Hussamy 2017 (Continued)

**Inclusion criteria:** women with class III obesity (BMI > 40 kg/m²) undergoing caesarean delivery

**Exclusion criteria:** women on anticoagulation, with HIV infection, sensitive skin disorders, or silver or acrylic allergies

**Interventions**

**Aim/s:** to compare the efficacy of closed incision negative pressure therapy (cINPT) with a standard surgical dressing in the prevention of postoperative wound morbidity in women with class III obesity undergoing caesarean delivery

**Group 1 (NPWT) intervention:** a cINPT dressing at time of caesarean

**Group 2 (control) intervention:** a standard surgical dressing

**Study date/s:** January 2015 to July 2016 (18 months)

**Outcomes**

- wound morbidity including wound disruption requiring the use of antimicrobials, prolonged postoperative hospitalisation, hospital readmission, or reoperation within 30 days of delivery

**Validity of measure/s:** not stated

**Time points:** not stated

**Notes**

Only the abstract was available.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>441 participants were enrolled and analysed.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes were reported in the abstract.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

**Hyldig 2019a**

**Study characteristics**

**Methods**

**Study design:** pragmatic randomised controlled trial

**Study grouping:** parallel
**Hyldig 2019a** (Continued)

**Ethics and informed consent:** yes

**Follow-up period:** 30 days

**Sample size estimate:** yes; a sample size of 870 for a reduction in surgical site infection of 50% in the intervention group compared with an expected baseline event rate of 10% in the control group, with a two-sided 5% significance level and a power of 80%

**ITT analysis:** yes (for surgical site infection only), **number randomised:** 876, **number analysed:** 876 for surgical site infection and 827 for other outcomes

**Funding:** grants from the University of Southern Denmark, Odense University Hospital, the Region of Southern Denmark, Lundbeckfonden, and an unrestricted grant from the INPWT device manufacturer Smith & Nephew (devices and operating funding)

**Preregistration:** yes; ClinicalTrials.gov (NCT 01890720)

### Participants

**Location:** Denmark (two tertiary referral centres and three Danish teaching hospitals)

**Intervention group:** n = 432, **control group:** n = 444 (6 received INWPT dressing)

**Mean age:** a range from 18 to 46 years across groups; **intervention group:** 32 (SD 5), **control group:** 32 (SD 5)

**Inclusion criteria:** pregnant women undergoing elective or emergency caesarean section, aged >= 18 years; who had a prepregnancy body mass index >= 30 kg/m2, and could read and understand Danish

**Exclusion criteria:** women who had given informed consent but subsequently delivered vaginally

### Interventions

**Aim/s:** to investigate the effectiveness of prophylactic INPWT after caesarean section in obese women; hypothesis: INPWT would be associated with fewer surgical site infection and other wound complications (i.e., wound exudate and dehiscence) compared with standard postoperative dressing.

**Group 1 (NPWT) intervention:** incisional negative pressure wound therapy (INPWT; PICO, SIZE 10 * 30 cm or 10 * 40 cm, Smith & Nephew, Hull, UK) in which dressing was left in situ for approximately 5 days

**Group 2 (control) intervention:** standard postoperative dressing in which dressing was left in situ for at least 24 hours

**Study date/s:** September 2013 to October 2016

### Outcomes

- Surgical site infection, those infections requiring antibiotic treatment within the first 30 days after caesarean section
- Deep surgical site infection, those infections requiring surgery
- Minor dehiscence, defined as a gap between the sides of the wound
- Health-related quality of life (EQ-5D-5L)
- Readmissions to hospital/contact to the general practitioner on suspicion of infection following caesarean section (listed in ClinicalTrials.gov)

### Validity of measure/s:

**Time points:** within the first 30 days after surgery

### Notes

Results were submitted to ClinicalTrials.gov in September 2018 but were not posted online. Could contact authors to request such data

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;Participants were randomised in the operating theatre during surgery using a web-based randomisation programme with a 1:1 allocation ratio and random block sizes of 4–6, stratified by centre and type of caesarean section (emergency versus elective).&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: low risk of bias due to valid random sequence generation</td>
</tr>
</tbody>
</table>
**Hyldig 2019a (Continued)**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk Level</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;The random allocation sequence was generated by an external data manager with no clinical involvement in the study&quot;. Comment: low risk of bias due to likely appropriate approach taken to conceal randomisation process.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: &quot;Blinding was not possible due to the nature of the intervention&quot;. Comment: high risk of bias because it was clearly stated no blinding of participants and personnel.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>ITT analysis was conducted for surgical site infection and for other outcomes; only 22 of 432 in Group 1 and 27 of 444 in Group 2 were excluded from analyses. Low risk of attrition bias.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
<td>Readmission to hospital/contact to the GP was listed on ClinicalTrials.gov but not presented in the full text. High risk of reporting bias.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
</tbody>
</table>

**Hyldig 2019b**

**Study characteristics**

**Methods**

- **Study design:** cost-effectiveness analysis (economic evaluation based on the Hyldig 2019a RCT)
- **Analytical approach:** Decision-analytic model
- **Effectiveness data:** Data from a multicentre RCT (n = 876) (Hyldig 2019a): SSI. Both risk and severity of infection were incorporated. The Danish crosswalk value sets were used to derive preference-based index values.
- **Perspective:** Danish healthcare
- **Utility valuations:** QALYs informed by EuroQol EQ-5D-5L (scoring algorithm not specified but Danish-specific context taken into account) were calculated based on SSI costs for superficial and deep SSIs avoided including antibiotic prescription costs and need for further surgery.
- **Measure of benefit:** surgical site infection avoided; QALY
- **Cost data:** Costs were estimated using data from four Danish National Databases and analysed from a Danish healthcare perspective with a time horizon of 3 months after birth. Conversion from DK to Euro using the year 2015 value. No discount rate was applied. Total costs consisted of four cost components: hospital costs; costs of using GPs; costs of antibiotics; and postoperative dressing cost. These were all from the Cost Database. Costs of INPWT dressing was Euro 151.40, including device itself and time costs for its application.
- **Analysis of uncertainty:** probabilistic sensitivity analysis including an expanded time horizon and an extrapolation of QALY gain to 5 years (3% annual discount). Deterministic sensitivity analyses conducted to permit determination of possible uncertainty in the ICER that would result from a change in a single parameter in the analysis. Scenario analyses to evaluate the impact of missing cost and QALY data, and the influence of one outlier on the ICER.
A subgroup analysis stratifying by BMI explored the impact of the intervention in women with a pre-pregnancy BMI $\geq 35$.

**Participants**
- **Location**: Denmark (two tertiary referral centres and three Danish teaching hospitals)
- **Intervention group**: $n = 432$, **control group**: $n = 444$
- **Mean age**: a range from 18 to 46 years across groups; **intervention group**: $32$ (SD 5), **control group**: $32$ (SD 5)
- **Inclusion criteria**: pregnant women undergoing elective or emergency caesarean section, aged $\geq 18$ years; who had a pre-pregnancy body mass index $\geq 30$ kg/m$^2$, and could read and understand Danish
- **Exclusion criteria**: women who had given informed consent but subsequently delivered vaginally

**Interventions**
- **Aim/s**: To evaluate the cost-effectiveness of incisional negative pressure wound therapy (iNPWT) in preventing surgical site infection in obese women after caesarean section

**Group 1 (NPWT) intervention**: Incisional negative pressure wound therapy (iNPWT; PICO, SIZE 10 x 30 cm or 10 x 40 cm, Smith & Nephew, Hull, UK) in which dressing was left in situ for approximately 5 days ($n = 432$ in a trial)

**Group 2 (control) intervention**: Standard postoperative dressing in which dressing was left in situ for at least 24 hours ($n = 444$ in a trial)

**Study date/s**: September 2013 to October 2016

**Outcomes**
- For data see **Hyldig 2019b** and for clinical data see **Hyldig 2019a** in additional table 1
- **SSI**
- **Costs (Euro)**
- **QALY (measure of benefit)**.
- **ICER with 95% CrI to inform probability of strategy being cost-effective/dominant using the willingness-to-pay threshold of 30,000 Euro/QALY**

**Notes**
- **Authors’ conclusions**: Incisional NPWT appears to be cost saving compared with standard dressings but this finding is not statistically significant. The cost savings were primarily found in women with a pre-pregnancy BMI $\geq 35$ kg/m$^2$.
- **Funding**: University of Southern Denmark, Odense University Hospital, the Region of Southern Denmark, Lundbeckfonden, and an unrestricted grant from the iNPWT device manufacturer Smith & Nephew (devices and operating funding)

**Quality assessment**: CHEERS score 91.7%

**Javed 2018**

**Study characteristics**

**Methods**
- **Study design**: randomised controlled trial
- **Study grouping**: parallel
- **Ethics and informed consent**: yes
- **Follow-up period**: 30 days after operations
- **Sample size estimate**: yes; a sample size of 124 patients was assumed to provide a power of 80% to detect a 20% relative reduction in surgical site infection incidence (decreasing from 30% to 10%) at a 2-sided alpha level of 0.05
- **ITT analysis**: yes; number randomised: 124, number analysed: 123
Funding: KCI/Acelity (Grant number #125164)

Participants

Location: America (single site)
Intervention group: n = 62, control group: n = 62

Mean age: intervention group mean 66.4 (SD 9.3) years, control group 66.1 (9.0)
Inclusion criteria: adults (18 yrs of age) who had a SSI risk score of 1 as defined by the risk score proposed by Poruk et al. This included patients who had received neoadjuvant chemotherapy, preoperative biliary stenting, or both.
Exclusion criteria: pancreaticoduodenectomies (PD) performed minimally invasively or known allergies or sensitivity to silver or acrylic adhesives

Interventions

Aim/s: to evaluate the efficacy of negative pressure wound therapy for surgical-site infection (SSI) after open pancreaticoduodenectomy

Group 1 (NPWT) intervention: negative pressure wound therapy (NPWT) device is shown in Figure S1. The PREVENA™ CUSTOMIZABLE™ device is comprised of a PREVENA™ CUSTOMIZABLE™ dressing, sealing strips, KCI drapes, and Interface Pad.

Group 2 (control) intervention: standard closure technique
Study date/s: January 2017 through February 2018

Outcomes

• Surgical site infection defined by the National Health Safety Network definition of the Centers for Disease Control and Prevention (CDC)
• Need for reoperation
• 30-day readmission related to SSI
• Cost of hospitalisation

Validity of measure/s:

Time points: 30 days after operation

Notes

Haematoma, seroma, or skin separation were considered under the outcome of surgical site infection (SSI) according to the judgement criteria used for SSI. Data of these outcomes were not extracted or used for this review.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk | Quote: "Using the simple randomization method, a random allocation sequence was generated." "Once the surgeon committed to performing a PD by ruling out metastatic disease or inoperable local vascular involvement, the circulating nurse contacted the research staff for randomization. The presealed envelope was opened to randomize the patient."
Comment: unclear risk of bias because the method of generating random sequence was not specified |
| Allocation concealment (selection bias) | Low risk | Quote: "Allocation concealment was achieved by printing allocation onto a gray-shaded card that was folded and sealed in a secured envelope before initiation of the study". |
Comment: low risk of bias given an appropriate strategy was used to conceal allocation |
| Blinding of participants and personnel (performance bias) | Unclear risk | Quote: "All patients also received standard infection-prevention measures..." |
Comment: insufficient information on blinding of participants and personnel |
**Javed 2018 (Continued)**

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 6 weeks
- **Sample size estimate:** pilot study
- **ITT analysis:** yes, **number randomised:** 220, **number analysed:** 209

**Funding:** study funded through a grant from Smith & Nephew UK to cover the cost of NPWT dressings and data collection costs. 2 investigators declared they had funding and consultancy fees from Smith & Nephew.

**Preregistration:** no

**Participants**

- **Location:** Oswestry, UK
- **Intervention group:** n = 110, **control group:** n = 110

  - **Mean age (SD):** intervention group = 69 (9.0), control group = 69.2 (9.0)

- **Inclusion criteria:** patients undergoing total hip or knee arthroplasties (for any indication) with any of 3 consultant surgeons

- **Exclusion criteria:** patients who had known allergies to dressing, were undergoing revision joint surgery, were unwilling to attend additional clinics, and those on warfarin were excluded.

**Interventions**

- **Aim/s:** to evaluate the effectiveness of incisional negative pressure wound therapy dressing (iNPWTd)

  - **Group 1 (NPWT) intervention:** PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

  - **Group 2 (control) intervention:** Comfeel dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

- **Study date/s:** July 2012 to April 2014

---

**Karlakki 2016**

**Study characteristics**

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 6 weeks
- **Sample size estimate:** pilot study
- **ITT analysis:** yes, **number randomised:** 220, **number analysed:** 209

**Funding:** study funded through a grant from Smith & Nephew UK to cover the cost of NPWT dressings and data collection costs. 2 investigators declared they had funding and consultancy fees from Smith & Nephew.

**Preregistration:** no

---

**Blinding of outcome assessment (detection bias)**

- **All outcomes:** Low risk

  Quote: “patients’ EMR were reviewed independently by the principal investigator (MJW) blinded to study-group assignments to determine if SSI was documented at any time during the 30-day postoperative period.”

  Comment: low risk of bias for SSI because the outcome assessors were blinded.

**Incomplete outcome data (attrition bias)**

- **All outcomes:** Low risk

  Comment: Low risk of bias because 123 of 124 participants randomised were analysed. One of the 62 participants that were randomised to Group 2 (Control) was excluded from the analysis because the surgeon decided to use NPWT for that person rather than the control intervention.

**Selective reporting (reporting bias)**

- **Low risk**

  All outcomes listed in the Methods were reported in the Results.

**Other bias**

- **Low risk**

  None detected

---

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Karlaki 2016 (Continued)

**Outcomes**
- SSI
- blisters
- haematoma
- hospital readmission

**Validity of measure/s:** not described

**Time points:** 1, 2, and 6 weeks postsurgery

**Notes**
Investigator contacted for additional details

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;the randomisation was performed using sealed opaque envelopes with a block size of 20 shuffled envelopes&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Comment:</strong> no sequence generation was required.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;the randomisation was performed using sealed opaque envelopes with a block size of 20 shuffled envelopes&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Comment:</strong> allocation was unknown until envelope opened.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: &quot;This was a non-blinded single-centre randomised controlled parallel group study&quot;.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td><strong>Comment:</strong> non-blinded study</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Outcome assessors were aware of group allocation.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>7.3% in intervention group and 2.7% in control group</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td><strong>PP analysis</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Comment:</strong> more participants were excluded from the analysis in the intervention group (8 intervention vs 3 control).</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Intervention participants were seen in a wound clinic at 1 week, and control participants were not.</td>
</tr>
</tbody>
</table>

### Keeney 2019

**Study characteristics**

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 35 days
Sample size estimate: not reported

ITT analysis: no; number randomised: 526; number analysed: 398

Funding: Institution of authors received research funding from Smith & Nephew Orthopaedics that was related to this study.

Preregistration: not reported

Participants

Location: America (one site)

Intervention group: 185 analysed; control group: 213 analysed

Mean age: intervention group 60.6 years, control group 60.5

Inclusion criteria: consenting age, surgical treatment with primary or revision THA, surgical treatment with primary or revision TKA; and having an advanced technology device capable of digital photography

Exclusion criteria: pregnancy, history of poor compliance with medical treatment, allergy to silicone adhesives or polyurethane films, and unwillingness to participate in an RCT

Interventions

Aims: to assess whether a portable NPWT device affects wound appearance, postoperative wound drainage, dressing-related complications, wound healing complications, infection rates, and reoperation rates when compared with a standard of care (SOC) postoperative dressing

Group 1 (NPWT) intervention: incisional negative pressure wound therapy (INPWT), a battery-operated, portable NPWT device with an exchangeable cartridge (PICO, Smith & Nephew Orthopaedics, Memphis, TN) with negative pressure applied at 80 mmHg (± 20 mmHg) for an initial period of 7 days

Group 2 (control) intervention: a standard of care (SOC) postoperative dressing, including nonadherent incisional cover (Adaptic or Xeroform gauze), 4.4 inch gauze, and an abdominal dressing. Dressings were changed on postoperative day 2 with subsequent dressing changes performed at 3- to 5-day intervals until the incision was dry.

Study date/s: enrolment between April 1, 2014, and January 31, 2017

Outcomes

• Superficial and late wound infection rates 7/185 vs. 8/213
• Return to the operating room to manage a wound-related concern within the first 3 months

Validity of measure/s:

Time points:

Notes

The number of patients randomised in either group was not reported. The authors also reported wound appearance; all-cause complications, wound drainage, and dressing concerns outcomes. These outcomes were not extracted for this review. Regarding outcomes of interest to this review, the authors also stated that "Two patients in each group underwent surgical treatment for a superficial wound infection during the first 90 days after surgery... Four TKA patients in the standard dressing control group were returned to the operating room within the first 35 days for management of a wound-related complication but deep infection was not diagnosed". These data were not extracted for this review because it was unclear whether they were systematically collected.

Risk of bias

Bias | Authors' judgement | Support for judgement
--- | --- | ---
Random sequence generation (selection bias) | Unclear risk | Quote: "A total of 526 patients (22.5%) consented to participate in the study and were randomised into either the INPWT device or SOC dressing treatment groups".

Comment: unclear risk of bias because no method of generating random sequence was specified
### Keeney 2019 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment</td>
<td>Unclear</td>
<td>Not reported</td>
</tr>
<tr>
<td>(selection bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear</td>
<td>Understandably difficult to blind participants and personnel in this trial</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear</td>
<td>Quote: &quot;Wound appearance was assessed from patient-provided incision photographs by a single trained research team member, blinded to time point and group, using a previously published and validated 100-mm visual analog scale.&quot;</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: it appears that only wound appearance outcome was assessed in a blinding way. However, this outcome was not of interest to this review. It is unclear whether blinding of outcome assessment was undertaken for other outcomes.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High</td>
<td>Quote: &quot;A total of 526 patients (22.5%) consented to participate in the study and were randomised ... After the initial randomization, 94 patients were excluded ... After excluding 34 unicompartmental knee arthroplasty patients, 398 patients remained for assessment...&quot;</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: high risk of bias because a high proportion of randomised participants (24%, 128 of 526) were excluded from data analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low</td>
<td>All outcomes mentioned in the Methods were reported in the Results though the reporting appeared to be implicit.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low</td>
<td>None detected</td>
</tr>
</tbody>
</table>

### Kuncewitz 2017

#### Study characteristics

| Study design: | randomised controlled trial |
| Study grouping: | parallel |
| Ethics and informed consent: | not reported |
| Follow-up period: | not reported |
| Sample size estimate: | not reported |
| ITT analysis: | yes, number randomised: 73, number analysed: 73 |
| Funding: | not reported |
| Preregistration: | not reported |

| Location: | not reported |
| Intervention group: | n = 36, control group: n = 37 |
| Mean age (SD): | not reported |
| Inclusion criteria: | high-risk surgical oncology patients undergoing laparotomy |
| Exclusion criteria: | not stated |

| Aim/s: | to investigate the effects of NPWT on short- and long-term wound outcomes in people undergoing pancreatectomy |
Kuncwetch 2017 (Continued)

**Group 1 (NPWT) intervention:** NPWT

**Group 2 (control) intervention:** standard surgical dressing

**Study date/s:** 2012 to 2016

**Outcomes**
- postoperative wound complications in the first 30 days
- incisional hernia rates
- rates of pancreatic fistula
- delayed gastric emptying

**Validity of measurements:** not described

**Time points:** not stated

**Notes**
- Only the abstract was available.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>73 participants were enrolled and analysed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Expected outcomes were reported in the abstract.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Abstract only</td>
</tr>
</tbody>
</table>

Kwon 2018

**Study characteristics**

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study grouping: parallel</td>
</tr>
<tr>
<td></td>
<td>Ethics and informed consent: yes</td>
</tr>
<tr>
<td></td>
<td>Follow-up period: 30 days</td>
</tr>
<tr>
<td></td>
<td>Sample size estimate: pilot study informed the calculation which was based on power 0.80 to demonstrate reduction from 30% to 15% in SSI. This was based on incisions not patients.</td>
</tr>
</tbody>
</table>
ITT analysis: no, number randomised: 123, number analysed: 119 incisions was the unit of analysis; 24 participants had 48 incisions

Funding: performed without any support, financial or otherwise, from the makers of the Prevena dressing

Preregistration: not stated

Participants

Location: USA single hospital
Intervention group: 59, control group: 60 incisions; 24 people contributed 48 incisions (24 to each group)

Mean age: intervention group 64.6 (44-83), control group 67.4 (41-84)
Inclusion criteria: patients aged 18 years and older undergoing elective vascular surgery under the supervision of the Division of Vascular and Endovascular Surgery at Thomas Jefferson University Hospital involving unilateral or bilateral groin incisions; presence of any of the following criteria: body mass index (BMI) > 30 kg/m²; significant pannus overlying groin skin or abnormal skin as evidenced by fungal infection; reoperative groin surgery; placement of prosthetic vascular graft; poor nutrition (BMI < 18 kg/m², cachectic in appearance); immunosuppression (use of any immunosuppressive medications); and poorly controlled diabetes (hemoglobin A1c >8%)
Exclusion criteria: emergency operation and those unwilling or unable to provide informed consent

Interventions

Aim/s: to determine whether application of a negative pressure dressing (Prevena Incision Management System) is superior to a standard surgical dressing in preventing vascular groin wound complications and their associated hospital costs.

Group 1 (NPWT) intervention: negative pressure dressing (Prevena) applied according to the manufacturer’s instructions. It involved application of an antibiotic sponge (0.019% ionic silver), cut to cover the closed groin wound, covered by a clear occlusive dressing attached to a suction device that applied -125 mmHg pressure. This device was inspected daily and left in place for 5 days, after which a dry gauze dressing was placed, inspected and replaced daily until discharge.

Group 2 (control) intervention: standard surgical dressing consisting of gauze covered by Tegaderm (3M, St. Paul, Minn). This dressing was removed on postoperative day 2 and replaced with a dry gauze dressing that was inspected and replaced daily until discharge.

Study date/s: January 1st, 2015 to December 31st, 2016

Outcomes

- SSI
- (skin) dehiscence
- lymph leakage (seroma or fistula) but no separate data on seroma
- haematoma
- reoperation
- hospital readmission
- costs

Validity of measure/s: The Szilagyi classification of vascular wound infection was also used to classify the infection.

Time points: daily until hospital discharge; within 10 to 14 days, whereupon staples were removed; and within 25 to 30 days to complete the study

Notes

Risk of bias

| Bias | Authors' judgement | Support for judgement |
Kwon 2018 (Continued)

Random sequence generation (selection bias) | Unclear risk | Quote "They used a coin toss to determine whether the patient was to receive standard dressing or negative pressure therapy. To maintain 1:1 randomization as well as to provide future analysis using internal controls, any high-risk patient undergoing bilateral groin incisions would receive both a standard dressing and negative pressure therapy”.

Comment: adequate method for the unilateral surgery; unclear for the bilateral

| Allocation concealment (selection bias) | Unclear risk | Not stated |
| Blinding of participants and personnel (performance bias) | High risk | Quote: “Other than the fact that the 30-day examination occurred without the overt knowledge of the patient’s initial treatment, no blinding was instituted”.

Comment: The surgical team, clinical staff, and patient were not blinded to the intervention status.

| Blinding of outcome assessment (detection bias) | High risk | Quote: " Wound assessment was made by both the primary surgeon and nurse practitioners.....Furthermore, a major limitation to the study was that it was not a blinded study and therefore subject to observer bias. Assessment of complications is qualitative, and ultimate management of infections, such as opening an infected wound, was left to the discretion of the attending surgeon.”

Comment: Outcome assessment was performed by an unblinded assessor.

| Incomplete outcome data (attrition bias) | Low risk | Quote: “Because a contralateral complication would penalize the uncomplicated groin incision in terms of LOS and hospital variable costs, in this circumstance the uncomplicated groin incision data were dropped from consideration in terms of LOS and variable costs”. “As such, for the high-risk, standard dressing group (n = 60), five were dropped because of a contralateral complication (n = 55); for the high-risk, Prevena group (n = 59), eight were dropped because of a contralateral complication (n = 51)”;

In the intervention group, two incisions discontinued intervention because of graft failure postoperative Day 1; in the control group, two incisions discontinued intervention because of reopening of incision for graft failure postoperative Day 1 and fatal myocardial infarction post-operative Day 3.

Comment: Clear from the study how many participants withdrew and the reasons

| Selective reporting (reporting bias) | Low risk | Comment: protocol not found, but according to the method, all results were reported.

| Other bias | Unclear risk | This was a planned? interim analysis after 80% recruitment with a stopping guideline if 50% reduction in SSI. The unit of analysis was the incision and the unit of randomisation appeared to be the incision where there was bilateral incision. Unclear how this paired data dealt with in analysis

Lee 2017a

Study characteristics

Study design: randomised controlled trial

Study grouping: parallel
Ethics and informed consent: yes
Follow-up period: 6 weeks
Sample size estimate: not reported
ITT analysis: no, number randomised: 60, number analysed: 44
Funding: KCI USA Incorporated, an Acelity company
Preregistration: yes

Participants
Location: Canada
Intervention group: n = 33, control group: n = 27
Mean age (± SD): intervention group = 67.1 (± 7.2), control group = 68.3 (± 9.7)
Inclusion criteria: receiving an isolated elective or semi-elective CABG and above 18 years of age living within 1 hour of the institution
Exclusion criteria: emergent surgery, previous CABG or lower leg surgical intervention, severe peripheral vascular disease, dialysis-dependent renal failure, and chronic steroid administration

Interventions
Aim/s: to establish the safety and feasibility of using NPWT on the GSV harvest site postcardiac surgery and to examine the effects on infection, complications, and overall patient function
Group 1 (NPWT) intervention: NPWT device was placed at the time of GSV harvest in the operating room and then maintained in situ until the day prior to hospital discharge or to a maximum of 7 days. The device was removed if poorly tolerated by the participant or for any safety concerns.
Group 2 (control) intervention: conventional dry gauze dressings
Study date/s: not stated

Outcomes
- rates of device complication and malfunction
- rates of SSI, lower leg complications, discharge date, and quality of life at discharge and 6 weeks

Validity of measure/s: complications were classified as major if they required a medical or surgical intervention. All complications and device malfunctions were recorded. The total length of therapy with the NPWT device was recorded, and also if therapy was prematurely interrupted for any reason. SSIs was determined through assessment of the ASEPSIS score. The incidence of leg complications was also examined including pain, heaviness, weakness, stiffness, itching, paraesthesia, numbness, burning, discoloration, rash, and oedema. These complications were graded as 'not present', 'mild', 'moderate', and 'severe'. Only the moderate and severe complaints were included for incidence analysis. Discharge dates were also recorded for all participants. Self reported assessments of mobility, overall pain or discomfort, feelings of anxiety or depression, ability for self care, and ability to perform usual activities were performed. These measures were graded as no issues, some issues, and severe issues or inability.

Quality of life was also measured using the EQ-5D-3L Measure of Health Status.

Time points: initial and 6 weeks

Notes
33 vs 27 participants randomised; high loss to follow-up recorded

Risk of bias

Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Consented patients were randomised by use of sealed ballot envelopes in a 1-to-1 fashion.
Allocation concealment (selection bias) Unclear risk Not stated
Lee 2017a (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: &quot;We performed a prospective, randomised, single-blind, single centre, clinical feasibility study&quot;. Comment: Single-blinded - and the person who was blinded was the outcome assessor.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>A research assistant blinded to the grouping assessed the incision and participant prior to discharge and at 6 weeks postoperatively. A second, unblinded research assistant recorded and managed any device-related complications. Participants were discharged based on standardised institutional discharge criteria.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>12 participants were lost to follow-up at 6 weeks, 4 in the NPWT group and 8 in the control group. These participants were not included in the data analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol registered on ClinicalTrials.gov (NCT01698372)</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>High loss to follow-up without reasons for loss being provided; unclear whether additional risks of bias</td>
</tr>
</tbody>
</table>

Lee 2017b

**Study characteristics**

**Methods**

- **Study design**: randomised controlled trial
- **Study grouping**: parallel
- **Ethics and informed consent**: yes
- **Follow-up period**: 90 days
- **Sample size estimate**: yes
- **ITT analysis**: no, **number randomised**: 102, **number analysed**: 102
- **Funding**: not company funded
- **Preregistration**: yes

**Participants**

- **Location**: Canada
- **Intervention group**: n = 53, **control group**: n = 49
- **Mean age**: intervention group = 69 ± 10, control group = 68 ± 10
- **Inclusion criteria**: patients with 1 of the following 3 risk factors for SSIs were enrolled in the trial: obesity defined as a BMI of > 30 kg/m², previous femoral artery exposure, or presence of minor or major ischaemic tissue loss.
- **Exclusion criteria**: patients with pre-existing groin infection, a known allergy to dressing material, or those who could not be followed postoperatively were excluded from the study.

**Interventions**

- **Aim/s**: to perform an RCT to study the role of NPWT on SSI in primarily closed groin incisions after lower extremity revascularisation in vascular surgery patients
- **Group 1 (NPWT) intervention**: NPWT remained on until either hospital discharge or postoperative day 8, whichever occurred earlier.
- **Group 2 (control) intervention**: standard gauze dressing (the dressing removed on postoperative day 2, and then had daily dressing changes with inspection of the wound)
Lee 2017b (Continued)

**Study date/s**: August 2014 to December 2015

**Outcomes**

- the incidence of SSI within 30 days of revascularisation
- duration of hospital stay
- SSI within 90 days
- reoperation and readmission rate owing to SSI within 90 days
- mortality within 90 days

**Validity of measure/s**: SSI was diagnosed using the CDC guideline as a superficial or deep infection. The Szilagyi classification of vascular wound infection was also used to classify the infection.

**Time points**: once discharged, both groups were followed up in the clinic at 30 and 90 postoperative days.

**Notes**

---

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Random sequence generation (selection bias)</strong></td>
<td>Low risk</td>
<td>Eligible patients were randomised to NPWT or a standard sterile gauze dressing using an internet-based software, sealedenvelope.com (London, UK), using block randomisation.</td>
</tr>
<tr>
<td><strong>Allocation concealment (selection bias)</strong></td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td><strong>Blinding of participants and personnel (performance bias)</strong></td>
<td>High risk</td>
<td>Quote: “patients and surgeons were not blinded to the treatment they had received”. Comment: no blinding of participants or personnel</td>
</tr>
<tr>
<td><strong>Blinding of outcome assessment (detection bias)</strong></td>
<td>Low risk</td>
<td>Wounds were inspected at each clinic visit by a wound specialist nurse who was blinded to the treatment groups. If she was uncertain, the staff physician determined the presence or absence of an SSI. An SSI could also be diagnosed by the patient care team if there were clinical signs and symptoms of infection.</td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias)</strong></td>
<td>Low risk</td>
<td>102 participants were enrolled and analysed.</td>
</tr>
<tr>
<td><strong>Selective reporting (reporting bias)</strong></td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol registered on ClinicalTrials.gov (NCT02084017)</td>
</tr>
<tr>
<td><strong>Other bias</strong></td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>

Leon 2016

**Study characteristics**

**Methods**

- **Study design**: prospective, randomised, multicentre study
- **Study grouping**: parallel
- **Ethics and informed consent**: not reported
- **Follow-up period**: not reported
### Participants

<table>
<thead>
<tr>
<th>Location: Spain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention group: n = 47, control group: n = 34</td>
</tr>
<tr>
<td>Mean age (SD): not reported</td>
</tr>
<tr>
<td>Inclusion criteria: patients undergoing open and programmed colorectal surgery</td>
</tr>
<tr>
<td>Exclusion criteria: not stated</td>
</tr>
</tbody>
</table>

### Interventions

<table>
<thead>
<tr>
<th>Aim/s: to evaluate the benefits of negative pressure therapy to reduce surgical site infection rate in open colorectal surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 (NPWT) intervention: NPWT</td>
</tr>
<tr>
<td>Group 2 (control) intervention: usual dressing group</td>
</tr>
<tr>
<td>Study date/s: not reported</td>
</tr>
</tbody>
</table>

### Outcomes

- SSI rate
- Validity of measure/s: not described
- Time points: a daily evaluation through hospitalisation and a 15- and 30-day evaluation

### Notes

- Only the abstract was available.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All enrolled participants were accounted for in the analyses.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Abstract only</td>
</tr>
</tbody>
</table>
Lozano-Balderas 2017

**Study characteristics**

**Methods**
- **Study design:** randomised controlled trial
- **Ethics and informed consent:** ethics approved
- **Sample size calculation:** no
- **ITT analysis:** yes, **number randomised:** 81, **number analysed:** 81
- **Follow-up period:** healed (when in hospital) or in a 30-day period after surgery (if discharged)
- **Funding:** non-industry
- **Preregistration:** yes

**Participants**
- **Location:** Mexico
- **Intervention group:** n = 25, **control group:** n = 27, (3 arms: **delayed primary closure group:** n = 29)
- **Median age (IQR):** intervention group = 32 (22 to 46); control group = 30 (20 to 43)
- **Inclusion criteria:** minimum age of 18; a laparotomised wound with class III or IV (contaminated/dirty-infected) surgical wounds
- **Exclusion criteria:** not specified

**Interventions**
- **Aim/s:** to compare infection rates between primary, delayed primary, and vacuum-assisted closures in contaminated/dirty-infected surgical wounds
- **Group 1 (NPWT) intervention:** the VAC was used with routine changes of dressings every 48 hours until healthy granulation tissue was found and a surgeon decided to close it.
- **Group 2 (control) intervention:** subcutaneous tissue was approximated with polyglycolic acid, and polypropylene was used for the skin.
- **Study date/s:** January to July 2014

**Outcomes**
- **SSI**

**Validity of measure/s:** according to the CDC Surgical Wound Classification

**Time points:** daily when in hospital or in a 30-day period after surgery

**Notes**

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “patients were allocated to each group with the software Research Randomizer® (Urbaniak, G. C., &amp; Plous, S., Version 4.0)”.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Outcome assessors were aware of group allocation.</td>
</tr>
</tbody>
</table>
Lozano-Balderas 2017 (Continued)

| Incomplete outcome data (attrition bias) | Low risk | 81 participants were enrolled and analysed. |
| Selective reporting (reporting bias) | Low risk | Expected outcomes reported. Protocol retrospectively registered on Clinical-Trials.gov (NCT02649543). |
| Other bias | Low risk | No other biases detected |

Manoharan 2016

**Study characteristics**

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** bilateral knees were randomised to intervention or control knees
- **Ethics and informed consent:** yes
- **Sample size estimate:** yes, but sample did not reach target, stopped due to financial constraints
- **Follow-up period:** 10 days
- **ITT analysis:** yes, **number randomised:** 21, **number analysed:** 21
- **Funding:** KCI, Acelity Inc provided the negative pressure wound therapy dressings for the study.
- **Preregistration:** retrospectively registered as ANZCTR 12615001350516

**Participants**

- **Location:** Queensland, Australia
- **Intervention group:** n = 21 knees, **control group:** n = 21 knees
- **Mean age (range):** 66 (45 to 80)
- **Inclusion criteria:** patients undergoing a bilateral knee arthroplasty
- **Exclusion criteria:** aged < 18 years or pregnant

**Interventions**

- **Aim/s:** to assess the effect of NPWT on outcomes after primary arthroplasty
- **Group 1 (NPWT) intervention:** the intervention group received PREVENA Incision Management System, Acelity, KCI, which was placed over the closed surgical incision under sterile conditions at the end of the procedure. The NPWT device provided a continuous negative pressure of 125 mmHg for a duration of 8 days.
- **Group 2 (control) intervention:** the conventional dry dressing was placed over the closed surgical incision under sterile conditions at the end of the procedure. Neither the type of control dressing nor when the dressing was removed was reported.
- **Study date/s:** February to December 2014

**Outcomes**

- SSI
- blisters
- cost
- QoL

**Validity of measure/s:** no

**Time points:** 10 to 12 days postsurgery

**Notes**

Investigator contacted for additional details
Manoharan 2016 (Continued)

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Simple randomisation was performed by the research assistants via online computer software that indicated the side to which the intervention, NPWT, would be applied.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>The surgeons were notified on the day of surgery, before the commencement of the procedure. It was also unclear if consecutive patients for each of the 3 surgeons were recruited.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: “A final evaluation form at the outpatient review assessed the patients rated experience and preference for type of dressing. The final incision assessment was performed by the surgeon and clinic nurse and was witnessed by one of the research assistants. There were no independent observers attached to this assessment.”</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: Patients were aware of assignment, appeared that surgeons were not blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>The final incision assessment was performed by the surgeon and clinic nurse and witnessed by 1 of the research assistants. There were no independent observers attached to this assessment.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>It was unclear if all participants were accounted for in the results as the numbers analysed for each outcome were not stated.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported. Protocol retrospectively registered as ANZCTR 12615001350516.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>

Martin 2019

**Study characteristics**

**Methods**

- **Study design**: RCT
- **Study grouping**: parallel
- **Ethics and informed consent**: not reported
- **Follow-up period**: one year
- **Sample size estimate**: not reported
- **ITT analysis**: yes, number randomised: 40, number analysed: 40 (not clearly reported)
- **Funding**: Not stated
- **Preregistration**: Not stated

**Participants**

- **Location**: not reported
- **Intervention group**: 20, **control group**: 20
- **Mean age**: 60.82 years, **intervention group** NR, **control group** NR
- **Inclusion criteria**: patients undergoing hepatectomy or pancreatectomy
### Exclusion criteria

- not reported

### Interventions

**Aim/s:** to evaluate the effect of NPWT on SSI in this population (patients who have had hepatectomy or pancreatectomy)

**Group 1 (NPWT) intervention:** incisional NPWT (PICO TM, Smith & Nephew, Hull, UK)

**Group 2 (control) intervention:** sterile island dressing

**Study date/s:** not reported

### Outcomes

- SSI
- dehiscence

**Validity of measure/s:** Not reported

**Time points:** Not reported

### Notes

- Abstract only

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote &quot;Patients were randomised&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: method of generating randomisation sequence was not clear.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote &quot;Patients were randomised&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear if appropriate methods were used to conceal allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: appeared likely that it would be impossible to blind participants or personnel to treatment allocation but insufficient information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: unclear who assessed the outcomes or whether they were blinded to treatment allocation</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Comment: All participants appeared to be included in the analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Comment: insufficient information</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Comment: No evidence of other bias but insufficient information to be sure</td>
</tr>
</tbody>
</table>

### Study characteristics

**Methods**

**Study design:** randomised controlled trial

**Ethics and informed consent:** the study was approved by the Georgetown University Institutional Review Board. Consent was not specifically stated, but those patients not capable of undergoing informed consent were excluded.
Sample size calculation: yes
Follow-up period: mean 113 days
ITT analysis: available-case analysis
Funding: 2 of the investigators are consultants for KCI, and the study was funded by the manufacturer of the intervention product.

Participants
Location: Columbus, Ohio, USA

**Intervention group:** n = 50, **control group:** n = 43
Mean age: **intervention group** = 61.3 years (range 40 to 101), **control group** = 61.3 years (range 38 to 86)
Inclusion criteria: patients scheduled to undergo radial forearm free flap
Exclusion criteria: "patients not capable of undergoing informed consent and those patients with tape allergies or who otherwise could not tolerate NPWT ... patients with lower extremity amputations distal to the forefoot were excluded”.

Interventions
Aim/s: to evaluate the effect of NPWT on closed surgical incisions. Prospective randomised controlled clinical trial comparing NPWT to standard dry dressings on surgical incisions
Primary: "to evaluate the effectiveness of NPWT in patients with multiple comorbidities"
Secondary: "to evaluate factors that contribute to wound complication"

**Intervention/s in both groups:** "the graft was covered with a single layer of paraffin gauze dressing (Jelonet, Smith & Nephew, UK); then, 3 sheets of polyurethane (high-density foam, Nuris Luisa, Santiago, Chile) with a fenestrated silicone drainage tube between the layers was placed over the gauze and covered with a transparent adhesive dressing (Opsite, Smith & Nephew, UK) providing the vacuum seal. We used a double layer under the tube to prevent pressure ulcers at the bed of the suction tube”.

**Group 1 (NPWT) intervention:** "NPWT group ... underwent placement of a V.A.C. system (KCI, San Antonio, Texas) along the line of closure set at −125 mmHg continuous pressure at the time of closure”.

**Group 2 (control) intervention:** "the control group ... received a standard dry sterile dressing consisting of a non adhesive silicone layer (Mepitel, Mölnlycke Health Care AB, Göteborg, Sweden) and a bacteriostatic single silver layer (Acticoat, Smith & Nephew, Hull, UK)".

Study date/s: October 2008 to August 2010

Outcomes
- wound infection
- dehiscence
- reoperation
- LOS

Validity of measure/s: not stated

Time points: "all incisions assessed on the third postoperative day ... and reassessed at the first outpatient postoperative visit, as well as any subsequent visit (the last recorded infection was at 66 days post surgery)”. However, the abstract stated that "average follow-up was 113 days".

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk           | Evidence: quote (from correspondence with the author): "used a randomization generator through Excel in groups of 8 (4 controls, 4 experimental)"
|                                     |                    | Comment: adequate method                                   |
Masden 2012 (Continued)

Allocation concealment (selection bias) Low risk Evidence: quote (from correspondence with the author): "when the patient was recruited ... they contacted one of the investigators and the patient was assigned to whichever group was next on the list".

Comment: adequate method

Blinding of participants and personnel (performance bias) Unclear risk Evidence: Insufficient information

Blinding of outcome assessment (detection bias) Low risk Evidence: quote: "the evaluations were performed by a member of the research team not involved in the enrolment or the operative treatment and, thus, were blinded as to randomization group".

Comment: adequate method

Incomplete outcome data (attrition bias) Low risk Evidence: quote: "twelve subjects were lost to follow-up in the immediate postoperative period and were excluded from the final analysis".

Comment: equal number of losses in both groups

Selective reporting (reporting bias) Low risk Comment: protocol unavailable, but expected outcomes reported

Other bias Unclear risk Comment: the standard dressing contained a silver layer, which may have influenced the outcome.

Murphy 2019

Study characteristics

Methods

Study design: randomised controlled trial
Study grouping: 2 parallel groups
Ethics and informed consent: ethics approved and consent obtained
Follow-up period: 30 days
Sample size estimate: yes
ITT analysis: no, number randomised: 300, number analysed: 284; 16 participants "randomised in error") were not included in analysis
Funding: yes
Preregistration: yes

Participants

Location: two separate sites within a single hospital system (London Health Sciences Centre, London, Ontario, Canada)
Intervention group: 144 analysed, control group: 140 analysed
Mean age: intervention group 64 years, control group 64 years
Inclusion criteria: patients who were 18 years or older and scheduled for planned (elective) colorectal resection via laparotomy with midline incision (or booked for laparoscopy if converted to an open procedure with midline incision). Eligible surgical procedures included: segmental, subtotal or total colectomies, as well as low and ultra-low anterior resection.
Exclusion criteria: patients who undergoing abdominoperineal resection (APR), pelvic exenteration, emergent colectomy or patients with bowel perforation at the time of operation, who were pregnant, palliative (life expectancy under 3 months) or had a known sensitivity to the NPWT device

Interventions

Aim/s: to determine if negative pressure wound therapy (NPWT) reduces surgical site infection (SSI) in primarily closed incision after open and laparoscopic-converted colorectal surgery

Group 1 (NPWT) intervention: NPWT via a continuous vacuum set to -125 mm Hg which remained on until postoperative day (POD) 5 or the date of hospital discharge, whichever came first

Group 2 (control) intervention: gauze adhesive dressing which was removed on POD 2 and changed daily thereafter

Study date/s: January 2015 to February 2017

Outcomes

• SSI
• mortality
• reoperation

Validity of measure/s: not reported

Time points: 30 days postsurgery

Notes

Funding: industry grant from Kinetic Concepts Inc (San Antonio TX). The devices were also supplied free of charge.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: “Randomization will take place centrally using random permuted blocks of 4, 6 or 8 and will be stratified based on site (University Hospital or Victoria Hospital) of the operation.”  
Comment: adequate method |
| Allocation concealment (selection bias) | Low risk | Quote: “After the fascia is closed a member of the surgical team will use a centralized web-server to randomize the patient.”  
Comment: adequate method |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Quote: "we performed a single-institution, prospective, randomised, open label, blind endpoint trial".  
Comment: This was an open-label trial; participants and personnel were not blinded. |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | Quote: “The primary outcome was assessed by a blinded member of our Stoma Wound and Ostomy (SWOT) team or a physician uninvolved in the patient’s care at POD five if the patient was in hospital or on the date of discharge if prior to POD five, as well as at the postoperative clinic visit occurring within the first 30 postoperative days.”  
Comment: adequate method |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | Quote: “Sixteen patients were excluded from the main analysis. Of the 284 patients remaining, we analyzed patients according to assigned group (144 NPWT and 140 Standard Dressing). There was no difference in demographics, type, or surgery performed or indication for surgery between groups.” |
Murphy 2019 (Continued)

Comment: clear from the study how many participants were excluded; these 16 participants were excluded because they were randomised in error, with reasons given.

### Selective reporting (reporting bias)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting</td>
<td>High risk</td>
<td>“Secondary outcomes assessed will include the need for, and duration of, at-home nursing care (home care) related to SSI. Additional secondary outcomes assessed will include the length of hospital stay, the number of return visits related to a potential or actual SSI, and cost.” Comment: According to the protocol, some secondary outcomes were not reported in the results.</td>
</tr>
</tbody>
</table>

### Other bias

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No evidence of other risk of bias</td>
</tr>
</tbody>
</table>

Newman 2019

**Study characteristics**

### Methods

- **Study design:** Randomised controlled trial
- **Study grouping:** Parallel
- **Ethics and informed consent:**
- **Follow-up period:** 12 weeks
- **Sample size estimate:** determined using an estimated wound complication rate (associated with current standard of care protocols) of 20% and a desired wound complication rate of 5%. Using a significance level of 0.05 with a power of 80%, the sample was estimated at 160 total subjects, with 80 subjects assigned to each group.
- **ITT analysis:** yes, **number randomised:** 160, **number analysed:** 179
- **Funding:** KCI/Acelity Inc. (San Antonio TX)
- **Preregistration:** Yes

### Participants

- **Location:** US Hospital
- **Intervention group:** 80, **control group:** 80
- **Mean age:** intervention group 65 (SD 11), control group 65 (SD 11)
- **Inclusion criteria:** patients who were scheduled to undergo revision THA or TKA by one of the 6 fellowship-trained orthopaedic surgeons met at least one of the following criteria: body mass index greater than 35 kg/m², use of anticoagulants other than aspirin, peripheral vascular disease, depression, diabetes mellitus, current smoker, history of a periprosthetic joint infection in the limb undergoing revision surgery, on immunomodulators or corticosteroids, current history of cancer or haematological malignancy, inflammatory arthritis, renal failure or dialysis, malnutrition, liver disease, history of organ transplant, or human immunodeficiency virus infection
- **Exclusion criteria:** lived more than 100 miles from the hospital, less than 18 years of age, had a silver allergy, had a history of wound coverage with soft tissue flaps on the index joint, or had a recent acute wound complication (i.e. defined as less than 4 weeks since previous surgery in the affected joint). Additionally, patients were excluded if they were enrolled in another interventional study, had no risk factors, undergoing a conversion arthroplasty, were not having implants revised, surgery was cancelled, altered mental status, and were screened but already met enrolment capacity.

### Interventions

- **Aim/s:** to compare the use of ciNPWT with our standard of care dressing in revision arthroplasty patients who were at high risk to develop wound complications
Newman 2019  (Continued)

**Group 1 (NPWT) intervention:** cNPWT device (PREVENA; KCI/Acelity, San Antonio, TX) for at least 2 days unless a wound complication was reported

**Group 2 (control) intervention:** standard of care silver-impregnated wound dressing (AQUACEL; ConvaTec, Greensboro, NC) for at least 7 days unless a wound complication was reported

**Study date/s:** eligibility assessed from August 2014 to January 2017

### Outcomes
- SSI
- Dehiscence
- Haematoma
- Blisters
- Readmission
- Reoperation

**Validity of measure/s:** Clear definitions given but not using validated measures

**Time points:** 2, 4 and 12 weeks

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias)   | Low risk           | Quote "Patients who consented and enrolled to be included in the study were block randomised by categorizing as hip or knee surgery groups and then were assigned a sealed, opaque envelope that was randomly generated by an independent researcher who allocated them."
Comment: computer-generated randomisation sequence |
| Allocation concealment (selection bias)       | Low risk           | Quote "an independent researcher […] who allocated them groups and then were assigned a sealed, opaque envelope that was randomly generated by an independent researcher who allocated them to receive either a cNPWT device (PREVENA; KCI/Acelity, San Antonio, TX) or the standard of care silver-impregnated wound dressing (AQUACEL; ConvaTec, Greensboro, NC). The envelopes were opened on the day of surgery and the surgeon was informed as to which group the patient was randomly assigned at the time of dressing placement. After a patient consented to be involved in the study, the next sequential envelope was selected."
Comment: central allocation generated opaque sealed sequential envelopes. |
| Blinding of participants and personnel (performance bias) All outcomes | Unclear risk       | The nature of the intervention makes blinding of participants and some personnel very difficult but no clear information |
| Blinding of outcome assessment (detection bias) All outcomes | Unclear risk       | Quote "Wounds were examined at 2, 4, and 12 weeks after the procedure. Any complication reported was visualized at the time of the evaluation."
Comment: did not state who performed the outcome assessment or whether they were blinded to intervention group |
| Incomplete outcome data (attrition bias) All outcomes | Low risk           | Quote "One patient in the treatment arm was lost to follow-up and was not included in the analyses."
Comment: All except one participant were included in the analysis. |
Newman 2019 (Continued)

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>All of the planned outcomes were fully reported.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No evidence of additional bias and reasonable reporting to suggest none.</td>
</tr>
</tbody>
</table>

Nherera 2017

Study characteristics

Methods

- **Study design:** cost-effectiveness analysis (based on the Karlakki 2016 RCT)
- **Analytical approach:** Trial-based decision analytic model (Based on Karlakki 2016, N = 220)
- **Effectiveness data:** Data from the UK trial (Karlakki 2016)
- **Perspective:** UK National Health Service
- **Utility valuations:** Time horizon of 6 weeks for surgical site complications (SSI) avoided and length of stay. Expected complications in standard care taken from the RCT. No discount rate was applied due to the short time horizon. Complications were assumed to have standard costs, readmission was excluded from the base case. Utility values were obtained from converting quality of life that was measured using SF-36.
- **Measure of benefit:** surgical site complication avoided; QALY (obtained from the NICE guideline on surgical site infections 2008)
- **Cost data:** Costs derived from standard cost references with resource utilisation valued in GBP (2015/16). Costs were also converted to USD by factor 1.42. (1) NHS reference costs of relevant medical diagnosis groups used for inpatient care (with confidence intervals). Model assumes all standard care dressing costs and nursing costs included in these. (2) Cost of a GP visit taken from Unit Costs and Social Care 2015–2016; (3) costs of oral antibiotics taken from the national Drug Tariff; length of stay (not considered in costs) (4) Cost of NPWT was taken from the national Drug Tariff.
- **Analysis of uncertainty:** Sensitivity analysis used to model discounted price for intervention through NHS bulk purchasing; additional length of stay following complications and readmission. Baseline data were varied across the 95% CI from the trial. Probabilistic sensitivity analysis for cost-effectiveness at willingness-to-pay threshold

Participants

- **Location:** UK hospital
- **Intervention group:** n = 110, control group: n = 110
- **Mean age (SD): intervention group = 69 (9.0), control group = 69.2 (9.0)**
- **Inclusion criteria:** patients undergoing THAs or TKAs (for any indication) with 3 consultant surgeons (SLK, NMG, and RDB – authors of this study)
- **Exclusion criteria:** patients who had known allergies to dressing, were undergoing revision joint surgery, were unwilling to attend additional clinics, and those on warfarin were excluded.

Interventions

- **Aim/s:** To evaluate the cost-effectiveness of single-use negative pressure wound therapy in patients undergoing primary hip and knee replacements
- **Group 1 (NPWT) intervention:** Incisional negative pressure wound therapy dressing (INPWTD) PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for one week (n = 110).
- **Group 2 (Control) intervention:** conventional dressing (either Mepore (Möllycke Health Care AB) or Tegaderm (3M Health Care Ltd)) applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for an unspecified period, and changed to OPSITE Post-Op Visible dressing on the second post-operative day (n = 110).
All patients received enoxaparin postsurgery.

**Study date/s:** July 2012 to April 2014

### Outcomes

For data see Nherera 2017 and for clinical data see Karlakki 2016 in additional table 1

- Costs (GBP)
- SSI complications avoided
- QALY (measure of benefit)

**Probability of being cost-effective using NICE threshold of £20,000/QALY**

### Notes

Funding: two authors are employees of Smith & Nephew. The Karlakki 2016 RCT was funded by Smith & Nephew.

Authors’ conclusions: Single-use negative pressure wound therapy can be considered a cost-saving intervention to reduce surgical site complications following primary hip and knee replacements compared with standard care. Providers should consider targeting therapy to those patients at elevated risk of surgical site complications to maximise efficiency.

Quality rating using the CHEERS checklist was 85.4%.

---

### Study characteristics

#### Methods

| **Study design:** cost-effectiveness analysis (based partly on the Witt-Majchrzak 2015 RCT) |
| **Analytical approach:** Decision analytic model |
| **Effectiveness data:** baseline data on revision operations, length of stay, readmissions to hospital, and mortality were derived from single-centre prospective observational study over 36 months in Germany. Effectiveness data for NPWT were taken from the trial (n = 80) of Witt-Majchrzak 2015 (SSI and wound dehiscence). A length of stay reduction was applied from a meta-analysis (Strugala & Martin). All-cause mortality was obtained from German Federal Statistical Office and assumptions about relationship between mortality and revision surgery applied from literature. |
| **Perspective:** Germany Statutory Health Insurance payer |
| **Utility valuations:** Health state utilities were sourced from published literature including discharge with and without complications from study by Tuffaha 2015. |
| **Measure of benefit:** Wound healing without complications (complications avoided); QALY |
| **Cost data:** Costs derived from standard cost references, resource utilisation valued in Euro. Inpatient care taken data from Cristofolini. Patient stay costs from hospital management site; reimbursement cost for procedure from Germany Diagnosis Related group Report Browser 2017. Standard care dressing’s costs and nursing costs covered in the diagnosis-related group costs. Rehabilitation costs obtained from a study by Zeidler. One community doctor and cardiologist visit cost, and the cost of community nurse visit once a week estimated. No discounting done due to a short time horizon (12 weeks). |
| **Analysis of uncertainty:** One-way sensitivity analyses; probabilistic sensitivity analyses using Monte Carlo simulation; subgroup analysis for people with high BMI. |

#### Participants

| **Location:** Hospital, Poland |
| **Intervention group:** n = 40, **control group:** n = 40 |

**Mean age:** intervention group = 66.2 (± 8), 53 to 80, control group = 62.1 (± 9.1), 41 to 78

**Inclusion criteria:** patients who underwent an off-pump coronary artery bypass grafting procedure, using the internal mammary artery
**Exclusion criteria:** not stated

**Interventions**

**Aim/s:** To estimate the cost-effectiveness of single use negative pressure wound therapy (sNPWT) compared with standard of care in patients following coronary artery bypass grafting surgery (CABG) procedure to reduce surgical site complications (SSC) defined as dehiscence and sternotomy infections.

**Group 1 (NPWT) intervention:** Primary closure with NPWT (PICO, Smith & Nephew) using continuous negative pressure of −80 mmHg. Dressing changed on day 2 or 3 and on day 5 or 6 after surgery.

**Group 2 (control)** Conventional dressings applied after primary closure. Dressings changed daily.

**Study date/s:** not stated

**Outcomes**

**Outcomes** (for data see additional table 1; for clinical data see Witt-Majchrzak 2015)

**Costs**

Wound healing without complication (complications avoided); QALY (measure of benefit)

**ICER**

Probability of being cost-effective

**Notes**

Authors' conclusions: The sNPWT can be considered a cost-saving intervention that reduces surgical site complications following CABG surgery compared with standard care. However, we recommend that additional economic studies should be conducted as new evidence on the use of sNPWT in CABG patients becomes available to validate the results of this economic analysis.

Funding: NR for economic evaluation; see Witt-Majchrzak 2015 for RCT funding

Quality rating using the CHEERS checklist was 87.0%.

---

**Nordmeyer 2016**

**Study characteristics**

**Methods**

**Study design:** randomised controlled trial

**Study grouping:** parallel

**Ethics and informed consent:** yes

**Sample size estimate:** no

**Follow-up period:** unknown

**ITT analysis:** yes, **number randomised:** 20, **number analysed:** unclear

**Funding:** unclear. MHB gave scientific presentations for KCI.

**Preregistration:** no

**Participants**

**Location:** Nuremberg, Germany

**Intervention group:** n = 10, **control group:** n = 10

**Mean age:** intervention group = 52.3 (16.3), control group = 57.8 (15.2)

**Inclusion criteria:** patients with spinal fractures who were scheduled for internal fixation

**Exclusion criteria:** not reported

**Interventions**

**Aim/s:** to evaluate the different aspects of wound healing in spinal fractures treated with internal fixation
Group 1 (NPWT) intervention: the NPWT group was treated with a PICO system (Smith & Nephew, UK). The PICO system was left on the wound for 5 days including the day of surgery. In addition to daily clinical examination, all wounds/seroma were analysed by ultrasonography on day 5 and day 10 after surgery.

Group 2 (control) intervention: standard department wound dressing consisting of dry wound coverage (compresses attached to the skin) was used.

Study date/s: not reported

Outcomes

- seroma

Validity of measure/s: ultrasound was used as a standardised imaging modality to detect seromas in the wound area.

Time points: day 5 and day 10 after surgery

Notes

Investigator contacted for additional details

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Numbers analysed were not reported.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Only seroma reported, not wound infection; unclear if all planned outcomes addressed.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
</tr>
</tbody>
</table>

O’Leary 2017

Study characteristics

Methods

- Study design: randomised controlled trial
- Study grouping: parallel
- Ethics and informed consent: yes
- Sample size estimate: yes, but it was based on a reduction in SSI from 35% to 10%
ITT analysis: yes, number randomised: 50, number analysed: 49

Follow-up period: 30 days

Funding: support was received from Smith & Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors.

Preregistration: ClinicalTrials.gov registration NCT02780453 (registered after study completed – May 2016)

Participants

Location: Limerick, Ireland
Intervention group: n = 25, control group: n = 25
Mean age: intervention group = 58 (range 31 to 73), control group = 63 (range 33 to 76) Inclusion criteria: patients undergoing elective or emergency open abdominal surgery with a clean, clean-contaminated, or contaminated wound Exclusion criteria: dirty wound; BMI ≥ 40; ASA grade > 3

Interventions

Aim/s: to assess the effect of NPWT on SSI

Group 1 (NPWT) intervention: PICO dressing (Smith & Nephew) was applied to the wound by the operating surgeon, and the edges of the dressing were reinforced with self adherent tape.

Group 2 (control) intervention: transparent waterproof dressing (Smith & Nephew) Study date/s: February 2013 to April 2016

Outcomes

• SSI
• reoperation
• pain

Validity of measure/s: CDC definitions and criteria for superficial, deep, and organ/space SSI were used for the primary outcome. A visual analogue scale was used to assess pain.

Time points: day 4 and day 30 postsurgery

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation codes were generated on <a href="http://www.randomization.com">www.randomization.com</a>.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation was performed using a &quot;closed envelope method&quot;.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote &quot;A randomised, controlled, open-label trial&quot; Comment: no blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Quote: &quot;the ... study assessor was a senior member of the operating surgical team. The study assessor was not blinded to the treatment group&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>1 participant was removed from the intervention arm for a protocol violation, but ITT analysis was provided.</td>
</tr>
</tbody>
</table>
### O’Leary 2017 (Continued)

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>Expected outcomes reported, but the study protocol was published after the completion of the trial.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias identified</td>
</tr>
</tbody>
</table>

### Pachowsky 2012

#### Study characteristics

**Methods**
- **Study design**: randomised controlled trial
- **Ethics and informed consent**: ethics approved and consent obtained.
- **Sample size calculation**: no
- **ITT analysis**: yes, **number randomised**: 19, **number analysed**: 19
- **Follow-up period**: 10 days
- **Funding**: support received from Smith & Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors.
- **Preregistration**: no

**Participants**
- **Location**: University Hospital, Erlangen, Germany
  - **Intervention group**: n = 9, **control group**: n = 10
  - **Mean age**: intervention group = 66.2 years (SD 17.83), control group = 70.0 years (SD 11.01)
  - **Inclusion criteria**: “consecutive patients who were scheduled for a total hip arthroplasty (THA) for osteoarthritis of the hip were randomised”.
  - **Exclusion criteria**: not stated

**Interventions**
- **Aim/s**: to evaluate the use of NPWT to improve wound healing after total hip arthroplasty
- **Intervention/s in both groups**: “the surgical intervention was identical for both groups. All patients received two Redon drains, one in the deep area of the wound close to the prostheses and one above the closed fascia. The postoperative physiotherapy and mobilisation was also identical for both groups. Both groups received perioperative prophylaxis with antibiotics either Augmentin (amoxicillin trihydrate with potassium clavulanate) or ciprofloxacin”.
  - **Group 1 (NPWT) intervention**: “the NPWT group was treated with a PREVENA™ system (KCI, San Antonio, USA). The PREVENA system was left on the wound for five days including the day of surgery”.
  - **Group 2 control**: the control group received “the standard wound dressing of our department, consisting of a dry wound coverage”.
- **Study date/s**: not stated

**Outcomes**
- incidence of seroma (by ultrasound)
- amount of wound drainage in the Redon drain canisters
- duration of prophylactic antibiotics
- secretion from the wound

**Validity of measure/s**: "all patients underwent an ultrasound (Zonare, Z.one Ultra SP 4.2, Erlangen, ZONARE Medical Systems, Inc., Mountain View, USA) of the wound”.

**Time points**: day 5 and day 10 of postoperative period

**Notes**
Pachowsky 2012 (Continued)

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Dressings were left in place for 5 days. The ultrasound was performed on day 5. It was unclear if the person performing the ultrasound was aware of the group to which the participant had been allocated.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All enrolled participants were accounted for in the analyses.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Evidence: quote: &quot;Matthias H. Brem gave scientific presentations for KCI. The PREVENA wound treatment system was provided by KCI free of charge&quot;. Support was received from Smith &amp; Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors. 1 participant in the NPWT group removed the Redon drain by himself on the first postoperative day.</td>
</tr>
</tbody>
</table>

Pauser 2016

Study characteristics

Methods

Study design: randomised controlled trial
Study grouping: parallel
Ethics and informed consent: yes
Sample size estimate: no
Follow-up period: 10 days
ITT analysis: yes, number randomised: 21, number analysed: 21
Funding: "Prevena wound treatment system was provided by KCI free of charge".
Preregistration: no

Participants

Location: Nuremberg, Germany
Intervention group: n = 11, control group: n = 10
### Pauser 2016 (Continued)

**Mean age:** intervention group = 81.6 ± 5.2 years, control group = 82.6 ± 8.6 years  
**Inclusion criteria:** patients with femoral neck fracture who were scheduled for hip hemiarthroplasty  
**Exclusion criteria:** not stated

#### Interventions

**Aim/s:** "to evaluate different aspects of wound healing after fractures of the femoral neck treated by hemiarthroplasty"

**Group 1 (NPWT) intervention:** the NPWT group was treated with a PREVENA system (KCI, San Antonio, Texas). The PREVENA system was left on the wound for 5 days including the day of surgery.

**Group 2 control:** control group received the standard wound dressing of our department, consisting of a dry wound coverage (compresses attached to the skin).

**Study date/s:** not reported

#### Outcomes

- **seroma**

**Validity of measure/s:** ultrasound was used as a standardised imaging modality to detect seromas in the wound area.

**Time points:** day 5 and day 10 after surgery

#### Notes

Investigator contacted for additional details

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All those recruited appear to have been included in the analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unclear if all the planned outcomes were reported fully</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Data for the NPWT group reported at day 5 and day 10, but data for the control group only reported overall</td>
</tr>
</tbody>
</table>

### Pleger 2018

#### Study characteristics

**Methods**

**Study design:** randomised controlled trial
Study grouping: parallel
Ethics and informed consent: yes
Sample size estimate: no
Follow-up period: 30 days postoperatively
ITT analysis: yes, number randomised: 129 groin incisions (100 participants), number analysed: 129 incisions
Funding: “funded by our own department, without any financial or scientific involvement or support from KCI, ACELITY Company”
Preregistration: no

Participants
Location: Germany
Intervention group: n = 58 incisions, control group: n = 71 incisions
Mean age: intervention group = 71 (range 54 to 89), control group = 66.5 (range 41 to 86)
Inclusion criteria: vascular procedures with access to the common femoral artery with at least 1 of the known main risk factors of wound healing: age > 50 years, diabetes mellitus, renal insufficiency, malnutrition, obesity, and chronic obstructive pulmonary disease
Exclusion criteria: not stated

Interventions
Aim/s: to investigate the effectiveness of cNPT compared with conventional therapy with regard to the incidence of groin WHC on postoperative days 5 to 7 and 30 and the incidence of surgery revisions 30 days postoperatively after various vascular surgeries
Group 1 (NPWT) intervention: cNPT applied for postoperative days 5 to 7
Group 2 (control) intervention: a conventional adhesive plaster that was changed daily
Study date/s: 1 February to 30 October 2015

Outcomes
- wound complications including SSI
Validity of measure/s: Szilagyi classification
Time points: the first evaluation took place on postoperative days 5 to 7 during the hospital stay, while the second evaluation was conducted on postoperative day 30 in the outpatient clinic.

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
</tbody>
</table>
**Pleger 2018 (Continued)**

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias)</th>
<th>Low risk</th>
<th>All those recruited appear to have been included in the analysis.</th>
</tr>
</thead>
<tbody>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Selective reporting (reporting bias)</th>
<th>Low risk</th>
<th>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Unclear risk</th>
<th>Unequal number of participants in each group; results reported per fracture, so there is a potential unit of analysis issue.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Ruhstaller 2017**

**Study characteristics**

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** not reported
- **Follow-up period:** not reported
- **Sample size estimate:** not reported
- **ITT analysis:** yes, **number randomised:** 136, **number analysed:** not stated

**Funding:** KCI collaborated in the trial.

**Preregistration:** yes

**Participants**

- **Location:** Philadelphia, USA
- **Intervention group:** n = 67, **control group:** n = 69

- **Mean age:** not reported

- **Inclusion criteria:** BMI greater than or equal to 30 kg/m² at less than or equal to 22 weeks of gestation; woman is labouring; woman is having an unplanned caesarean section; woman will have Pfannenstiel skin incision; has the ability to take a picture and email it to a secure account; receives prenatal care in the University of Pennsylvania health system and plans to follow up postpartum in the system; is 18 years of age or older

- **Exclusion criteria:** woman cannot read or speak English; is not 18 years of age or older; does not have ability to send a picture by email; has pre-existing diabetes mellitus (type 1 or type 2), is using chronic steroids or immunosuppressants, OR is being actively treated for a malignancy; woman is undergoing a scheduled caesarean section; woman is allergic to silver

**Interventions**

- **Aim/s:** to determine whether NPWT lowers the rate of wound complications in obese pregnant women undergoing an unscheduled intrapartum caesarean section

- **Group 1 (NPWT) intervention:** NPWT device (PREVENA Incision Management System; Acelity)

- **Group 2 control:** standard postcaesarean wound care (not defined)

- **Study date/s:** not stated

**Outcomes**

- **Planned outcomes:**
  - primary outcome variable is wound complications defined as:
    - any readmission for a wound issue within 4 weeks of discharge;
    - infection;
    - wound breakdown.
  - quality of life
### Ruhstaller 2017 (Continued)

**Reported outcomes:**
- SSI
- blisters
- reoperation

**Validity of measures:** not reported

**Time points:** 4 weeks postsurgery

**Notes**
Only the abstract and CTR report were available at the time of preparation of this review. Investigator contacted for additional details

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Once decision for caesarean delivery was established, randomisation was performed using a computer-generated randomisation scheme (Research Electronic Data Capture (REDCap)).</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td><strong>Intervention group:</strong> n = 61/67 (91%); <strong>control group:</strong> n = 58/69 (84%). It was unclear from the abstract if reasons for loss to follow-up were similar across groups.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Results for outcomes identified in the methods section were reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No other bias identified but insufficient reporting</td>
</tr>
</tbody>
</table>

### Sabat 2016

#### Study characteristics

**Methods**

- **Study design:** 1:1 parallel-group randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Sample size estimate:** no
- **Follow-up period:** 4 months
- **ITT analysis:** no
Sabat 2016

### Participants
- **Location:** Philadelphia, USA
- **Intervention group:** n = 33 wounds, **control group:** n = 30 wounds (total 49 participants)
- **Mean age:** not reported
- **Inclusion criteria:** people undergoing open vascular surgery involving a groin incision
- **Exclusion criteria:** not stated

### Interventions
- **Aim/s:** to compare the effect of postoperative negative pressure therapy to conventional dressings on wound occurrences
- **Group 1 (NPWT) intervention:** NPWT device
- **Group 2 control:** conventional dressing (gauze and Tegaderm)
- **Study date/s:** not stated

### Outcomes
- SSI
- Wound dehiscence

### Notes
- Abstract only; unit analysis

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>All those recruited appear to have been included in the analysis.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unit of analysis issue - unclear if accounted for</td>
</tr>
</tbody>
</table>

Schmid 2018

### Study characteristics

#### Methods
- **Study design:** Randomised controlled trial
Study grouping: Parallel group
Ethics and informed consent: Not reported
Follow-up period: 14 days
Sample size estimate: Not reported
ITT analysis: number randomised: 25, number analysed: 25
Funding: Not reported
Preregistration: Yes

Participants
Location: Germany
Intervention group: n = 25, control group: n = 25
Mean age: intervention group: Not reported, control group: Not reported
Inclusion criteria: Patients with penile cancer and indication for bilateral inguinal lymph node dissection (tumour stage ≥ pT1 G2 or palpable inguinal enlarged lymph nodes)
Exclusion criteria: Status post inguinal surgery

Interventions
Aim/s: To prospectively analyse the effect of an epidermal vacuum wound dressing on lymphorroe, complications and reintervention in patients with inguinal lymphadenectomy for penile cancer
Group 1 (NPWT) intervention: Epidermal negative-pressure wound dressings (Prevena) for 7-8 days
Group 2 (control) intervention: Conventional compression bandages for 24 hours
Study date/s: May 2013 –

Outcomes
• Reintervention (reoperation?)
• SSI may be included in wound complications but not reported
Validity of measure/s: No definition of SSI reported
Time points: 14 days

Notes
Planned interim analysis. Abstract only

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote “Patients were randomised to receive conventional wound care and suction drainage on one side (conventional) vs. epidermal vacuum wound dressing (VAC) and suction drainage on the other side”. Comment: No indication how the randomisation sequence was generated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No statement</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Open study (no masking) (obtained from protocol)</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>High risk</td>
<td>Open study (no masking) (obtained from protocol)</td>
</tr>
</tbody>
</table>
Incomplete outcome data (attrition bias) | Low risk | Quote “We present the results of the first planned interim analysis after 25 patients”.

Selective reporting (reporting bias) | High risk | Not all prespecified secondary outcomes reported (obtained from protocol)

Other bias | Unclear risk | Abstract so limited reporting - no obvious source of bias but insufficient information to be certain

### Study characteristics

**Methods**

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes

Sample size estimate: yes (based on a real SSI reduction of 6% from 17% to 11%)

Follow-up period: 30 days

ITT analysis: yes, number randomised: 375, number analysed: 265

Funding: non-industry

Preregistration: yes

**Participants**

Location: Wake Forest University Health Sciences, North Carolina, USA

Intervention group: n = 187, control group: n = 188

Median age (range): intervention group = 59.5 (25 to 85), control group = 62 (30 to 81)

Inclusion criteria: patients who underwent open resection of intra-abdominal neoplasms, where the scheduled procedure was to be performed via midline laparotomy and was a clean-contaminated (class II) case (includes gastric, small bowel, and colorectal resections, as well as bile or pancreatic duct transections); the patient had the ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorised representative)

Exclusion criteria: emergent cases; pregnant patients; clean (class I), contaminated (class III), and dirty (class IV) procedures; patients on chronic immunosuppressive medications, including steroids, within the past 3 months; patients with a history of skin allergy to iodine or adhesive drapes were not included in the study

**Interventions**

**Aim/s:** to decrease the incidence of superficial and deep SSIs

Group 1 (NPWT) intervention: PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

Group 2 control: Comfeel dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

**Study date/s:** July 2012 to April 2014

**Outcomes**

- SSI
- seroma
- haematoma
Shen 2017 (Continued)

- incisional cellulitis
- dehiscence
- wound opening for any reason

Validity of measure/s: CDC definitions for SSI were used.

Time points: 30 days after surgery

Notes
Investigator contacted for additional details

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “the program nQuery was used to create the randomization schema”. The study used permuted-block randomisation with varying block sizes.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “an email was sent the day before surgery to the attending surgeon about to which treatment arm the patient had been assigned”. Comment: scope for surgeons to anticipate the randomisation sequence</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: “There was no blinding of the patients or care providers to the study intervention. An email was sent the day before surgery to the attending surgeon about to which treatment arm the patient had been assigned”. Comment: patients and participants were not blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Investigator team assessed outcomes.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Approximately 30% of participants were lost to follow-up or excluded from each arm of the trial. However, reasons for losses were similar between groups. NPWT group: 2 died and 19 were reoperated; standard care group: 5 died and 16 were reoperated</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Prospectively reported. Outcomes were consistent with proposal (National Cancer Institute CCSG P30CA012197).</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias identified</td>
</tr>
</tbody>
</table>

Shim 2018

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes

Follow-up period: 1 year

Sample size estimate: no

ITT analysis: yes, number randomised: 51, number analysed: 51
Funding: Not reported
Preregistration: Not reported

Participants

Location: Korea; single-centre (hospital)

Intervention group: 30, control group: 21

Mean age: intervention group 38.77 ± 1.68, control group 41.38 ± 10.92

Inclusion criteria: > 20 years, acute multi-tissue hand injury of moderate severity (assessed by HISS score 21-50), underwent reconstruction within 3 days after injury by two surgeons

Exclusion criteria: history of impaired motor function, injury to the peripheral nerves and/or vessels distal to the wrist, or a bone fracture requiring transarticular fixation with a Kirchner (K) wire, a congenital hand deformity, an operation history on the same hand, and underlying diseases including autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus or those taking medications that could influence wound healing

Interventions

Aim/s: To compare outcomes in patients with acute hand injury who were managed with or without NPWT after reconstructive surgery

Group 1 (NPWT) intervention: NPWT (CuravAC, CGBio, Seongnam-si, Gyeonggi-do, Korea) applied at a pressure of 75 mmHg in continuous mode and secondary dressing including Vaseline gauze

Group 2 (control) intervention: Conventional dressing, including vaseline gauze was applied over the closed skin using polyurethane foam with a compressible elastic bandage, and a short arm splint was applied in a functional position; dressing and NPWT were changed every 3 days.

Study date/s: January 2013 - December 2016

Outcomes

• SSI/infection
• haematoma
• wound disruption (dehiscence)

Validity of measure/s: unclear what definition was used for infection

Time points: 1 month and 1 year

Notes

Risk of bias

Bias Authors’ judgement Support for judgement
Random sequence generation (selection bias) Low risk Quote: "Patients were randomly assigned to the control or experimental group following a simple randomization procedure (computerized random numbers) achieved using opaque envelopes".
Comment: randomisation with computer

Allocation concealment (selection bias) Unclear risk Quote: "Patients were randomly assigned to the control or experimental group following a simple randomization procedure (computerized random numbers) achieved using opaque envelopes. Allocation information to each group was not provided to reduce bias".
Comment: allocation concealed with opaque envelopes but these were not noted as sequentially numbered

Blinding of participants and personnel (performance bias) All outcomes High risk Quote "This was a prospective open trial".
Comment: No blinding of participants or personnel
### Shim 2018 (Continued)

<table>
<thead>
<tr>
<th>Risk of Bias</th>
<th>Outcome</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blinding of outcome assessment (detection bias)</strong></td>
<td>All outcomes</td>
<td>High risk</td>
</tr>
<tr>
<td><strong>Incomplete outcome data (attrition bias)</strong></td>
<td>All outcomes</td>
<td>Low risk</td>
</tr>
<tr>
<td><strong>Selective reporting (reporting bias)</strong></td>
<td>All outcomes</td>
<td>Low risk</td>
</tr>
<tr>
<td><strong>Other bias</strong></td>
<td></td>
<td>Unclear risk</td>
</tr>
</tbody>
</table>

### Study characteristics

#### Methods

**Study design:** multicentre randomised controlled trial (four centres, each a level 1 trauma centre)

**Ethics and informed consent:** ethics approved and consent obtained

**Sample size calculation:** no

**Follow-up period:** not reported

**ITT analysis:** wounds, not people were assessed

**Funding:** “funds from corporate/industry were received from Kinetic Concepts, Inc to support this work”.

#### Participants

**Location:** Columbus, Ohio, USA

**Intervention group:** n = 130, participants; 141 fractures, **control group:** n = 119 participants; 122 fractures

**Mean age:** not stated

**Inclusion criteria:** people > 18 years of age who had sustained a high-energy tibial plateau, pilon, or calcaneus fracture and were able to comply with research protocol and willing to give informed consent

**Exclusion criteria:** non-operative calcaneus, tibia plateau, or pilon fractures; patients with open calcaneus fractures; tibial plateau or calcaneus fractures receiving definitive surgery more than 16 days after injury; pilon fractures receiving definitive surgery more than 21 days after injury; prisoners; pregnant women; patients with one of these fractures as a result of a low-energy mechanism of injury; patients or family members unable or unwilling to sign study informed consent; and patients unable to comply with the protocol

#### Interventions

**Aim/s:** "to investigate the use of NPWT to prevent wound dehiscence and infection after high-risk lower extremity trauma"

**Intervention/s in both groups:** dressings or NPWT were applied in the operating room and then changed on postoperative day 2 and every 1 to 2 days thereafter.

**Group 1 (NPWT) intervention:** NPWT over the surgical incision after open reduction and internal fixation of the fracture

**Group 2 (control) intervention:** standard postoperative dressing (dressing not described)

**Study date/s:** not stated

#### Outcomes

- wound infection and dehiscence
- time to discharge from hospital
### Stannard 2012 (Continued)

<table>
<thead>
<tr>
<th>Validity of measure/s:</th>
<th>&quot;all infections were confirmed with cultures&quot;.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time points:</td>
<td>not stated - unclear for how long participants were followed up</td>
</tr>
</tbody>
</table>

#### Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Evidence: quote: &quot;patients were enrolled and then randomised to receive either standard postoperative dressings (control) or NPWT (study)&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: additional author information: &quot;the randomization was done via a computer generated randomization program&quot;.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Comment: method not clarified</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Evidence for participants: not possible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unlikely to affect outcomes</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Evidence for personnel: not possible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unlikely to affect outcomes</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Evidence: quote: &quot;a patient was diagnosed as having an infection when a combination of clinical signs and symptoms (purulent drainage, erythema, fever, chills, etc) and laboratory data documented the infection. All infections were confirmed with cultures. Wound dehiscence was defined as any separation of the surgical incision that required either local wound care or surgical treatment&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: not clear whether those assessing outcomes were aware of group assignment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Comment: a total of 249 participants were recruited. The same number of participants were reported for both acute and long-term follow-up (follow-up period not defined). Given that 4 hospitals were involved in the study, it seems unusual that complete follow-up would have occurred, suggesting that an available-case analysis may have been performed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: registered in CTR (NCT00582998) 9 months after final data collection date, so it is unclear whether reported outcomes matched the original protocol. However, infection and dehiscence were the expected outcomes.</td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Comment:</td>
</tr>
</tbody>
</table>

• unequal number of participants in each group
• appeared from the protocol that data collection was over many years, but no dates or explanation in manuscript
• results reported per fracture, so there is a potential unit of analysis issue

### Tanaydin 2018

#### Study characteristics
Methods

**Study design:** randomised controlled trial

**Study grouping:** parallel

**Ethics and informed consent:** ethics approved and consent obtained

**Sample size calculation:** no

**Follow-up period:** 365 days postsurgery

**ITT analysis:** wounds (breasts), not people were assessed

**Funding:** funded by Smith & Nephew Ltd, who provided the PICO dressings and the Cutometer and financed a research assistant for carrying out the assessments and measurements

Participants

**Location:** the Netherlands

**Intervention group:** n = 32, **control group:** n = 32 (participants served as their own control)

**Mean age (range):** 40.9 (18 to 61)

**Inclusion criteria:** patients > 18 years of age who underwent bilateral superomedial pedicle Wise-pattern breast reduction mammoplasty and had postsurgical incisions of similar length on each breast

**Exclusion criteria:** pregnancy or lactation, using steroids, or other immune modulators known to affect wound healing; history of radiation of the breast; tattoos in the area of the incision; skin conditions such as cutis laxa that would result in poor healing or widen scars, history of radiation of the breast, patients with a known significant history of hypertrophic scarring or keloids, and postsurgical incisions still actively bleeding, exposure of blood vessels, organs, bone, or tendon at the base of the reference wound; and incisions > 12 inches (30 cm) maximum linear dimension

Interventions

**Aim/s:** to evaluate the effectiveness of postsurgery incision treatment comparing a portable disposable NPWT system with standard care using fixation strips

**Group 1 (NPWT) intervention:** a single-use NPWT system without an exudate canister

**Group 2 (control) intervention:** fixation strips (Steri-Strip; 3M, St Paul, Minnesota, USA)

**Study date/s:** 1 June 2012 to 9 April 2014

Outcomes

- the number of wound-healing complications within 21 days
- aesthetic appearance and quality of scarring (additional measurements at 42, 90, 180, and 365 days)

**Validity of measure/s:** wound-healing complications were defined as delayed healing (surgical incision not 100% closed at day 7 postsurgery), or occurrence of dehiscence or infection within 21 days postsurgery

**Time points:** all included participants (N = 32) had follow-up visits and assessments at screening (pre-surgery), day 0 (baseline, postsurgery), day 7, 21, 42, 90, 180, and 365 postsurgery.

Notes

The breasts were randomised and served as own control.

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomization was used for allocation of NPWT and fixation strip to the right or left breast incision site per patient, using sealed envelopes. Treatment site information was accessed digitally (<a href="http://www.sealedenvelope.com">www.sealedenvelope.com</a>) upon the start of the treatment postsurgically.&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomization was used for allocation of NPWT and fixation strip to the right or left breast incision site per patient, using sealed envelopes. Treat-</td>
</tr>
</tbody>
</table>
### Tanaydin 2018 (Continued)

- **Blinding of participants and personnel (performance bias)**
  - All outcomes: High risk
  - Quote: "As NPWT and fixation strips are optically different, blinding of the physician and patients was not feasible".
  - Comment: Appears to be a web-based allocation centre

- **Blinding of outcome assessment (detection bias)**
  - All outcomes: Low risk
  - Quote: "As NPWT and fixation strips are optically different, blinding of the physician and patients was not feasible; however, data analysis was performed blinded".

- **Incomplete outcome data (attrition bias)**
  - All outcomes: Low risk
  - 32 enrolled participants were accounted for in the analyses.

- **Selective reporting (reporting bias)**
  - All outcomes: Low risk
  - Expected outcomes reported. Protocol retrospectively registered as NL40698.068.12/METC12-3-026

- **Other bias**
  - Unclear risk
  - This was a 'split-body' or 'intra-individual' design where a person with 2 wounds had 1 wound randomised to each treatment. It was not clear whether the analysis took this into account.

### Tuuli 2017

#### Study characteristics

**Methods**

- **Study design:** randomised controlled trial (abstract only available)
- **Study grouping:** parallel
- **Ethics and informed consent:** not recorded
- **Sample size estimate:** not recorded
- **Follow-up period:** 30 days
- **ITT analysis:** yes, **number randomised:** 120, **number analysed:** 120
- **Funding:** non-industry
- **Preregistration:** yes ([NCT02578745](https://clinicaltrials.gov/ct2/show/NCT02578745)). Registered 11 June 2012

**Participants**

- **Location:** St Louis, Missouri, USA
- **Intervention group:** n = 60, **control group:** n = 60
- **Mean age:** not recorded
- **Inclusion criteria:**
  - gestational age ≥ 23 weeks
  - BMI ≥ 30 at the time of delivery
  - planned or unplanned caesarean delivery (procedure in which NPWT is being tested)
- **Exclusion criteria:**
  - not available for postoperative follow-up
### Interventions

**Aim/s:** to assess the feasibility of a definitive RCT to test the effectiveness and safety of prophylactic NPWT in obese women after caesarean section

**Group 1 (NPWT) intervention:** prophylactic NPWT with the PICO device (Smith & Nephew). Removed at discharge (usually on day 4)

**Group 2 (control) intervention:** standard wound dressing (routine postoperative wound dressing consisting of layers of gauze and adhesive tape). The dressing was removed 24 to 48 hours.

**Study date/s:** October 2016 to March 2016

### Outcomes

**Primary outcome/s:** composite of superficial or deep surgical site infection; wound separation ≥ 2 cm; SSI; haematoma; seroma

**Secondary outcome/s:** pain score on postoperative day 2 and skin reactions

**Validity of measure/s:** wound infection defined by CDC criteria (information extracted from CTR)

**Time points:** 30 days

### Notes

Investigator contacted for additional details

---

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Abstract indicated that 120 participants were randomised and 120 analysed. This was consistent with the number proposed in NCT02578745.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Reporting was consistent with outcomes proposed in NCT02578745.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>None detected. Independently funded trial, however no baseline data presented.</td>
</tr>
</tbody>
</table>
**Hussamy 2017 (Continued)**

### Methods

- **Study design:** randomised controlled trial
- **Ethics and informed consent:** not reported
- **Sample size calculation:** yes
- **Follow-up period:** not stated
- **ITT analysis:** yes
- **Funding:** not stated

### Participants

- **Location:** Texas, USA
- **Intervention group:** n = 222, **control group:** n = 219
- **Mean age:** not reported
- **Inclusion criteria:** women with class III obesity (BMI > 40 kg/m²) undergoing caesarean delivery
- **Exclusion criteria:** women on anticoagulation, with HIV infection, sensitive skin disorders, or silver or acrylic allergies

### Interventions

- **Aim/s:** to compare the efficacy of closed incision negative pressure therapy (cNPT) with a standard surgical dressing in the prevention of postoperative wound morbidity in women with class III obesity undergoing caesarean delivery
- **Group 1 (NPWT) intervention:** a cNPT dressing at time of caesarean
- **Group 2 (control) intervention:** a standard surgical dressing
- **Study date/s:** January 2015 to July 2016 (18 months)

### Outcomes

- Wound morbidity including wound disruption requiring the use of antimicrobials, prolonged postoperative hospitalisation, hospital readmission, or reoperation within 30 days of delivery
- **Validity of measure/s:** not stated
- **Time points:** not stated

### Notes

- Only the abstract was available.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>441 participants were enrolled and analysed.</td>
</tr>
</tbody>
</table>

---

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Selective reporting (reporting bias)**

<table>
<thead>
<tr>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low</td>
<td>Expected outcomes were reported in the abstract.</td>
</tr>
<tr>
<td>Unclear</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

**Hussamy 2017** (Continued)

**Other bias**

<table>
<thead>
<tr>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unclear</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

**Hyldig 2019a**

**Study characteristics**

**Methods**

- **Study design:** pragmatic randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 30 days
- **Sample size estimate:** yes; a sample size of 870 for a reduction in surgical site infection of 50% in the intervention group compared with an expected baseline event rate of 10% in the control group, with a two-sided 5% significance level and a power of 80%
- **ITT analysis:** yes (for surgical site infection only), **number randomised:** 876, **number analysed:** 876 for surgical site infection and 827 for other outcomes
- **Funding:** grants from the University of Southern Denmark, Odense University Hospital, the Region of Southern Denmark, Lundbeckfonden, and an unrestricted grant from the INPWT device manufacturer Smith & Nephew (devices and operating funding)
- **Preregistration:** yes; ClinicalTrials.gov (NCT 01890720)

**Participants**

- **Location:** Denmark (two tertiary referral centres and three Danish teaching hospitals)
- **Intervention group:** n = 432, **control group:** n = 444 (6 received INWPT dressing)
- **Mean age:** a range from 18 to 46 years across groups; **intervention group:** 32 (SD 5), **control group** 32 (SD 5)
- **Inclusion criteria:** pregnant women undergoing elective or emergency caesarean section, aged >= 18 years; who had a prepregnancy body mass index >= 30 kg/m2, and could read and understand Danish
- **Exclusion criteria:** women who had given informed consent but subsequently delivered vaginally

**Interventions**

- **Aim/s:** to investigate the effectiveness of prophylactic INPWT after caesarean section in obese women; hypothesis: INPWT would be associated with fewer surgical site infection and other wound complications (i.e., wound exudate and dehiscence) compared with standard postoperative dressing.
- **Group 1 (NPWT) intervention:** incisional negative pressure wound therapy (INPWT; PICO, SIZE 10 * 30 cm or 10 * 40 cm, Smith & Nephew, Hull, UK) in which dressing was left in situ for approximately 5 days
- **Group 2 (control) intervention:** standard postoperative dressing in which dressing was left in situ for at least 24 hours
- **Study date/s:** September 2013 to October 2016

**Outcomes**

- Surgical site infection, those infections requiring antibiotic treatment within the first 30 days after caesarean section
- Deep surgical site infection, those infections requiring surgery
- Minor dehiscence, defined as a gap between the sides of the wound
- Health-related quality of life (EQ-5D-5L)
- Readmissions to hospital/contact to the general practitioner on suspicion of infection following caesarean section (listed in ClinicalTrials.gov)

**Validity of measure/s:**
### Hyldig 2019a (Continued)

**Time points:** within the first 30 days after surgery

**Notes**
Results were submitted to ClinicalTrials.gov in September 2018 but were not posted online. Could contact authors to request such data

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: “Participants were randomised in the operating theatre during surgery using a web-based randomisation programme with a 1:1 allocation ratio and random block sizes of 4–6, stratified by centre and type of caesarean section (emergency versus elective).”
Comment: low risk of bias due to valid random sequence generation |
| Allocation concealment (selection bias) | Low risk | Quote: “The random allocation sequence was generated by an external data manager with no clinical involvement in the study”.
Comment: low risk of bias due to likely appropriate approach taken to conceal randomisation process |
| Blinding of participants and personnel (performance bias) | High risk | Quote: “Blinding was not possible due to the nature of the intervention”.
Comment: high risk of bias because it was clearly stated no blinding of participants and personnel |
| Blinding of outcome assessment (detection bias) | Unclear risk | Not reported |
| Incomplete outcome data (attrition bias) | Low risk | ITT analysis was conducted for surgical site infection and for other outcomes; only 22 of 432 in Group 1 and 27 of 444 in Group 2 were excluded from analyses. Low risk of attrition bias |
| Selective reporting (reporting bias) | High risk | Readmission to hospital/contact to the GP was listed on ClinicalTrials.gov but not presented in the full text. High risk of reporting bias |
| Other bias | Low risk | None detected |

### Hyldig 2019b

**Study characteristics**

**Methods**

- **Study design:** cost-effectiveness analysis (economic evaluation based on the Hyldig 2019a RCT)
- **Analytical approach:** Decision-analytic model
- **Effectiveness data:** Data from a multicentre RCT (n = 876) (Hyldig 2019a): SSI. Both risk and severity of infection were incorporated. The Danish crosswalk value sets were used to derive preference-based index values.
- **Perspective:** Danish healthcare
- **Utility valuations:** QALYs informed by EuroQol EQ-5D-5L (scoring algorithm not specified but Danish-specific context taken into account) were calculated based on SSI costs for superficial and deep SSIs avoided including antibiotic prescription costs and need for further surgery.
Measure of benefit: surgical site infection avoided; QALY

Cost data: Costs were estimated using data from four Danish National Databases and analysed from a Danish healthcare perspective with a time horizon of 3 months after birth. Conversion from DK to Euro using the year 2015 value. No discount rate was applied. Total costs consisted of four cost components: hospital costs; costs of using GPs; costs of antibiotics; and postoperative dressing cost. These were all from the Cost Database. Costs of INPWT dressing was Euro 151.40, including device itself and time costs for its application.

Analysis of uncertainty: probabilistic sensitivity analysis including an expanded time horizon and an extrapolation of QALY gain to 5 years (3% annual discount). Deterministic sensitivity analyses conducted to permit determination of possible uncertainty in the ICER that would result from a change in a single parameter in the analysis. Scenario analyses to evaluate the impact of missing cost and QALY data, and the influence of one outlier on the ICER.

A subgroup analysis stratifying by BMI explored the impact of the intervention in women with a pre-pregnancy BMI ≥ 35.

Participants

Location: Denmark (two tertiary referral centres and three Danish teaching hospitals)

Intervention group: n = 432, control group: n = 444

Mean age: a range from 18 to 46 years across groups; intervention group: 32 (SD 5), control group 32 (SD 5)

Inclusion criteria: pregnant women undergoing elective or emergency caesarean section, aged ≥ 18 years; who had a pre-pregnancy body mass index ≥ 30 kg/m², and could read and understand Danish

Exclusion criteria: women who had given informed consent but subsequently delivered vaginally

Interventions

Aim/s: To evaluate the cost-effectiveness of incisional negative pressure wound therapy (INPWT) in preventing surgical site infection in obese women after caesarean section

Group 1 (NPWT) intervention: Incisional negative pressure wound therapy (INPWT; PICO, SIZE 10 x 30 cm or 10 x 40 cm, Smith & Nephew, Hull, UK) in which dressing was left in situ for approximately 5 days (n = 432 in a trial)

Group 2 (control) intervention: Standard postoperative dressing in which dressing was left in situ for at least 24 hours (n = 444 in a trial)

Study date/s: September 2013 to October 2016

Outcomes

For data see Hyldig 2019b and for clinical data see Hyldig 2019a in additional table 1

SSI

Costs (Euro)

QALY (measure of benefit).

ICER with 95% CrI to inform probability of strategy being cost-effective/dominant using the willingness-to-pay threshold of 30,000 Euro/QALY

Notes

Authors’ conclusions: Incisional NPWT appears to be cost saving compared with standard dressings but this finding is not statistically significant. The cost savings were primarily found in women with a pre-pregnancy BMI ≥ 35 kg/m².

Funding: University of Southern Denmark, Odense University Hospital, the Region of Southern Denmark, Lundbeckfonden, and an unrestricted grant from the INPWT device manufacturer Smith & Nephew (devices and operating funding)

Quality assessment: CHEERS score 91.7%
Study characteristics

Methods

Study design: randomised controlled trial
Study grouping: parallel
Ethics and informed consent: yes
Follow-up period: 30 days after operations
Sample size estimate: yes; a sample size of 124 patients was assumed to provide a power of 80% to detect a 20% relative reduction in surgical site infection incidence (decreasing from 30% to 10%) at a 2-sided alpha level of 0.05
ITT analysis: yes; number randomised: 124, number analysed: 123
Funding: KCI/Acelity (Grant number #125164)
Preregistration: Not reported

Participants

Location: America (single site)
Intervention group: n = 62, control group: n = 62
Mean age: intervention group mean 66.4 (SD 9.3) years, control group 66.1 (9.0)
Inclusion criteria: adults (18 yrs of age) who had a SSI risk score of 1 as defined by the risk score proposed by Poruk et al. This included patients who had received neoadjuvant chemotherapy, preoperative biliary stenting, or both.
Exclusion criteria: pancreaticoduodenectomies (PD) performed minimally invasively or known allergies or sensitivity to silver or acrylic adhesives

Interventions

Aim/s: to evaluate the efficacy of negative pressure wound therapy for surgical-site infection (SSI) after open pancreaticoduodenectomy

Group 1 (NPWT) intervention: negative pressure wound therapy (NPWT) device is shown in Figure S1. The PREVENA™ CUSTOMIZABLE™ device is comprised of a PREVENA™ CUSTOMIZABLE™ dressing, sealing strips, KCI drapes, and Interface Pad.

Group 2 (control) intervention: standard closure technique
Study date/s: January 2017 through February 2018

Outcomes

• Surgical site infection defined by the National Health Safety Network definition of the Centers for Disease Control and Prevention (CDC)
• Need for reoperation
• 30-day readmission related to SSI
• Cost of hospitalisation

Validity of measure/s:

Time points: 30 days after operation

Risk of bias

Bias

Authors' judgement
Support for judgement

Random sequence generation (selection bias)
Unclear risk
Quote: "Using the simple randomization method, a random allocation sequence was generated. "Once the surgeon committed to performing a PD by ruling out metastatic disease or inoperable local vascular involvement, the cir-
Javed 2018 (Continued)

Allocating nurse contacted the research staff for randomization. The presealed envelope was opened to randomize the patient.”

Comment: unclear risk of bias because the method of generating random sequence was not specified

Allocation concealment (selection bias) | Low risk | Quote: “Allocation concealment was achieved by printing allocation onto a gray-shaded card that was folded and sealed in a secured envelope before initiation of the study”.

Comment: low risk of bias given an appropriate strategy was used to conceal allocation

Blinding of participants and personnel (performance bias) | Unclear risk | Quote: “All patients also received standard infection-prevention measures...”

Comment: insufficient information on blinding of participants and personnel

Blinding of outcome assessment (detection bias) | Low risk | Quote: “patients' EMR were reviewed independently by the principal investigator (MJW) blinded to study-group assignments to determine if SSI was documented at any time during the 30-day postoperative period. ”

Comment: low risk of bias for SSI because the outcome assessors were blinded

Incomplete outcome data (attrition bias) | Low risk | Comment: Low risk of bias because 123 of 124 participants randomised were analysed. One of the 62 participants that were randomised to Group 2 (Control) was excluded from the analysis because the surgeon decided to use NPWT for that person rather than the control intervention.

Selective reporting (reporting bias) | Low risk | All outcomes listed in the Methods were reported in the Results.

Other bias | Low risk | None detected

Karlakki 2016

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes

Follow-up period: 6 weeks

Sample size estimate: pilot study

ITT analysis: yes, number randomised: 220, number analysed: 209

Funding: study funded through a grant from Smith & Nephew UK to cover the cost of NPWT dressings and data collection costs. 2 investigators declared they had funding and consultancy fees from Smith & Nephew.

Preregistration: no

Participants

Location: Oswestry, UK

Intervention group: n = 110, control group: n = 110

Mean age (SD): intervention group = 69 (9.0), control group = 69.2 (9.0)
Inclusion criteria: patients undergoing total hip or knee arthroplasties (for any indication) with any of
3 consultant surgeons
Exclusion criteria: patients who had known allergies to dressing, were undergoing revision joint
surgery, were unwilling to attend additional clinics, and those on warfarin were excluded.

Interventions

Aim/s: to evaluate the effectiveness of incisional negative pressure wound therapy dressing (iNPWTd)

Group 1 (NPWT) intervention: PICO dressing applied over the primarily closed incision by the surgeon
in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or
dislodged.

Group 2 (control) intervention: Comfeel dressing applied over the primarily closed incision by the
surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless
soiled or dislodged.

Study date/s: July 2012 to April 2014

Outcomes

- SSI
- blisters
- haematoma
- hospital readmission

Validity of measure/s: not described

Time points: 1, 2, and 6 weeks postsurgery

Notes

Investigator contacted for additional details

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;the randomisation was performed using sealed opaque envelopes with a block size of 20 shuffled envelopes&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: no sequence generation was required.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;the randomisation was performed using sealed opaque envelopes with a block size of 20 shuffled envelopes&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: allocation was unknown until envelope opened.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: &quot;This was a non-blinded single-centre randomised controlled parallel group study&quot;.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: non-blinded study</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Outcome assessors were aware of group allocation.</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>7.3% in intervention group and 2.7% in control group</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>PP analysis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: more participants were excluded from the analysis in the intervention group (8 intervention vs 3 control).</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported</td>
</tr>
</tbody>
</table>

Karlakki 2016 (Continued)
Other bias | High risk | Intervention participants were seen in a wound clinic at 1 week, and control participants were not.

---

**Karlakki 2016** (Continued)

**Study characteristics**

**Methods**

**Study design:** randomised controlled trial  
**Study grouping:** parallel  
**Ethics and informed consent:** yes  
**Follow-up period:** 35 days  
**Sample size estimate:** not reported  
**ITT analysis:** no; **number randomised:** 526; **number analysed:** 398  
**Funding:** Institution of authors received research funding from Smith & Nephew Orthopaedics that was related to this study.  
**Preregistration:** not reported

**Participants**

**Location:** America (one site)  
**Intervention group:** 185 analysed; **control group:** 213 analysed  
**Mean age: intervention group** 60.6 years, **control group** 60.5  
**Inclusion criteria:** consenting age, surgical treatment with primary or revision THA, surgical treatment with primary or revision TKA; and having an advanced technology device capable of digital photography  
**Exclusion criteria:** pregnancy, history of poor compliance with medical treatment, allergy to silicone adhesives or polyurethane films, and unwillingness to participate in an RCT

**Interventions**

**Aim/s:** to assess whether a portable iNPWTh device affects wound appearance, postoperative wound drainage, dressing-related complications, wound healing complications, infection rates, and reoperation rates when compared with a standard of care (SOC) postoperative dressing  
**Group 1 (NPWT) intervention:** incisional negative pressure wound therapy (iNPWT), a battery-operated, portable NPWT device with an exchangeable cartridge (PICO, Smith & Nephew Orthopaedics, Memphis, TN) with negative pressure applied at 80 mmHg (± 20 mmHg) for an initial period of 7 days  
**Group 2 (control) intervention:** a standard of care (SOC) postoperative dressing, including nonadherent incisional cover (Adaptic or Xeroform gauze), 4.4 inch gauze, and an abdominal dressing. Dressings were changed on postoperative day 2 with subsequent dressing changes performed at 3- to 5-day intervals until the incision was dry.

**Study date/s:** enrolment between April 1, 2014, and January 31, 2017

**Outcomes**

- Superficial and late wound infection rates 7/185 vs. 8/213  
- Return to the operating room to manage a wound-related concern within the first 3 months

**Validity of measure/s:**

**Time points:**

**Notes**

The number of patients randomised in either group was not reported. The authors also reported wound appearance; all-cause complications, wound drainage, and dressing concerns outcomes. These outcomes were not extracted for this review. Regarding outcomes of interest to this review, the authors also stated that "Two patients in each group underwent surgical treatment for a superficial wound infec-
tion during the first 90 days after surgery... Four TKA patients in the standard dressing control group were returned to the operating room within the first 35 days for management of a wound-related complication but deep infection was not diagnosed”. These data were not extracted for this review because it was unclear whether they were systematically collected.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;A total of 526 patients (22.5%) consented to participate in the study and were randomised into either the INPWT device or SOC dressing treatment groups&quot;. Comment: unclear risk of bias because no method of generating random sequence was specified</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Understandably difficult to blind participants and personnel in this trial</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Quote: &quot;Wound appearance was assessed from patient-provided incision photographs by a single trained research team member, blinded to time point and group, using a previously published and validated 100-mm visual analog scale.&quot; Comment: it appears that only wound appearance outcome was assessed in a blinding way. However, this outcome was not of interest to this review. It is unclear whether blinding of outcome assessment was undertaken for other outcomes.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>High risk</td>
<td>Quote: &quot;A total of 526 patients (22.5%) consented to participate in the study and were randomised ... After the initial randomization, 94 patients were excluded ... After excluding 34 unicompartmental knee arthroplasty patients, 398 patients remained for assessment...” Comment: high risk of bias because a high proportion of randomised participants (24%, 128 of 526) were excluded from data analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All outcomes mentioned in the Methods were reported in the Results though the reporting appeared to be implicit.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None detected</td>
</tr>
</tbody>
</table>

### Study characteristics

#### Methods

**Study design:** randomised controlled trial  
**Study grouping:** parallel  
**Ethics and informed consent:** not reported  
**Follow-up period:** not reported
### Sample size estimate
- Not reported

### ITT analysis
- Yes, number randomised: 73, number analysed: 73

### Funding
- Not reported

### Preregistration
- Not reported

<table>
<thead>
<tr>
<th>Participants</th>
<th>Location: not reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention group:</td>
<td>n = 36, control group: n = 37</td>
</tr>
<tr>
<td>Mean age (SD):</td>
<td>Not reported</td>
</tr>
<tr>
<td>Inclusion criteria:</td>
<td>High-risk surgical oncology patients undergoing laparotomy</td>
</tr>
<tr>
<td>Exclusion criteria:</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Aim/s: to investigate the effects of NPWT on short- and long-term wound outcomes in people undergoing pancreatectomy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1 (NPWT intervention):</td>
<td>NPWT</td>
</tr>
<tr>
<td>Group 2 (control intervention):</td>
<td>Standard surgical dressing</td>
</tr>
<tr>
<td>Study date/s:</td>
<td>2012 to 2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>• Postoperative wound complications in the first 30 days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Incisional hernia rates</td>
</tr>
<tr>
<td></td>
<td>• Rates of pancreatic fistula</td>
</tr>
<tr>
<td></td>
<td>• Delayed gastric emptying</td>
</tr>
<tr>
<td>Validity of measure/s:</td>
<td>Not described</td>
</tr>
<tr>
<td>Time points:</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

### Notes
- Only the abstract was available.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>73 participants were enrolled and analysed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Expected outcomes were reported in the abstract.</td>
</tr>
</tbody>
</table>
Kuncewitch 2017 (Continued)

Study characteristics

Methods

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 30 days
- **Sample size estimate:** pilot study informed the calculation which was based on power 0.80 to demonstrate reduction from 30% to 15% in SSI. This was based on incisions not patients.
- **ITT analysis:** no, **number randomised:** 123, **number analysed:** 119 incisions was the unit of analysis; 24 participants had 48 incisions
- **Funding:** performed without any support, financial or otherwise, from the makers of the Prevena dressing
- **Preregistration:** not stated

Participants

- **Location:** USA single hospital
- **Intervention group:** 59, **control group:** 60 incisions; 24 people contributed 48 incisions (24 to each group)
- **Mean age:** intervention group 64.6 (44-83), control group 67.4 (41-84)
- **Inclusion criteria:** patients aged 18 years and older undergoing elective vascular surgery under the supervision of the Division of Vascular and Endovascular Surgery at Thomas Jefferson University Hospital involving unilateral or bilateral groin incisions; presence of any of the following criteria: body mass index (BMI) > 30 kg/m²; significant pannus overlying groin skin or abnormal skin as evidenced by fungal infection; reoperative groin surgery; placement of prosthetic vascular graft; poor nutrition (BMI < 18 kg/m², cachectic in appearance); immunosuppression (use of any immunosuppressive medications); and poorly controlled diabetes (hemoglobin A1c >8%)
- **Exclusion criteria:** emergency operation and those unwilling or unable to provide informed consent

Interventions

- **Aim/s:** to determine whether application of a negative pressure dressing (Prevena Incision Management System) is superior to a standard surgical dressing in preventing vascular groin wound complications and their associated hospital costs.
- **Group 1 (NPWT) intervention:** negative pressure dressing (Prevena) applied according to the manufacturer’s instructions. It involved application of an antibiotic sponge (0.019% ionic silver), cut to cover the closed groin wound, covered by a clear occlusive dressing attached to a suction device that applied -125 mmHg pressure. This device was inspected daily and left in place for 5 days, after which a dry gauze dressing was placed, inspected and replaced daily until discharge.
- **Group 2 (control) intervention:** standard surgical dressing consisting of gauze covered by Tegaderm (3M, St. Paul, Minn). This dressing was removed on postoperative day 2 and replaced with a dry gauze dressing that was inspected and replaced daily until discharge.
- **Study date/s:** January 1st, 2015 to December 31st, 2016

Outcomes

- SSI
- (skin) dehiscence
- lymph leakage (seroma or fistula) but no separate data on seroma
- haematoma

Kwon 2018

Study characteristics

Methods

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 30 days
- **Sample size estimate:** pilot study informed the calculation which was based on power 0.80 to demonstrate reduction from 30% to 15% in SSI. This was based on incisions not patients.
- **ITT analysis:** no, **number randomised:** 123, **number analysed:** 119 incisions was the unit of analysis; 24 participants had 48 incisions
- **Funding:** performed without any support, financial or otherwise, from the makers of the Prevena dressing
- **Preregistration:** not stated

Participants

- **Location:** USA single hospital
- **Intervention group:** 59, **control group:** 60 incisions; 24 people contributed 48 incisions (24 to each group)
- **Mean age:** intervention group 64.6 (44-83), control group 67.4 (41-84)
- **Inclusion criteria:** patients aged 18 years and older undergoing elective vascular surgery under the supervision of the Division of Vascular and Endovascular Surgery at Thomas Jefferson University Hospital involving unilateral or bilateral groin incisions; presence of any of the following criteria: body mass index (BMI) > 30 kg/m²; significant pannus overlying groin skin or abnormal skin as evidenced by fungal infection; reoperative groin surgery; placement of prosthetic vascular graft; poor nutrition (BMI < 18 kg/m², cachectic in appearance); immunosuppression (use of any immunosuppressive medications); and poorly controlled diabetes (hemoglobin A1c >8%)
- **Exclusion criteria:** emergency operation and those unwilling or unable to provide informed consent

Interventions

- **Aim/s:** to determine whether application of a negative pressure dressing (Prevena Incision Management System) is superior to a standard surgical dressing in preventing vascular groin wound complications and their associated hospital costs.
- **Group 1 (NPWT) intervention:** negative pressure dressing (Prevena) applied according to the manufacturer’s instructions. It involved application of an antibiotic sponge (0.019% ionic silver), cut to cover the closed groin wound, covered by a clear occlusive dressing attached to a suction device that applied -125 mmHg pressure. This device was inspected daily and left in place for 5 days, after which a dry gauze dressing was placed, inspected and replaced daily until discharge.
- **Group 2 (control) intervention:** standard surgical dressing consisting of gauze covered by Tegaderm (3M, St. Paul, Minn). This dressing was removed on postoperative day 2 and replaced with a dry gauze dressing that was inspected and replaced daily until discharge.
- **Study date/s:** January 1st, 2015 to December 31st, 2016

Outcomes

- SSI
- (skin) dehiscence
- lymph leakage (seroma or fistula) but no separate data on seroma
- haematoma
**Kwon 2018 (Continued)**

- reoperation
- hospital readmission
- costs

**Validity of measure/s:** The Szilagyi classification of vascular wound infection was also used to classify the infection.

**Time points:** daily until hospital discharge; within 10 to 14 days, whereupon staples were removed; and within 25 to 30 days to complete the study

---

**Notes**

---

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Unclear risk | Quote "They used a coin toss to determine whether the patient was to receive standard dressing or negative pressure therapy. To maintain 1:1 randomization as well as to provide future analysis using internal controls, any high-risk patient undergoing bilateral groin incisions would receive both a standard dressing and negative pressure therapy".  
Comment: adequate method for the unilateral surgery; unclear for the bilateral |
| Allocation concealment (selection bias) | Unclear risk | Not stated |
| Blinding of participants and personnel (performance bias) | High risk | Quote: “Other than the fact that the 30-day examination occurred without the overt knowledge of the patient’s initial treatment, no blinding was instituted”.  
Comment: The surgical team, clinical staff, and patient were not blinded to the intervention status. |
| Blinding of outcome assessment (detection bias) | High risk | Quote: “Wound assessment was made by both the primary surgeon and nurse practitioners.....Furthermore, a major limitation to the study was that it was not a blinded study and therefore subject to observer bias. Assessment of complications is qualitative, and ultimate management of infections, such as opening an infected wound, was left to the discretion of the attending surgeon.”  
Comment: Outcome assessment was performed by an unblinded assessor. |
| Incomplete outcome data (attrition bias) | Low risk | Quote: “Because a contralateral complication would penalize the uncomplicated groin incision in terms of LOS and hospital variable costs, in this circumstance the uncomplicated groin incision data were dropped from consideration in terms of LOS and variable costs”. “As such, for the high-risk, standard dressing group (n = 60), five were dropped because of a contralateral complication (n = 55); for the high-risk, Prevena group (n = 59), eight were dropped because of a contralateral complication (n = 51)”; In the intervention group, two incisions discontinued intervention because of graft failure post-operative Day 1; In the control group, two incisions discontinued intervention because of reopening of incision for graft failure post-operative Day 1 and fatal myocardial infarction post-operative Day 3.  
Comment: Clear from the study how many participants withdrew and the reasons |
| Selective reporting (reporting bias) | Low risk | Comment: protocol not found, but according to the method, all results were reported. |
Kwon 2018 (Continued)

Other bias

Unclear risk

This was a planned interim analysis after 80% recruitment with a stopping guideline if 50% reduction in SSI. The unit of analysis was the incision and the unit of randomisation appeared to be the incision where there was bilateral incision. Unclear how this paired data dealt with in analysis.

Lee 2017a

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes

Follow-up period: 6 weeks

Sample size estimate: not reported

ITT analysis: no, number randomised: 60, number analysed: 44

Funding: KCI USA Incorporated, an Acelity company

Preregistration: yes

Participants

Location: Canada

Intervention group: n = 33, control group: n = 27

Mean age (± SD): intervention group = 67.1 (± 7.2), control group = 68.3 (± 9.7)

Inclusion criteria: receiving an isolated elective or semi-elective CABG and above 18 years of age living within 1 hour of the institution

Exclusion criteria: emergent surgery, previous CABG or lower leg surgical intervention, severe peripheral vascular disease, dialysis-dependent renal failure, and chronic steroid administration

Interventions

Aim/s: to establish the safety and feasibility of using NPWT on the GSV harvest site postcardiac surgery and to examine the effects on infection, complications, and overall patient function

Group 1 (NPWT) intervention: NPWT device was placed at the time of GSV harvest in the operating room and then maintained in situ until the day prior to hospital discharge or to a maximum of 7 days. The device was removed if poorly tolerated by the participant or for any safety concerns.

Group 2 (control) intervention: conventional dry gauze dressings

Study date/s: not stated

Outcomes

- rates of device complication and malfunction
- rates of SSI, lower leg complications, discharge date, and quality of life at discharge and 6 weeks

Validity of measure/s: complications were classified as major if they required a medical or surgical intervention. All complications and device malfunctions were recorded. The total length of therapy with the NPWT device was recorded, and also if therapy was prematurely interrupted for any reason. SSIs was determined through assessment of the ASEPSIS score. The incidence of leg complications was also examined including pain, heaviness, weakness, stiffness, itching, paraesthesia, numbness, burning, discoloration, rash, and oedema. These complications were graded as ‘not present’, ‘mild’, ‘moderate’, and ‘severe’. Only the moderate and severe complaints were included for incidence analysis. Discharge dates were also recorded for all participants. Self reported assessments of mobility, overall pain or discomfort, feelings of anxiety or depression, ability for self care, and ability to perform usual activities were performed. These measures were graded as no issues, some issues, and severe issues or inability.

Quality of life was also measured using the EQ-5D-3L Measure of Health Status.
Lee 2017a (Continued)

**Time points:** initial and 6 weeks

**Notes**
33 vs 27 participants randomised; high loss to follow-up recorded

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Consented patients were randomised by use of sealed ballot envelopes in a 1-to-1 fashion.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: &quot;We performed a prospective, randomised, single-blind, single centre, clinical feasibility study&quot;. Comment: Single-blinded - and the person who was blinded was the outcome assessor.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>A research assistant blinded to the grouping assessed the incision and participant prior to discharge and at 6 weeks postoperatively. A second, unblinded research assistant recorded and managed any device-related complications. Participants were discharged based on standardised institutional discharge criteria.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>12 participants were lost to follow-up at 6 weeks, 4 in the NPWT group and 8 in the control group. These participants were not included in the data analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol registered on ClinicalTrials.gov (NCT01698372)</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>High loss to follow-up without reasons for loss being provided; unclear whether additional risks of bias</td>
</tr>
</tbody>
</table>

### Lee 2017b

#### Study characteristics

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 90 days
- **Sample size estimate:** yes
- **ITT analysis:** no, **number randomised:** 102, **number analysed:** 102
- **Funding:** not company funded
- **Preregistration:** yes

**Participants**

- **Location:** Canada
- **Intervention group:** n = 53, **control group:** n = 49
- **Mean age:** intervention group = 69 ± 10, control group = 68 ± 10
Inclusion criteria: patients with 1 of the following 3 risk factors for SSIs were enrolled in the trial: obesity defined as a BMI of > 30 kg/m², previous femoral artery exposure, or presence of minor or major ischaemic tissue loss.

Exclusion criteria: patients with pre-existing groin infection, a known allergy to dressing material, or those who could not be followed postoperatively were excluded from the study.

Interventions

Aim/s: to perform an RCT to study the role of NPWT on SSI in primarily closed groin incisions after lower extremity revascularisation in vascular surgery patients

Group 1 (NPWT) intervention: NPWT remained on until either hospital discharge or postoperative day 8, whichever occurred earlier.

Group 2 (control) intervention: standard gauze dressing (the dressing removed on postoperative day 2, and then had daily dressing changes with inspection of the wound)

Study date/s: August 2014 to December 2015

Outcomes

- the incidence of SSI within 30 days of revascularisation
- duration of hospital stay
- SSI within 90 days
- reoperation and readmission rate owing to SSI within 90 days
- mortality within 90 days

Validity of measure/s: SSI was diagnosed using the CDC guideline as a superficial or deep infection. The Szilagyi classification of vascular wound infection was also used to classify the infection.

Time points: once discharged, both groups were followed up in the clinic at 30 and 90 postoperative days.

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Eligible patients were randomised to NPWT or a standard sterile gauze dressing using an internet-based software, sealedenvelope.com (London, UK), using block randomisation.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: “patients and surgeons were not blinded to the treatment they had received”. Comment: no blinding of participants or personnel</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Wounds were inspected at each clinic visit by a wound specialist nurse who was blinded to the treatment groups. If she was uncertain, the staff physician determined the presence or absence of an SSI. An SSI could also be diagnosed by the patient care team if there were clinical signs and symptoms of infection.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>102 participants were enrolled and analysed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) All outcomes</td>
<td>Low risk</td>
<td>Planned outcomes reported. Protocol registered on ClinicalTrials.gov (NCT02084017)</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>
### Leon 2016

#### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
<th>Study design: prospective, randomised, multicentre study</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Study grouping: parallel</td>
</tr>
<tr>
<td></td>
<td>Ethics and informed consent: not reported</td>
</tr>
<tr>
<td>Follow-up period</td>
<td>not reported</td>
</tr>
<tr>
<td>Sample size estimate</td>
<td>not reported</td>
</tr>
<tr>
<td>ITT analysis</td>
<td>yes, number randomised: 81, number analysed: 81</td>
</tr>
<tr>
<td>Funding</td>
<td>not reported</td>
</tr>
<tr>
<td>Preregistration</td>
<td>not reported</td>
</tr>
</tbody>
</table>

| Participants     | Location: Spain                                          |
|                  | Intervention group: n = 47, control group: n = 34          |
|                  | Mean age (SD): not reported                               |
|                  | Inclusion criteria: patients undergoing open and programmed colorectal surgery |
|                  | Exclusion criteria: not stated                            |

| Interventions    | Aim/s: to evaluate the benefits of negative pressure therapy to reduce surgical site infection rate in open colorectal surgery |
|                  | Group 1 (NPWT) intervention: NPWT                         |
|                  | Group 2 (control) intervention: usual dressing group       |
|                  | Study date/s: not reported                                  |

| Outcomes         | • SSI rate                                                |
|                  | Validity of measure/s: not described                      |
|                  | Time points: a daily evaluation through hospitalisation and a 15- and 30-day evaluation |

| Notes            | Only the abstract was available.                         |

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

---

*Negative pressure wound therapy for surgical wounds healing by primary closure (Review)*

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Leon 2016 (Continued)

<table>
<thead>
<tr>
<th>Incomplete outcome data (attrition bias)</th>
<th>Low risk</th>
<th>All enrolled participants were accounted for in the analyses.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Abstract only</td>
</tr>
</tbody>
</table>

Lozano-Balderas 2017

### Study characteristics

#### Methods
- **Study design:** randomised controlled trial
- **Ethics and informed consent:** ethics approved
- **Sample size calculation:** no
- **ITT analysis:** yes, **number randomised:** 81, **number analysed:** 81
- **Follow-up period:** healed (when in hospital) or in a 30-day period after surgery (if discharged)
- **Funding:** non-industry
- **Preregistration:** yes

#### Participants
- **Location:** Mexico
- **Intervention group:** n = 25, **control group:** n = 27, **(3 arms: delayed primary closure group:** n = 29)
- **Median age (IQR):** intervention group = 32 (22 to 46); control group = 30 (20 to 43)
- **Inclusion criteria:** minimum age of 18; a laparotomised wound with class III or IV (contaminated/dirty-infected) surgical wounds
- **Exclusion criteria:** not specified

#### Interventions
- **Aim/s:** to compare infection rates between primary, delayed primary, and vacuum-assisted closures in contaminated/dirty-infected surgical wounds
- **Group 1 (NPWT) intervention:** the VAC was used with routine changes of dressings every 48 hours until healthy granulation tissue was found and a surgeon decided to close it.
- **Group 2 (control) intervention:** subcutaneous tissue was approximated with polyglycolic acid, and polypropylene was used for the skin.
- **Study date/s:** January to July 2014

#### Outcomes
- • **SSI**

#### Validity of measure/s:
- according to the CDC Surgical Wound Classification

#### Time points:
- daily when in hospital or in a 30-day period after surgery

### Notes

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: “patients were allocated to each group with the software Research Randomizer® (Urbaniak, G. C., & Plous, S., Version 4.0)”.

Copyrigh © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Lozano-Balderas 2017 (Continued)

<table>
<thead>
<tr>
<th>Bias Description</th>
<th>Risk Level</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>No information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Outcome assessors were aware of group allocation.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>81 participants were enrolled and analysed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported. Protocol retrospectively registered on Clinical-Trials.gov (NCT02649543).</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>

Manoharan 2016

Study characteristics

Methods

- **Study design:** randomised controlled trial
- **Study grouping:** bilateral knees were randomised to intervention or control knees
- **Ethics and informed consent:** yes
- **Sample size estimate:** yes, but sample did not reach target, stopped due to financial constraints
- **Follow-up period:** 10 days
- **ITT analysis:** yes, **number randomised:** 21, **number analysed:** 21
- **Funding:** KCI, Acelity Inc provided the negative pressure wound therapy dressings for the study.
- **Preregistration:** retrospectively registered as ANZCTR 12615001350516

Participants

- **Location:** Queensland, Australia
- **Intervention group:** n = 21 knees
- **Control group:** n = 21 knees
- **Mean age (range):** 66 (45 to 80)
- **Inclusion criteria:** patients undergoing a bilateral knee arthroplasty
- **Exclusion criteria:** aged < 18 years or pregnant

Interventions

- **Aim/s:** to assess the effect of NPWT on outcomes after primary arthroplasty
- **Group 1 (NPWT) intervention:** the intervention group received PREVENA Incision Management System, Acelity, KCI, which was placed over the closed surgical incision under sterile conditions at the end of the procedure. The NPWT device provided a continuous negative pressure of 125 mmHg for a duration of 8 days.
- **Group 2 (control) intervention:** the conventional dry dressing was placed over the closed surgical incision under sterile conditions at the end of the procedure. Neither the type of control dressing nor when the dressing was removed was reported.
### Study date/s
February to December 2014

### Outcomes
- SSI
- blisters
- cost
- QoL

### Validity of measure/s:
no

### Time points:
10 to 12 days postsurgery

### Notes
Investigator contacted for additional details

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Simple randomisation was performed by the research assistants via online computer software that indicated the side to which the intervention, NPWT, would be applied.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>The surgeons were notified on the day of surgery, before the commencement of the procedure. It was also unclear if consecutive patients for each of the 3 surgeons were recruited.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote: “A final evaluation form at the outpatient review assessed the patients rated experience and preference for type of dressing. The final incision assessment was performed by the surgeon and clinic nurse and was witnessed by one of the research assistants. There were no independent observers attached to this assessment.”  Comment: Patients were aware of assignment, appeared that surgeons were not blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>The final incision assessment was performed by the surgeon and clinic nurse and witnessed by 1 of the research assistants. There were no independent observers attached to this assessment.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>It was unclear if all participants were accounted for in the results as the numbers analysed for each outcome were not stated.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported. Protocol retrospectively registered as ANZCTR 12615001350516.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other biases detected</td>
</tr>
</tbody>
</table>

### Study characteristics

<table>
<thead>
<tr>
<th>Methods</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study design: RCT</td>
</tr>
<tr>
<td>Study grouping: parallel</td>
</tr>
<tr>
<td>Ethics and informed consent: not reported</td>
</tr>
<tr>
<td>Follow-up period: one year</td>
</tr>
</tbody>
</table>
Martin 2019 (Continued)

**Sample size estimate:** not reported

**ITT analysis:** yes, number randomised: 40, number analysed: 40 (not clearly reported)

**Funding:** Not stated

**Preregistration:** Not stated

### Participants

**Location:** not reported

**Intervention group:** 20, **control group:** 20

**Mean age:** 60.82 years, **intervention group** NR, **control group** NR

**Inclusion criteria:** patients undergoing hepatectomy or pancreatectomy

**Exclusion criteria:** not reported

### Interventions

**Aim/s:** to evaluate the effect of NPWT on SSI in this population (patients who have had hepatectomy or pancreatectomy)

**Group 1 (NPWT) intervention:** incisional NPWT (PICO TM, Smith & Nephew, Hull, UK)

**Group 2 (control) intervention:** sterile island dressing

**Study date/s:** not reported

### Outcomes

- SSI
- dehiscence

**Validity of measure/s:** Not reported

**Time points:** Not reported

### Notes

Abstract only

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Quote &quot;Patients were randomised&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: method of generating randomisation sequence was not clear.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote &quot;Patients were randomised&quot;.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: unclear if appropriate methods were used to conceal allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: appeared likely that it would be impossible to blind participants or personnel to treatment allocation but insufficient information</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Comment: unclear who assessed the outcomes or whether they were blinded to treatment allocation</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Comment: All participants appeared to be included in the analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Comment: insufficient information</td>
</tr>
</tbody>
</table>
Martin 2019 (Continued)

Other bias  Unclear risk  Comment: No evidence of other bias but insufficient information to be sure

Masden 2012

Study characteristics

Methods

- **Study design:** randomised controlled trial
- **Ethics and informed consent:** the study was approved by the Georgetown University Institutional Review Board. Consent was not specifically stated, but those patients not capable of undergoing informed consent were excluded.
- **Sample size calculation:** yes
- **Follow-up period:** mean 113 days
- **ITT analysis:** available-case analysis
- **Funding:** 2 of the investigators are consultants for KCI, and the study was funded by the manufacturer of the intervention product.

Participants

- **Location:** Columbus, Ohio, USA
- **Intervention group:** n = 50, **control group:** n = 43
- **Mean age:** intervention group = 61.3 years (range 40 to 101), control group = 61.3 years (range 38 to 86)
- **Inclusion criteria:** patients scheduled to undergo radial forearm free flap
- **Exclusion criteria:** "patients not capable of undergoing informed consent and those patients with tape allergies or who otherwise could not tolerate NPWT ... patients with lower extremity amputations distal to the forefoot were excluded".

Interventions

- **Aim/s:** to evaluate the effect of NPWT on closed surgical incisions. Prospective randomised controlled clinical trial comparing NPWT to standard dry dressings on surgical incisions
- **Primary:** "to evaluate the effectiveness of NPWT in patients with multiple comorbidities"
- **Secondary:** "to evaluate factors that contribute to wound complication"
- **Intervention/s in both groups:** "the graft was covered with a single layer of paraffin gauze dressing (Jelonet, Smith & Nephew, UK); then, 3 sheets of polyurethane (high-density foam, Nurus Luisa, Santiago, Chile) with a fenestrated silicone drainage tube between the layers was placed over the gauze and covered with a transparent adhesive dressing (Opsite, Smith & Nephew, UK) providing the vacuum seal. We used a double layer under the tube to prevent pressure ulcers at the bed of the suction tube".
- **Group 1 (NPWT) intervention:** "NPWT group ... underwent placement of a V.A.C. system (KCI, San Antonio, Texas) along the line of closure set at −125 mmHg continuous pressure at the time of closure".
- **Group 2 (control) intervention:** "the control group ... received a standard dry sterile dressing consisting of a non adhesive silicone layer (Mepitel, Mölnlycke Health Care AB, Goteborg, Sweden) and a bacteriostatic single silver layer (Acticoat, Smith & Nephew, Hull, UK)".
- **Study date/s:** October 2008 to August 2010

Outcomes

- wound infection
- dehiscence
- reoperation
- LOS

Validity of measure/s: not stated
**Masden 2012** (Continued)

**Time points:** "all incisions assessed on the third postoperative day ... and reassessed at the first outpatient postoperative visit, as well as any subsequent visit (the last recorded infection was at 66 days post surgery)". However, the abstract stated that "average follow-up was 113 days".

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk           | **Evidence:** quote (from correspondence with the author): "used a randomization generator through Excel in groups of 8 (4 controls, 4 experimental)"
|                                           |                    | **Comment:** adequate method                                                                                  |
| Allocation concealment (selection bias)   | Low risk           | **Evidence:** quote (from correspondence with the author): "when the patient was recruited ... they contacted one of the investigators and the patient was assigned to whichever group was next on the list". |
|                                           |                    | **Comment:** adequate method                                                                                  |
| Blinding of participants and personnel (performance bias) | Unclear risk | Insufficient information                                                                                   |
| All outcomes                              |                    |                                                                                                             |
| Blinding of outcome assessment (detection bias) | Low risk           | **Evidence:** quote: "the evaluations were performed by a member of the research team not involved in the enrolment or the operative treatment and, thus, were blinded as to randomization group". |
| All outcomes                              |                    | **Comment:** adequate method                                                                                  |
| Incomplete outcome data (attrition bias)  | Low risk           | **Evidence:** quote: "twelve subjects were lost to follow-up in the immediate postoperative period and were excluded from the final analysis". |
| All outcomes                              |                    | **Comment:** equal number of losses in both groups                                                             |
| Selective reporting (reporting bias)      | Low risk           | **Comment:** protocol unavailable, but expected outcomes reported                                            |
| Other bias                                | Unclear risk       | **Comment:** the standard dressing contained a silver layer, which may have influenced the outcome.      |

### Murphy 2019

#### Study characteristics

**Methods**

**Study design:** randomised controlled trial

**Study grouping:** 2 parallel groups

**Ethics and informed consent:** ethics approved and consent obtained

**Follow-up period:** 30 days

**Sample size estimate:** yes

**ITT analysis:** no, **number randomised:** 300, **number analysed:** 284; 16 participants "randomised in error") were not included in analysis
Murphy 2019 (Continued)

**Funding:** yes  
**Preregistration:** yes

**Participants**  
**Location:** two separate sites within a single hospital system (London Health Sciences Centre, London, Ontario, Canada)  
**Intervention group:** 144 analysed, **control group:** 140 analysed  
**Mean age:** intervention group 64 years, control group 64 years  
**Inclusion criteria:** patients who were 18 years or older and scheduled for planned (elective) colorectal resection via laparotomy with midline incision (or booked for laparoscopy if converted to an open procedure with midline incision). Eligible surgical procedures included: segmental, subtotal or total colectomies, as well as low and ultra-low anterior resection.  
**Exclusion criteria:** patients who undergoing abdominoperineal resection (APR), pelvic exenteration, emergent coectomy or patients with bowel perforation at the time of operation, who were pregnant, palliative (life expectancy under 3 months) or had a known sensitivity to the NPWT device

**Interventions**  
**Aim/s:** to determine if negative pressure wound therapy (NPWT) reduces surgical site infection (SSI) in primarily closed incision after open and laparoscopic-converted colorectal surgery  
**Group 1 (NPWT) intervention:** NPWT via a continuous vacuum set to -125 mm Hg which remained on until postoperative day (POD) 5 or the date of hospital discharge, whichever came first  
**Group 2 (control) intervention:** gauze adhesive dressing which was removed on POD 2 and changed daily thereafter  
**Study date/s:** January 2015 to February 2017

**Outcomes**  
- SSI  
- mortality  
- reoperation  
**Validity of measure/s:** not reported  
**Time points:** 30 days postsurgery

**Notes**  
Funding: industry grant from Kinetic Concepts Inc (San Antonio TX). The devices were also supplied free of charge.

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk | Quote: “Randomization will take place centrally using random permuted blocks of 4, 6 or 8 and will be stratified based on site (University Hospital or Victoria Hospital) of the operation.”  
Comment: adequate method |
| Allocation concealment (selection bias) | Low risk | Quote: “After the fascia is closed a member of the surgical team will use a centralized web-server to randomize the patient.”  
Comment: adequate method |
| Blinding of participants and personnel (performance bias) All outcomes | High risk | Quote: "we performed a single-institution, prospective, randomised, open label, blind endpoint trial".  
Comment: This was an open-label trial; participants and personnel were not blinded. |
| Blinding of outcome assessment (detection bias) | Low risk | Quote: “The primary outcome was assessed by a blinded member of our Stoma Wound and Ostomy (SWOT) team or a physician uninvolved in the pa- |
Murphy 2019 (Continued)

### All outcomes

- **Patient’s care at POD five if the patient was in hospital or on the date of discharge if prior to POD five, as well as at the postoperative clinic visit occurring within the first 30 postoperative days.**

  **Comment:** Adequate method

### Incomplete outcome data (attrition bias)

- **Low risk**

  - **Quote:** “Sixteen patients were excluded from the main analysis. Of the 284 patients remaining, we analyzed patients according to assigned group (144 NPWT and 140 Standard Dressing). There was no difference in demographics, type, or surgery performed or indication for surgery between groups.”

  **Comment:** Clear from the study how many participants were excluded; these 16 participants were excluded because they were randomised in error, with reasons given.

### Selective reporting (reporting bias)

- **High risk**

  - **Quote:** “Secondary outcomes assessed will include the need for, and duration of, at-home nursing care (home care) related to SSI. Additional secondary outcomes assessed will include the length of hospital stay, the number of return visits related to a potential or actual SSI, and cost.”

  **Comment:** According to the protocol, some secondary outcomes were not reported in the results.

### Other bias

- **Low risk**

  - No evidence of other risk of bias

---

Newman 2019

### Study characteristics

#### Methods

- **Study design:** Randomised controlled trial
- **Study grouping:** Parallel
- **Ethics and informed consent:**
- **Follow-up period:** 12 weeks
- **Sample size estimate:** determined using an estimated wound complication rate (associated with current standard of care protocols) of 20% and a desired wound complication rate of 5%. Using a significance level of 0.05 with a power of 80%, the sample was estimated at 160 total subjects, with 80 subjects assigned to each group.
- **ITT analysis:** yes, **number randomised:** 160, **number analysed:** 179
- **Funding:** KCI/Acelity Inc. (San Antonio TX)
- **Preregistration:** Yes

#### Participants

- **Location:** US Hospital
- **Intervention group:** 80, **control group:** 80
- **Mean age:** intervention group 65 (SD 11), control group 65 (SD 11)
- **Inclusion criteria:** patients who were scheduled to undergo revision THA or TKA by one of the 6 fellowship-trained orthopaedic surgeons met at least one of the following criteria: body mass index greater than 35 kg/m², use of anticoagulants other than aspirin, peripheral vascular disease, depression, diabetes mellitus, current smoker, history of a periprosthetic joint infection in the limb undergoing revision surgery, on immunomodulators or corticosteroids, current history of cancer or haematological malignancy, inflammatory arthritis, renal failure or dialysis, malnutrition, liver disease, history of organ transplant, or human immunodeficiency virus infection
Exclusion criteria: lived more than 100 miles from the hospital, less than 18 years of age, had a silver allergy, had a history of wound coverage with soft tissue flaps on the index joint, or had a recent acute wound complication (i.e. defined as less than 4 weeks since previous surgery in the affected joint). Additionally, patients were excluded if they were enrolled in another interventional study, had no risk factors, undergoing a conversion arthroplasty, were not having implants revised, surgery was cancelled, altered mental status, and were screened but already met enrolment capacity.

Interventions

Aim/s: to compare the use of ciNPWT with our standard of care dressing in revision arthroplasty patients who were at high risk to develop wound complications

Group 1 (NPWT) intervention: ciNPWT device (PREVENA; KCI/Acelity, San Antonio, TX) for at least 2 days unless a wound complication was reported

Group 2 (control) intervention: standard of care silver-impregnated wound dressing (AQUACEL; Convatec, Greensboro, NC) for at least 7 days unless a wound complication was reported

Study date/s: eligibility assessed from August 2014 to January 2017

Outcomes

- SSI
- Dehiscence
- Haematoma
- Blisters
- Readmission
- Reoperation

Validity of measure/s: Clear definitions given but not using validated measures

Time points: 2, 4 and 12 weeks

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Patients who consented and enrolled to be included in the study were block randomised by categorizing as hip or knee surgery groups and then were assigned a sealed, opaque envelope that was randomly generated by an independent researcher who allocated them.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: computer-generated randomisation sequence</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;an independent researcher [] who allocated them groups and then were assigned a sealed, opaque envelope that was randomly generated by an independent researcher who allocated them to receive either a ciNPWT device (PREVENA; KCI/Acelity, San Antonio, TX) or the standard of care silver-impregnated wound dressing (AQUACEL; Convatec, Greensboro, NC). The envelopes were opened on the day of surgery and the surgeon was informed as to which group the patient was randomly assigned at the time of dressing placement. After a patient consented to be involved in the study, the next sequential envelope was selected.&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment: central allocation generated opaque sealed sequential envelopes.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>The nature of the intervention makes blinding of participants and some personnel very difficult but no clear information</td>
</tr>
</tbody>
</table>
### Newman 2019 (Continued)

| **Blinding of outcome assessment (detection bias)** | **Unclear risk** | Quote "Wounds were examined at 2, 4, and 12 weeks after the procedure. Any complication reported was visualized at the time of the evaluation."
Comment: did not state who performed the outcome assessment or whether they were blinded to intervention group |
|---|---|---|
| **Incomplete outcome data (attrition bias)** | **Low risk** | Quote "One patient in the treatment arm was lost to follow-up and was not included in the analyses."
Comment: All except one participant were included in the analysis. |
| **Selective reporting (reporting bias)** | **Low risk** | All of the planned outcomes were fully reported. |
| **Other bias** | **Low risk** | No evidence of additional bias and reasonable reporting to suggest none. |

### Nherera 2017

#### Study characteristics

**Methods**

**Study design:** cost-effectiveness analysis (based on the Karlakki 2016 RCT)

**Analytical approach:** Trial-based decision analytic model (Based on Karlakki 2016, N = 220)

**Effectiveness data:** Data from the UK trial (Karlakki 2016)

**Perspective:** UK National Health Service

**Utility valuations:** Time horizon of 6 weeks for surgical site complications (SSI) avoided and length of stay. Expected complications in standard care taken from the RCT. No discount rate was applied due to the short time horizon. Complications were assumed to have standard costs, readmission was excluded from the base case. Utility values were obtained from converting quality of life that was measured using SF-36.

**Measure of benefit:** surgical site complication avoided; QALY (obtained from the NICE guideline on surgical site infections 2008)

**Cost data:** Costs derived from standard cost references with resource utilisation valued in GBP (2015/16). Costs were also converted to USD by factor 1.42. (1) NHS reference costs of relevant medical diagnosis groups used for inpatient care (with confidence intervals). Model assumes all standard care dressing costs and nursing costs included in these. (2) Cost of a GP visit taken from Unit Costs and Social Care 2015–2016; (3) costs of oral antibiotics taken from the national Drug Tariff; length of stay (not considered in costs) (4) Cost of NPWT was taken from the national Drug Tariff.

**Analysis of uncertainty:** Sensitivity analysis used to model discounted price for intervention through NHS bulk purchasing; additional length of stay following complications and readmission. Baseline data were varied across the 95% CI from the trial. Probabilistic sensitivity analysis for cost-effectiveness at willingness-to-pay threshold

**Participants**

**Location:** UK hospital

**Intervention group:** n = 110, **control group:** n = 110

**Mean age (SD):** intervention group = 69 (9.0), control group = 69.2 (9.0)

**Inclusion criteria:** patients undergoing THAs or TKAs (for any indication) with 3 consultant surgeons (SLK, NMG, and RDB – authors of this study)

**Exclusion criteria:** patients who had known allergies to dressing, were undergoing revision joint surgery, were unwilling to attend additional clinics, and those on warfarin were excluded.

---

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Aim/s: To evaluate the cost-effectiveness of single-use negative pressure wound therapy in patients undergoing primary hip and knee replacements

**Group 1 (NPWT) intervention:** Incisional negative pressure wound therapy dressing (iNPWTd) PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for one week (n = 110).

**Group 2 (Control) intervention:** conventional dressing (either Mepore (Mölnlycke Health Care AB) or Tegaderm (3M Health Care Ltd)) applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for an unspecified period, and changed to OPSITE Post-Op Visible dressing on the second post-operative day (n = 110).

All patients received enoxaparin postsurgery.

**Study date/s:** July 2012 to April 2014

### Outcomes

For data see Nherera 2017 and for clinical data see Karlakki 2016 in additional table 1

- Costs (GBP)
- SSI complications avoided
- QALY (measure of benefit)

Probability of being cost-effective using NICE threshold of £20,000/QALY

### Notes

Funding: two authors are employees of Smith & Nephew. The Karlakki 2016 RCT was funded by Smith & Nephew.

Authors' conclusions: Single-use negative pressure wound therapy can be considered a cost-saving intervention to reduce surgical site complications following primary hip and knee replacements compared with standard care. Providers should consider targeting therapy to those patients at elevated risk of surgical site complications to maximise efficiency.

Quality rating using the CHEERS checklist was 85.4%.

### Study characteristics

#### Methods

**Study design:** cost-effectiveness analysis (based partly on the Witt-Majchrzak 2015 RCT)

**Analytical approach:** Decision analytic model

**Effectiveness data:** baseline data on revision operations, length of stay, readmissions to hospital, and mortality were derived from single-centre prospective observational study over 36 months in Germany. Effectiveness data for NPWT were taken from the trial (n = 80) of Witt-Majchrzak 2015 (SSI and wound dehiscence). A length of stay reduction was applied from a meta-analysis (Strugala & Martin). All-cause mortality was obtained from German Federal Statistical Office and assumptions about relationship between mortality and revision surgery applied from literature.

**Perspective:** Germany Statutory Health Insurance payer

**Utility valuations:** Health state utilities were sourced from published literature including discharge with and without complications from study by Tuffaha 2015.

**Measure of benefit:** Wound healing without complications (complications avoided); QALY

**Cost data:** Costs derived from standard cost references, resource utilisation valued in Euro. Inpatient care taken data from Cristofolini. Patient stay costs from hospital management site; reimbursement cost for procedure from Germany Diagnosis Relater group Report Browser 2017. Standard care dress-
ing's costs and nursing costs covered in the diagnosis-related group costs. Rehabilitation costs obtained from a study by Zeidler. One community doctor and cardiologist visit cost, and the cost of community nurse visit once a week estimated. No discounting done due to a short time horizon (12 weeks).

**Analysis of uncertainty:** One-way sensitivity analyses; probabilistic sensitivity analyses using Monte Carlo simulation; subgroup analysis for people with high BMI.

### Participants

**Location:** Hospital, Poland  
**Intervention group:** n = 40, **control group:** n = 40

**Mean age: intervention group** = 66.2 (± 8), 53 to 80; **control group** = 62.1 (± 9.1), 41 to 78  
**Inclusion criteria:** patients who underwent an off-pump coronary artery bypass grafting procedure, using the internal mammary artery  
**Exclusion criteria:** not stated

### Interventions

**Aim/s:** To estimate the cost-effectiveness of single use negative pressure wound therapy (sNPWT) compared with standard of care in patients following coronary artery bypass grafting surgery (CABG) procedure to reduce surgical site complications (SSC) defined as dehiscence and sternotomy infections

**Group 1 (NPWT intervention):** Primary closure with NPWT (PICO, Smith & Nephew) using continuous negative pressure of ~80 mmHg. Dressing changed on day 2 or 3 and on day 5 or 6 after surgery.  
**Group 2 (control):** Conventional dressings applied after primary closure. Dressings changed daily

**Study date/s:** not stated

### Outcomes

**Outcomes** (for data see additional table 1; for clinical data see Witt-Majchrzak 2015)

- Costs
- Wound healing without complication (complications avoided); QALY (measure of benefit)
- ICER
- Probability of being cost-effective

### Notes

**Authors' conclusions:** The sNPWT can be considered a cost-saving intervention that reduces surgical site complications following CABG surgery compared with standard care. However, recommend that additional economic studies should be conducted as new evidence on the use of sNPWT in CABG patients becomes available to validate the results of this economic analysis.

**Funding:** NR for economic evaluation; see Witt-Majchrzak 2015 for RCT funding

**Quality rating using the CHEERS checklist was 87.0%**.
**Funding:** unclear. MHB gave scientific presentations for KCI.

**Preregistration:** no

### Participants

**Location:** Nuremberg, Germany  
**Intervention group:** n = 10, **control group:** n = 10  
**Mean age:** intervention group = 52.3 (16.3), control group = 57.8 (15.2)  
**Inclusion criteria:** patients with spinal fractures who were scheduled for internal fixation  
**Exclusion criteria:** not reported

### Interventions

**Aim/s:** to evaluate the different aspects of wound healing in spinal fractures treated with internal fixation  
**Group 1 (NPWT) intervention:** the NPWT group was treated with a PICO system (Smith & Nephew, UK). The PICO system was left on the wound for 5 days including the day of surgery. In addition to daily clinical examination, all wounds/seroma were analysed by ultrasonography on day 5 and day 10 after surgery.  
**Group 2 (control) intervention:** standard department wound dressing consisting of dry wound coverage (compresses attached to the skin) was used.  
**Study date/s:** not reported

### Outcomes

- **seroma**  
**Validity of measure/s:** ultrasound was used as a standardised imaging modality to detect seromas in the wound area.  
**Time points:** day 5 and day 10 after surgery

### Notes

Investigator contacted for additional details

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Numbers analysed were not reported.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Only seroma reported, not wound infection; unclear if all planned outcomes addressed.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>None identified</td>
</tr>
</tbody>
</table>

---

**Nordmeyer 2016 (Continued)**

**Nordmeyer 2016**  
**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

---

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Study characteristics

Methods

Study design: randomised controlled trial
Study grouping: parallel
Ethics and informed consent: yes
Sample size estimate: yes, but it was based on a reduction in SSI from 35% to 10%
ITT analysis: yes, number randomised: 50, number analysed: 49
Follow-up period: 30 days
Funding: support was received from Smith & Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors.

Participants

Location: Limerick, Ireland
Intervention group: n = 25, control group: n = 25
Mean age: intervention group = 58 (range 31 to 73), control group = 63 (range 33 to 76)
Inclusion criteria: patients undergoing elective or emergency open abdominal surgery with a clean, clean-contaminated, or contaminated wound
Exclusion criteria: dirty wound; BMI ≥ 40; ASA grade > 3

Interventions

Aim/s: to assess the effect of NPWT on SSI

Group 1 (NPWT) intervention: PICO dressing (Smith & Nephew) was applied to the wound by the operating surgeon, and the edges of the dressing were reinforced with self adherent tape.

Group 2 (control) intervention: transparent waterproof dressing (Smith & Nephew)

Study date/s: February 2013 to April 2016

Outcomes

• SSI
• reoperation
• pain

Validity of measure/s: CDC definitions and criteria for superficial, deep, and organ/space SSI were used for the primary outcome. A visual analogue scale was used to assess pain.

Time points: day 4 and day 30 postsurgery

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation codes were generated on <a href="http://www.randomization.com">www.randomization.com</a>.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Allocation was performed using a &quot;closed envelope method&quot;.</td>
</tr>
</tbody>
</table>
### O’Leary 2017 (Continued)

<table>
<thead>
<tr>
<th>Study characteristic</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
</table>
| **Blinding of participants and personnel (performance bias)** | High risk | Quote "A randomised, controlled, open-label trial"
| | | Comment: no blinding |
| **Blinding of outcome assessment (detection bias)** | High risk | Quote: "the ... study assessor was a senior member of the operating surgical team. The study assessor was not blinded to the treatment group". |
| **Incomplete outcome data (attrition bias)** | Low risk | 1 participant was removed from the intervention arm for a protocol violation, but ITT analysis was provided. |
| **Selective reporting (reporting bias)** | Low risk | Expected outcomes reported, but the study protocol was published after the completion of the trial. |
| **Other bias** | Low risk | No other bias identified |

### Pachowsky 2012

**Study characteristics**

**Methods**

- **Study design**: randomised controlled trial
- **Ethics and informed consent**: ethics approved and consent obtained.
- **Sample size calculation**: no
- **ITT analysis**: yes, **number randomised**: 19, **number analysed**: 19
- **Follow-up period**: 10 days
- **Funding**: support received from Smith & Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors.
- **Preregistration**: no

**Participants**

- **Location**: University Hospital, Erlangen, Germany
- **Intervention group**: n = 9, **control group**: n = 10
- **Mean age: intervention group** = 66.2 years (SD 17.83), **control group** = 70.0 years (SD 11.01)
- **Inclusion criteria**: "consecutive patients who were scheduled for a total hip arthroplasty (THA) for osteoarthritis of the hip were randomised".
- **Exclusion criteria**: not stated

**Interventions**

- **Aim/s**: to evaluate the use of NPWT to improve wound healing after total hip arthroplasty
- **Intervention/s in both groups**: “the surgical intervention was identical for both groups. All patients received two Redon drains, one in the deep area of the wound close to the prostheses and one above the closed fascia. The postoperative physiotherapy and mobilisation was also identical for both groups. Both groups received perioperative prophylaxis with antibiotics either Augmentin (amoxicillin trihydrate with potassium clavulanate) or ciprofloxacin”.

  **Group 1 (NPWT) intervention**: “the NPWT group was treated with a PREVENA™ system (KCI, San Antonio, USA). The PREVENA system was left on the wound for five days including the day of surgery”.

  **Group 2 control**: the control group received “the standard wound dressing of our department, consisting of a dry wound coverage”.
- **Study date/s**: not stated
Outcomes

- incidence of seroma (by ultrasound)
- amount of wound drainage in the Redon drain canisters
- duration of prophylactic antibiotics
- secretion from the wound

Validity of measure/s: "all patients underwent an ultrasound (Zonare, Z.One Ultra SP 4.2, Erlangen, ZONARE Medical Systems, Inc., Mountain View, USA) of the wound".

Time points: day 5 and day 10 of postoperative period

Notes

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Dressings were left in place for 5 days. The ultrasound was performed on day 5. It was unclear if the person performing the ultrasound was aware of the group to which the participant had been allocated.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All enrolled participants were accounted for in the analyses.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias) Low risk</td>
<td>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</td>
<td></td>
</tr>
<tr>
<td>Other bias High risk</td>
<td>Evidence: quote: &quot;Matthias H. Brem gave scientific presentations for KCI. The PREVENA wound treatment system was provided by KCI free of charge&quot;. Support was received from Smith &amp; Nephew. The authors were responsible for trial design, data analysis, and manuscript writing. The decision to publish trial results was made between study authors and study sponsors.</td>
<td></td>
</tr>
</tbody>
</table>

1 participant in the NPWT group removed the Redon drain by himself on the first postoperative day.

Study characteristics

Methods

Study design: randomised controlled trial

Study grouping: parallel

Ethics and informed consent: yes
Pauser 2016 (Continued)

**Sample size estimate:** no

**Follow-up period:** 10 days

**ITT analysis:** yes, **number randomised:** 21, **number analysed:** 21

**Funding:** "Prevena wound treatment system was provided by KCI free of charge".

**Preregistration:** no

### Participants

**Location:** Nuremberg, Germany

**Intervention group:** n = 11, **control group:** n = 10

**Mean age:** intervention group = 81.6 ± 5.2 years, control group = 82.6 ± 8.6 years

**Inclusion criteria:** patients with femoral neck fracture who were scheduled for hip hemiarthroplasty

**Exclusion criteria:** not stated

### Interventions

**Aim/s:** "to evaluate different aspects of wound healing after fractures of the femoral neck treated by hemiarthroplasty"

**Group 1 (NPWT) intervention:** the INPW group was treated with a PREVANA system (KCI, San Antonio, Texas). The PREVANA system was left on the wound for 5 days including the day of surgery.

**Group 2 control:** control group received the standard wound dressing of our department, consisting of a dry wound coverage (compresses attached to the skin).

**Study date/s:** not reported

### Outcomes

- **seroma**

**Validity of measure/s:** ultrasound was used as a standardised imaging modality to detect seromas in the wound area.

**Time points:** day 5 and day 10 after surgery

### Notes

Investigator contacted for additional details

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All those recruited appear to have been included in the analysis.</td>
</tr>
</tbody>
</table>
### Pauser 2016 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Unclear if all the planned outcomes were reported fully</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Data for the NPWT group reported at day 5 and day 10, but data for the control group only reported overall</td>
</tr>
</tbody>
</table>

### Study characteristics

#### Methods

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Sample size estimate:** no
- **Follow-up period:** 30 days postoperatively
- **ITT analysis:** yes, **number randomised:** 129 groin incisions (100 participants), **number analysed:** 129 incisions
- **Funding:** "funded by our own department, without any financial or scientific involvement or support from KCI, ACELITY Company"
- **Preregistration:** no

#### Participants

- **Location:** Germany
- **Intervention group:** n = 58 incisions, **control group:** n = 71 incisions
- **Mean age:** intervention group = 71 (range 54 to 89), control group = 66.5 (range 41 to 86)
- **Inclusion criteria:** vascular procedures with access to the common femoral artery with at least 1 of the known main risk factors of wound healing: age > 50 years, diabetes mellitus, renal insufficiency, malnutrition, obesity, and chronic obstructive pulmonary disease
- **Exclusion criteria:** not stated

#### Interventions

- **Aim/s:** to investigate the effectiveness of cINPT compared with conventional therapy with regard to the incidence of groin WHC on postoperative days 5 to 7 and 30 and the incidence of surgery revisions 30 days postoperatively after various vascular surgeries
- **Group 1 (NPWT) intervention:** cINPT applied for postoperative days 5 to 7
- **Group 2 (control) intervention:** a conventional adhesive plaster that was changed daily
- **Study date/s:** 1 February to 30 October 2015

#### Outcomes

- • wound complications including SSI
- **Validity of measure/s:** Szilagyi classification
- **Time points:** the first evaluation took place on postoperative days 5 to 7 during the hospital stay, while the second evaluation was conducted on postoperative day 30 in the outpatient clinic.

### Notes

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
### Pleger 2018 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information given</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All those recruited appear to have been included in the analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unequal number of participants in each group; results reported per fracture, so there is a potential unit of analysis issue.</td>
</tr>
</tbody>
</table>

### Ruhstaller 2017

#### Study characteristics

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** not reported
- **Follow-up period:** not reported
- **Sample size estimate:** not reported
- **ITT analysis:** yes, **number randomised:** 136, **number analysed:** not stated
- **Funding:** KCI collaborated in the trial.
- **Preregistration:** yes

**Participants**
- **Location:** Philadelphia, USA
- **Intervention group:** n = 67, **control group:** n = 69
- **Mean age:** not reported
- **Inclusion criteria:** BMI greater than or equal to 30 kg/m² at less than or equal to 22 weeks of gestation; woman is labouring; woman is having an unplanned caesarean section; woman will have Pfannenstiel skin incision; has the ability to take a picture and email it to a secure account; receives prenatal care in the University of Pennsylvania health system and plans to follow up postpartum in the system; is 18 years of age or older
- **Exclusion criteria:** woman cannot read or speak English; is not 18 years of age or older; does not have ability to send a picture by email; has pre-existing diabetes mellitus (type 1 or type 2), is using chronic steroids or immunosuppressants, OR is being actively treated for a malignancy; woman is undergoing a scheduled caesarean section; woman is allergic to silver
**Ruhstaller 2017** (Continued)

**Interventions**

**Aim/s:** to determine whether NPWT lowers the rate of wound complications in obese pregnant women undergoing an unscheduled intrapartum caesarean section

**Group 1 (NPWT) intervention:** NPWT device (PREVENA Incision Management System; Acelity)

**Group 2 control:** standard postcaesarean wound care (not defined)

**Study date/s:** not stated

**Outcomes**

**Planned outcomes:**
- primary outcome variable is wound complications defined as:
  - any readmission for a wound issue within 4 weeks of discharge;
  - infection;
  - wound breakdown.
- quality of life

**Reported outcomes:**
- SSI
- blisters
- reoperation

**Validity of measure/s:** not reported

**Time points:** 4 weeks postsurgery

**Notes**

Only the abstract and CTR report were available at the time of preparation of this review. Investigator contacted for additional details

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Once decision for caesarean delivery was established, randomisation was performed using a computer-generated randomisation scheme (Research Electronic Data Capture (REDCap)).</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>Intervention group: n = 61/67 (91%); control group: n = 58/69 (84%). It was unclear from the abstract if reasons for loss to follow-up were similar across groups.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Results for outcomes identified in the methods section were reported.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No other bias identified but insufficient reporting</td>
</tr>
</tbody>
</table>
### Study characteristics

**Methods**

- **Study design:** 1:1 parallel-group randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Sample size estimate:** no
- **Follow-up period:** 4 months
- **ITT analysis:** no
- **Funding:** not stated
- **Preregistration:** not stated

**Participants**

- **Location:** Philadelphia, USA
- **Intervention group:** n = 33 wounds, **control group:** n = 30 wounds (total 49 participants)
- **Mean age:** not reported
- **Inclusion criteria:** people undergoing open vascular surgery involving a groin incision
- **Exclusion criteria:** not stated

**Interventions**

- **Aim/s:** to compare the effect of postoperative negative pressure therapy to conventional dressings on wound occurrences
- **Group 1 (NPWT) intervention:** NPWT device
- **Group 2 control:** conventional dressing (gauze and Tegaderm)
- **Study date/s:** not stated

**Outcomes**

- **SSI**
- **wound dehiscence**

**Notes**

- Abstract only; unit analysis

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Not stated</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>All those recruited appear to have been included in the analysis.</td>
</tr>
</tbody>
</table>
### Sabat 2016 (Continued)
All outcomes

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Results for outcomes identified in the methods section were reported. We did not see the original protocol.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Unit of analysis issue - unclear if accounted for</td>
</tr>
</tbody>
</table>

### Schmid 2018

#### Study characteristics

**Methods**
- **Study design:** Randomised controlled trial
- **Study grouping:** Parallel group
- **Ethics and informed consent:** Not reported
- **Follow-up period:** 14 days
- **Sample size estimate:** Not reported
- **ITT analysis:** number randomised: 25, number analysed: 25
- **Funding:** Not reported
- **Preregistration:** Yes

**Participants**
- **Location:** Germany
- **Intervention group:** n = 25, **control group:** n = 25
- **Mean age:** intervention group: Not reported, control group: Not reported
- **Inclusion criteria:** Patients with penile cancer and indication for bilateral inguinal lymph node dissection (tumour stage ≥ pT1 G 2 or palpable inguinal enlarged lymph nodes)
- **Exclusion criteria:** Status post inguinal surgery

**Interventions**
- **Aim/s:** To prospectively analyse the effect of an epidermal vacuum wound dressing on lymphorrhoea, complications and reintervention in patients with inguinal lymphadenectomy for penile cancer
  - **Group 1 (NPWT) intervention:** Epidermal negative-pressure wound dressings (Prevena) for 7-8 days
  - **Group 2 (control) intervention:** Conventional compression bandages for 24 hours
- **Study date/s:** May 2013 –

**Outcomes**
- Reintervention (reoperation?)
- SSI may be included in wound complications but not reported
- **Validity of measure/s:** No definition of SSI reported
- **Time points:** 14 days

**Notes**
- Planned interim analysis. Abstract only

**Risk of bias**
- **Bias:** Random sequence generation (selection bias)
- **Authors’ judgement:** Unclear risk
- **Support for judgement:** Quote “Patients were randomised to receive conventional wound care and suction drainage on one side (conventional) vs. epidermal vacuum wound dressing (VAC) and suction drainage on the other side”.
### Schmid 2018 (Continued)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Comment: No indication how the randomisation sequence was generated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>High risk</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
</tr>
</tbody>
</table>

### Shen 2017

**Study characteristics**

**Methods**

- **Study design**: randomised controlled trial
- **Study grouping**: parallel
- **Ethics and informed consent**: yes
- **Sample size estimate**: yes (based on a real SSI reduction of 6% from 17% to 11%)
- **Follow-up period**: 30 days
- **ITT analysis**: yes, **number randomised**: 375, **number analysed**: 265
- **Funding**: non-industry
- **Preregistration**: yes

**Participants**

- **Location**: Wake Forest University Health Sciences, North Carolina, USA
- **Intervention group**: \( n = 187 \), **control group**: \( n = 188 \)
- **Median age (range)**: intervention group = 59.5 (25 to 85), control group = 62 (30 to 81)
- **Inclusion criteria**: patients who underwent open resection of intra-abdominal neoplasms, where the scheduled procedure was to be performed via midline laparotomy and was a clean-contaminated (class II) case (includes gastric, small bowel, and colorectal resections, as well as bile or pancreatic duct transections); the patient had the ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorised representative)
- **Exclusion criteria**: emergent cases; pregnant patients; clean (class I), contaminated (class III), and dirty (class IV) procedures; patients on chronic immunosuppressive medications, including steroids, within the last 3 months; patients with a history of skin allergy to iodine or adhesive drapes were not included in the study
**Aim/s:** to decrease the incidence of superficial and deep SSIs

**Group 1 (NPWT) intervention:** PICO dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

**Group 2 control:** Comfeel dressing applied over the primarily closed incision by the surgeon in the operating room. Dressing was left on for 4 days, or longer if drainage continued, unless soiled or dislodged.

**Study date/s:** July 2012 to April 2014

**Outcomes**
- SSI
- seroma
- haematoma
- incisional cellulitis
- dehiscence
- wound opening for any reason

**Validity of measure/s:** CDC definitions for SSI were used.

**Time points:** 30 days after surgery

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “the program nQuery was used to create the randomization schema”. The study used permuted-block randomisation with varying block sizes.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: “an email was sent the day before surgery to the attending surgeon about to which treatment arm the patient had been assigned”. Comment: scope for surgeons to anticipate the randomisation sequence</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: “There was no blinding of the patients or care providers to the study intervention. An email was sent the day before surgery to the attending surgeon about to which treatment arm the patient had been assigned”. Comment: patients and participants were not blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Investigator team assessed outcomes.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>Approximately 30% of participants were lost to follow-up or excluded from each arm of the trial. However, reasons for losses were similar between groups. NPWT group: 2 died and 19 were reoperated; standard care group: 5 died and 16 were reoperated</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Prospectively reported. Outcomes were consistent with proposal (National Cancer Institute CCSG P30CA012197).</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias identified</td>
</tr>
</tbody>
</table>
### Shim 2018

#### Study characteristics

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** yes
- **Follow-up period:** 1 year
- **Sample size estimate:** no
- **ITT analysis:** yes, **number randomised:** 51, **number analysed:** 51
- **Funding:** Not reported
- **Preregistration:** Not reported

**Participants**
- **Location:** Korea; single-centre (hospital)
- **Intervention group:** 30, **control group:** 21
- **Mean age:** intervention group 38.77 ± 1.68, control group 41.38 ± 10.92
- **Inclusion criteria:** > 20 years, acute multi-tissue hand injury of moderate severity (assessed by HISS score 21-50), underwent reconstruction within 3 days after injury by two surgeons
- **Exclusion criteria:** history of impaired motor function, injury to the peripheral nerves and/or vessels distal to the wrist, or a bone fracture requiring transarticular fixation with a Kirchner (K) wire, a congenital hand deformity, an operation history on the same hand, and underlying diseases including autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus or those taking medications that could influence wound healing

**Interventions**
- **Aim/s:** To compare outcomes in patients with acute hand injury who were managed with or without NPWT after reconstructive surgery
- **Group 1 (NPWT) intervention:** NPWT (CuraVAC, CGBio, Seongnam-si, Gyeonggi-do, Korea) applied at a pressure of 75 mmHg in continuous mode and secondary dressing including Vaseline gauze
- **Group 2 (control) intervention:** Conventional dressing, including vaseline gauze was applied over the closed skin using polyurethane foam with a compressible elastic bandage, and a short arm splint was applied in a functional position; dressing and NPWT were changed every 3 days.
- **Study date/s:** January 2013 - December 2016

**Outcomes**
- **• SSI/infection**
- **• haematoma**
- **• wound disruption (dehiscence)**
- **Validity of measure/s:** unclear what definition was used for infection
- **Time points:** 1 month and 1 year

**Notes**

#### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote: “Patients were randomly assigned to the control or experimental group following a simple randomization procedure (computerized random numbers) achieved using opaque envelopes”.</td>
</tr>
</tbody>
</table>

**Risk of bias**
### Shim 2018 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Quote: &quot;Patients were randomly assigned to the control or experimental group following a simple randomization procedure (computerized random numbers) achieved using opaque envelopes. Allocation information to each group was not provided to reduce bias&quot;.  &lt;br&gt;  Comment: allocation concealed with opaque envelopes but these were not noted as sequentially numbered</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)  &lt;br&gt; All outcomes</td>
<td>High risk</td>
<td>Quote &quot;This was a prospective open trial&quot;.  &lt;br&gt;  Comment: No blinding of participants or personnel</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)  &lt;br&gt; All outcomes</td>
<td>High risk</td>
<td>Quote &quot;This was a prospective open trial&quot;.  &lt;br&gt;  Comment: No blinding of outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)  &lt;br&gt; All outcomes</td>
<td>Low risk</td>
<td>No patients lost to follow-up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All prespecified outcomes fully reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No evidence of other bias but reporting insufficient to be certain</td>
</tr>
</tbody>
</table>

### Stannard 2012

#### Study characteristics

- **Study design:** multicentre randomised controlled trial (four centres, each a level 1 trauma centre)
- **Ethics and informed consent:** ethics approved and consent obtained
- **Sample size calculation:** no
- **Follow-up period:** not reported
- **ITT analysis:** wounds, not people were assessed
- **Funding:** "funds from corporate/industry were received from Kinetic Concepts, Inc to support this work".

#### Participants

- **Location:** Columbus, Ohio, USA
- **Intervention group:** n = 130, participants; 141 fractures,  <br>  **control group:** n = 119 participants; 122 fractures  <br>  **Mean age:** not stated  <br>  **Inclusion criteria:** people > 18 years of age who had sustained a high-energy tibial plateau, pilon, or calcaneus fracture and were able to comply with research protocol and willing to give informed consent  <br>  **Exclusion criteria:** non-operative calcaneus, tibia plateau, or pilon fractures; patients with open calcaneus fractures; tibial plateau or calcaneus fractures receiving definitive surgery more than 16 days after injury; pilon fractures receiving definitive surgery more than 21 days after injury; prisoners; pregnant women; patients with one of these fractures as a result of a low-energy mechanism of injury; patients or family members unable or unwilling to sign study informed consent; and patients unable to comply with the protocol
**Stannard 2012 (Continued)**

### Interventions

**Aim/s:** "to investigate the use of NPWT to prevent wound dehiscence and infection after high-risk lower extremity trauma"

**Intervention/s in both groups:** dressings or NPWT were applied in the operating room and then changed on postoperative day 2 and every 1 to 2 days thereafter.

**Group 1 (NPWT) intervention:** NPWT over the surgical incision after open reduction and internal fixation of the fracture

**Group 2 (control) intervention:** standard postoperative dressing (dressing not described)

**Study date/s:** not stated

### Outcomes

- wound infection and dehiscence
- time to discharge from hospital

**Validity of measure/s:** "all infections were confirmed with cultures".

**Time points:** not stated - unclear for how long participants were followed up

### Notes

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td><strong>Evidence:</strong> quote: &quot;patients were enrolled and then randomised to receive either standard postoperative dressings (control) or NPWT (study)&quot;.</td>
</tr>
<tr>
<td><strong>Comment:</strong> additional author information: &quot;the randomization was done via a computer generated randomization program&quot;.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td><strong>Comment:</strong> method not clarified</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td><strong>Evidence for participants:</strong> not possible</td>
</tr>
<tr>
<td><strong>Comment:</strong> unlikely to affect outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Evidence for personnel:</strong> not possible</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Comment:</strong> unlikely to affect outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td><strong>Evidence:</strong> quote: &quot;a patient was diagnosed as having an infection when a combination of clinical signs and symptoms (purulent drainage, erythema, fever, chills, etc) and laboratory data documented the infection. All infections were confirmed with cultures. Wound dehiscence was defined as any separation of the surgical incision that required either local wound care or surgical treatment&quot;.</td>
</tr>
<tr>
<td><strong>Comment:</strong> not clear whether those assessing outcomes were aware of group assignment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> a total of 249 participants were recruited. The same number of participants were reported for both acute and long-term follow-up (follow-up period not defined). Given that 4 hospitals were involved in the study, it seems unusual that complete follow-up would have occurred, suggesting that an available-case analysis may have been performed.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td><strong>Comment:</strong> registered in CTR (NCT00582998) 9 months after final data collection date, so it is unclear whether reported outcomes matched the original protocol. However, infection and dehiscence were the expected outcomes.</td>
</tr>
</tbody>
</table>
Stannard 2012 (Continued)

Other bias | High risk
---|---
**Comment:**
- unequal number of participants in each group
- appeared from the protocol that data collection was over many years, but no dates or explanation in manuscript
- results reported per fracture, so there is a potential unit of analysis issue

Tanaydin 2018

**Study characteristics**

**Methods**
- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** ethics approved and consent obtained
- **Sample size calculation:** no
- **Follow-up period:** 365 days postsurgery
- **ITT analysis:** wounds (breasts), not people were assessed
- **Funding:** funded by Smith & Nephew Ltd, who provided the PICO dressings and the Cutometer and financed a research assistant for carrying out the assessments and measurements

**Participants**
- **Location:** the Netherlands
  - **Intervention group:** n = 32, **control group:** n = 32 (participants served as their own control)
  - **Mean age (range):** 40.9 (18 to 61)
  - **Inclusion criteria:** patients > 18 years of age who underwent bilateral superomedial pedicle Wise-pattern breast reduction mammoplasty and had postsurgical incisions of similar length on each breast
  - **Exclusion criteria:** pregnancy or lactation, using steroids, or other immune modulators known to affect wound healing; history of radiation of the breast; tattoos in the area of the incision; skin conditions such as cutis laxa that would result in poor healing or widen scars, history of radiation of the breast, patients with a known significant history of hypertrophic scarring or keloids, and postsurgical incisions still actively bleeding, exposure of blood vessels, organs, bone, or tendon at the base of the reference wound; and incisions > 12 inches (30 cm) maximum linear dimension

**Interventions**
- **Aim/s:** to evaluate the effectiveness of postsurgery incision treatment comparing a portable disposable NPWT system with standard care using fixation strips
  - **Group 1 (NPWT) intervention:** a single-use NPWT system without an exudate canister
  - **Group 2 (control) intervention:** fixation strips (Steri-Strip; 3M, St Paul, Minnesota, USA)
- **Study date/s:** 1 June 2012 to 9 April 2014

**Outcomes**
- the number of wound-healing complications within 21 days
- aesthetic appearance and quality of scarring (additional measurements at 42, 90, 180, and 365 days)
- **Validity of measure/s:** wound-healing complications were defined as delayed healing (surgical incision not 100% closed at day 7 postsurgery), or occurrence of dehiscence or infection within 21 days postsurgery
- **Time points:** all included participants (N = 32) had follow-up visits and assessments at screening (pre-surgery), day 0 (baseline, postsurgery), day 7, 21, 42, 90, 180, and 365 postsurgery.

**Notes**
- The breasts were randomised and served as own control.
### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomization was used for allocation of NPWT and fixation strip to the right or left breast incision site per patient, using sealed envelopes. Treatment site information was accessed digitally (<a href="http://www.sealedenvelope.com">www.sealedenvelope.com</a>) upon the start of the treatment postsurgically.&quot;</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomization was used for allocation of NPWT and fixation strip to the right or left breast incision site per patient, using sealed envelopes. Treatment site information was accessed digitally (<a href="http://www.sealedenvelope.com">www.sealedenvelope.com</a>) upon the start of the treatment postsurgically.&quot;</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote: &quot;As NPWT and fixation strips are optically different, blinding of the physician and patients was not feasible&quot;.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Quote: &quot;as NPWT and fixation strips are optically different, blinding of the physician and patients was not feasible; however, data analysis was performed blinded&quot;.</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>32 enrolled participants were accounted for in the analyses.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Expected outcomes reported. Protocol retrospectively registered as NL40698.068.12/METC12-3-026</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>This was a 'split-body' or 'intra-individual' design where a person with 2 wounds had 1 wound randomised to each treatment. It was not clear whether the analysis took this into account.</td>
</tr>
</tbody>
</table>

#### Study characteristics

**Methods**
- **Study design:** randomised controlled trial (abstract only available)
- **Study grouping:** parallel
- **Ethics and informed consent:** not recorded
- **Sample size estimate:** not recorded
- **Follow-up period:** 30 days
- **ITT analysis:** yes, number randomised: 120, number analysed: 120
- **Funding:** non-industry
- **Preregistration:** yes (NCT02578745). Registered 11 June 2012
Participants

Location: St Louis, Missouri, USA

**Intervention group:** n = 60, **control group:** n = 60

**Mean age:** not recorded

**Inclusion criteria:**
- gestational age ≥ 23 weeks
- BMI ≥ 30 at the time of delivery
- planned or unplanned caesarean delivery (procedure in which NPWT is being tested)

**Exclusion criteria:**
- not available for postoperative follow-up
- contraindication to NPWT applicable to women undergoing caesarean: pre-existing infection around incision site, bleeding disorder, therapeutic anticoagulation, allergy to any component of the dressing (e.g. silicone, adhesive tape)

Interventions

**Aim/s:** to assess the feasibility of a definitive RCT to test the effectiveness and safety of prophylactic NPWT in obese women after caesarean section

**Group 1 (NPWT) intervention:** prophylactic NPWT with the PICO device (Smith & Nephew). Removed at discharge (usually on day 4)

**Group 2 (control) intervention:** standard wound dressing (routine postoperative wound dressing consisting of layers of gauze and adhesive tape). The dressing was removed 24 to 48 hours.

**Study date/s:** October 2016 to March 2016

Outcomes

- **Primary outcome/s:** composite of superficial or deep surgical site infection; wound separation ≥ 2 cm; SSI; haematoma; seroma
- **Secondary outcome/s:** pain score on postoperative day 2 and skin reactions

**Validity of measure/s:** wound infection defined by CDC criteria (information extracted from CTR)

**Time points:** 30 days

Notes

Investigator contacted for additional details

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Insufficient information in abstract to permit judgement</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Abstract indicated that 120 participants were randomised and 120 analysed. This was consistent with the number proposed in NCT02578745.</td>
</tr>
</tbody>
</table>
### Study characteristics

**Methods**

- **Study design:** randomised controlled trial
- **Study grouping:** parallel
- **Ethics and informed consent:** ethical approval and consent obtained (appropriate procedures for retrospective consent where necessary)
- **Follow-up period:** 6 months
- **Sample size estimate:** yes, full published statistical analysis plan; 1540 required to provide 90% power to detect reduction in deep infection from 15% to 9% with 20% loss to follow-up
- **ITT analysis:** yes, number randomised: 1548 (1629 randomised but 81 did not consent or were ineligible), number analysed: 1547
- **Funding:** National Institute for Health Research (NIHR) Health Technology Assessment programme
- **Preregistration:** yes

**Participants**

- **Location:** UK (24 sites)
- **Intervention group:** n = 785; **control group:** n = 763
- **Mean age: intervention group** ≤ 40: 283 (36.1%); > 40: 501 (63.9%), **control group** ≤ 40: 278 (36.4%); > 40: 485 (63.6%)
- **Inclusion criteria:** adult patients (16 years minimum) presenting to hospital within 72 hours of sustaining major trauma and who required a surgical incision to treat a fractured lower limb
- **Exclusion criteria:** open fracture of the lower limb that could not be closed primarily; evidence that the patient would be unable to adhere to trial procedures or complete questionnaires

**Interventions**

- **Aim/s:** To assess the deep surgical site infection (SSI) rate, disability, quality of life, patient assessment of the surgical scar and resource use in patients with surgical incisions associated with fractures following major trauma to the lower limbs, treated with incisional negative-pressure wound therapy (NPWT) versus standard dressings (cost-effectiveness was also assessed)
- **Group 1 (NPWT) intervention:** NPWT uses a non-adherent absorbent dressing covered with a semi-permeable dressing. A sealed tube connects the dressing to a built-in mini-pump that creates a partial vacuum over the wound. NPWT applied as per treating surgeon’s normal practice and according to manufacturer’s instructions
- **Group 2 (control) intervention:** standard dressing (non-adhesive layer covered by sealed dressing or bandage)
- **Study date/s:** September 2016 to April 2018

**Outcomes**

- SSI (deep), i.e. wound infection involving the tissues deep to the skin
- dehiscence (forms part of deep SSI criteria)
- health-related quality of life (EQ-5D) and Disability rating index (DRI)
- pain (and neuropathic pain)
- resource use
- cost-effectiveness

---

**Selective reporting (reporting bias)**

- **Low risk** Reporting was consistent with outcomes proposed in NCT02578745..

**Other bias**

- **Unclear risk** None detected. Independently funded trial, however no baseline data presented.
### WHIST 2019a (Continued)

- death (reported in Table 10 as a reason of dropout)
- reoperation (further surgery)

**Validity of measure/s:** CDC definitions and criteria were used for deep infection (30 days and 90 days as per original and revised criteria)

**Time points:** pre-injury, post-injury, 30 days, 3 months, 6 months

### Notes

Current Controlled Trials ISRCTN 12702354 and UKCRN Portfolio ID20416

Funding (cost-effectiveness assessment) National Institute for Health Research (NIHR) Health Technology Assessment programme

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomisation was on a 1:1 basis, using a validated computer randomisation program managed centrally by the Oxford Clinical Trials Research Unit... all participants were being randomised to treatment groups by simple randomisation without reference to their minimisation factors&quot;. Comment: adequate method of sequence generation</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Quote &quot;Randomisation was on a 1:1 basis, using a validated computer randomisation program managed centrally by the Oxford Clinical Trials Research Unit&quot;. Comment: Central allocation using a secure remote system; allocated treatment administered immediately after receipt of allocation</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Quote &quot;As the wound dressings and topical devices were clearly visible, the treating surgeon and trial participants could not be blinded to treatment allocation&quot;. Patients and personnel could not be blinded.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Quote &quot;the treating surgeons were not involved in study follow-up assessments or data collection for the trial. Data from clinical reporting forms was entered onto a central database administered by a data clerk in the trial central office. Wound photographs taken at outpatient clinic at approximately 30 days postsurgery were reviewed independently by two experienced assessors (tissue viability specialist) blinded to the treatment allocation.&quot; Blinded outcome assessment</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Primary outcome all accounted for; other outcomes had available case analysis.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Comment: Fully reported. A planned mortality analysis was not undertaken because &lt; 5% participants died before 30 days. planned analyses undertaken or deviations accounted for in plan.</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>Comprehensively reported and no evidence of other sources of bias</td>
</tr>
</tbody>
</table>
**Methods**

**Study design:** cost-effectiveness analysis based on the WHIST 2019a RCT

**Analytical approach:** Trial-based decision model

**Effectiveness data:** SSI (deep) and QoL (EQ-5D) both derived from WHIST 2019 (UK multicentre RCT, N = 1548)

**Perspective:** NHS and personal social services (PSS) perspectives

**Utility valuations:** EQ-5D and NHS/PSS resource use values derived from 623 trial participants with complete profiles.

**Measure of benefit:** QALY calculated using EQ-5D-3L utility scores using UK scoring algorithm

**Cost data:** Unit direct medical costs associated with the intervention obtained from the NHS Supply Chain Catalogue 2018/2019. These include cost of standard dressing, the cost of orthotic cast, the cost associated with dressing change, the cost per working hour of the nurse (obtained from the Personal Social Service Research Unit (PSSRU) 2018). The cost of inpatient care derived using the NHS HRG4+ 2017/18 Reference Cost Grouper and the NHS Reference Costs 2017/18. Unit costs of medical items other than those directly attributable to the intervention sourced from the NHS Reference Costs. Medication costs sourced from the BNF. Unit costs for direct non-medical cost items obtained from PSSRU. The costs of aids and adaptations obtained from the NHS Supply Chain Catalogue. The total cost per patient for additional (private) cost items incurred by patients and their next-of-kin obtained from the patients directly. The daily median wage obtained from the Office for National Statistics. Cost data were derived from the key resource inputs of the WHIST 2019 trial and expressed in 2017/2018 UK pounds sterling (£) (completed case analyses); a societal perspective was considered in a sensitivity analysis. Unit costs adjusted to 2017/2018 prices using the NHS Hospital & Community Health Services (HCHS) index for health service resources. No discounting of costs applied due to a short-time horizon.

**Analysis of uncertainty:** results of ICERs and cost-effectiveness acceptability curves (CEACs) generated via nonparametric bootstrapping with 1,000 replicates for accommodating sampling (or stochastic) uncertainty and varying levels of willingness-to-pay. Sensitivity analysis incorporated societal perspective; 3 different willingness-to-pay thresholds considered.

**Participants**

**Location:** UK hospitals

**Intervention group:** n = 785, **control group:** n = 763

**Mean age:** <40: 283 (36.1%); > 40: 501 (63.9%), **control group** <40: 278 (36.4%); > 40: 485 (63.6%)

**Inclusion criteria:** adult patients (16 years minimum) presenting to hospital within 72 hours of sustaining major trauma and who required a surgical incision to treat a fractured lower limb

**Exclusion criteria:** open fracture of the lower limb that could not be closed primarily; evidence that the patient would be unable to adhere to trial procedures or complete questionnaires

**Interventions**

**Aim/s:** To investigate, using appropriate statistical and economic analysis methods, the resource use, and thereby the cost effectiveness, of NPWT versus standard dressing for wounds associated with major trauma to the lower limbs

**Group 1 (NPWT) intervention:** NPWT using a non-adherent absorbent dressing covered with a semi-permeable dressing. A sealed tube connects the dressing to a built-in mini-pump that creates a partial vacuum over the wound. NPWT applied as per treating surgeon’s normal practice and according to manufacturer’s instructions (n = 785 in the trial)

**Group 2 (control) Standard dressing (non-adhesive layer covered by sealed dressing or bandage) (n = 763 in the trial)**

**Study date/s:** October 2016 to March 2016

**Outcomes**

**Outcomes** (for data see additional table 1 for WHIST 2019b, and for clinical data WHIST 2019a)

**Costs (GBP)**
WHIST 2019b (Continued)

QALY (measure of benefit)

ICER

Probability of being cost-effective at three different thresholds

Notes

Funding: NIHR

Authors’ conclusions: Contrary to the existing literature, incisional NPWT do not provide a clinical or economic benefit for patients having surgical incisions associated with major trauma to the lower limb.

Notes: Not currently a separate publication for cost-effectiveness, data taken from monograph which focuses on RCT

Quality rating using the CHEERS checklist was 89.1%

Wihbey 2018

Study characteristics

Methods

Study design: Randomized controlled trial

Study grouping: Parallel

Ethics and informed consent: Institutional review board approval was obtained from the Dartmouth Committee for the Protection of Human Subjects on April 21, 2015 (#00005211) and from the Southern New Hampshire Medical Center Clinical Trials Office (#2015-01). Women were recruited and consented to participate in this study before the onset of active labor during any routine prenatal visit or inpatient admission.

Follow-up period: 30 days

Sample size estimate: Yes. 400 women (200 prophylactic negative pressure wound therapy, 200 standard dressing) would need to be recruited to have an 80% power to detect a 50% decrease in superficial surgical site infection (assuming $P < .05$).

ITT analysis: Yes, number randomised: 166, number analysed: 166

Funding: The devices used in this study were provided by an unrestricted research grant from KCI Medical (San Antonio, Texas).

Preregistration: Yes. This trial was registered with clinical-trials.gov (Clinical Trial Registration: NCT02390401).

Participants

Location: Two centres (USA)

Intervention group: n = 80, control group: n = 86

Mean age: intervention group $31 \pm 6$, control group $30.2 \pm 5$

Inclusion criteria: Women undergoing caesarean delivery for a viable neonate and their BMI on admission to the labor and delivery floor was 35 or higher

Exclusion criteria: Women who were younger than 18 years old, did not speak English, had an allergy to silver or adhesives products, or who had a skin incision that would not fit the device or standard dressing (e.g. “T” skin incision)

Interventions

Aim/s: To compare the occurrence of superficial surgical site infections in women with class II or III obesity as defined by the Centers for Disease Control and Prevention using prophylactic negative pressure wound therapy compared with standard dressings after caesarean delivery

Group 1 (NPWT) intervention: Prophylactic NPWT supplied by KCI Medical (San Antonio, Texas) was applied at the time of primary skin closure at caesarean delivery and was placed over the closed surgi-
cal incision under sterile conditions and removed between postoperative day 5 and 7 at the time of incision check

**Group 2 (control) intervention:** Standard dressing after caesarean delivery was applied using a sterile technique. If subcuticular closure was used, sterile slim adhesive strips (also known as Steri-Strips) were applied. For both subcuticular and staple closure, the dressing consisted of a sterile nonadherent wound dressing (also known as Telfa), a sterile gauze, and a waterproof transparent adhesive dressing (also known as Tegaderm). The standard dressing was removed on postoperative day 2.

**Study date/s:** January 2015-January 2017

**Outcomes**

- Primary outcome: occurrence of surgical site infection defined according to Centers for Disease Control and Prevention criteria (superficial SSI)
- Composite wound complication, including superficial, deep, or organ-space surgical site infection;
- Wound dehiscence
- Seroma within 30 days of surgery
- Haematoma within 30 days of surgery
- 30-day readmission, 30-day reoperation

**Validity of measure/s:** Centers for Disease Control and prevention criteria were used.

**Time points:** 1 week and 30 days postoperatively

---

**Risk of bias**

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
</table>
| Random sequence generation (selection bias) | Low risk           | Quote: "A randomization program (www.randomization.com, Alberta, Canada) was used to generate sealed opaque envelopes with study assignment. Women were randomised at the conclusion of the cesarean delivery, during skin closure, when the envelopes were opened by a circulating operating room nurse. Two randomization strata were created using permuted blocks with varying block sizes for women with BMIs from 35 to less than 40 and women with BMIs of 40 or higher and for each site to ensure equal distribution of study allocation across these two separate BMI categories and sites."
   Comment: Appropriate method of sequence generation                                                                 |
| Allocation concealment (selection bias)  | Low risk           | Quote: "A randomization program (www.randomization.com, Alberta, Canada) was used to generate sealed opaque envelopes with study assignment. Women were randomised at the conclusion of the cesarean delivery, during skin closure, when the envelopes were opened by a circulating operating room nurse. Two randomization strata were created using permuted blocks with varying block sizes for women with BMIs from 35 to less than 40 and women with BMIs of 40 or higher and for each site to ensure equal distribution of study allocation across these two separate BMI categories and sites."
   Comment: centrally generated sequence of sealed opaque envelopes. Sequential numbering of envelopes may be inferred |
| Blinding of participants and personnel (performance bias) | High risk        | Quote: "We conducted a randomised controlled, nonblinded, multicenter study".                                                                                                                                            |
   All outcomes                                                                                                                          |
| Blinding of outcome assessment (detection bias) | High risk        | Quote: "We conducted a randomised controlled, nonblinded, multicenter study".                                                                                                                                            |
   All outcomes                                                                                                                          |
Wihbey 2018 (Continued)

Incomplete outcome data (attrition bias)
All outcomes
Low risk
Small attrition rate. Worst case scenario analysis performed for patients lost to follow-up

Selective reporting (reporting bias)
Low risk
All prespecified outcomes fully reported

Other bias
Low risk
No evidence of other sources of bias; adequate reporting

Witt-Majchrzak 2015

Study characteristics

Methods
Study design: randomised controlled trial
Study grouping: parallel
Ethics yes and informed consent: not stated
Follow-up period: 6 weeks
Sample size estimate: no
ITT analysis: yes, number randomised: 80, number analysed: 80
Funding: not stated
Preregistration: no

Participants
Location: Olsztyn, Poland
Intervention group: n = 40, control group: n = 40
Mean age: intervention group = 66.2 (± 8), 53 to 80, control group = 62.1 (± 9.1), 41 to 78
Inclusion criteria: patients who underwent an off-pump coronary artery bypass grafting procedure, using the internal mammary artery
Exclusion criteria: not stated

Interventions
Aim/s: not stated

Group 1 (NPWT) intervention: primary closure with NPWT (PICO, Smith & Nephew) using continuous negative pressure of −80 mmHg. Dressing changed on day 2 or 3 and on day 5 or 6 after surgery
Group 2 control: conventional dressings were applied after closure. Dressings changed daily
Study date/s: not stated

Outcomes
Primary outcome/s: surgical site infection
Secondary outcome/s: dehiscence, blisters, reoperation

Notes

Risk of bias

Bias
Authors' judgement
Support for judgement
Random sequence generation (selection bias)
Unclear risk
Authors stated only that participants were randomised, without describing method of randomisation.
### Witt-Majchrzac 2015 (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Level</th>
<th>Reason</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>Not reported</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>High risk</td>
<td>Quote “An open label prospective study”</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: open label study with no blinding</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>High risk</td>
<td>Quote “An open label prospective study”</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td>Comment: open label study with no blinding</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>There was no attrition in either arm of the trial.</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>While no study protocol was available, outcomes identified in the aims were reported (although it is unclear if the authors may have a priori identified other outcomes that were not reported on).</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>Baseline imbalance in age; NPWT group was older</td>
</tr>
</tbody>
</table>

### Abbreviations

- APR: abdominopерineal resection
- ASA: American Society of Anesthesiologists
- ASEPSIS: ASEPSIS score - a quantitative scoring method using objective criteria based on wound appearance to evaluate wound infection
- AUSD: Australian dollars
- BMI: body mass index
- BNF: British National Formulary
- CABG: coronary artery bypass graft
- CDC: US Centers for Disease Control and Prevention
- CEACs: cost-effectiveness acceptability curves
- CHEERS: Checklist for Economic Evaluation for Health Interventions
- CI: confidence interval
- cINPT: closed incision negative pressure therapy
- CrI: credible interval
- CS: caesarean section
- CTR: clinical trials registry
- DK: Danish Krona
- DRI: Disability Rating Index
- DVT: deep venous thrombosis
- EMR: electronic medical record
- EQ-5D-3L/5L: EuroQol 5D questionnaire, version 3L
- GP: general practitioner
- GSV: great saphenous vein
- HCHS: hospital and community health services
- HISS: Hand Injury Severity Score
- ICER: Incremental cost effectiveness ratio
- iNPWT: incisional negative pressure wound therapy
- IQR: interquartile range
- ITT: intention-to-treat
- LOS: length of stay
- NHS: National Health Service (United Kingdom)
- NPC: negative pressure closure
- NPD: negative pressure device
- NPWT: negative pressure wound therapy
Study characteristics

Methods

**Study design:** cost-effectiveness analysis based on the WHIST 2019a RCT

**Analytical approach:** Trial-based decision model

**Effectiveness data:** SSI (deep) and QoL (EQ-5D) both derived from WHIST 2019 (UK multicentre RCT, N = 1548)

**Perspective:** NHS and personal social services (PSS) perspectives

**Utility valuations:** EQ-5D and NHS/PSS resource use values derived from 623 trial participants with complete profiles.

**Measure of benefit:** QALY calculated using EQ-5D-3L utility scores using UK scoring algorithm

**Cost data:** Unit direct medical costs associated with the intervention obtained from the NHS Supply Chain Catalogue 2018/2019. These include cost of standard dressing, the costs of orthotic cast, the cost associated with dressing change, the cost per working hour of the nurse (obtained from the Personal Social Service Research Unit (PSSRU) 2018). The cost of inpatient care derived using the NHS HRG4+ 2017/18 Reference Cost Grouper and the NHS Reference Costs 2017/18. Unit costs of medical items other than those directly attributable to the intervention sourced from the NHS Reference Costs. Medication costs sourced from the BNF. Unit costs for direct non-medical cost items obtained from PSSRU. The costs of aids and adaptations obtained from the NHS Supply Chain Catalogue. The total cost per patient for additional (private) cost items incurred by patients and their next-of-kin obtained from the patients directly. The daily median wage obtained from the Office for National Statistics. Cost data were derived from the key resource inputs of the WHIST 2019 trial and expressed in 2017/2018 UK pounds sterling (£) (completed case analyses); a societal perspective was considered in a sensitivity analysis.
Unit costs adjusted to 2017/2018 prices using the NHS Hospital & Community Health Services (HCHS) index for health service resources. No discounting of costs applied due to a short-time horizon.

Analysis of uncertainty: results of ICERs and cost-effectiveness acceptability curves (CEACs) generated via nonparametric bootstrapping with 1,000 replicas for accommodating sampling (or stochastic) uncertainty and varying levels of willingness-to-pay, sensitivity analysis incorporated societal perspective; 3 different willingness-to-pay thresholds considered

Participants

Location: UK hospitals

Intervention group: n = 785, control group: n = 763

Mean age: \(\leq 40: 283\) (36.1%); \(> 40: 501\) (63.9%), control group \(\leq 40: 278\) (36.4%); \(> 40: 485\) (63.6%)

Inclusion criteria: adult patients (16 years minimum) presenting to hospital within 72 hours of sustaining major trauma and who required a surgical incision to treat a fractured lower limb

Exclusion criteria: open fracture of the lower limb that could not be closed primarily; evidence that the patient would be unable to adhere to trial procedures or complete questionnaires

Interventions

Aim/s: To investigate, using appropriate statistical and economic analysis methods, the resource use, and thereby the cost effectiveness, of NPWT versus standard dressing for wounds associated with major trauma to the lower limbs

Group 1 (NPWT) intervention: NPWT using a non-adherent absorbent dressing covered with a semi-permeable dressing. A sealed tube connects the dressing to a built-in mini-pump that creates a partial vacuum over the wound. NPWT applied as per treating surgeon’s normal practice and according to manufacturer’s instructions (n = 785 in the trial)

Group 2 (control) Standard dressing (non-adhesive layer covered by sealed dressing or bandage) (n = 763 in the trial)

Study date/s: October 2016 to March 2016

Outcomes

Outcomes (for data see additional table 1 for WHIST 2019b, and for clinical data WHIST 2019a)

Costs (GBP)

QALY (measure of benefit)

ICER

Probability of being cost-effective at three different thresholds

Notes

Funding: NIHR

Authors’ conclusions: Contrary to the existing literature, incisional NPWT do not provide a clinical or economic benefit for patients having surgical incisions associated with major trauma to the lower limb.

Notes: Not currently a separate publication for cost-effectiveness, data taken from monograph which focuses on RCT

Quality rating using the CHEERS checklist was 89.1%

Wihbey 2018

Study characteristics

Methods

Study design: Randomized controlled trial

Study grouping: Parallel

Ethics and informed consent: Institutional review board approval was obtained from the Dartmouth Committee for the Protection of Human Subjects on April 21, 2015 (H00005211) and from the Southern...
New Hampshire Medical Center Clinical Trials Office (#2015-01). Women were recruited and consented to participate in this study before the onset of active labor during any routine prenatal visit or inpatient admission.

**Follow-up period:** 30 days

**Sample size estimate:** Yes. 400 women (200 prophylactic negative pressure wound therapy, 200 standard dressing) would need to be recruited to have an 80% power to detect a 50% decrease in superficial surgical site infection (assuming P < .05).

**ITT analysis:** Yes, number randomised: 166, number analysed: 166

**Funding:** The devices used in this study were provided by an unrestricted research grant from KCI Medical (San Antonio, Texas).

**Preregistration:** Yes. This trial was registered with clinical-trials.gov (Clinical Trial Registration: NCT02390401).

### Participants

**Location:** Two centres (USA)

**Intervention group:** n = 80, **control group:** n = 86

**Mean age:** intervention group 31 ± 6, control group 30.2 ± 5

**Inclusion criteria:** Women undergoing caesarean delivery for a viable neonate and their BMI on admission to the labor and delivery floor was 35 or higher

**Exclusion criteria:** Women who were younger than 18 years old, did not speak English, had an allergy to silver or adhesives products, or who had a skin incision that would not fit the device or standard dressing (e.g. “T” skin incision)

### Interventions

**Aim/s:** To compare the occurrence of superficial surgical site infections in women with class II or III obesity as defined by the Centers for Disease Control and Prevention using prophylactic negative pressure wound therapy compared with standard dressings after caesarean delivery

**Group 1 (NPWT) intervention:** Prophylactic NPWT supplied by KCI Medical (San Antonio, Texas) was applied at the time of primary skin closure at caesarean delivery and was placed over the closed surgical incision under sterile conditions and removed between postoperative day 5 and 7 at the time of incision check

**Group 2 (control) intervention:** Standard dressing after caesarean delivery was applied using a sterile technique. If subcuticular closure was used, sterile slim adhesive strips (also known as Steri-Strips) were applied. For both subcuticular and staple closure, the dressing consisted of a sterile nonadherent wound dressing (also known as Telfa), a sterile gauze, and a waterproof transparent adhesive dressing (also known as Tegaderm). The standard dressing was removed on postoperative day 2.

**Study date/s:** January 2015-January 2017

### Outcomes

- Primary outcome: occurrence of surgical site infection defined according to Centers for Disease Control and Prevention criteria (superficial SSI)
- Composite wound complication, including superficial, deep, or organ-space surgical site infection;
- Wound dehiscence
- Seroma within 30 days of surgery
- Haematoma within 30 days of surgery
- 30-day readmission, 30-day reoperation

**Validity of measure/s:** Centers for Disease Control and prevention criteria were used.

**Time points:** 1 week and 30 days postoperatively

### Notes

**Risk of bias**
### Random sequence generation (selection bias)

- **Bias**: Random sequence generation (selection bias)
- **Authors' judgement**: Low risk
- **Support for judgement**: Quote: "A randomization program (www.randomization.com, Alberta, Canada) was used to generate sealed opaque envelopes with study assignment. Women were randomised at the conclusion of the cesarean delivery, during skin closure, when the envelopes were opened by a circulating operating room nurse. Two randomization strata were created using permuted blocks with varying block sizes for women with BMIs from 35 to less than 40 and women with BMIs of 40 or higher and for each site to ensure equal distribution of study allocation across these two separate BMI categories and sites."
- **Comment**: Appropriate method of sequence generation.

### Allocation concealment (selection bias)

- **Bias**: Allocation concealment (selection bias)
- **Authors' judgement**: Low risk
- **Support for judgement**: Quote: "A randomization program (www.randomization.com, Alberta, Canada) was used to generate sealed opaque envelopes with study assignment. Women were randomised at the conclusion of the cesarean delivery, during skin closure, when the envelopes were opened by a circulating operating room nurse. Two randomization strata were created using permuted blocks with varying block sizes for women with BMIs from 35 to less than 40 and women with BMIs of 40 or higher and for each site to ensure equal distribution of study allocation across these two separate BMI categories and sites."
- **Comment**: Centrally generated sequence of sealed opaque envelopes. Sequential numbering of envelopes may be inferred.

### Blinding of participants and personnel (performance bias)

- **Bias**: Blinding of participants and personnel (performance bias)
- **Authors' judgement**: High risk
- **Support for judgement**: Quote: "We conducted a randomised controlled, nonblinded, multicenter study".
- **Comment**: Not blinded.

### Blinding of outcome assessment (detection bias)

- **Bias**: Blinding of outcome assessment (detection bias)
- **Authors' judgement**: High risk
- **Support for judgement**: Quote: "We conducted a randomised controlled, nonblinded, multicenter study".
- **Comment**: Not blinded.

### Incomplete outcome data (attrition bias)

- **Bias**: Incomplete outcome data (attrition bias)
- **Authors' judgement**: Low risk
- **Support for judgement**: Small attrition rate. Worst case scenario analysis performed for patients lost to follow-up.

### Selective reporting (reporting bias)

- **Bias**: Selective reporting (reporting bias)
- **Authors' judgement**: Low risk
- **Support for judgement**: All prespecified outcomes fully reported.

### Other bias

- **Bias**: Other bias
- **Authors' judgement**: Low risk
- **Support for judgement**: No evidence of other sources of bias; adequate reporting.

### Study characteristics

#### Methods

- **Study design**: randomised controlled trial
- **Study grouping**: parallel
- **Ethics**: yes and informed consent: not stated
- **Follow-up period**: 6 weeks
- **Sample size estimate**: no
- **ITT analysis**: yes, number randomised: 80, number analysed: 80
Witt-Majchrzak 2015 (Continued)

Funding: not stated

Preregistration: no

Participants

Location: Olsztyn, Poland

Intervention group: n = 40, control group: n = 40

Mean age: intervention group = 66.2 (± 8), 53 to 80, control group = 62.1 (± 9.1), 41 to 78

Inclusion criteria: patients who underwent an off-pump coronary artery bypass grafting procedure, using the internal mammary artery

Exclusion criteria: not stated

Interventions

Aim/s: not stated

Group 1 (NPWT) intervention: primary closure with NPWT (PICO, Smith & Nephew) using continuous negative pressure of −80 mmHg. Dressing changed on day 2 or 3 and on day 5 or 6 after surgery

Group 2 control: conventional dressings were applied after closure. Dressings changed daily

Study date/s: not stated

Outcomes

Primary outcome/s: surgical site infection

Secondary outcome/s: dehiscence, blisters, reoperation

Notes

Risk of bias

Bias Authors’ judgement Support for judgement

Random sequence generation (selection bias) Unclear risk Authors stated only that participants were randomised, without describing method of randomisation.

Allocation concealment (selection bias) Unclear risk Not reported

Blinding of participants and personnel (performance bias) All outcomes High risk Quote "An open label prospective study"

Comment: open label study with no blinding

Blinding of outcome assessment (detection bias) All outcomes High risk Quote "An open label prospective study"

Comment: open label study with no blinding

Incomplete outcome data (attrition bias) All outcomes Low risk There was no attrition in either arm of the trial.

Selective reporting (reporting bias) Low risk While no study protocol was available, outcomes identified in the aims were reported (although it is unclear if the authors may have a priori identified other outcomes that were not reported on).

Other bias Unclear risk Baseline imbalance in age; NPWT group was older

Abbreviations

APR: abdominoperineal resection
ASA: American Society of Anesthesiologists
ASEPSSIS: ASEPSSIS score - a quantitative scoring method using objective criteria based on wound appearance to evaluate wound infection

Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Characteristics of excluded studies [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Al-Inany 2002</td>
<td>Ineligible intervention</td>
</tr>
<tr>
<td>Albert 2012</td>
<td>No acute wounds were included.</td>
</tr>
<tr>
<td>Anderson 2014</td>
<td>Feasibility study. Predefined criteria used to assess feasibility included: recruitment (&gt; 75% participation); loss to follow-up (&lt; 10%); intervention fidelity (= 95%); and interrater reliability (kappa = 0.8). Assessment of clinical outcomes was not planned or conducted.</td>
</tr>
<tr>
<td>Athanasiou 2018</td>
<td>Commentary on an RCT; not original research</td>
</tr>
<tr>
<td>Banasiewicz 2013</td>
<td>Included infected wounds</td>
</tr>
<tr>
<td>Bi 2017</td>
<td>Ineligible intervention</td>
</tr>
<tr>
<td>Bondokji 2011</td>
<td>Prospective cohort study</td>
</tr>
<tr>
<td>Braakenburg 2006</td>
<td>Chronic and acute wounds were reported together, and further information was not available.</td>
</tr>
<tr>
<td>Chang 2018</td>
<td>Discussion article</td>
</tr>
<tr>
<td>Chiang 2017</td>
<td>Open wounds</td>
</tr>
<tr>
<td>Chio 2010</td>
<td>Skin graft study</td>
</tr>
<tr>
<td>Costa 2018</td>
<td>Ineligible population - wounds healing by secondary intention</td>
</tr>
<tr>
<td>Dorafshar 2012</td>
<td>The study used NPWT to treat existing non-healing skin graft wounds.</td>
</tr>
<tr>
<td>Eisenhardt 2012</td>
<td>Skin graft study; no inclusion of wounds healing by primary closure</td>
</tr>
<tr>
<td>Erne 2018</td>
<td>Ineligible intervention</td>
</tr>
<tr>
<td>Fleming 2018</td>
<td>Ineligible study design - not an RCT</td>
</tr>
<tr>
<td>Frazee 2018</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Grauhan 2013</td>
<td>Quasi-randomised study: &quot;A total of 156 patients were enrolled and allocated to 2 study groups, alternating according to the time of operation&quot;.</td>
</tr>
<tr>
<td>Hu 2009</td>
<td>Acute, subacute, and chronic wounds were included. Acute wounds were defined as those that had been &quot;open&quot; for less than 1 week.</td>
</tr>
<tr>
<td>Johannesson 2008</td>
<td>The intervention dressing was not a continuous negative pressure device.</td>
</tr>
<tr>
<td>Joos 2015</td>
<td>Commentary on an RCT in wounds healing by secondary intention</td>
</tr>
<tr>
<td>Kim 2007</td>
<td>The study was not a randomised controlled trial.</td>
</tr>
<tr>
<td>Krishnamoorthy 2012</td>
<td>Use of NPWT was not the only difference between the groups.</td>
</tr>
<tr>
<td>Study</td>
<td>Reason for exclusion</td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>Li 2016</td>
<td>Quasi-randomisation (by odd and even numbers)</td>
</tr>
<tr>
<td>Llanos 2006</td>
<td>Skin graft study</td>
</tr>
<tr>
<td>Moisidis 2004</td>
<td>Skin graft study; no inclusion of wounds healing by primary closure</td>
</tr>
<tr>
<td>Mouës 2004</td>
<td>No inclusion of acute wounds</td>
</tr>
<tr>
<td>Mouës 2007</td>
<td>No inclusion of acute wounds</td>
</tr>
<tr>
<td>Muller-Sloof 2018</td>
<td>Ineligible population</td>
</tr>
<tr>
<td>Pellino 2014</td>
<td>Non-randomised study in people with Crohn’s disease</td>
</tr>
<tr>
<td>Petkar 2012</td>
<td>Skin graft study</td>
</tr>
<tr>
<td>Rahmanian-Schwarz 2012</td>
<td>Included chronic and acute wounds, and these were not separately reported</td>
</tr>
<tr>
<td>Sinha 2016</td>
<td>Ineligible population; infected wounds</td>
</tr>
<tr>
<td>Stannard 2006</td>
<td>Ineligible population; not closed incision wounds</td>
</tr>
<tr>
<td>Svensson-Bjork 2018</td>
<td>Non-randomised subgroup of RCT participants</td>
</tr>
<tr>
<td>Trofa 2019</td>
<td>Ineligible comparison</td>
</tr>
<tr>
<td>Visser 2017</td>
<td>The vacuum therapy device was a syringe inserted subcutaneously into the dressing, which was used to create a vacuum. Consequently, it was not a standard, continuous pressure device.</td>
</tr>
<tr>
<td>Walker 2018</td>
<td>Ineligible intervention</td>
</tr>
<tr>
<td>Yu 2017</td>
<td>A drain was left inside the wound, so not strictly a primarily closed wound.</td>
</tr>
<tr>
<td>Zotes 2015</td>
<td>Ineligible population; infected wounds</td>
</tr>
</tbody>
</table>

NPWT: negative pressure wound therapy

**Characteristics of studies awaiting classification [ordered by study ID]**

**Nagata 2018**

Methods
- **Study design:** Randomised controlled trial
- **Study grouping:** Intra-individual
- **Ethics and informed consent:** N/A
- **Follow-up period:** 6 months
- **Sample size estimate:** Target sample size of 20 (sample size estimate calculation not reported)
- **ITT analysis:** yes, number randomised: 13, number analysed: 13
- **Funding:** None
- **Preregistration:** This trial was registered under the name “Tissue Expander (TE) Insertion Comparison of Negative Pressure Fixation (NPF) and Film Dressing (FD) Effects on Suture Wound
Nagata 2018 (Continued)

Open Label Randomized Single Facility Comparison Test,” UMIN Clinical Trial Registry number UMIN000014424.

Participants

Location: Single-centre – Japan

Intervention group: n = 13, control group: n = 13

Mean age: 46.2, intervention group 46.2, control group 46.2

Inclusion criteria: Women aged 18 to 65 years undergoing tissue expander insertion for two-stage breast reconstruction after mastectomy were included.

Exclusion criteria: Excluded patients were those who (1) did not provide consent, (2) received radiotherapy after surgery, (3) had an adverse reaction to the adhesive film, (4) had a local infection or wound dehiscence at study initiation, or (5) underwent tissue expander replacement with a silicone breast implant within 6 months after the first operation.

Interventions

Aim/s: To evaluate the effects of negative-pressure fixation on scar appearance and histochemical properties in comparison to those for film dressing without negative pressure

Group 1 (NPWT) intervention: Application of negative pressure inside polyurethane foam (Hydrosite Plus; Smith & Nephew, London, United Kingdom) sealed by a film dressing (Airwall; Kiyowa, Osaka, Japan)

Group 2 (control) intervention: Film dressing

Study date/s: 3 July 2014 to 31 August 2016

Outcomes

• Visual analogue scale
• Scar width
• Immunohistochemistry

Validity of measure/s: N/A

Time points: 6 months postoperative

Notes

NCT00654641

Methods
Randomised controlled trial

Participants
Obese women undergoing caesarean delivery

Interventions
Negative pressure wound therapy versus standard wound closure

Outcomes
Total number of women experiencing a wound complication

Notes

NCT00724750

Methods
Randomised controlled trial

Participants
Hospitalised patients with acute wounds resulting from either trauma, dehiscence, or surgical complications

Notes
### Interventions

Gauze suction (G-SUC) negative pressure wound therapy versus vacuum-assisted closure device (VAC) negative pressure wound therapy

### Outcomes

Per cent change per day in wound surface area; per cent change per day in wound volume

### Notes

G-SUC: gauze suction
HOOS: hip disability and osteoarthritis outcome score
KOOS: knee disability and osteoarthritis outcome score
VAC: vacuum-assisted closure
VAS: visual analogue scale
VR-12: Veterans RAND 12-Item Health Survey

### Characteristics of ongoing studies [ordered by study ID]

#### ACTRN12615000175572

<table>
<thead>
<tr>
<th>Study name</th>
<th>Do suction assisted negative pressure dressings reduce the incidence of surgical site infections after abdominal surgery: a randomized controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing laparotomy (where abdominal incision breaches peritoneum, and wound is large enough to at least fit the surgeon’s hand)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard dressing used with a clear film with an absorbent layer</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound infection; patient satisfaction</td>
</tr>
<tr>
<td>Starting date</td>
<td>2015</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:peeyau.tan@monashhealth.org">peeyau.tan@monashhealth.org</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

#### ACTRN12618000026224p

<table>
<thead>
<tr>
<th>Study name</th>
<th>Effect of negative pressure dressing versus standard wound dressing on the rate of wound dehiscence in patients undergoing pilonidal surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing pilonidal surgery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Rate of wound dehiscence; time taken for the wound to fully heal; rate of disease recurrence; analgesia requirements for the wound; ratio of wound size; patient satisfaction 2 months postoperatively; QoL</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
</tbody>
</table>
### ACTRN12618000026224p (Continued)

<table>
<thead>
<tr>
<th>Contact information</th>
<th><a href="mailto:Ram.Nataraja@monashhealth.org">Ram.Nataraja@monashhealth.org</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### ACTRN12618001611213

<table>
<thead>
<tr>
<th>Study name</th>
<th>The effect of PICO dressings on surgical site infection following bowel resection: a randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>All adults (aged 18 and over) undergoing elective or emergency small or large bowel resection</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy (PICO dressing) versus standard dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; Patient and Observer Scar Assessment Scale (POSAS); patient satisfaction</td>
</tr>
<tr>
<td>Starting date</td>
<td>2018</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:Alexandra.Gordon@midcentraldhb.govt.nz">Alexandra.Gordon@midcentraldhb.govt.nz</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### ACTRN12618002006224

<table>
<thead>
<tr>
<th>Study name</th>
<th>Efficacy of negative pressure wound therapy in the prevention of surgical wound complications in the cesarean section at risk population: a randomised multi-centre trial, the CYGNUS trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Pregnant women between 18-50 years undergoing caesarean section</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; wound dehiscence</td>
</tr>
<tr>
<td>Starting date</td>
<td>2018</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:kylie.sandy-hodgetts@uwa.edu.au">kylie.sandy-hodgetts@uwa.edu.au</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### ChiCTR-IOR-15006439

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prevention surgical site infection with using negative pressure wound therapy in abdominal incision</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Parallel randomised controlled trial</td>
</tr>
</tbody>
</table>
### ChiCTR-IOR-15006439 (Continued)

<table>
<thead>
<tr>
<th>Participants</th>
<th>High-risk patients: including abdominal surgery for malignancy, colorectal, abdominal wall reconstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus routine approach</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Rate of surgical site infection</td>
</tr>
<tr>
<td>Starting date</td>
<td>2015</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:hpzhangly@163.com">hpzhangly@163.com</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### DRKS00006199

<table>
<thead>
<tr>
<th>Study name</th>
<th>Postoperative negative pressure incision therapy following open colorectal surgery: a randomized-controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing planned elective open colorectal surgery via median or transverse laparotomy</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Rate of SSI; length of hospital stay; rate of reoperations; rate of antibiotic therapy; duration of postoperative negative pressure incision therapy (intervention arm only); wound pain assessed with VAS; rate of wound complications other than wound infections; rate of serious adverse events</td>
</tr>
<tr>
<td>Starting date</td>
<td>1 October 2015</td>
</tr>
<tr>
<td>Contact information</td>
<td>Unclear</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### DRKS00011033

<table>
<thead>
<tr>
<th>Study name</th>
<th>Evaluation of negative pressure incisional therapy in urgent gastro-intestinal surgery for reduction of superficial surgical site infections compared to non-occlusive conventional plaster - a prospective, randomized, controlled, multicenter clinical trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing urgent laparotomy due to an acute gastrointestinal disorder</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus non-occlusive conventional plaster</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; prolongation of hospitalisation due to SSI; cosmetic result; safety endpoints: AEs, SAEs</td>
</tr>
<tr>
<td>Starting date</td>
<td>21 September 2016</td>
</tr>
<tr>
<td>Contact information</td>
<td>Unclear</td>
</tr>
<tr>
<td>Study name</td>
<td>Negative pressure wound therapy (NPWT) on closed incisions to prevent surgical site infection in HPB-surgery</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients &gt; 49 years of age undergoing hepatopancreatobiliary surgery with midline, transverse or L-formed laparotomy</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative wound pressure therapy (Prevena) versus standard dressing (plaster bandage)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Superficial and deep incisional SSI; haematoma, seroma, dehiscence, necrosis; fascial dehiscence; EQ-5D-5L; usage of antibiotics; secondary intervention and reoperation</td>
</tr>
<tr>
<td>Starting date</td>
<td>2019</td>
</tr>
<tr>
<td>Contact information</td>
<td>frank.brennfleck at ukr.de</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Negative pressure wound therapy versus standard care dressing to prevent surgical site infections in obese women undergoing caesarean section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Obese women following caesarean section</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Presence of SSI; wound complications; hospital readmissions; hospital length of stay; QoL</td>
</tr>
<tr>
<td>Starting date</td>
<td>2015</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:b.gillespie@griffith.edu.au">b.gillespie@griffith.edu.au</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Wound healing in surgical trauma</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Major trauma patients aged 16 years or over requiring surgery to treat a broken leg</td>
</tr>
</tbody>
</table>
### ISRCTN12702354 (Continued)

**Interventions**
Negative pressure wound therapy versus standard-of-care wound dressing

**Outcomes**
Deep infection rate; QoL; wound healing; number and nature of further surgical interventions; cost-effectiveness; long-term disability; chronic neuropathic pain

**Starting date**
January 2016

**Contact information**
WHIST@ndorms.ox.ac.uk

**Notes**

---

### ISRCTN31224450

**Study name**
Negative pressure therapy in large incisional hernia surgery

**Methods**
Randomised controlled trial (case-control)

**Participants**
Patients undergoing elective surgery for incisional hernia with diameters exceeding 10 cm

**Interventions**
Negative pressure wound therapy versus traditional dressing

**Outcomes**
Primary: volume accumulated in the drains every 24 hours in millilitres; number of days needed to reduce this volume under 50 mL per 24 hours
Secondary: postoperative complications; cost

**Starting date**
1 February 2013

**Contact information**
drcarlesolona@gmail.com

**Notes**

---

### ISRCTN55305726

**Study name**
WHITE 7 - WHISH – wound healing in surgery for hip fractures

**Methods**
Randomised controlled trial

**Participants**
Adults aged 65 years or older with a hip fracture that requires surgery

**Interventions**
Negative pressure wound therapy versus standard wound dressing

**Outcomes**
Deep infection; mortality rate; QoL; complications and surgical interventions; cost consequences and resource use; mobility; residential status; recruitment rate; retention rate

**Starting date**
1 March 2017

**Contact information**
lucy.sansom@ndorms.ox.ac.uk

**Notes**
<table>
<thead>
<tr>
<th>Study name</th>
<th>Prevention of seroma following inguinal lymph node dissection with prophylactic, incisional, negative-pressure wound therapy (SEROMA trial)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients ≥18 years undergoing inguinal lymph node dissection for metastatic melanoma</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy (Smith &amp; Nephew) versus standard dressing (Micropore)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Seroma; cumulative volume of aspirated seromas; cumulative number of seroma aspirations; SSI; days until the last suction drain(s) removed; cumulative volume of collected lymph fluid; EQ-5D-5L; wound dehiscence; necrosis; haematoma; length of hospitalisation; readmission times; reoperation; lymphoedema; lymphoedema-related quality of life; regional recurrence of melanoma</td>
</tr>
<tr>
<td>Starting date</td>
<td>2018</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:jens.sorensen@rsyd.dk">jens.sorensen@rsyd.dk</a></td>
</tr>
<tr>
<td>Notes</td>
<td>Duplicate with NCT03433937</td>
</tr>
</tbody>
</table>

| Study name | A randomized phase II study to evaluate efficacy of negative pressure wound therapy on prophylaxis of the incisional hernia after reversal of temporary [sic] diverting stoma |
| Methods | Randomised controlled trial |
| Participants | Patients 20-85 years with temporary stoma and planned closure following initial surgery |
| Interventions | Negative pressure wound therapy versus standard therapy |
| Outcomes | Incidence of radiological incisional hernia after one year of surgery |
| Starting date | 2018 |
| Contact information | skomat2718@gmail.com |
| Notes | |

| Study name | The effectiveness of negative pressure wound dressing for the wound healing after stoma closure: an prospective, open-label, randomized control study |
| Methods | Randomised controlled study |
| Participants | Patients 20-85 years with ileostomy or colostomy undergoing reversal |
| Interventions | Negative pressure wound therapy versus standard dressing |
### KCT0004063 (Continued)

**Outcomes**
Complete wound healing period; SSI; number of wound dressings; number of wound visits; length of hospital stay; patient and observer scar assessment scale (POSAS)

**Starting date**
2019

**Contact information**
+82-53-620-3580

**Notes**

---

### Masters 2018

**Study name**
Randomised controlled feasibility trial of standard wound management versus negative-pressure wound therapy in the treatment of adult patients having surgical incisions for hip fractures

**Methods**
Randomised controlled trial

**Participants**
Patients > 65 years undergoing surgery for hip fracture

**Interventions**
Negative pressure wound therapy versus standard care

**Outcomes**
SSI (deep infection); EQ-5D-5L; mobility; mortality; late complications

**Starting date**
2017

**Contact information**
james.masters@ndorms.ox.ac.uk

**Notes**

---

### Mihaljevic 2015

**Study name**
Postoperative negative-pressure incision therapy following open colorectal surgery (Poniy): a randomized-controlled trial

**Methods**
Randomised controlled trial

**Participants**
All adult (≥ 18 years of age) surgical patients scheduled for elective open colorectal surgery

**Interventions**
Negative-pressure incision therapy device versus standard dressing

**Outcomes**
SSI; length of hospital stay; reoperation; duration of postoperative antibiotic treatment; duration of negative-pressure incision therapy; wound pain; wound complications; serious adverse events

**Starting date**
2014

**Contact information**
kleeff@tum.de

**Notes**
### NCT01450631

**Study name**  
The use of the Prevena incision management system on post-surgical cesarean section incisions

**Methods**  
Randomised controlled trial

**Participants**  
Patients undergoing caesarean section procedures using a subcuticular skin closure technique within the next 42 days

**Interventions**  
PREVENA Incision Management System versus standard-of-care dressing

**Outcomes**  
Incidence of postoperative surgical site occurrences post-caesarean section surgery

**Starting date**  
2011

**Contact information**  
Robert Heine, Duke University

**Notes**  
NCT01 450631

---

### NCT01770067

**Study name**  
Prophylactic treatment of high-risk patients with cardiovascular implantable electronic devices (CIED) with continuous in-situ ultra high-dose antibiotics (CITA) under regulated negative pressure-assisted wound therapy (RNPT)

**Methods**  
Randomised controlled trial

**Participants**  
Patients undergoing cardiovascular implantable electronic devices surgery

**Interventions**  
High-dose antibiotics (CITA) under regulated negative pressure-assisted wound therapy (RNPT) versus CITA

**Outcomes**  
Lack of CIED infection

**Starting date**  
February 2013

**Contact information**  
Unknown

**Notes**  
NCT01 770067

---

### NCT01891006

**Study name**  
Intervention for postpartum infections following caesarean section (APIPICS)

**Methods**  
Randomised controlled trial

**Participants**  
Patients 18 years of age or older with postpartum infections following caesarean section

**Interventions**  
Negative pressure wound therapy versus standard wound dressing

**Outcomes**  
Frequency of re-rupture in each study group; length of hospitalisation; readmission to hospital; decreased health-related quality of life score; cosmetic outcome

**Starting date**  
2013

---

*Negative pressure wound therapy for surgical wounds healing by primary closure (Review)*

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Study name</th>
<th>Negative pressure wound therapy to reduce surgical site infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Scheduled for an elective surgery in either open CRS or open HPBS</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus conventional wound therapy</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Incidence of surgical site infection; characterisation of surgical site infection; length of hospital stay</td>
</tr>
<tr>
<td>Starting date</td>
<td>2013</td>
</tr>
<tr>
<td>Contact information</td>
<td>Trey Blazer, Duke University</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>PICO above incisions after vascular surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients 18 years of age and above undergoing elective vascular surgery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy with PICO versus standard dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound infection; cost</td>
</tr>
<tr>
<td>Starting date</td>
<td>2013</td>
</tr>
<tr>
<td>Contact information</td>
<td>Stefan Acosta, Skåne University Hospital</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Negative pressure wound therapy for prevention of poststernotomy infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing open heart surgery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>NCT02020018 (Continued)</td>
<td></td>
</tr>
<tr>
<td>-------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Wound infection after open-heart surgery; reoperation for wound infection; length of stay</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>December 2013</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td>Unknown</td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02064270</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02118558</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>
### NCT02127281

**Study name**

The management of closed surgical incisions resulting from incisional hernia repair and/or functional panniculectomy using the Prevena Customizable dressing

**Methods**

Randomised controlled trial

**Participants**

Adults undergoing panniculectomy or hernia repair; BMI ≥ 30; preoperatively assessed to undergo a procedure resulting in a clean/clean-contaminated wound

**Interventions**

PREVENA Customizable Dressing with ACTIV.A.C. therapy unit versus standard dressing

**Outcomes**

Incidence of SSI or dehiscence within 30 days of surgery; incidence of clinically relevant intervention (antimicrobial treatment, drainage, debridement, reoperation, application of NPWT) within 30 days of surgery

**Starting date**

2015

**Contact information**

Not stated

**Notes**

NCT02302222

**Study name**

The management of closed surgical incisions resulting from incisional hernia repair and/or functional panniculectomy using the Prevena Customizable dressing

**Methods**

Randomised controlled trial

**Participants**

Adults undergoing panniculectomy or hernia repair; BMI ≥ 30; preoperatively assessed to undergo a procedure resulting in a clean/clean-contaminated wound

**Interventions**

PREVENA Customizable Dressing with ACTIV.A.C. therapy unit versus standard dressing

**Outcomes**

Incidence of SSI or dehiscence within 30 days of surgery; incidence of clinically relevant intervention (antimicrobial treatment, drainage, debridement, reoperation, application of NPWT) within 30 days of surgery

**Starting date**

2015

**Contact information**

Not stated

**Notes**

NCT02309944

**Study name**

Negative pressure wound therapy in obese gynecologic oncology patients

**Methods**

Randomised controlled trial

**Participants**

Patients undergoing laparotomy for suspected gynecologic malignancy

**Interventions**

Negative pressure wound therapy versus standard wound management
<table>
<thead>
<tr>
<th>NCT02309944 (Continued)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
</tr>
<tr>
<td>Starting date</td>
</tr>
<tr>
<td>Contact information</td>
</tr>
<tr>
<td>Notes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02331485</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
</tr>
<tr>
<td>Methods</td>
</tr>
<tr>
<td>Participants</td>
</tr>
<tr>
<td>Interventions</td>
</tr>
<tr>
<td>Outcomes</td>
</tr>
<tr>
<td>Starting date</td>
</tr>
<tr>
<td>Contact information</td>
</tr>
<tr>
<td>Notes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02348034</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
</tr>
<tr>
<td>Methods</td>
</tr>
<tr>
<td>Participants</td>
</tr>
<tr>
<td>Interventions</td>
</tr>
<tr>
<td>Outcomes</td>
</tr>
<tr>
<td>Starting date</td>
</tr>
<tr>
<td>Contact information</td>
</tr>
<tr>
<td>Notes</td>
</tr>
<tr>
<td>NCT02389023</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02408835</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
<td>Negative pressure wound therapy in groin dissection</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients undergoing inguinal lymphadenectomy for metastatic carcinoma of cutaneous origin</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Negative pressure wound therapy versus conventional wound care</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Time to wound healing; wound infection; lymphoedema; need for further surgical interventions to achieve wound healing; scar appearance; patient-reported outcomes</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>July 2015</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td><a href="mailto:s.mcallister@qub.ac.uk">s.mcallister@qub.ac.uk</a></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT02492854</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
<td>Standard versus PICO dressings in lower-extremity bypass patients (PICO-LEB)</td>
</tr>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients undergoing lower extremity bypass using ipsilateral great saphenous vein harvest</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>PICO single-use negative pressure dressings versus sterile gauze dressings</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Infection of surgical site incision; function and quality of life; resource utilisation in dollars</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>2015</td>
</tr>
</tbody>
</table>
### NCT02492854 (Continued)

**Contact information**  
Jeffrey.Siracuse@bmc.org; twtcheng@bu.edu

**Notes**

### NCT02509260

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prevena incisional negative pressure wound therapy in re-operative colorectal surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients undergoing open reoperative colorectal surgery</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Occurrence of superficial surgical site infection; length of hospital stay; cost-effectiveness; clinical efficacy of the device in relation to the degree of contamination</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>July 2015</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td><a href="mailto:ASHBURJ@ccf.org">ASHBURJ@ccf.org</a></td>
</tr>
</tbody>
</table>

**Notes**

### NCT02558764

<table>
<thead>
<tr>
<th>Study name</th>
<th>Effects of preventive negative pressure wound therapy with PICO on surgical wounds of kidney transplant patients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients admitted for cadaveric kidney transplant surgery</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Negative pressure wound therapy versus basic wound contact absorbent dressings</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Post-kidney transplant wound complication rates</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>November 2015</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td>Unknown</td>
</tr>
</tbody>
</table>

**Notes**

### NCT02578745

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prophylactic incisional care in obese women at cesarean (PICO-C)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients with planned or unplanned caesarean delivery with a BMI ≥ 30 at the time of delivery</td>
</tr>
</tbody>
</table>
### NCT02578745 (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Prophylactic NPWT versus standard dressing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Surgical site infection or other wound complications; individual components of composite wound complications; pain score on 0-to-10 scale; positive wound cultures and specific organisms such as MRSA; prophylactic negative pressure-related adverse events including blisters</td>
</tr>
<tr>
<td>Starting date</td>
<td>2015</td>
</tr>
<tr>
<td>Contact information</td>
<td>Methodius G Tuuli, Washington University School of Medicine</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### NCT02664168

| Study name | A comparative study to assess the prevention of surgical site infection (SSIs) in revision total joint arthroplasty patients treated with single-use negative pressure wound therapy (PICO) or standard care dressings (AQUACEL Ag surgical dressing) |
| Methods    | Randomised controlled trial               |
| Participants | Patients undergoing revision total knee arthroplasty or revision total hip arthroplasty |
| Interventions | Single-use negative pressure wound therapy versus AQUACEL Ag surgical dressing |
| Outcomes   | Incidence of surgical site infection     |
| Starting date | January 2016                                   |
| Contact information | tiffany.morrison@rothmaninstitute.com |
| Notes      |                                           |

### NCT02682316

| Study name | Negative pressure wound therapy in post-operative incision management |
| Methods    | Randomised controlled trial               |
| Participants | Women of any BMI undergoing a laparotomy procedure for a presumed gynaecologic malignancy, or morbidly obese |
| Interventions | Negative pressure wound therapy versus usual standard dry gauze |
| Outcomes   | Number of postoperative wound complications |
| Starting date | February 2016                                   |
| Contact information | Mario Leitao |
| Notes      |                                           |
### NCT02790385

<table>
<thead>
<tr>
<th>Study name</th>
<th>Negative pressure wound therapy - a multi-centered randomized control trial (NPWT)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing posterior spinal surgery categorised as high risk for infection</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard gauze treatment</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound infection; time for wound closure; cosmetic results; caregiver/parental satisfaction; wound dehiscence; foreign body reaction</td>
</tr>
<tr>
<td>Starting date</td>
<td>July 2014</td>
</tr>
<tr>
<td>Contact information</td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### NCT02799667

<table>
<thead>
<tr>
<th>Study name</th>
<th>Do single use negative pressure dressings reduce wound complications in obese women after cesarean delivery?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Obese women (BMI &gt; 40 kg/m²) undergoing caesarean delivery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus conventional dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Presence of wound complications</td>
</tr>
<tr>
<td>Starting date</td>
<td>May 2016</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:sbakaysa@tuftsmedicalcenter.org">sbakaysa@tuftsmedicalcenter.org</a></td>
</tr>
</tbody>
</table>

### NCT02892435

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prevena incision management system vs conventional management for wound healing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients submitted to contaminated or dirty abdominal surgery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus conventional dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; reduction in wound complications in participants with associated risk factors (e.g. diabetes, obesity, and cancer)</td>
</tr>
<tr>
<td>Starting date</td>
<td>November 2014</td>
</tr>
</tbody>
</table>

---

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
<table>
<thead>
<tr>
<th>Study name</th>
<th>N PW T in so /tissue sarco ma surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Adults undergoing primary soft tissue sarcoma excision that is primarily closed</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Surgical site infection; time to wound dryness; delay to discharge from hospital; adverse events; cost analysis</td>
</tr>
<tr>
<td>Starting date</td>
<td>2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prophylactic post-cesarean incisional negative-pressure wound therapy in morbidly obese patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Morbidly obese patients who have undergone caesarean section</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard dry sterile dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound complications</td>
</tr>
<tr>
<td>Starting date</td>
<td>August 2016</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prophylactic application of an incisional wound vac to prevent wound complications in obese spine surgery patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients scheduled to have posterior spine surgery; BMI ≥ 35</td>
</tr>
</tbody>
</table>
**NCT02926924** (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Wound VAC versus standard dressing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Postoperative infection requiring return to operating room</td>
</tr>
<tr>
<td>Starting date</td>
<td>2016</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:jaimeeg@med.umich.edu">jaimeeg@med.umich.edu</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

**NCT02954835**

<table>
<thead>
<tr>
<th>Study name</th>
<th>Negative pressure therapy for groin wounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing vascular surgery with a groin incision</td>
</tr>
<tr>
<td>Interventions</td>
<td>PREVENA versus traditional dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Infection rate</td>
</tr>
<tr>
<td>Starting date</td>
<td>2016</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:thomas.bernik@ehmchealth.org">thomas.bernik@ehmchealth.org</a>; <a href="mailto:courtney.woodhull@ehmchealth.org">courtney.woodhull@ehmchealth.org</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

**NCT02967627**

<table>
<thead>
<tr>
<th>Study name</th>
<th>VAC dressings for colorectal resections (VACCRR)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing elective colorectal resection for benign or malignant disease</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus sterile gauze dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; wound complication; length of stay; wound-related visits postsurgery; need for and duration of home care; blistering/reaction to wound dressings; postoperative complications</td>
</tr>
<tr>
<td>Starting date</td>
<td>November 2016</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:mitchell.webb@alumni.ubc.ca">mitchell.webb@alumni.ubc.ca</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

**NCT030000010**

<table>
<thead>
<tr>
<th>Study name</th>
<th>Wound Vac bandage comparison after spinal fusion (WV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study name</td>
<td>Preventing adverse incisional outcomes at cesarean multicenter trial (Prevena-C)</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Women undergoing planned or unplanned caesarean delivery</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Frequency of superficial or deep surgical site infections</td>
</tr>
<tr>
<td>Starting date</td>
<td>February 2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:martins@wudosis.wustl.edu">martins@wudosis.wustl.edu</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Incisional negative pressure wound therapy in high risk patients undergoing panniculectomy: a prospective randomized controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing panniculectomy in preparation for renal transplantation</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard closure</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound-healing complications; time to drain removal; scarring; pain; QoL</td>
</tr>
<tr>
<td>Starting date</td>
<td>December 2015</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:cbailey@ucdavis.edu">cbailey@ucdavis.edu</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
<tr>
<td>Study name</td>
<td>Comparison between wound vacuum dressing and standard closure to reduce rates of surgical site infections</td>
</tr>
<tr>
<td>----------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patient to undergo pancreaticoduodenectomy for pancreatic tumours at the Johns Hopkins Hospital</td>
</tr>
<tr>
<td>Interventions</td>
<td>PREVENA Peel &amp; Place dressing versus standard closure of surgical incision</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Rate of surgical site infection; prolonged length of stay; rate of readmission; time to adjuvant therapy</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td>Matthew J Weiss, Johns Hopkins University</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Closed incision negative pressure therapy vs standard care (Prevena)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing primary total hip arthroplasty through a direct anterior approach with: diabetes; obesity (BMI &gt; 30); active smoking; previous hip surgery</td>
</tr>
<tr>
<td>Interventions</td>
<td>PREVENA versus AQUACEL</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Prevalence of wound complications; duration of wound-healing delay; length of hospital stay; number of days on antibiotic therapy; average cost of wound treatment</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:mh3818@cumc.columbia.edu">mh3818@cumc.columbia.edu</a>; <a href="mailto:rs3464@cumc.columbia.edu">rs3464@cumc.columbia.edu</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>iNPWT in immediate breast reconstruction</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients ≥ 18 admitted for immediate breast reconstruction</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Time to removal of surgical drains; SSI; skin necrosis; hospitalisation time; participant and observer assessment of the scars; patient satisfaction and quality of life</td>
</tr>
</tbody>
</table>
NCT03069885 (Continued)

Starting date November 2017
Contact information Aarhus University Hospital
Notes

NCT03082664

Study name Negative pressure wound therapy to prevent wound complications following cesarean section in high risk patients
Methods Randomised controlled trial
Participants Caesarean section in high-risk obstetric patients
Interventions Negative pressure wound therapy versus standard wound dressings
Outcomes Wound complications: wound breakdown, infection, separation, dehiscence
Starting date June 2015
Contact information meganhill@obgyn.arizona.edu
Notes

NCT03144726

Study name RCT on NPWT for incisions following major lower-limb amputation to reduce surgical site infection
Methods Randomised controlled trial
Participants Any patient 18 years or older undergoing amputation of the lower limb, either an above-knee amputation or below-knee amputation
Interventions Negative pressure wound therapy versus standard dressing
Outcomes Surgical site infection; length of stay; antibiotic use; reoperation; death
Starting date 2017
Contact information oonagh.scallan@lhsc.on.ca
Notes

NCT03175718

Study name INPWT on wound complications & clinical outcomes after lower extremity sarcoma surgery preop radiation therapy patients (VAC)
Methods Randomised controlled trial
### NCT03175718 (Continued)

<table>
<thead>
<tr>
<th><strong>Participants</strong></th>
<th>Patients with lower extremity soft tissue sarcoma confirmed by tissue pathology</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Interventions</strong></td>
<td>VAC wound dressing versus wound dressing</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Wound complications including reoperation for superficial or deep site infection; quality of life; functional outcome; overall cost</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>2017</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td><a href="mailto:yalmosuli@ohri.ca">yalmosuli@ohri.ca</a>; <a href="mailto:jdobransky@ohri.ca">jdobransky@ohri.ca</a></td>
</tr>
</tbody>
</table>

### NCT03180346

<table>
<thead>
<tr>
<th><strong>Study name</strong></th>
<th>A prospective, randomized, comparative study to assess the prevention of surgical site infection (SSIs) in revision total joint arthroplasty patients treated with single-use negative pressure wound therapy (PICO) or standard care dressings (AQUACEL Ag surgical dressing)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patients undergoing revision total knee arthroplasty or revision total hip arthroplasty</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>Negative pressure wound therapy versus standard care</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>SSI</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>March 2017</td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td>Unknown</td>
</tr>
</tbody>
</table>

### NCT03250442

<table>
<thead>
<tr>
<th><strong>Study name</strong></th>
<th>Evaluating the outcomes for incisional application of negative pressure for nontraumatic amputations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Methods</strong></td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td><strong>Participants</strong></td>
<td>Patient requires closure of a non-traumatic transmetatarsal amputation, below-knee amputation, knee disarticulation, or above-knee amputation.</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td>PREVENA device versus standard dry dressing</td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
<td>Proportion of postoperative incision complications between the 2 arms; length of hospital stay; number of surgically related wound readmissions; Medical Outcomes Study 12-item Short Form Health Survey (SF-12); percentage of closed incisions remaining closed at 1, 2, and 3 months post-hospital discharge</td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
<td>2017</td>
</tr>
</tbody>
</table>
### NCT03250442 (Continued)

**Contact information**  
Paul J Kim  
paul.j.kim@gunet.georgetown.edu

**Notes**

### NCT03269968

**Study name**  
Use of negative pressure wound therapy in morbidly obese women after cesarean delivery

**Methods**  
Randomised controlled trial

**Participants**  
Obese women undergoing elective caesarean delivery

**Interventions**  
Negative pressure wound therapy versus standard wound dressings

**Outcomes**  
Composite wound complication; patient survey

**Starting date**  
October 2017

**Contact information**  
Tetsuya Kawakita  
tetsuya.x.kawakita@medstar.net

**Notes**

### NCT03274466

**Study name**  
Closed incision negative pressure therapy versus standard of care surgical dressing in revision total knee arthroplasty (PROMISES)

**Methods**  
Randomised controlled trial

**Participants**  
Patient requires a TKA revision defined as: a 1-stage aseptic revision procedure; a 1-stage septic exchange procedure for acute postoperative infection; removal of cement spacer and re-implantation procedure; open reduction and internal fixation of periprosthetic fractures.

**Interventions**  
Closed incision negative pressure therapy (ciNPT) versus standard-of-care dressing

**Outcomes**  
Surgical site complications; surgical site infection; deep surgical site infection

**Starting date**  
2017

**Contact information**  
eric.synatschk@celity.com; jane.hart@kci1.com

**Notes**

### NCT03321799

**Study name**  
Comparison of negative pressure wound therapy versus conventional dressings for the prevention of wound complications after revision THA

**Methods**  
Randomised controlled trial
### NCT03321799 (Continued)

<table>
<thead>
<tr>
<th>Participants</th>
<th>Patients &gt; 18 years undergoing a revision total hip arthroplasty procedure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus sterile antimicrobial dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound complications; reoperation; cost comparison</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:chris.culvern@rushortho.com">chris.culvern@rushortho.com</a></td>
</tr>
</tbody>
</table>

### NCT03345771

<table>
<thead>
<tr>
<th>Study name</th>
<th>Antimicrobial barrier dressing versus closed-incision negative pressure therapy in the obese primary total joint arthroplasty</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients identified at preoperative testing to have an elevated BMI (&gt; 35)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus antimicrobial barrier dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Visual analogue scale pain score; wound evaluation scale</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:Afshin.Anoushiravani@nyumc.org">Afshin.Anoushiravani@nyumc.org</a></td>
</tr>
</tbody>
</table>

### NCT03346694

<table>
<thead>
<tr>
<th>Study name</th>
<th>Reducing surgical site infection rates using an alternative sternal dressing</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients who will undergo cardiac surgery via a sternotomy incision</td>
</tr>
<tr>
<td>Interventions</td>
<td>Standard island dressing versus PREVENA negative pressure versus Mepilex Border Post-Op Ag</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Rates of surgical site infection pertaining to each dressing studied; impact of alternative dressings on rates of sternal wound incision infection</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:jackboyd@stanford.edu">jackboyd@stanford.edu</a>; <a href="mailto:jniesen@stanfordhealthcare.org">jniesen@stanfordhealthcare.org</a></td>
</tr>
</tbody>
</table>

---

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### NCT03395613

**Study name**  
Negative pressure incision management system in infrainguinal vascular surgery  

**Methods**  
Randomised controlled trial  

**Participants**  
Not stated  

**Interventions**  
Negative pressure wound therapy versus standard sterile gauze dressing  

**Outcomes**  
Postoperative SSI; postoperative SSI within 90 days; antibiotic prescriptions for skin and soft tissue infections; postoperative SSI within 90 days requiring surgical revision; adverse events directly related the NPWT dressing; major lower limb amputation and/or mortality; changes in reported quality of life; assessment of healthcare-related costs; assessment of quality of life during the first 7-day period  

**Starting date**  
2018  

**Contact information**  
alireza.daryapeyma@sll.se; rebecka.hultgren@sll.se  

**Notes**

---

### NCT03402945

**Study name**  
Prevention of infections in cardiac surgery (PICS) Prevena study (PICS-Prevena)  

**Methods**  
Randomised controlled trial - 4-arm factorial design  

**Participants**  
Patients ≥ 18 years of age undergoing open-heart surgery  

**Interventions**  
PREVENA and cefazolin versus PREVENA and cefazolin and vancomycin versus standard wound dressing and cefazolin versus standard wound dressing and cefazolin and vancomycin  

**Outcomes**  
Adherence to the wound management system; adherence to the antibiotic regimen; loss of follow-up; deep incisional and organ/space sternal surgical site infection; wound dehiscence; Clostridium difficile infection; mortality in participants with an active infection; intensive care unit and hospital stay; pain on day 7; acute kidney injury  

**Starting date**  
2018  

**Contact information**  
prevena@phri.ca  

**Notes**

---

### NCT03414762

**Study name**  
PICO negative pressure wound therapy in obese women undergoing elective cesarean delivery  

**Methods**  
Randomised controlled trial  

**Participants**  
Obese women undergoing elective caesarean delivery  

**Interventions**  
Negative pressure wound therapy versus standard wound dressings  

---

**Copyrighth © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.**
NCT03414762 (Continued)

Outcomes
Surgical site occurrence; surgical incision intervention

Starting date
November 2018

Contact information
Sarah Pachtman (spachtman@northwell.edu)

Notes

NCT03458663

Study name
Randomized trial comparing Prevena and ActiV.A.C. system to conventional care after Bascom’s cleft lift surgery

Methods
Randomised controlled trial

Participants
Patients with recurrence after previous surgery for pilonidal disease, cases of poor postoperative healing, or primary extensive/fistulating disease referred to Randers Regional Hospital for assessment for reconstructive Bascom’s cleft lift surgery

Interventions
PREVENA versus conventional postoperative care

Outcomes
Primary healing; health perception; long-term healing; early recurrence; postoperative pain

Starting date
2018

Contact information
susahaas@rm.dk; marlesoe@rm.dk

Notes

NCT03460262

Study name
Negative pressure wound therapy for prevention of groin infection following vascular surgery (PI-CO)

Methods
Randomised controlled trial

Participants
High-risk patients undergoing vascular surgery with groin incision (without ongoing infection)

Interventions
PICO versus standard cutiplast

Outcomes
Rate of wound complications

Starting date
2018

Contact information
parla.astarci@uclouvain.be; julien.possoz@uclouvain.be

Notes
<table>
<thead>
<tr>
<th>Study name</th>
<th>Clinical study on the prevention of surgical wound complications for aneurysmal thoracic-abdominal aortic pathology using the &quot;PREVENA&quot; system (TVAC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients with surgical wounds to treat thoracic-abdominal aortic pathology</td>
</tr>
<tr>
<td>Interventions</td>
<td>PREVENA versus standard medication</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Reduction of surgical site infections; reduction of adverse events</td>
</tr>
<tr>
<td>Starting date</td>
<td>2018</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:domenico.baccellieri@hsr.it">domenico.baccellieri@hsr.it</a>; <a href="mailto:elisa.simonini@hsr.it">elisa.simonini@hsr.it</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>Prospective, randomized, comparative study about effects of preventive negative pressure therapy with PICO or standard care dressing (MEPORE) on surgical wounds after large incisional hernia repair</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients 18-90 years undergoing surgical repair of large incisional hernia (type W2 or W3)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy (PICO dressing) versus standard therapy (MEPORE dressing)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI</td>
</tr>
<tr>
<td>Starting date</td>
<td>1 May 2017</td>
</tr>
<tr>
<td>Contact information</td>
<td>Hospital Universitari La Fe</td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study name</th>
<th>A prospective randomized clinical trial comparing incisional negative pressure wound therapy to conventional sterile dressing in patients undergoing thoracolumbar posterior spine surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients ≥ 17 years who require spine surgery with a posterior midline incision that involves the thoracic, lumbar and/or sacral spine</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy (Prevena) versus standard dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI; revision; acute spinal cord injury</td>
</tr>
<tr>
<td>Starting date</td>
<td>18 March 2017</td>
</tr>
<tr>
<td>NCT03632005 (Continued)</td>
<td></td>
</tr>
<tr>
<td>--------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
<td><a href="mailto:allan.aludino@vch.ca">allan.aludino@vch.ca</a>; <a href="mailto:leilani.reichl@vch.ca">leilani.reichl@vch.ca</a></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT03688438</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT03700086</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
<tr>
<td><strong>Participants</strong></td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
</tr>
<tr>
<td><strong>Outcomes</strong></td>
</tr>
<tr>
<td><strong>Starting date</strong></td>
</tr>
<tr>
<td><strong>Contact information</strong></td>
</tr>
<tr>
<td><strong>Notes</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NCT03716687</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study name</strong></td>
</tr>
<tr>
<td><strong>Methods</strong></td>
</tr>
</tbody>
</table>

**Negative pressure wound therapy for surgical wounds healing by primary closure (Review)**

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
**Study name** | Evaluation of closed incision negative pressure dressing (PREVENA) to prevent lower extremity amputation wound complications  
---|---  
**Methods** | Randomised controlled trial  
**Participants** | Patients ≥ 18 years undergoing lower extremity amputation  
**Interventions** | Negative pressure wound therapy (Prevena) versus standard dressing  
**Outcomes** | Wound complications; length of stay; 30-day return to operating room; 30-day hospital readmissions; dehiscence; seroma; lymph leak; infection; haematoma; ischaemia; necrosis; hospital costs  
**Starting date** | 15 January 2019  
**Contact information** | laura.anatale.tardiff@jefferson.edu  
**Notes** |  

**Study name** | Efficacy of negative pressure wound therapy (NPWT) for prevention of wound infection and improvement of wound healing after stoma reversal  
---|---  
**Methods** | Randomised controlled trial  
**Participants** | Patients ≥ 18 years who underwent elective open or laparoscopic rectal resection ostomy construction (loop/end ileostomy; loop/end colostomy) for either oncological and inflammatory bowel disease indications  
**Interventions** | Negative pressure wound therapy (PICO) versus standard care  
**Outcomes** | SSI; wound healing timing; EQ-5D-5L; McGill pain questionnaire  
**Starting date** | 1 April 2019  
**Contact information** | annalisa.maroli@humanitas.it  
**Notes** |
### NCT03816293

**Study name**  
SUppress SSI - single use negative pressure wound therapy (NPWT) to reduce surgical site infections (SUppressSSI)

**Methods**  
Randomised controlled trial

**Participants**  
Patients ≥ 18 years undergoing caesarean section, abdominal hysterectomy or colon procedures and either obese (BMI > 30 kg/m²) or diabetic

**Interventions**  
Negative pressure wound therapy (Prevena) versus standard dressing

**Outcomes**  
SSI; length of stay; readmission; seroma; haematoma; dehiscence

**Starting date**  
1 May 2019

**Contact information**  
Susan Bleasdale, University of Illinois at Chicago

**Notes**

### NCT03820219

**Study name**  
A pilot study comparing incisional negative pressure wound therapy (Prevena) to conventional sterile dressing in patients undergoing thoracolumbar posterior spine surgery

**Methods**  
Randomised controlled trial

**Participants**  
All patients ≥ 17 years who require spine surgery with a posterior midline incision that involves the thoracic, lumbar and/or sacral spine

**Interventions**  
Negative pressure wound therapy (Prevena) versus standard dressing

**Outcomes**  
SSI; seroma or dehiscence; resource time commitment; return visits

**Starting date**  
15 March 2019

**Contact information**  
Unknown

**Notes**

### NCT03871023

**Study name**  
The use of prophylactic negative wound therapy in emergency and elective laparotomy wounds

**Methods**  
Randomised controlled trial (3 treatment arms)

**Participants**  
All patients > 18 years of age undergoing a laparotomy

**Interventions**  
Negative pressure wound therapy (Prevena) versus negative pressure wound therapy (PICO) versus standard therapy
**NCT03871023** (Continued)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Superficial site infection (Southampton scoring system); wound dehiscence; wound healing/cosmesis; length of stay; home care therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting date</td>
<td>6 November 2019</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:donlonn@tcd.ie">donlonn@tcd.ie</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

**NCT03886818**

| Study name | Evaluation of the efficacy of negative pressure wound therapy on incisional wound healing after a total ankle arthroplasty: a randomized study |
| Methods | Randomised controlled trial |
| Participants | Patients ≥ 18 years undergoing total ankle arthroplasty |
| Interventions | Negative pressure wound therapy (PICO) versus standard dressing |
| Outcomes | Number of days from suture removal to achieve complete wound healing; rate of technical failures of the PICO device, and type of failure; number and type of adverse effects related to the PICO device; rate of wound healing complications: presence of exudate; blister; necrosis; wound dehiscence; SSI; surgical revision; incremental cost-effectiveness ratio |
| Starting date | 1 April 2019 |
| Contact information | jean-luc.besse@chu-lyon.fr; stephanie.vincente01@chu-lyon.fr |
| Notes | |

**NCT03900078**

| Study name | Inzisionelle negative drucktherapie nach resektion von weichteiltumoren - eine prospektive, randomisierte, kontrollierte klinische studie |
| Methods | Randomised controlled trial |
| Participants | Patients ≥ 18 years with soft tissue tumour of extremities or trunk with expected resection of > 10cm tissue in any dimension |
| Interventions | Negative pressure wound therapy versus standard dressing |
| Outcomes | Amount of drainage fluid; wound complications; wound margin perfusion |
| Starting date | 1 December 2018 |
| Contact information | mehran.dadras@bergmannsheil.de; bjorn.behr@rub.de |
| Notes | |
### Study NCT03905213

**Study name**: Impact of the use of three dressings in the prevention of surgical wound infection in patients undergoing major cardiac surgery: a clinical prospective and randomized study

**Methods**: Randomised controlled trial (3 treatment arms)

**Participants**: Patients ≥ 18 years undergoing cardiac surgery

**Interventions**: Negative pressure wound therapy (PICCO) versus absorbent dressing (MEPILEX) versus standard dressing (MEPORE)

**Outcomes**: Surgical wound infection; hospital stay; antimicrobial consumption; dressing consumption cost

**Starting date**: 1 September 2019

**Contact information**: massus@hotmail.es; javier.hortal@gamil.com

**Notes**: NCT03905213

### Study NCT03935659

**Study name**: Negative pressure wound therapy for surgical site infection prevention in vascular surgery patients undergoing common femoral artery exposure

**Methods**: Randomised controlled trial

**Participants**: Adults ≥ 18 years with one or more of: body mass index >30 kg/m²; critical limb ischaemia; procedure time > 240 min; end stage renal disease on dialysis; glycated hemoglobin ≥ 8.5%; transfusion ≥ 3 units packed red blood cells; previous femoral artery cut-down

**Interventions**: Negative pressure wound therapy versus standard dressing

**Outcomes**: Superficial SSI; mortality; limb loss; emergency department visit for wound complication; local reaction to negative wound dressing

**Starting date**: 26 March 2018

**Contact information**: LKABBAN1@hfhs.org; arteil1@hfhs.org

**Notes**: NCT03935659

### Study NCT03948412

**Study name**: Negative pressure wound therapy (PREVENA) versus standard dressings for incision management after renal transplant (IMPART)

**Methods**: Randomised controlled trial

**Participants**: Patients ≥ 18 years undergoing renal transplant

**Interventions**: Negative pressure wound therapy (Prevena) versus standard dressing

**Notes**: NCT03948412
### NCT03948412 (Continued)

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Wound complications; length of hospital stay; graft function; delayed graft function; pain score; scar quality; EQ-5D-5L; graft function; ASEPSIS wound score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starting date</td>
<td>10 May 2019</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:Linda.Pallot@health.nsw.gov.au">Linda.Pallot@health.nsw.gov.au</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### Nguyen 2017

<table>
<thead>
<tr>
<th>Study name</th>
<th>Incisional negative pressure wound therapy following colorectal resection: preliminary report from a single site, prospective, randomized control trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Single-institution, prospective, randomised, open-label, superiority trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients scheduled for elective colorectal resection with or without creation of an ostomy (open or laparoscopic)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Patients will be randomised to receive NPWT or conventional dressings.</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Primary outcomes will be wound complications within the first 30 postoperative days. SSI rate will also be reported as a subgroup analysis. Secondary outcomes will include length of stay, number of postoperative visits in the 30-day period, complications, wound VAC-specific complications, and patient satisfaction.</td>
</tr>
<tr>
<td>Starting date</td>
<td>Unclear</td>
</tr>
<tr>
<td>Contact information</td>
<td>University of British Columbia (no contact details available)</td>
</tr>
<tr>
<td>Notes</td>
<td>Very limited information available.</td>
</tr>
</tbody>
</table>

### NL6488

<table>
<thead>
<tr>
<th>Study name</th>
<th>PREventing Surgical Site occurrences using negative pressURE wound therapy?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients scheduled for elective, open abdominal wall reconstruction</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus conventional wound care</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Surgical site occurrence; QoL; recurrence 1 year after surgery; individual components of primary outcome SSO; peri-incisional SSO; percentage of participants with signs of SSO on photographs by blinded outcome assessment; frequency and type of procedures related to SSO; hospital stay after surgery in days; earlier removal of INPWT because of SSO; emergency department visits after discharge; readmission; non-primary outcome complications; cost-effectiveness</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:p.r.zwanenburg@amc.nl">p.r.zwanenburg@amc.nl</a></td>
</tr>
</tbody>
</table>
### NL6488 (Continued)

<table>
<thead>
<tr>
<th>Notes</th>
<th>Previously registered as NTR6675; starting date may not reflect previous registration</th>
</tr>
</thead>
</table>

### NTR6481

<table>
<thead>
<tr>
<th>Study name</th>
<th>Randomized controlled clinical trial incisional NPWT versus sterile surgical dressing for surgical wounds after arterial vascular surgery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing bypass: aortic-iliac, iliacal-femoral, femoral-femoral, femoral-popliteal, femoral-crus, femoral-tibial; endarterectomy: iliacal, femoral; reconstruction aneurysm: femoral; embolectomy: iliacal, femoral</td>
</tr>
<tr>
<td>Interventions</td>
<td>Incisional negative pressure wound therapy versus sterile surgical dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Incidence of wound complications; complete wound-healing percentages; hospital stay in days; additional surgery; readmissions; extra visits to the outpatient clinic</td>
</tr>
<tr>
<td>Starting date</td>
<td>2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:prevenastudie@haaglandenmc.nl">prevenastudie@haaglandenmc.nl</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### Sandy-Hodgetts 2017

<table>
<thead>
<tr>
<th>Study name</th>
<th>Effectiveness of negative pressure wound therapy (NPWT) in the prevention of postoperative surgical wound dehiscence in at risk patients following abdominal surgery; a multicentre randomised control trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients undergoing an abdominal surgical procedure that uses a midline laparotomy as the surgical entry</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure wound therapy versus standard wound dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Occurrence of surgical wound dehiscence; occurrence of surgical site infection, economic analysis</td>
</tr>
<tr>
<td>Starting date</td>
<td>2012</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:kylie.sandy-hodgetts@curtin.edu.au">kylie.sandy-hodgetts@curtin.edu.au</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

### SUNRISE 2017

<table>
<thead>
<tr>
<th>Study name</th>
<th>SUNRISE: Single Use Negative pRessure dressing for Reduction In Surgical site infection following Emergency laparotomy</th>
</tr>
</thead>
</table>
### SUNRISE 2017 (Continued)

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Patients undergoing emergency laparotomy</td>
</tr>
<tr>
<td>Interventions</td>
<td>Portable single-use NPWT dressings, Standard dressings</td>
</tr>
<tr>
<td>Outcomes</td>
<td>SSI at 30 days; length of stay; readmission; reintervention; adverse events; pain; HRQoL; cost-effectiveness</td>
</tr>
<tr>
<td>Starting date</td>
<td>November 2017</td>
</tr>
<tr>
<td>Contact information</td>
<td>Dr Laura Magill, University of Birmingham, UK</td>
</tr>
<tr>
<td>Notes</td>
<td>ISRCTN17599457</td>
</tr>
</tbody>
</table>

### TCTR20170331001

<table>
<thead>
<tr>
<th>Study name</th>
<th>Antiseptic dressing versus negative pressure dressing techniques for uncomplicated pediatric appendicitis, randomized controlled trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Randomised controlled trial (3 treatment arms)</td>
</tr>
<tr>
<td>Participants</td>
<td>Patients &lt; 15 years undergoing surgery for uncomplicated appendicitis</td>
</tr>
<tr>
<td>Interventions</td>
<td>Negative pressure dressing versus antiseptic dressing versus conventional dressing</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Wound infection; time to heal; wound seroma; wound dehiscence</td>
</tr>
<tr>
<td>Starting date</td>
<td>29 March 2017</td>
</tr>
<tr>
<td>Contact information</td>
<td><a href="mailto:goofywasun@gmail.com">goofywasun@gmail.com</a></td>
</tr>
<tr>
<td>Notes</td>
<td></td>
</tr>
</tbody>
</table>

AE: adverse event  
A SEPSIS: ASEPSIS score - a quantitative scoring method using objective criteria based on wound appearance to evaluate wound infection  
BMI: body mass index  
CABG: coronary artery bypass graft  
CIED: cardiovascular implantable electronic devices  
cINPT: closed incision negative pressure wound therapy  
CITA: continuous in-situ ultra high dose antibiotics  
CRS: cryosurgery  
CS: caesarean section  
EQ-5D-SL: EuroQol 5D questionnaire SL version  
HOOS: hip disability and osteoarthritis outcome score  
HPBS(s): hepatopancreatobiliary (surgery)  
HRQoL: health-related quality of life  
iNPWT: incisional negative pressure wound therapy  
KA: knee arthroplasty  
KOOS: knee disability and osteoarthritis outcome score  
LDex: lymphedema index  
LYMQOL: Lymphoedema Quality-of-Life Questionnaire
### Comparison 1. Negative pressure wound therapy versus standard dressing

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.1 Mortality</strong></td>
<td>4</td>
<td>2107</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.86 [0.50, 1.47]</td>
</tr>
<tr>
<td><strong>1.2 Surgical site infection</strong></td>
<td>31</td>
<td>6204</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.66 [0.55, 0.80]</td>
</tr>
<tr>
<td>1.2.1 Orthopaedic: Hip/knee arthroplasties</td>
<td>4</td>
<td>836</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.69 [0.32, 1.49]</td>
</tr>
<tr>
<td>1.2.2 Orthopaedic: Limb fractures</td>
<td>3</td>
<td>1676</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>1.15 [0.61, 2.20]</td>
</tr>
<tr>
<td>1.2.3 Obstetric: Caesarean</td>
<td>7</td>
<td>1886</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.73 [0.55, 0.98]</td>
</tr>
<tr>
<td>1.2.4 Vascular: peripheral bypass</td>
<td>4</td>
<td>541</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.46 [0.32, 0.66]</td>
</tr>
<tr>
<td>1.2.5 Vascular: cardiac surgery</td>
<td>2</td>
<td>136</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.17 [0.03, 0.96]</td>
</tr>
<tr>
<td>1.2.6 General: abdominal</td>
<td>7</td>
<td>834</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.69 [0.45, 1.06]</td>
</tr>
<tr>
<td>1.2.7 General: Hepatopancreatiobiliary</td>
<td>2</td>
<td>163</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.36 [0.18, 0.73]</td>
</tr>
<tr>
<td>1.2.8 General: Mixed</td>
<td>2</td>
<td>132</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.45 [0.13, 1.56]</td>
</tr>
<tr>
<td><strong>1.3 SSI grouped by contamination class</strong></td>
<td>31</td>
<td>6204</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.66 [0.55, 0.80]</td>
</tr>
<tr>
<td>1.3.1 Clean</td>
<td>12</td>
<td>1670</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.55 [0.39, 0.78]</td>
</tr>
<tr>
<td>1.3.2 Clean-contaminated</td>
<td>15</td>
<td>2831</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.72 [0.58, 0.90]</td>
</tr>
<tr>
<td>1.3.3 Contaminated</td>
<td>1</td>
<td>1519</td>
<td>Risk Ratio (M-H, Random, 95% CI)</td>
<td>0.88 [0.59, 1.29]</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 1: Mortality

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>1074</strong></td>
<td><strong>1033</strong></td>
<td><strong>0.86 [0.50, 1.47]</strong></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>1</td>
<td>2</td>
<td>0.46 [0.04, 4.94]</td>
</tr>
<tr>
<td>Murphy 2019</td>
<td>3</td>
<td>2</td>
<td>1.46 [0.25, 8.60]</td>
</tr>
<tr>
<td>Shen 2017</td>
<td>3</td>
<td>5</td>
<td>0.60 [0.15, 2.48]</td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>18</td>
<td>19</td>
<td>0.90 [0.48, 1.71]</td>
</tr>
</tbody>
</table>

Total events: 25

Heterogeneity: $T^2 = 0.00$; $Chi^2 = 3$ (df = 3, $P = 0.83$); $I^2 = 0$

Test for overall effect: $Z = 0.55$ (df = 0.00)

Test for subgroup differences: Not applicable
## Analysis 1.2. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 2: Surgical site infection

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Risk Ratio</th>
<th>Weight</th>
<th>M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.2.1 Orthopaedic: Hip/knee arthroplasties</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>2</td>
<td>3</td>
<td>1.1%</td>
<td>35</td>
<td>0.67 [0.12 , 3.75]</td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>1</td>
<td>102</td>
<td>0.7%</td>
<td>107</td>
<td>0.17 [0.02 , 1.43]</td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>7</td>
<td>185</td>
<td>2.9%</td>
<td>8</td>
<td>1.01 [0.37 , 2.73]</td>
</tr>
<tr>
<td>Newman 2019</td>
<td>0</td>
<td>79</td>
<td>0.3%</td>
<td>1</td>
<td>0.34 [0.01 , 8.16]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>401</strong></td>
<td><strong>435</strong></td>
<td><strong>5.0%</strong></td>
<td></td>
<td><strong>0.69 [0.32 , 1.49]</strong></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td></td>
<td></td>
<td></td>
<td><strong>18</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Heterogeneity:</strong> Tau² = 0.00; Chi² = 2.46, df = 3 (P = 0.48); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Test for overall effect:</strong> Z = 0.96 (P = 0.34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| **1.2.2 Orthopaedic: Limb fractures** | | | | | |
| Crist 2014         | 5    | 49                | 1.3%       | 42     | 2.14 [0.44 , 10.48] |
| Crist 2017         | 5    | 33                | 1.3%       | 33     | 2.50 [0.52 , 11.98] |
| WHIST 2019a        | 45   | 770               | 9.7%       | 749    | 0.88 [0.59 , 1.29]  |
| **Subtotal (95% CI)** | **852** | **824** | **12.2%** | | **1.15 [0.61 , 2.20]** |
| **Total events:** | | | | **54** | | |
| **Heterogeneity:** Tau² = 0.11; Chi² = 2.63, df = 2 (P = 0.27); I² = 24% |
| **Test for overall effect:** Z = 0.44 (P = 0.66) |

| **1.2.3 Obstetric: Caesarean** | | | | | |
| Chaboyer 2014       | 10   | 44                | 4.7%       | 43     | 0.81 [0.39 , 1.68]  |
| Gunatilake 2017     | 1    | 39                | 0.7%       | 43     | 0.28 [0.03 , 2.36]  |
| Hussamy 2017        | 21   | 222               | 6.8%       | 219    | 0.83 [0.48 , 1.44]  |
| Hyldig 2019a        | 20   | 432               | 7.3%       | 444    | 0.50 [0.30 , 0.84]  |
| Rubstaller 2017     | 3    | 61                | 1.5%       | 58     | 0.71 [0.17 , 3.05]  |
| Tuni 2017           | 3    | 60                | 1.0%       | 2      | 1.50 [0.26 , 8.66]  |
| Wibby 2018          | 13   | 80                | 4.8%       | 12     | 1.10 [0.53 , 2.26]  |
| **Subtotal (95% CI)** | **938** | **948** | **26.8%** | | **0.73 [0.55 , 0.98]** |
| **Total events:** | | | | **100** | | |
| **Heterogeneity:** Tau² = 0.00; Chi² = 5.00, df = 6 (P = 0.54); I² = 0% |
| **Test for overall effect:** Z = 2.11 (P = 0.03) |

| **1.2.4 Vascular: peripheral bypass** | | | | | |
| DiMarzo 2017        | 6    | 59                | 3.5%       | 60     | 0.41 [0.17 , 0.98]  |
| Engelhardt 2016     | 9    | 64                | 4.8%       | 68     | 0.50 [0.25 , 1.03]  |
| Gombert 2018        | 13   | 98                | 6.3%       | 90     | 0.40 [0.22 , 0.71]  |
| Lee 2017b           | 7    | 53                | 3.6%       | 11     | 0.59 [0.25 , 1.40]  |
| **Subtotal (95% CI)** | **274** | **267** | **18.3%** | | **0.46 [0.32 , 0.66]** |
| **Total events:** | | | | **75** | | |
| **Heterogeneity:** Tau² = 0.00; Chi² = 0.68, df = 3 (P = 0.88); I² = 0% |
| **Test for overall effect:** Z = 4.23 (P < 0.0001) |

| **1.2.5 Vascular: cardiac surgery** | | | | | |
| Lee 2017a           | 0    | 31                | 0.3%       | 25     | 0.27 [0.01 , 6.37]  |
| Witt-Majchrzak 2015 | 1    | 40                | 0.8%       | 40     | 0.14 [0.02 , 1.11]  |
| **Subtotal (95% CI)** | **71** | **65** | **1.1%** | | **0.17 [0.03 , 0.96]** |
| **Total events:** | | | | **8** | | |
| **Heterogeneity:** Tau² = 0.00; Chi² = 0.11, df = 1 (P = 0.74); I² = 0% |
| **Test for overall effect:** Z = 2.00 (P = 0.05) |

| **1.2.6 General: abdominal** | | | | | |
| Bobkiewicz 2018     | 2    | 15                | 1.3%       | 15     | 0.50 [0.11 , 2.33]  |
| Kunczewicz 2017     | 8    | 36                | 3.6%       | 8      | 1.03 [0.43 , 2.44]  |
| Leon 2016           | 5    | 47                | 3.0%       | 10     | 0.36 [0.14 , 0.96]  |
| Lozano-Balderas 2017| 0    | 25                | 0.4%       | 10     | 0.05 [0.00 , 0.83]  |
| Murphy 2019         | 46   | 144               | 11.0%      | 48     | 0.93 [0.67 , 1.30]  |
| O’Leary 2017        | 2    | 24                | 1.5%       | 8      | 0.26 [0.06 , 1.10]  |
| Shen 2017           | 26   | 132               | 8.0%       | 28     | 0.94 [0.58 , 1.51]  |
| **Subtotal (95% CI)** | **423** | **411** | **28.8%** | | **0.69 [0.45 , 1.06]** |
### Analysis 1.2. (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Subtotal 95% CI</th>
<th>Total events</th>
<th>Heterogeneity: Tau², Chi², df, P</th>
<th>Test for overall effect: Z, P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shen 2017</td>
<td>26</td>
<td>132</td>
<td>80% 0.94 [0.58, 1.51]</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>423</strong></td>
<td><strong>411</strong></td>
<td>28.8% 0.69 [0.45, 1.06]</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>89</td>
<td>116</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Heterogeneity: Tau² = 0.12, Chi² = 11.04, df = 6 (P = 0.09); I² = 46%</td>
<td>Test for overall effect: Z = 1.70 (P = 0.09)</td>
</tr>
</tbody>
</table>

1.2.7 General: Hepatopancreatobiliary

| Javed 2018        | 6              | 62           | 61 3.7% 0.31 [0.13, 0.72]        |                               |
| Martin 2019      | 3              | 20           | 6 20 2.0% 0.50 [0.14, 1.73]      |                               |
| **Subtotal 95% CI** | **82**         | **81**      | 5.7% 0.36 [0.18, 0.73]           |                               |
| Total events      | 9              | 25           |                                 |                               |
| Heterogeneity: Tau² = 0.00, Chi² = 0.39, df = 1 (P = 0.53); I² = 0% | Test for overall effect: Z = 2.85 (P = 0.004) |

1.2.8 General: Mixed

| Masden 2012        | 3              | 44           | 5 37 1.7% 0.50 [0.13, 1.97]      |                               |
| Shim 2018         | 0              | 30           | 1 21 0.3% 0.24 [0.01, 5.54]      |                               |
| **Subtotal 95% CI** | **74**         | **58**      | 2.0% 0.45 [0.13, 1.56]           |                               |
| Total events       | 3              | 6            |                                 |                               |
| Heterogeneity: Tau² = 0.00, Chi² = 0.19, df = 1 (P = 0.66); I² = 0% | Test for overall effect: Z = 1.26 (P = 0.21) |

| Total (95% CI)     | **3115**       | **3089**     | **100.0%** 0.66 [0.55, 0.80]    |                               |
| Total events       | 273            | 402          |                                 |                               |
| Heterogeneity: Tau² = 0.05, Chi² = 39.01, df = 30 (P = 0.13); I² = 23% | Test for overall effect: Z = 4.34 (P < 0.0001) |
| Test for subgroup differences: Chi² = 12.58, df = 7 (P = 0.08), I² = 44.3% |                               |

**Test for subgroup differences:** Chi² = 12.58, df = 7 (P = 0.08), I² = 44.3%
Analysis 1.3. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 3: SSI grouped by contamination class

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1.3.1 Clean</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crist 2014</td>
<td>5</td>
<td>49</td>
<td>0.66 [0.55, 0.80]</td>
<td></td>
</tr>
<tr>
<td>Crist 2017</td>
<td>5</td>
<td>33</td>
<td>0.27 [0.06, 1.10]</td>
<td></td>
</tr>
<tr>
<td>DiMuzio 2017</td>
<td>6</td>
<td>59</td>
<td>0.24 [0.01, 5.54]</td>
<td></td>
</tr>
<tr>
<td>Engelhardt 2016</td>
<td>9</td>
<td>64</td>
<td>0.05 [0.00, 0.83]</td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>2</td>
<td>35</td>
<td>0.26 [0.06, 1.10]</td>
<td></td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>13</td>
<td>98</td>
<td>0.93 [0.67, 1.30]</td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>1</td>
<td>102</td>
<td>0.27 [0.01, 6.37]</td>
<td></td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>7</td>
<td>185</td>
<td>0.50 [0.14, 1.73]</td>
<td></td>
</tr>
<tr>
<td>Lee 2017a</td>
<td>0</td>
<td>31</td>
<td>0.27 [0.01, 6.37]</td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>7</td>
<td>53</td>
<td>0.59 [0.25, 1.40]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>0</td>
<td>79</td>
<td>0.34 [0.01, 8.16]</td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzac 2015</td>
<td>1</td>
<td>40</td>
<td>0.14 [0.02, 1.11]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>828</td>
<td>842</td>
<td>0.55 [0.39, 0.78]</td>
<td></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>56</td>
<td>105</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.05; Chi² = 12.65, df = 11 (P = 0.32); P = 13%
Test for overall effect: Z = 3.31 (P = 0.0009)

**1.3.2 Clean-contaminated**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobkiewicz 2018</td>
<td>2</td>
<td>15</td>
<td>0.72 [0.58, 0.90]</td>
<td></td>
</tr>
<tr>
<td>Chaboyer 2014</td>
<td>10</td>
<td>44</td>
<td>0.27 [0.06, 1.10]</td>
<td></td>
</tr>
<tr>
<td>Gummatake 2017</td>
<td>1</td>
<td>39</td>
<td>0.28 [0.03, 2.36]</td>
<td></td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>21</td>
<td>222</td>
<td>0.88 [0.59, 1.29]</td>
<td></td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>20</td>
<td>432</td>
<td>0.72 [0.58, 0.90]</td>
<td></td>
</tr>
<tr>
<td>Javed 2018</td>
<td>6</td>
<td>62</td>
<td>0.31 [0.13, 0.72]</td>
<td></td>
</tr>
<tr>
<td>Kuncewicz 2017</td>
<td>8</td>
<td>36</td>
<td>1.03 [0.43, 2.44]</td>
<td></td>
</tr>
<tr>
<td>Leon 2016</td>
<td>5</td>
<td>47</td>
<td>0.36 [0.14, 0.96]</td>
<td></td>
</tr>
<tr>
<td>Marin 2019</td>
<td>3</td>
<td>20</td>
<td>0.50 [0.14, 1.73]</td>
<td></td>
</tr>
<tr>
<td>Murphy 2019</td>
<td>46</td>
<td>144</td>
<td>0.93 [0.67, 1.30]</td>
<td></td>
</tr>
<tr>
<td>O'Leary 2017</td>
<td>2</td>
<td>24</td>
<td>0.26 [0.06, 1.10]</td>
<td></td>
</tr>
<tr>
<td>Rohstaller 2017</td>
<td>3</td>
<td>61</td>
<td>0.71 [0.17, 3.05]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>26</td>
<td>132</td>
<td>0.94 [0.58, 1.51]</td>
<td></td>
</tr>
<tr>
<td>Tauti 2017</td>
<td>3</td>
<td>60</td>
<td>1.50 [0.26, 8.66]</td>
<td></td>
</tr>
<tr>
<td>Wibbery 2018</td>
<td>13</td>
<td>80</td>
<td>1.10 [0.53, 2.26]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>1418</td>
<td>1413</td>
<td>0.72 [0.58, 0.90]</td>
<td></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>169</td>
<td>231</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.03; Chi² = 17.24, df = 14 (P = 0.24); P = 19%
Test for overall effect: Z = 2.91 (P = 0.004)

**1.3.3 Contaminated**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHIST 2019a</td>
<td>45</td>
<td>770</td>
<td>0.88 [0.59, 1.29]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>770</td>
<td>749</td>
<td>0.88 [0.59, 1.29]</td>
<td></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>45</td>
<td>50</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Not applicable
Test for overall effect: Z = 0.67 (P = 0.50)

**1.3.4 Dirty**

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Loxano-Balderrcas 2017</td>
<td>0</td>
<td>25</td>
<td>0.27 [0.06, 1.12]</td>
<td></td>
</tr>
<tr>
<td>Masden 2012</td>
<td>3</td>
<td>44</td>
<td>0.50 [0.13, 1.97]</td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>0</td>
<td>30</td>
<td>0.24 [0.01, 5.54]</td>
<td></td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>99</td>
<td>85</td>
<td>0.27 [0.06, 1.12]</td>
<td></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>3</td>
<td>16</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.40; Chi² = 2.55, df = 2 (P = 0.28); P = 22%
Test for overall effect: Z = 1.81 (P = 0.07)

**Total (95% CI)**

<table>
<thead>
<tr>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>3115</td>
<td>3089</td>
<td>0.66 [0.55, 0.80]</td>
<td></td>
</tr>
<tr>
<td><strong>Total events:</strong></td>
<td>273</td>
<td>402</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Tau² = 0.05; Chi² = 39.01, df = 30 (P = 0.13); P = 23%
Test for overall effect: Z = 4.34 (P < 0.0001)
### Analysis 1.3. (Continued)

Heterogeneity: \( \tau^2 = 0.05, \chi^2 = 39.01, df = 30 (P = 0.13); I^2 = 23\% \)

Test for overall effect: \( Z = 4.34 (P < 0.0001) \)

Test for subgroup differences: \( \chi^2 = 4.87, df = 3 (P = 0.18), I^2 = 38.3\% \)

---

### Analysis 1.4. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 4: SSI (superficial)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Weight</th>
<th>Risk Ratio</th>
<th>Risk Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobkiewicz 2018</td>
<td>2</td>
<td>15</td>
<td>4</td>
<td>0.50 [0.11, 2.33]</td>
<td></td>
</tr>
<tr>
<td>Chaboyer 2014</td>
<td>5</td>
<td>44</td>
<td>7</td>
<td>0.70 [0.24, 2.03]</td>
<td></td>
</tr>
<tr>
<td>Engelhardt 2016</td>
<td>7</td>
<td>58</td>
<td>16</td>
<td>0.51 [0.23, 1.16]</td>
<td></td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>13</td>
<td>98</td>
<td>28</td>
<td>0.43 [0.24, 0.77]</td>
<td></td>
</tr>
<tr>
<td>Hassamy 2017</td>
<td>20</td>
<td>37</td>
<td>25</td>
<td>0.89 [0.60, 1.30]</td>
<td></td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>12</td>
<td>432</td>
<td>32</td>
<td>0.39 [0.20, 0.74]</td>
<td></td>
</tr>
<tr>
<td>Javed 2018</td>
<td>4</td>
<td>62</td>
<td>17</td>
<td>0.23 [0.08, 0.65]</td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>1</td>
<td>102</td>
<td>6</td>
<td>0.17 [0.02, 1.43]</td>
<td></td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>1</td>
<td>185</td>
<td>4</td>
<td>0.29 [0.03, 2.55]</td>
<td></td>
</tr>
<tr>
<td>Kunczewicz 2017</td>
<td>5</td>
<td>36</td>
<td>6</td>
<td>0.86 [0.29, 2.56]</td>
<td></td>
</tr>
<tr>
<td>Martin 2019</td>
<td>2</td>
<td>20</td>
<td>4</td>
<td>0.50 [0.10, 2.43]</td>
<td></td>
</tr>
<tr>
<td>O’Leary 2017</td>
<td>2</td>
<td>24</td>
<td>6</td>
<td>0.35 [0.08, 1.55]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>21</td>
<td>132</td>
<td>21</td>
<td>1.01 [0.58, 1.75]</td>
<td></td>
</tr>
<tr>
<td>Wiltbey 2018</td>
<td>12</td>
<td>80</td>
<td>8</td>
<td>1.52 [0.66, 3.52]</td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzak 2015</td>
<td>1</td>
<td>40</td>
<td>7</td>
<td>0.14 [0.02, 1.11]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI): 1365 / 1418 / 100.0% / 0.58 [0.42, 0.79]

Total events: 108 / 191

Heterogeneity: \( \tau^2 = 0.13, \chi^2 = 23.78, df = 14 (P = 0.05); I^2 = 41\% \)

Test for overall effect: \( Z = 3.40 (P = 0.0007) \)

Test for subgroup differences: Not applicable
### Analysis 1.5. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 5: SSI (deep)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>NPWT Total</th>
<th>Standard dressing Events</th>
<th>Standard dressing Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaboyer 2014</td>
<td>5</td>
<td>44</td>
<td>5</td>
<td>43</td>
<td>5.8%</td>
<td>0.98 [0.30, 3.14]</td>
<td></td>
</tr>
<tr>
<td>Crist 2014</td>
<td>5</td>
<td>49</td>
<td>2</td>
<td>42</td>
<td>3.2%</td>
<td>2.14 [0.44, 10.48]</td>
<td></td>
</tr>
<tr>
<td>Crist 2017</td>
<td>5</td>
<td>33</td>
<td>2</td>
<td>33</td>
<td>3.2%</td>
<td>2.50 [0.52, 11.98]</td>
<td></td>
</tr>
<tr>
<td>Engelhardt 2016</td>
<td>0</td>
<td>58</td>
<td>0</td>
<td>68</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>0</td>
<td>98</td>
<td>2</td>
<td>90</td>
<td>0.9%</td>
<td>0.18 [0.01, 3.78]</td>
<td></td>
</tr>
<tr>
<td>Hassamy 2017</td>
<td>1</td>
<td>37</td>
<td>0</td>
<td>41</td>
<td>0.8%</td>
<td>3.32 [0.14, 78.97]</td>
<td></td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>8</td>
<td>432</td>
<td>9</td>
<td>444</td>
<td>8.9%</td>
<td>0.91 [0.36, 2.35]</td>
<td></td>
</tr>
<tr>
<td>Javed 2018</td>
<td>2</td>
<td>62</td>
<td>2</td>
<td>61</td>
<td>2.1%</td>
<td>0.98 [0.14, 6.76]</td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>0</td>
<td>102</td>
<td>0</td>
<td>107</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>6</td>
<td>185</td>
<td>4</td>
<td>213</td>
<td>5.1%</td>
<td>1.73 [0.49, 6.03]</td>
<td></td>
</tr>
<tr>
<td>Kunczewitch 2017</td>
<td>3</td>
<td>36</td>
<td>2</td>
<td>37</td>
<td>2.7%</td>
<td>1.54 [0.27, 8.69]</td>
<td></td>
</tr>
<tr>
<td>Martin 2019</td>
<td>1</td>
<td>20</td>
<td>2</td>
<td>20</td>
<td>1.5%</td>
<td>0.50 [0.05, 5.08]</td>
<td></td>
</tr>
<tr>
<td>O’Leary 2017</td>
<td>0</td>
<td>24</td>
<td>2</td>
<td>25</td>
<td>0.9%</td>
<td>0.21 [0.01, 4.12]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>9</td>
<td>132</td>
<td>11</td>
<td>133</td>
<td>11.1%</td>
<td>0.82 [0.35, 1.92]</td>
<td></td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>45</td>
<td>770</td>
<td>50</td>
<td>749</td>
<td>52.2%</td>
<td>0.88 [0.59, 1.29]</td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzak 2015</td>
<td>0</td>
<td>40</td>
<td>0</td>
<td>40</td>
<td></td>
<td>Not estimable</td>
<td></td>
</tr>
</tbody>
</table>

**Total (95% CI)**

- **NPWT Events**: 2202
- **NPWT Total**: 2227
- **Standard dressing Events**: 100.0%
- **Risk Ratio M-H, Random, 95% CI**: 0.94 [0.71, 1.25]

**Heterogeneity**: $\tau^2 = 0.00$; $\chi^2 = 8.39$, df = 13 (P = 0.82); $I^2 = 0$

**Test for overall effect**: $Z = 0.42$ (P = 0.67)

**Test for subgroup differences**: Not applicable
Analysis 1.6. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 6: Dehiscence

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>NPWT Total</th>
<th>Standard dressing Events</th>
<th>Standard dressing Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Orthopaedic: hip/knee arthroplasty</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>1</td>
<td>35</td>
<td>1</td>
<td>35</td>
<td>0.8%</td>
<td>1.00 [0.07, 15.36]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>1</td>
<td>79</td>
<td>4</td>
<td>80</td>
<td>1.3%</td>
<td>0.25 [0.03, 2.22]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>114</td>
<td>115</td>
<td></td>
<td></td>
<td>2.2%</td>
<td>0.43 [0.08, 2.35]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>2</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.00; Chi² = 0.60, df = 1 (P = 0.44); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.97 (P = 0.33)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Orthopaedic: limb fracture</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>2</td>
<td>714</td>
<td>7</td>
<td>687</td>
<td>2.6%</td>
<td>0.27 [0.06, 1.32]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>714</td>
<td>687</td>
<td></td>
<td></td>
<td>2.6%</td>
<td>0.27 [0.06, 1.32]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>2</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.61 (P = 0.11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Obstetric: caesarean</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gunatilake 2017</td>
<td>1</td>
<td>39</td>
<td>5</td>
<td>43</td>
<td>1.4%</td>
<td>0.22 [0.03, 1.81]</td>
<td></td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>4</td>
<td>232</td>
<td>1</td>
<td>219</td>
<td>1.3%</td>
<td>3.95 [0.44, 35.02]</td>
<td></td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>62</td>
<td>410</td>
<td>69</td>
<td>417</td>
<td>63.4%</td>
<td>0.91 [0.67, 1.25]</td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>2</td>
<td>60</td>
<td>0</td>
<td>60</td>
<td>0.7%</td>
<td>5.00 [0.25, 102.00]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>731</td>
<td>739</td>
<td></td>
<td></td>
<td>66.8%</td>
<td>1.06 [0.39, 2.89]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>69</td>
<td>75</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.42; Chi² = 4.69, df = 3 (P = 0.20); I² = 36%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.12 (P = 0.90)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular: peripheral</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiMuzio 2017</td>
<td>5</td>
<td>59</td>
<td>11</td>
<td>60</td>
<td>6.4%</td>
<td>0.46 [0.17, 1.25]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>59</td>
<td>60</td>
<td></td>
<td></td>
<td>6.4%</td>
<td>0.46 [0.17, 1.25]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>5</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 1.52 (P = 0.13)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Vascular: cardiac</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzac 2015</td>
<td>1</td>
<td>40</td>
<td>1</td>
<td>40</td>
<td>0.8%</td>
<td>1.00 [0.06, 15.44]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>40</td>
<td>40</td>
<td></td>
<td></td>
<td>0.8%</td>
<td>1.00 [0.06, 15.44]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.00 (P = 1.00)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General: abdominal</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kuncewicz 2017</td>
<td>1</td>
<td>36</td>
<td>2</td>
<td>37</td>
<td>1.1%</td>
<td>0.51 [0.05, 5.42]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>3</td>
<td>132</td>
<td>3</td>
<td>133</td>
<td>2.5%</td>
<td>1.01 [0.21, 4.90]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>168</td>
<td>170</td>
<td></td>
<td></td>
<td>3.6%</td>
<td>0.82 [0.22, 3.04]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>4</td>
<td>5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Tau² = 0.00; Chi² = 0.22, df = 1 (P = 0.64); I² = 0%</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.30 (P = 0.76)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General: hepatopancreatiobiliary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marin 2019</td>
<td>1</td>
<td>20</td>
<td>2</td>
<td>20</td>
<td>1.2%</td>
<td>0.50 [0.05, 5.08]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>20</td>
<td>20</td>
<td></td>
<td></td>
<td>1.2%</td>
<td>0.50 [0.05, 5.08]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>1</td>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: Z = 0.59 (P = 0.56)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>General: mixed</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Masden 2012</td>
<td>16</td>
<td>44</td>
<td>11</td>
<td>37</td>
<td>15.8%</td>
<td>1.22 [0.65, 2.30]</td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>2</td>
<td>30</td>
<td>0</td>
<td>21</td>
<td>0.7%</td>
<td>3.55 [0.18, 70.34]</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>74</td>
<td>58</td>
<td></td>
<td></td>
<td>16.5%</td>
<td>1.28 [0.69, 2.37]</td>
<td></td>
</tr>
<tr>
<td>Total events:</td>
<td>10</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Negative pressure wound therapy for surgical wounds healing by primary closure (Review) 212
Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.6. (Continued)

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Weight</th>
<th>Risk Ratio IV, Random, 95% CI</th>
<th>Risk Ratio IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gombert 2018</td>
<td>5</td>
<td>98</td>
<td>6</td>
<td>0.77 [0.24, 2.42]</td>
<td></td>
</tr>
<tr>
<td>Gunatiilake 2017</td>
<td>1</td>
<td>39</td>
<td>6</td>
<td>0.18 [0.02, 1.46]</td>
<td></td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>14</td>
<td>222</td>
<td>10</td>
<td>1.38 [0.63, 3.04]</td>
<td></td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>1</td>
<td>185</td>
<td>4</td>
<td>0.29 [0.03, 2.55]</td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>2</td>
<td>53</td>
<td>1</td>
<td>1.85 [0.17, 19.76]</td>
<td></td>
</tr>
<tr>
<td>Masden 2012</td>
<td>9</td>
<td>44</td>
<td>8</td>
<td>0.95 [0.41, 2.20]</td>
<td></td>
</tr>
<tr>
<td>Murphy 2019</td>
<td>6</td>
<td>144</td>
<td>6</td>
<td>0.97 [0.32, 2.94]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>2</td>
<td>79</td>
<td>10</td>
<td>0.20 [0.05, 0.90]</td>
<td></td>
</tr>
<tr>
<td>O'Leary 2017</td>
<td>0</td>
<td>25</td>
<td>1</td>
<td>0.33 [0.01, 7.81]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>19</td>
<td>132</td>
<td>16</td>
<td>1.20 [0.64, 2.22]</td>
<td></td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>83</td>
<td>578</td>
<td>56</td>
<td>1.37 [1.00, 1.88]</td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>1</td>
<td>180</td>
<td>1</td>
<td>1.01 [0.06, 15.95]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) 1779 1744 100.0% 1.04 [0.78, 1.41]

### Analysis 1.7. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 7: Reoperation

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaboyer 2014</td>
<td>1</td>
<td>44</td>
<td>1</td>
<td>43</td>
<td>2.5% 0.98 [0.06, 15.13]</td>
<td></td>
</tr>
<tr>
<td>DiMaro 2017</td>
<td>4</td>
<td>59</td>
<td>10</td>
<td>60</td>
<td>15.6% 0.41 [0.14, 1.23]</td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>4</td>
<td>35</td>
<td>0</td>
<td>35</td>
<td>2.3% 9.00 [0.50, 161.13]</td>
<td></td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>13</td>
<td>222</td>
<td>9</td>
<td>219</td>
<td>27.6% 1.42 [0.62, 3.27]</td>
<td></td>
</tr>
<tr>
<td>Karriakis 2016</td>
<td>6</td>
<td>107</td>
<td>1</td>
<td>108</td>
<td>1.9% 0.34 [0.01, 8.17]</td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>2</td>
<td>53</td>
<td>2</td>
<td>49</td>
<td>5.1% 0.92 [0.14, 6.31]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>9</td>
<td>79</td>
<td>9</td>
<td>80</td>
<td>25.1% 1.01 [0.42, 2.42]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>3</td>
<td>118</td>
<td>6</td>
<td>119</td>
<td>10.2% 0.50 [0.13, 1.97]</td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>3</td>
<td>80</td>
<td>5</td>
<td>81</td>
<td>9.7% 0.61 [0.15, 2.46]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) 797 794 100.0% 0.88 [0.57, 1.35]

### Analysis 1.8. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 8: Readmission

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT</th>
<th>Standard dressing</th>
<th>Total</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaboyer 2014</td>
<td>1</td>
<td>44</td>
<td>1</td>
<td>43</td>
<td>2.5% 0.98 [0.06, 15.13]</td>
<td></td>
</tr>
<tr>
<td>DiMaro 2017</td>
<td>4</td>
<td>59</td>
<td>10</td>
<td>60</td>
<td>15.6% 0.41 [0.14, 1.23]</td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>4</td>
<td>35</td>
<td>0</td>
<td>35</td>
<td>2.3% 9.00 [0.50, 161.13]</td>
<td></td>
</tr>
<tr>
<td>Hussamy 2017</td>
<td>13</td>
<td>222</td>
<td>9</td>
<td>219</td>
<td>27.6% 1.42 [0.62, 3.27]</td>
<td></td>
</tr>
<tr>
<td>Karriakis 2016</td>
<td>6</td>
<td>107</td>
<td>1</td>
<td>108</td>
<td>1.9% 0.34 [0.01, 8.17]</td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>2</td>
<td>53</td>
<td>2</td>
<td>49</td>
<td>5.1% 0.92 [0.14, 6.31]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>9</td>
<td>79</td>
<td>9</td>
<td>80</td>
<td>25.1% 1.01 [0.42, 2.42]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>3</td>
<td>118</td>
<td>6</td>
<td>119</td>
<td>10.2% 0.50 [0.13, 1.97]</td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>3</td>
<td>80</td>
<td>5</td>
<td>81</td>
<td>9.7% 0.61 [0.15, 2.46]</td>
<td></td>
</tr>
</tbody>
</table>

Total (95% CI) 797 794 100.0% 0.88 [0.57, 1.35]
### Analysis 1.9. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 9: Seroma

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gillespie 2015</td>
<td>3</td>
<td>0</td>
<td>35</td>
<td>1.6%</td>
<td>7.00 [0.37, 130.69]</td>
<td></td>
</tr>
<tr>
<td>Kunczewitch 2017</td>
<td>4</td>
<td>6</td>
<td>37</td>
<td>10.0%</td>
<td>0.69 [0.21, 2.23]</td>
<td></td>
</tr>
<tr>
<td>Pachowsky 2012</td>
<td>4</td>
<td>9</td>
<td>10</td>
<td>24.1%</td>
<td>0.49 [0.23, 1.05]</td>
<td></td>
</tr>
<tr>
<td>Pauser 2016</td>
<td>6</td>
<td>8</td>
<td>10</td>
<td>35.9%</td>
<td>0.68 [0.37, 1.27]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>7</td>
<td>132</td>
<td>133</td>
<td>14.3%</td>
<td>0.88 [0.33, 2.36]</td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>0</td>
<td>60</td>
<td>60</td>
<td>1.4%</td>
<td>0.33 [0.01, 8.02]</td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>7</td>
<td>80</td>
<td>81</td>
<td>12.7%</td>
<td>1.18 [0.42, 3.36]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>363</strong></td>
<td><strong>366</strong></td>
<td><strong>363</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.72 [0.50, 1.05]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: \( \tau^2 = 0.00; \chi^2 = 5.06, df = 6 (P = 0.54); I^2 = 0\%

Test for overall effect: \( Z = 1.71 (P = 0.09) \)

Test for subgroup differences: Not applicable

### Analysis 1.10. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 10: Haematoma

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaboyer 2014</td>
<td>1</td>
<td>44</td>
<td>43</td>
<td>16.0%</td>
<td>0.24 [0.03, 2.10]</td>
<td></td>
</tr>
<tr>
<td>Gillespie 2015</td>
<td>3</td>
<td>35</td>
<td>35</td>
<td>15.1%</td>
<td>3.00 [0.33, 27.46]</td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>0</td>
<td>102</td>
<td>107</td>
<td>7.3%</td>
<td>0.35 [0.01, 8.48]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>1</td>
<td>79</td>
<td>80</td>
<td>9.7%</td>
<td>1.01 [0.06, 15.91]</td>
<td></td>
</tr>
<tr>
<td>Shen 2017</td>
<td>1</td>
<td>132</td>
<td>133</td>
<td>7.3%</td>
<td>3.02 [0.12, 73.53]</td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>0</td>
<td>30</td>
<td>21</td>
<td>8.3%</td>
<td>0.14 [0.01, 2.81]</td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>0</td>
<td>60</td>
<td>60</td>
<td>9.9%</td>
<td>Not estimable</td>
<td></td>
</tr>
<tr>
<td>Wihbey 2018</td>
<td>2</td>
<td>80</td>
<td>81</td>
<td>26.5%</td>
<td>0.51 [0.10, 2.69]</td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzac 2015</td>
<td>1</td>
<td>40</td>
<td>40</td>
<td>9.9%</td>
<td>1.00 [0.06, 15.44]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>602</strong></td>
<td><strong>600</strong></td>
<td><strong>602</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>0.67 [0.28, 1.59]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: \( \tau^2 = 0.00; \chi^2 = 4.94, df = 7 (P = 0.67); I^2 = 0\%

Test for overall effect: \( Z = 0.90 (P = 0.37) \)

Test for subgroup differences: Not applicable

### Analysis 1.11. Comparison 1: Negative pressure wound therapy versus standard dressing, Outcome 11: Skin blisters

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>NPWT Events</th>
<th>Standard dressing Events</th>
<th>Total Events</th>
<th>Weight</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
<th>Risk Ratio M-H, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chaboyer 2014</td>
<td>4</td>
<td>44</td>
<td>43</td>
<td>11.7%</td>
<td>8.80 [0.49 , 158.66]</td>
<td></td>
</tr>
<tr>
<td>Giannini 2018</td>
<td>6</td>
<td>50</td>
<td>50</td>
<td>21.4%</td>
<td>0.40 [0.17 , 0.95]</td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>11</td>
<td>102</td>
<td>107</td>
<td>15.6%</td>
<td>11.54 [1.52 , 87.78]</td>
<td></td>
</tr>
<tr>
<td>Manoharan 2016</td>
<td>1</td>
<td>21</td>
<td>21</td>
<td>10.7%</td>
<td>3.00 [0.13 , 69.70]</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>0</td>
<td>79</td>
<td>80</td>
<td>10.5%</td>
<td>0.34 [0.01 , 8.16]</td>
<td></td>
</tr>
<tr>
<td>Ruhtaller 2017</td>
<td>8</td>
<td>61</td>
<td>58</td>
<td>18.3%</td>
<td>3.80 [0.84 , 17.17]</td>
<td></td>
</tr>
<tr>
<td>Witt-Majchrzac 2015</td>
<td>5</td>
<td>40</td>
<td>40</td>
<td>11.8%</td>
<td>11.00 [0.63 , 192.56]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>397</strong></td>
<td><strong>399</strong></td>
<td><strong>397</strong></td>
<td><strong>100.0%</strong></td>
<td><strong>2.64 [0.65 , 10.68]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: \( \tau^2 = 2.19; \chi^2 = 19.57, df = 6 (P = 0.003); I^2 = 69\%

Test for overall effect: \( Z = 1.36 (P = 0.17) \)

Test for subgroup differences: Not applicable
<table>
<thead>
<tr>
<th>Study</th>
<th>Wounds characteristics</th>
<th>Comparison</th>
<th>Time points</th>
<th>Mortality</th>
<th>SSI</th>
<th>Dehiscence</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobkiewicz 2018</td>
<td>Stoma reversal surgery</td>
<td>Group A: cNPWT</td>
<td>Not reported</td>
<td>-</td>
<td>Group A: 2/15</td>
<td></td>
<td>&quot;In the standard dressing group the incidence of wound dehiscence was higher&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard dressing</td>
<td></td>
<td></td>
<td>Group B: 4/15</td>
<td></td>
<td>Superficial SSI defined according to CDC</td>
</tr>
<tr>
<td>Chaboyer 2014</td>
<td>Stoma reversal surgery</td>
<td>Group A: PICO dressing</td>
<td>1, 2, 3, and 4 weeks post-surgery</td>
<td>-</td>
<td>Group A: 10/44</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard dressing</td>
<td></td>
<td></td>
<td>Group B: 12/43</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crist 2014</td>
<td>Caesarean section in obese women</td>
<td>Group A: NPWT</td>
<td>12 months</td>
<td>-</td>
<td>Group A: 5/49</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard gauze dressing</td>
<td></td>
<td></td>
<td>Group B: 2/42</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crist 2017</td>
<td>Open reduction and internal fixation (ORIF) for acetabular fractures</td>
<td>Group A: NPWT</td>
<td>10 to 21 days, 6 weeks, 12 weeks, and every 6 to 8 weeks thereafter until bony union occurred</td>
<td>-</td>
<td>Group A: 5/33</td>
<td>-</td>
<td>Infection defined as &quot;deep infection&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard gauze dressing</td>
<td></td>
<td></td>
<td>Group B: 2/33</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>completed-case analysis - 5 lost after randomisation but group allocation not known</td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiMuzio 2017 Abstract</td>
<td>Groin wounds</td>
<td>Group A (59, high risk):</td>
<td>30 days</td>
<td>-</td>
<td>Group A: 6/59</td>
<td></td>
<td>Group A: 8.5% Group B: 15/60 Group C: 1/21 Group C: 4.8% Contacted authors for full text Group C not included in data analysis due to baseline heterogeneity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NPWT</td>
<td></td>
<td></td>
<td>Group B: 15/60</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>dressing</td>
<td></td>
<td></td>
<td>Group C: 1/21</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B (60, high risk):</td>
<td></td>
<td></td>
<td>Group B: 18.3%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>standard gauze dressing</td>
<td></td>
<td></td>
<td>Group C: 4.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group C (21, low risk):</td>
<td></td>
<td></td>
<td>Group C: 4.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>standard gauze dressing</td>
<td></td>
<td></td>
<td>Group C: 4.8%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engelhardt 2016</td>
<td>Groin wound</td>
<td>Group A: NPWT</td>
<td>5 and 42 days</td>
<td>-</td>
<td>Group A: 9/64</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Primary outcome data
<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Intervention</th>
<th>Wound Size</th>
<th>Follow-Up</th>
<th>Adverse Events</th>
<th>Infection Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Galiano 2018</td>
<td>Breast surgery</td>
<td>Group A: NPWT, 199 wounds</td>
<td>21 days</td>
<td>Group A 4/199</td>
<td>Group A 32/199</td>
<td>The severity of wound infection measured by the ASEPSIS score (higher score = worse wound healing; a score &gt; 10 = the increasing probability and severity of infection) mean (SD) of the score: 3.0 (1.89) in Group A; 5.1 (3.89) in Group B</td>
</tr>
<tr>
<td>Giannini 2018</td>
<td>Hip and knee prosthetic revision</td>
<td>Group A: single use NPWT (PICO) Group B: povidone-iodine gauze and patch wound dressing</td>
<td>7 days</td>
<td>Group A 4/199</td>
<td>Group A 32/199</td>
<td>-</td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>Vascular surgery (groin) for PAD</td>
<td>Group A NPWT (Prevena) Group B Cosmopore dressing</td>
<td>30 days</td>
<td>Group A 13/98</td>
<td>Group A 13/98</td>
<td>-</td>
</tr>
<tr>
<td>Gunatilake 2017</td>
<td>Caesarean</td>
<td>Group A: NPWT Group B: standard care dressing</td>
<td>42 ± 10 days postoperatively (days 1, 2, 6, 14, and 42)</td>
<td>Group A 1/39</td>
<td>Group A 1/39</td>
<td>ITT: n = 92; 82 completed the study</td>
</tr>
<tr>
<td>Howell 2011</td>
<td>Knee arthroplasty</td>
<td>Group A: NPWT Group B: gauze dressing</td>
<td>Followed up for 12 months postsurgery</td>
<td>Group A 1/24</td>
<td>Group A 1/24</td>
<td>-</td>
</tr>
</tbody>
</table>

Table 1. Primary outcome data (Continued)
### Table 1. Primary outcome data (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Group A</th>
<th>Group B</th>
<th>Outcome</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>30 days after operation</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Javed 2018</td>
<td>Open pancreatico-duodenectomy</td>
<td>NPWT</td>
<td>standard closure</td>
<td>SSI</td>
<td>Group A: 6/62</td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 days after operation</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>Total hip or knee arthroplasties</td>
<td>PICO dressing</td>
<td>Comfeel dressing</td>
<td>SSI</td>
<td>Group A: 2/102</td>
</tr>
<tr>
<td></td>
<td></td>
<td>1, 2, and 6 weeks post-surgery</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>Hip and knee total joint arthroplasty</td>
<td>NPWT</td>
<td>conventional wound dressing</td>
<td>Superficial and late wound infection rates</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>7, 14 and 35 days after operations; 2 years</td>
<td>-</td>
<td></td>
<td>Additional data on return to operating rooms; and infection outcome were</td>
</tr>
</tbody>
</table>
Table 1. Primary outcome data (Continued)

<table>
<thead>
<tr>
<th>Study, Year</th>
<th>Procedure</th>
<th>Group A: NPWT</th>
<th>Group B: standard surgical dressing</th>
<th>Follow-up</th>
<th>Primary outcome</th>
<th>Group A:</th>
<th>Group B:</th>
<th>Unable to contact authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kw 2018</td>
<td>Vascular groin incisions (high risk)</td>
<td>Group A: NPWT</td>
<td>Group B: standard gauze</td>
<td>30 days</td>
<td>Any</td>
<td>Group A 6/59 Group B 12/60</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>High-risk groin wounds</td>
<td>Group A: NPWT</td>
<td>Group B: standard care</td>
<td>30 days and 90 days</td>
<td>In-hospital SSI</td>
<td>Group A: 1/53 Group B: 1/49</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
- Superficial SSI:
  - Group A: 5/36
  - Group B: 6/37
- Deep SSI:
  - Group A: 3/36
  - Group B: 2/37
- Unable to contact authors
- Latest time point of SSI data used for analysis.
**Table 1. Primary outcome data** (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
<th>Group A: NPWT</th>
<th>Group B: usual dressing</th>
<th>15-day and 30-day evaluation</th>
<th>30-day SSI</th>
<th>90-day SSI</th>
<th>90-day SSI</th>
<th>Unable to contact authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leon 2016 Abstract</td>
<td>Open colorectal surgery</td>
<td>Group A: NPWT</td>
<td>Group B: usual dressing</td>
<td>15-day and 30-day evaluation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Unable to contact authors</td>
</tr>
<tr>
<td>Lozano-Balderas 2017</td>
<td>Laparotomised patients with class III or IV (contaminated/dirty-infected) surgical wounds</td>
<td>Group A: vacuum-assisted closure</td>
<td>Group B: primary closure Group C: delayed primary closure</td>
<td>15-day and 30-day evaluation</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Group C (delayed primary closure) not included in data analysis due to irrelevant wounds.</td>
</tr>
<tr>
<td>Manoharan 2016</td>
<td>Primary arthroplasty</td>
<td>Group A: NPWT</td>
<td>Group B: conventional dry dressing</td>
<td>10 to 12 days postsurgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Martin 2019</td>
<td>Hepatectomy or pancreatectomy</td>
<td>Group A: NPWT (PICO)</td>
<td>Group B: sterile island dressing</td>
<td>Not reported</td>
<td>-</td>
<td>Deep space</td>
<td>-</td>
<td>Abstract only</td>
</tr>
<tr>
<td>Masden 2012</td>
<td>Radial forearm free flap</td>
<td>Group A: NPWT</td>
<td>Group B: dry dressing</td>
<td>Not clear</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Study</td>
<td>Condition Description</td>
<td>Group A Treatment</td>
<td>Group B Treatment</td>
<td>Outcome Measures</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------</td>
<td>---------------------------------------------------------------------------------------</td>
<td>------------------------------------------</td>
<td>----------------------------------------</td>
<td>------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>Total hip or knee replacements</td>
<td>Group A: cNPWT</td>
<td>Group B: standard gauze dressing</td>
<td>Dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 weeks</td>
<td>Group B: 2/140</td>
<td>Group A: 0/79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B: 1/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 1/79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 4/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nordmeyer 2016</td>
<td>Spinal fractures treated with internal fixation</td>
<td>Group A: PICO dressing</td>
<td>Group B: standard silver dressing</td>
<td>Dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Day 5 and day 10 after surgery</td>
<td>Group B: 1/80</td>
<td>Group A 1/79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 4/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O'Leary 2017</td>
<td>Open abdominal surgery</td>
<td>Group A: PICO dressing</td>
<td>Group B: transparent waterproof dressing</td>
<td>Dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Day 4 and day 30 postsurgery</td>
<td>Group B: 8/25</td>
<td>Group A: 2/24</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pachowsky 2012</td>
<td>Hip arthroplasty</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>Dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Day 5 and day 10 in postoperative period</td>
<td>Group B: 1/80</td>
<td>Group A 1/79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 4/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pauser 2016</td>
<td>Fractures of the femoral neck treated by hemiarthroplasty</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>Dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Day 5 and day 10 after surgery</td>
<td>Group B: 1/80</td>
<td>Group A 1/79</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 4/80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Very small sample size</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pleger 2018</td>
<td>Groin wound</td>
<td>Group A: NPWT (n = 58 incisions)</td>
<td>Group B: control dressing (n = 71 incisions)</td>
<td>Superficial wound dehiscence</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Days 5 to 7 and 30 after surgery</td>
<td>Group B: 10/71</td>
<td>Group A: 3/58</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B: 4/71</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Deep wound dehiscence with fat necrosis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A: 1/58</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B: 4/71</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Unit of analysis error: 100 participants with 129 groin incisions</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Primary outcome data (Continued)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>Reconstructive surgery for acute hand injuries</td>
<td>Group A: NPWT</td>
<td>Group B: conventional dressing</td>
<td>1 month and 1 year</td>
<td>Group A: 0/30</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stannard 2012</td>
<td>Tibial plateau, pilon, or calcaneus fracture</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>Not stated</td>
<td>Group A: 14/144</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanaydin 2018</td>
<td>Bilateral breast reduction mammoplasty</td>
<td>Group A: NPWT</td>
<td>Group B: standard care (fixation strips)</td>
<td>21 days</td>
<td>Group A: 5/32</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>Caesarean delivery</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>30 days</td>
<td>Group A: 3/60</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
- Unit of analysis error
**Table 1. Primary outcome data (Continued)**

<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Group A: NPWT</th>
<th>Group B: standard dressing</th>
<th>Planned analysis could not be conducted</th>
<th>Deep infection</th>
<th>Dehisced but not deep SSI</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHIST 2019a</td>
<td>Lower limb fracture</td>
<td>30 days</td>
<td>90 days</td>
<td></td>
<td>30 days</td>
<td>30 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 45/770</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 50/749</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 12/745</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 15/711</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 60/590</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 78/590</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 60/590</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 78/590</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Group A: NPWT</th>
<th>Group B: standard dressing</th>
<th>Planned analysis could not be conducted</th>
<th>Deep infection</th>
<th>Dehisced but not deep SSI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wihbey 2018</td>
<td>Caesarean delivery</td>
<td>1 week and 30 days follow-up</td>
<td></td>
<td></td>
<td>Superficial</td>
<td>Group A 12/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 12/80</td>
<td>Group B 8/81</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Deep</td>
<td>Group A 0/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 0/81</td>
<td>Group A 0/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Organ</td>
<td>Group A 1/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 4/81</td>
<td>Group A 1/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 14/80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 13/81</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Group A: NPWT</th>
<th>Group B: conventional dressing</th>
<th>Planned analysis could not be conducted</th>
<th>Deep infection</th>
<th>Dehisced but not deep SSI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B 7/40</td>
</tr>
</tbody>
</table>

ASEPSIS: ASEPSIS score - a quantitative scoring method using objective criteria based on wound appearance to evaluate wound infection

CINPWT: closed incisional negative pressure wound therapy

CDC: Center for Disease Control

ICER: incremental cost-effectiveness ratio

IQR: interquartile range

ITT: intention-to-treat

NPWT: negative pressure wound therapy

ORIF: Open reduction internal fixation

PAD: peripheral arterial disease

QALY: quality-adjusted life year
### Table 2. Secondary outcome data

<table>
<thead>
<tr>
<th>Study</th>
<th>Wound characteristics</th>
<th>Comparison</th>
<th>Time-points</th>
<th>Reoperation</th>
<th>Readmission</th>
<th>Sero-Bradshaw</th>
<th>Pain blisters</th>
<th>Quality of Life</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bobkiewicz2018</td>
<td></td>
<td>Group A: cNPWT</td>
<td>Not reported</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Superficial SSI defined according to CDC</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard dressing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chaboyer2014</td>
<td></td>
<td>Group A: PICO dressing</td>
<td>1, 2, 3, and 4 weeks postsurgery</td>
<td>Group A: 1/44</td>
<td>-</td>
<td>-</td>
<td>Group A: 1/44</td>
<td>Group A: 1/44</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: Comfeel dressing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard dress</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crist2014</td>
<td>Open reduction and internal fixation of hip, pelvis, and acetabular fracture surgery</td>
<td>Group A: NPWT</td>
<td>12 months</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard gauze dressing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Crist2017</td>
<td>Open reduction internal fixation (ORIF) for acetabular fractures</td>
<td>Group A: NPWT</td>
<td>10 to 21 days, 6 weeks, 12 weeks</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Infection defined as &quot;deep infection&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B: standard gauze dressing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Group A</td>
<td>Group B</td>
<td>Group C</td>
<td>Contacted Authors for Full Text</td>
<td>Baseline Heterogeneity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td>--------------------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DiMuzio</td>
<td>Groin</td>
<td>(59, high risk): NPWT dressing</td>
<td>(60, high risk): standard gauze dressing</td>
<td>(21, low risk): standard gauze dressing</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group A</td>
<td>30 days</td>
<td>Group B</td>
<td>Group C</td>
<td>6.8%</td>
<td>16.7%</td>
<td>4.8%</td>
<td>Contacted authors for full text</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group B</td>
<td>-</td>
<td>Group C</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Group C not included in data analysis due to baseline heterogeneity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Group C</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Engelhardt</td>
<td>Groin</td>
<td>Group A: NPWT</td>
<td>Group B: conventional dressing</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>5 and 42 days</td>
<td>Group B</td>
<td>Group C</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Galiano</td>
<td>Breast surgery</td>
<td>Group A: NPWT 199 wounds</td>
<td>Group B: standard dressings 199 wounds</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21 days</td>
<td>Group B</td>
<td>Group C</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>Group A</td>
<td>Group C</td>
<td>0/199</td>
<td>1/199</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>-</td>
<td>Group B</td>
<td>Group C</td>
<td>1/199</td>
<td>1/199</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gianinni</td>
<td>Hip and knee prosthetic revision</td>
<td>Group A single use NPWT (PICO)</td>
<td>Group B povidone-iodine gauze and patch wound dressing</td>
<td>7 days</td>
<td>Group A</td>
<td>Group B</td>
<td>Group C</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A</td>
<td>Group B</td>
<td>Group C</td>
<td>Pain at dressing change</td>
<td>Pain</td>
<td>Pain</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6/50 B 15/50, range 1-6</td>
<td>mean 2.6 (median 1.6)</td>
<td>mean 4.8 (median 1.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Group A:</td>
<td>Group B:</td>
<td>Outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>---------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gille-Gispie 2015</td>
<td>Primary hip arthroplasty</td>
<td>PICO dressing</td>
<td>Comfeel dressing</td>
<td>QoL reported in Heard 2017.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 days and 6 weeks postsurgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gombert 2018</td>
<td>Vascular surgery (groin) for PAD</td>
<td>NPWT (prevena)</td>
<td>Cosmopore dressing</td>
<td>Pain reductions at rest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>30 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guinatilake 2017</td>
<td>Caesarean</td>
<td>NPWT</td>
<td>standard care dressing</td>
<td>Pain reductions with incisional pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>42 ± 10 days postsurgery (days 1, 2, 6, 14, and 42)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Howell 2011</td>
<td>Knee arthroplasty</td>
<td>NPWT</td>
<td>gauze dressing</td>
<td>Pain reductions at rest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>12 months postsurgery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Secondary outcome data (Continued)
### Table 2. Secondary outcome data (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Procedure</th>
<th>Group A: NPWT</th>
<th>Group B: standard dressing</th>
<th>30 days post-delivery</th>
<th>Need for reoperation (RR, 95% CI)</th>
<th>Rate of 30-day readmission</th>
<th>EQ index value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hussemy 2017</td>
<td>Caesarean section</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>14/222</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A:</td>
<td>Group B:</td>
<td>13/222</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A:</td>
<td>Group B:</td>
<td>10/219</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Hyldig 2019a</td>
<td>Caesarean section</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>30 days after operation</td>
<td>Mentioned in ClinicalTrials.gov but outcome data not reported</td>
<td>-</td>
<td>EQ index value</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A:</td>
<td>Group B:</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Group A: mean = 0.86, 95% CI 0.85–0.87</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group B:</td>
<td>Group B:</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Group B: mean = 0.86, 95% CI 0.84–0.87</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Overall self-rated health status (EQ VAS)</td>
<td></td>
<td>Overall self-rated health status (EQ VAS)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A: mean = 82, 95% CI 82–85;</td>
<td></td>
<td>Group A: mean = 82, 95% CI 82–85;</td>
</tr>
<tr>
<td>Javed 2018</td>
<td>Open pancreaticoduodenectomy</td>
<td>Group A: NPWT</td>
<td>Group B: standard closure</td>
<td>30 days after operation</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A:</td>
<td>Group B:</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Group A:</td>
<td>Group B:</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Group A: Treatment</td>
<td>Group B: Treatment</td>
<td>1, 2, 6 weeks postsurgery</td>
<td>Group A: Events</td>
<td>Group B: Events</td>
<td>Group A: Events</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------</td>
<td>-------------------</td>
<td>-------------------</td>
<td>---------------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>----------------</td>
</tr>
<tr>
<td>Karlakki 2016</td>
<td>Total hip or knee arthroplasties</td>
<td>PICO dressing</td>
<td>Comfeel dressing</td>
<td>0/107</td>
<td>0/102</td>
<td>11/102</td>
<td>1/107</td>
</tr>
<tr>
<td>Keeney 2019</td>
<td>Hip and knee total joint arthroplasty</td>
<td>iNPWT</td>
<td>conventional wound dressing</td>
<td>1/185</td>
<td>4/213</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
### Table 2. Secondary outcome data  (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention</th>
<th>Group A: NPWT</th>
<th>Group B: standard surgical dressing</th>
<th>30 days post-surgery follow-up</th>
<th>Reported composite outcome including seroma only</th>
<th>Major outcome</th>
<th>Any Group A 0/59</th>
<th>Group B 1/60</th>
<th>EQ-5D-3L:</th>
<th>EQ-5D-3L:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kuncewitch 2017</td>
<td>Pancreatectomy</td>
<td>Group A: NPWT</td>
<td>Group B: standard surgical dressing</td>
<td>30 days</td>
<td>Group A 5/59</td>
<td>Group B 11/60</td>
<td>Reported composite outcome including seroma only</td>
<td>Group A 0/59</td>
<td>Group B 1/60</td>
<td>EQ-5D-3L:</td>
</tr>
<tr>
<td>Kwon 2018</td>
<td>Vascular groin incisions (high risk)</td>
<td>Group A: NPWT</td>
<td>Group B: standard gauze</td>
<td>30 days</td>
<td>Group A 4/36</td>
<td>Group B 6/37</td>
<td>Reported composite outcome including seroma only</td>
<td>Group A 0/59</td>
<td>Group B 1/60</td>
<td>EQ-5D-3L:</td>
</tr>
<tr>
<td>Lee 2017a</td>
<td>Great saphenous vein harvest</td>
<td>Group A: NPWT</td>
<td>Group B: standard surgical dressing</td>
<td>Initial assessment: not specified; endpoint assessment: 6 weeks</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>2 participants died (sepsis; stroke). 2 participants were delirious and unable to complete QoL, all other objective evaluations were done (all 4 in NPWT).</td>
</tr>
<tr>
<td>Lee 2017b</td>
<td>High-risk groin wounds</td>
<td>Group A: NPWT</td>
<td>Group A: 2/53</td>
<td>Group A: 2/53</td>
<td>Latest time point of SSI</td>
<td>2 participants died (sepsis; stroke). 2 participants were delirious and unable to complete QoL, all other objective evaluations were done (all 4 in NPWT).</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
Table 2. Secondary outcome data (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Wound type</th>
<th>Group A: NPWT</th>
<th>Group B: usual dressing</th>
<th>Daily evaluation</th>
<th>Group B: 2/49 for SSI</th>
<th>Data used for analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Leon 2016</td>
<td>Open colorectal surgery</td>
<td></td>
<td></td>
<td>15-day and 30-day evaluation</td>
<td>-</td>
<td>Unable to contact authors</td>
</tr>
<tr>
<td>Lozano-Balderas 2017</td>
<td>Laparotomised patients with</td>
<td></td>
<td></td>
<td>Daily when in hospital or in a 30-day period after surgery</td>
<td>-</td>
<td>Group C (delayed primary closure) not included in data analysis due to irrelevant wounds</td>
</tr>
<tr>
<td>Manoharan 2016</td>
<td>Primary arthroplasty</td>
<td></td>
<td></td>
<td>10 to 12 days postsurgery</td>
<td>Group A: 1/21 Group B: 0/21</td>
<td></td>
</tr>
<tr>
<td>Martin 2019</td>
<td>Hepatectomy or pancreatectomy</td>
<td></td>
<td></td>
<td>Not reported</td>
<td>-</td>
<td>Abstract only</td>
</tr>
<tr>
<td>Masden 2012</td>
<td>Radial forearm free flap</td>
<td></td>
<td></td>
<td>Not clear</td>
<td>Group A: 9/44 Group B: 8/37</td>
<td></td>
</tr>
<tr>
<td>Murphy 2019</td>
<td>Colorectal resections</td>
<td></td>
<td>Group A NPWT</td>
<td>30 days</td>
<td>Group A 6/144 Group B 6/140</td>
<td></td>
</tr>
<tr>
<td>Newman 2019</td>
<td>Total hip or knee replacements</td>
<td></td>
<td>Group A: ciNPWT</td>
<td>12 weeks</td>
<td>Reoperation Readmission Haematoma skin blisters</td>
<td></td>
</tr>
</tbody>
</table>

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Table 2. Secondary outcome data (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Intervention A</th>
<th>Intervention B</th>
<th>Outcome Measure</th>
<th>Time Points</th>
<th>Group A</th>
<th>Group B</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>Days 5 and day 10 after surgery</td>
<td>Group A: 6/11</td>
<td>Group B: 8/10</td>
<td>Group A: 0/58 0/58</td>
<td>Group B: B: 1/71 8/71</td>
</tr>
<tr>
<td>----------------------</td>
<td>----------------------------------</td>
<td>-------------------------------</td>
<td>-----------------------------</td>
<td>---------------------------------</td>
<td>---------------</td>
<td>---------------</td>
<td>---------------------</td>
<td>------------------------</td>
</tr>
<tr>
<td>Pauser 2016</td>
<td>Fractures of the femoral neck treated by hemi-arthroplasty</td>
<td>Group A: NPWT</td>
<td>Group B: control dressing</td>
<td>Days 5 to 7 and 30 after surgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Pleger 2018</td>
<td>Groin wound</td>
<td>Group A: NPWT (n = 58 incisions)</td>
<td>Group B: control dressing (n = 71 incisions)</td>
<td>4 weeks postsurgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Ruhstaller 2017</td>
<td>Unplanned caesarean section</td>
<td>Group A: NPWT</td>
<td>Group B: standard care</td>
<td>4 months postsurgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Sabat 2016</td>
<td>Groin wounds in vascular surgery</td>
<td>Group A: NPWT</td>
<td>Group B: conventional dressing (gauze and Tegaderm)</td>
<td>4 months postsurgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Schmid 2018</td>
<td>Inguinal lymph node dissection</td>
<td>Group A: NPWT (Prevena)</td>
<td>Group B: conventional compression bandages</td>
<td>14 days after surgery</td>
<td>Group A: 11/25</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Group A</td>
<td>Group B</td>
<td>Timepoints</td>
<td>Complications</td>
<td>Pain score (on 0-to-10 scale)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>---------</td>
<td>---------</td>
<td>------------</td>
<td>---------------</td>
<td>------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shim 2018</td>
<td>Reconstructive surgery for acute hand injuries</td>
<td>Group A: NPWT</td>
<td>Group B: conventional dressing</td>
<td>1 month and 1 year</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Standard 2012</td>
<td>Tibial plateau, pilon, or calcaneus fracture</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>Not stated</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tanay-din 2018</td>
<td>Bilateral breast reduction mammoplasty</td>
<td>Group A: NPWT</td>
<td>Group B: standard care (fixation strips)</td>
<td>21 days</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tuuli 2017</td>
<td>Caesarean delivery</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>30 days</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>WHIST 2019a</td>
<td>Lower limb fracture</td>
<td>Group A: NPWT</td>
<td>Group B: standard dressing</td>
<td>30 days</td>
<td>Deliberate surgical reopening or surgical treatment of wound complications</td>
<td>VAS (median IQR) 3 months</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>90 days</td>
<td>-</td>
<td>Group A 51.6 (23.46) (507)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Group A: NPWT, Group B: conventional dressing, Group B: standard dressing.*
<table>
<thead>
<tr>
<th>Group</th>
<th>2 months</th>
<th>6 months</th>
<th>6 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>40.6 (24.98)</td>
<td>40.2 (26.73)</td>
<td>40.6 (24.98)</td>
</tr>
<tr>
<td>Group B</td>
<td>40.6 (26.73)</td>
<td>40.2 (26.73)</td>
<td>40.6 (26.73)</td>
</tr>
</tbody>
</table>

Proportion with neuropathic pain (DN4 > 3) also reported:

<table>
<thead>
<tr>
<th>Group</th>
<th>Group A</th>
<th>Group B</th>
</tr>
</thead>
<tbody>
<tr>
<td>3 months</td>
<td>40.6 (0.29)</td>
<td>40.2 (0.29)</td>
</tr>
<tr>
<td>EQ-5D (utility)</td>
<td>0.5 (0.29)</td>
<td>0.5 (0.30)</td>
</tr>
<tr>
<td>EQ-VAS</td>
<td>64.1 (22.24)</td>
<td>64.1 (22.24)</td>
</tr>
</tbody>
</table>
### Table 2. Secondary outcome data (Continued)

<table>
<thead>
<tr>
<th>Wittbey 2018</th>
<th>Caesarean delivery</th>
<th>Group A: NPWT</th>
<th>1 week and 30 days follow-up</th>
<th>Group A: 1/80</th>
<th>Group B: 1/81</th>
<th>-</th>
<th>Group A: 7/80</th>
<th>2/80</th>
<th>-</th>
<th>-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group B: standard dressing</td>
<td>Group B: conventional dressing</td>
<td>6 weeks follow-up</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Group A: 1/40</td>
<td>Group B: 1/40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Witt-Majchrzac 2015 | Coronary artery by-pass surgery | Group A: NPWT | 6 weeks follow-up | 1/40 | 5/40 | 1/40 | 0/40 | - | - | |

| CDC: Center for Disease Control | cNPWT: closed incisional negative pressure wound therapy | CI: confidence interval | DN4: DN4 (Douleur Neuropathique 4) questionnaire | DRI: Disability Rating Index | EQ(VAS): EuroQoL Visual Analogue Scale | EQ-5D-3L: EuroQoL SD questionnaire, version 3L | INPWT: incisional negative pressure wound therapy | IQR: inter-quartile range | ITT: intention-to-treat | NPWT: negative pressure wound therapy | PAD: peripheral arterial disease |
Table 3. Economic outcome data

<table>
<thead>
<tr>
<th>Economic Study</th>
<th>RCT base</th>
<th>Population and perspective</th>
<th>Comparison</th>
<th>Time points</th>
<th>Dressing-related costs</th>
<th>Resource use</th>
<th>QALY</th>
<th>Relative cost effectiveness (e.g. ICER)</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heard 2017</td>
<td>Chaboyer 2014</td>
<td>Population: Obese women undergoing Caesarean section</td>
<td>Group A: PICO dressing</td>
<td>4 weeks</td>
<td>NPWT AUD 180 Standard AUD 5</td>
<td>Group A (44): 2871.5 ± 182.1 AUD</td>
<td>Per SSI prevented: ICER AUD 1347 (95% CI dominant to 41,873)</td>
<td>Data drawn from Chaboyer 2014</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Perspective: Australian public health care provider</td>
<td>Group B: Comfeel dressing</td>
<td></td>
<td>Dressing change cost (nurse time) AUD 35 for each group</td>
<td>Group A (44): 0.067 ± 0.01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hyldig 2019b</td>
<td>Hyldig 2019a</td>
<td>Population: Obese women undergoing Caesarean section</td>
<td>NPWT Standard dressing</td>
<td>30 days</td>
<td>NPWT €151.40 Standard €0.67 (assumed included in cost of treatment)</td>
<td>Total healthcare costs</td>
<td>NPWT €5793.60 Control 0.856</td>
<td>ICER not reported for all participants; NPWT reported as dominant; subgroups reported</td>
<td>Data drawn from Hyldig 2019a</td>
</tr>
<tr>
<td>Nherera 2018</td>
<td>Witt-Majchrzac 2015</td>
<td>Population: People undergoing coronary artery bypass surgery</td>
<td>NPWT Standard dressing</td>
<td>6 weeks</td>
<td>NPWT £153.00 (114.75 - 191.25) above standard cost</td>
<td>NPWT £19,986 Standard £20,572</td>
<td>NPWT reported as dominant for both SSI avoided and QALY gained in base case analysis</td>
<td>Data drawn from Witt-Majchrzac 2015</td>
<td></td>
</tr>
<tr>
<td>WHIST 2019b</td>
<td>WHIST 2019a</td>
<td>Population: People undergoing surgery for lower limb fracture Perspective: UK NHS and PSS</td>
<td>NPWT Standard dressing</td>
<td>3 months 6 months</td>
<td>Cost of intervention including dressing (plus cast, initial inpatient care, antibiotics, dressing changes)</td>
<td>Total cost after initial intervention - baseline to 6 months NHS and PSS</td>
<td>Group A £5420.66 (5559.95)</td>
<td>Group A £3100.83 (11251.93)</td>
<td>Group B £4774.15 (4633.18)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>-</td>
<td>DiMuzio 2017</td>
<td>Groin wounds NPWT Standard dressing</td>
<td>30 days -</td>
<td>Group A: USD 30,492</td>
<td>Group B: USD 36,537</td>
<td>NPWT reduced cost per patient of USD 6045 (USD 30,492 + USD 500 (device) in NWPT group vs USD 36,537 in dressing group)</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>-</td>
<td>Gillespie 2015</td>
<td>Total hip/knee arthroplasty NPWT 30 days</td>
<td>Group A: AUS 38.4 ± AUS 13.6</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Data not linked to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Procedure</td>
<td>Treatment</td>
<td>Duration</td>
<td>Group A</td>
<td>Group B</td>
<td>Comment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------</td>
<td>-----------</td>
<td>----------</td>
<td>---------</td>
<td>---------</td>
<td>---------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Javed 2018</td>
<td>Open pancreaticoduodenectomy</td>
<td>NPWT</td>
<td>30 days</td>
<td>Median cost of hospitalisation</td>
<td>$43,823 (IQR, $36,820–$59,352)</td>
<td>Data not linked to cost-effectiveness</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kwon 2018</td>
<td>Vascular groin incisions (high risk)</td>
<td>NPWT</td>
<td>30 days</td>
<td>Costs (hospital)</td>
<td>Group A $29,292 +/- 6 $29,320 (n 51; range, $8816–$192,658)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B $30,678 6 $23,338 (n ¼ 55; range, $9071–$131,464)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Costs (post index procedure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group A 30.492 +/- 30.678 ($8816–$192,658)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Group B $36,537 +/- $28,889 (range, $9071–$131,464)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manoharan 2016</td>
<td>Primary arthroplasty</td>
<td>NPWT</td>
<td>10-12 days</td>
<td>Group A: AUS 285.94 ± AUS 28.54</td>
<td>-</td>
<td>Data not linked to cost-effectiveness</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 3. Economic outcome data (Continued)
Table 3. Economic outcome data (Continued)

<table>
<thead>
<tr>
<th>Group B: AUS 43.51 ±</th>
</tr>
</thead>
<tbody>
<tr>
<td>Standard dressing</td>
</tr>
<tr>
<td>AUS 64.23</td>
</tr>
</tbody>
</table>

1 RCTs reporting cost data which were not subsequently used in an economic analysis

AUD: Australian dollars
CI: confidence intervals
GBP: pounds sterling (UK pounds)
ICER: incremental cost-effectiveness ratio
NHS: National Health Service (UK)
NPWT: negative pressure wound therapy
PSS: personal social services
QALY: quality adjusted life year
SSI: surgical site infection
UK: United Kingdom
USD: United States dollar

Table 4. Quality assessment of economic studies using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist

<table>
<thead>
<tr>
<th>Sections</th>
<th>Item number</th>
<th>Heard 2017</th>
<th>Hyldig 2019b</th>
<th>Nherera 2017</th>
<th>Nherera 2018</th>
<th>WHIST 2019a</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title and abstract</td>
<td>Title</td>
<td>1</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td></td>
<td>Abstract</td>
<td>2</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Introduction</td>
<td>Background and objectives</td>
<td>3</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Methods</td>
<td>Target population and subgroups</td>
<td>4</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Setting and locations</td>
<td>5</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Study perspectives</td>
<td>6</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Comparators</td>
<td>7</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Time horizon</td>
<td>8</td>
<td>X</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Discount rate</td>
<td>9</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Choice of health outcomes</td>
<td>10</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Item</td>
<td>Measurement of effectiveness</td>
<td>11a</td>
<td>11b</td>
<td>12</td>
<td>13a</td>
<td>13b</td>
</tr>
<tr>
<td>------</td>
<td>-----------------------------</td>
<td>-----</td>
<td>-----</td>
<td>----</td>
<td>-----</td>
<td>-----</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Measurement and valuation of preference-based outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Estimating resources and costs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Currency, price date and conversion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Choice of model</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assumptions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Analytical methods</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Results</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study parameters</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Incremental costs and outcomes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Characterising uncertainty</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Characterising heterogeneity</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Study findings, limitations, generalisability and current knowledge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Others</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Source of funding</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflicts of interest</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Total</td>
<td>20/24 (83.3%)</td>
<td>22.5/24 (91.7%)</td>
<td>20.5/24 (85.4%)</td>
<td>20/23* (87.0%)</td>
<td>20.5/23* (89.1%)</td>
</tr>
</tbody>
</table>

✓ Item met in full; ≠ Item partially met; X Item not met; N/A = Not applicable

*Scored out of 23 because item 21 is not applicable to these studies
APPENDICES

Appendix 1. Glossary of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dehiscence</td>
<td>Wound dehiscence is a complication of surgery in which a wound breaks open along the line of the surgical incision.</td>
</tr>
<tr>
<td>Negative pressure wound therapy (NPWT)</td>
<td>Negative pressure wound therapy is based on a closed, sealed system that produces negative pressure to the wound surface. The wound is covered or packed with an open-cell foam or gauze dressing and sealed with an occlusive drape. Intermittent or continuous suction is maintained by connecting suction tubes from the wound dressing to a vacuum pump and liquid waste collector. Standard negative pressure rates range between −50 mmHg and −125 mmHg (Ubbink 2008; Vikatmaa 2008).</td>
</tr>
<tr>
<td>Risk ratio (RR)</td>
<td>The risk ratio, or relative risk (RR) is the probability that a member of a group who is exposed to an intervention will develop an event relative to the probability that a member of an unexposed group will develop that same event.</td>
</tr>
</tbody>
</table>

Appendix 2. Search strategies

Cochrane Wounds Specialised Register

1 MESH DESCRIPTOR Negative-Pressure Wound Therapy EXPLODE ALL AND INREGISTER
2 MESH DESCRIPTOR Suction EXPLODE ALL AND INREGISTER
3 MESH DESCRIPTOR Vacuum EXPLODE ALL AND INREGISTER
4 "negative pressure" or negative-pressure or TNP or NWPT or NPWT AND INREGISTER
5 (sub-atmospheric or subatmospheric) AND INREGISTER
6 ((seal* next surface*) or (seal* next aspirat*)) AND INREGISTER
7 (wound near3 suction*) AND INREGISTER
8 (wound near3 drainage) AND INREGISTER
9 ((foam next suction) or (suction next dressing*)) AND INREGISTER
10 ((vacuum next therapy) or (vacuum next dressing*) or (vacuum next seal*) or (vacuum next assist*) or (vacuum near closure) or (vacuum next compression) or (vacuum next pack*) or (vacuum next drainage) or VAC) AND INREGISTER
11 ("vacuum-assisted") AND INREGISTER
12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 AND INREGISTER
13 MESH DESCRIPTOR Surgical Wound Infection EXPLODE ALL AND INREGISTER
14 MESH DESCRIPTOR Surgical Wound Dehiscence EXPLODE ALL AND INREGISTER
15 surg* near5 infect* AND INREGISTER
16 surg* near5 wound* AND INREGISTER
17 surg* near5 site* AND INREGISTER
18 surg* near5 incision* AND INREGISTER
19 surg* near 5 dehisc* AND INREGISTER
20 wound* near 5 dehisc* AND INREGISTER
21 #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 AND INREGISTER
22 #12 AND #21 AND INREGISTER

The Cochrane Central Register of Controlled Clinical Trials (CENTRAL) and NHS Economic Evaluation Database (NHS EED)

#1 MeSH descriptor: [Negative-Pressure Wound Therapy] explode all trees
#2 MeSH descriptor: [Suction] explode all trees
#3 MeSH descriptor: [Vacuum] explode all trees
#4 ("negative pressure" or negative-pressure or TNP or NWPT or NPWT).tw.,ab,kw
#5 (sub-atmospheric or subatmospheric).tw.,ab,kw
#6 ((seal* adj surface*) or (seal* adj aspirat*)).tw.,ab,kw
#7 (wound near/3 suction*).tw.,ab,kw
#8 (wound near/3 drainage).tw.,ab,kw
#9 ((foam adj surface*) or (suction adj dressing*)).tw.,ab,kw
#10 ((vacuum next therapy) or (vacuum next dressing*) or (vacuum next seal*) or (vacuum next assist*) or (vacuum near closure) or (vacuum near compression) or (vacuum next pack*) or (vacuum next drainage) or VAC).tw.,ab,kw
#11 ("vacuum-assisted").tw.,ab,kw
#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11)
#13 MeSH descriptor: [Surgical Wound Infection] explode all trees
#14 MeSH descriptor: [Surgical Wound Dehiscence] explode all trees
#15 surg* near/5 infect*:tw.,ab,kw
#16 surg* near/5 wound*:tw.,ab,kw
#17 surg* near/5 site*:tw.,ab,kw
#18 surg* near/5 incision*:tw.,ab,kw
#19 surg* near/5 dehisc*:tw.,ab,kw
#20 wound* near/5 dehisc*:tw.,ab,kw
#21 #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20
#22 #12 and #21

Ovid MEDLINE - RCT

1 exp Negative-Pressure Wound Therapy/
2 exp Suction/
3 exp Vacuum/
4 (negative pressure or negative-pressure or TNP or NPWT or NWPT).tw.
5 (sub-atmospheric or subatmospheric).tw.
6 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
7 (wound adj2 suction*).tw.
8 (wound adj5 drainage).tw.
9 ((foam adj suction) or (suction adj dressing*)).tw.
10 vacuum-assisted.tw.
11 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj closure) or (vacuum adj assist*) or (vacuum adj compression) or (vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage) or VAC).tw.
12 or/1-11
13 exp Surgical Wound Infection/
14 exp Surgical Wound Dehiscence/
15 (surg* adj5 infect*).tw.
16 (surg* adj5 wound*).tw.
17 (surg* adj5 site*).tw.
18 (surg* adj5 incision*).tw.
19 (surg* adj5 dehisc*).tw.
20 (wound* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 or/13-21
23 12 and 22
24 randomized controlled trial.pt.
25 controlled clinical trial.pt.
26 randomi?ed.ab.
27 placebo.ab.
28 clinical trials as topic.sh.
29 randomly.ab.
30 trial.ti.
31 or/24-30
32 exp animals/ not humans.sh.
33 31 not 32
34 23 and 33

Ovid MEDLINE – Economic
1 exp Negative-Pressure Wound Therapy/
2 exp Suction/
3 exp Vacuum/
4 (negative pressure or negative-pressure or TNP or NPWT or NWPT).tw.
5 (sub-atmospheric or subatmospheric).tw.
6 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
7 (wound adj2 suction*).tw.
8 (wound adj5 drainage).tw.
9 ((foam adj suction) or (suction adj dressing*)).tw.
10 vacuum-assisted.tw.
11 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj assist*) or (vacuum adj seal*) or (vacuum adj closure) or (vacuum adj compression) or (vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage) or VAC).tw.
12 or/1-11
13 exp Surgical Wound Infection/
14 exp Surgical Wound Dehiscence/
15 (surg* adj5 infect*).tw.
16 (surg* adj5 wound*).tw.
17 (surg* adj5 site*).tw.
18 (surg* adj5 incision*).tw.
19 (surg* adj5 dehisc*).tw.
20 (wound* adj5 dehisc*).tw.
21 (wound* adj5 dehisc*).tw.
22 or/13-21
23 12 and 22
24 economics/
25 exp "costs and cost analysis"/
26 economics, dental/
27 exp "economics, hospital"/
28 economics, medical/
29 economics, nursing/
30 economics, pharmaceutical/
31 (economic* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*).ti,ab.
32 (expenditure* not energy).ti,ab.
33 value for money.ti,ab.
34 budget*.ti,ab.
35 or/24-34
36 ((energy or oxygen) adj cost).ti,ab.
37 (metabolic adj cost).ti,ab.
38 ((energy or oxygen) adj expenditure).ti,ab.
39 or/36-38
40 35 not 39
41 letter.pt.
42 editorial.pt.
43 historical article.pt.
44 or/41-43
45 40 not 44
46 Animals/
47 Humans/
48 46 not (46 and 47)
49 45 not 48
50 23 and 49

**Ovid Embase – RCT**

1 exp suction drainage/

2 exp vacuum assisted closure/

3 (negative pressure or negative-pressure or TNP or NPWT or NWPT).tw.

4 (sub-atmospheric or subatmospheric).tw.

5 ((seal* adj surface*) or (seal* adj aspirat*)).tw.

6 (wound adj2 suction*).tw.

7 (wound adj5 drainage).tw.

8 ((foam adj suction) or (suction adj dressing*)).tw.

9 vacuum-assisted.tw.

10 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj assist*) or (vacuum adj closure) or (vacuum adj compression) or (vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage) or VAC).tw.

11 or/1-10

12 exp Surgical Wound Infection/

13 exp Surgical Wound Dehiscence/

14 (surg* adj5 infection*).tw.

15 (surg* adj5 wound*).tw.

16 (surg* adj5 site*).tw.

17 (surg* adj5 incision*).tw.

18 (surg* adj5 dehisc*).tw.

19 (wound* adj5 dehisc*).tw.

20 or/12-19

21 11 and 20

22 Randomized controlled trials/
23 Single-Blind Method/
24 Double-Blind Method/
25 Crossover Procedure/
26 (random* or factorial* or crossover* or cross over* or cross-over* or placebo* or assign* or allocat* or volunteer*).ti,ab.
27 (doubl* adj blind*).ti,ab.
28 (singl* adj blind*).ti,ab.
29 or/22-28
30 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/
31 human/ or human cell/
32 and/30-31
33 30 not 32
34 29 not 33
35 21 and 34

**Ovid Embase - Economic**

1 exp suction drainage/
2 exp vacuum assisted closure/
3 (negative pressure or negative-pressure or TNP or NPWT or NWPT).tw.
4 (sub-atmospheric or subatmospheric).tw.
5 ((seal* adj surface*) or (seal* adj aspirat*)).tw.
6 (wound adj2 suction*).tw.
7 (wound adj5 drainage).tw.
8 ((foam adj suction) or (suction adj dressing*)).tw.
9 vacuum-assisted.tw.
10 ((vacuum adj therapy) or (vacuum adj dressing*) or (vacuum adj seal*) or (vacuum adj assist*) or (vacuum adj closure) or (vacuum adj compression) or (vacuum adj pack*) or (vacuum adj drainage) or (suction* adj drainage) or VAC).tw.
11 or/1-10
12 exp Surgical Wound Infection/
13 exp Surgical Wound Dehiscence/
14 (surg* adj5 infection*).tw.
15 (surg* adj5 wound*).tw.
16 (surg* adj5 site*).tw.
17 (surg* adj5 incision*).tw.
18 (surg* adj5 dehisc*).tw.
19 (wound* adj5 dehisc*).tw.
20 or/12-19
21 11 and 20
22 health-economics/
23 exp economic-evaluation/
24 exp health-care-cost/
25 exp pharmacoeconomics/
26 or/22-25
27 (econom* or cost or costs or costly or costing or price or prices or pricing or pharmacoeconomic*).ti,ab.
28 (expenditure* not energy).ti,ab.
29 (value adj2 money).ti,ab.
30 budget*.ti,ab.
31 or/27-30
32 26 or 31
33 letter.pt.
34 editorial.pt.
35 note.pt.
36 or/33-35
37 32 not 36
38 (metabolic adj cost).ti,ab.
39 ((energy or oxygen) adj cost).ti,ab.
40 ((energy or oxygen) adj expenditure).ti,ab.
41 or/38-40
42 37 not 41
43 exp animal/
44 exp animal-experiment/
45 nonhuman/
46 (rat or rats or mouse or mice or hamster or hamsters or animal or animals or dog or dogs or cat or cats or bovine or sheep).ti,ab,sh.
47 or/43-46
48 exp human/
49 exp human-experiment/
50 or/48-49
51 47 not (47 and 50)
52 42 not 51
53 21 and 52

**EBSCO CINAHL Plus - RCT**

S37 S23 AND S36
Negative pressure wound therapy for surgical wounds healing by primary closure (Review)

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S3 (MH "Negative Pressure Wound Therapy")
S2 (MH "Vacuum")
S1 (MH "Suction+")

EBSCO CINAHL Plus – Economic
S46 S23 AND S45
S45 S41 NOT S44
S44 S19 NOT (S19 AND S43)
S43 MH "Human"
S42 MH "Animal Studies"
S41 S36 NOT S40
S40 S37 or S38 or S39
S39 PT commentary
S38 PT letter
S37 PT editorial
S36 S34 OR S35
S35 TI (cost or costs or economic* or pharmacoeconomic* or price* or pricing*) OR AB (cost or costs or economic* or pharmacoeconomic* or price* or pricing*)
S34 S30 OR S33
S33 S31 OR S32
S32 MH "Health Resource Utilization"
S31 MH "Health Resource Allocation"
S30 S24 NOT S29
S29 S25 OR S26 or S27 OR S28
S28 MH "Business+")
S27 MH "Financing, Organized+"
S26 MH "Financial Support+"
S25 MH "Financial Management+"
S24 MH "Economics+"
S23 S12 AND S22
S22 S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21
S21 TI (wound* N5 dehisc*) OR AB (wound* N5 dehisc*)
S20 TI (surg* N5 dehisc*) OR AB (surg* N5 dehisc*)
S19 TI (surg* N5 incision*) OR AB (surg* N5 incision*)
S18 TI (surg* N5 site*) OR AB (surg* N5 site*)
S17 TI (surg* N5 wound*) OR AB (surg* N5 wound*)
S16 TI (surg* N5 infection*) OR AB (surg* N5 infection*)
S15 (MH "Surgical Wound Dehiscence")
S14 (MH "Surgical Wound Dehiscence")
S13 (MH "Surgical Wound Infection")
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S11 TI (foam suction or suction dressing* or suction drainage) OR AB (foam suction or suction dressing* or suction drainage)
S10 TI vacuum-assisted OR AB vacuum-assisted
S9 TI (vacuum therapy or vacuum dressing* or vacuum seal* or vacuum closure or vacuum compression or vacuum pack or vacuum drainage or vacuum assisted or VAC) OR AB (vacuum therapy or vacuum dressing* or vacuum seal* or vacuum closure or vacuum compression or vacuum pack or vacuum drainage or vacuum assisted or VAC)
S8 TI (wound N5 drainage) OR AB (wound N5 drainage)
S7 TI (wound N5 suction*) OR AB (wound N5 suction*)
S6 TI (seal* N1 surface* or seal* N1 aspirat*) OR AB (seal* N1 surface* or seal* N1 aspirat*)
S5 TI (sub-atmospheric or subatmospheric) OR AB (sub-atmospheric or subatmospheric)
S4 TI (negative pressure or negative-pressure or TNP or NPWT or NWPT) OR AB (negative pressure or negative-pressure or TNP or NPWT or NWPT)
S3 (MH "Negative Pressure Wound Therapy")
S2 (MH "Vacuum")
S1 (MH "Suction+")

US National Institutes of Health Ongoing Trials Register (ClinicalTrials.gov)

(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | incision dehiscence
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | incision infection
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | operative wound
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | postoperative complications
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | postoperative infection
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | surgery
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | surgical incision
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | surgical site infection
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | surgical wound
(surgery OR surgical OR postoperative OR operative OR incision OR incisional OR incisions) AND (negative pressure OR vacuum assisted OR NPWT OR TNP) | surgical wound dehiscence
Appendix 3. 'Risk of bias' criteria

1. Was the allocation sequence randomly generated?

**Low risk of bias**

The investigators describe a random component in the sequence generation process such as: referring to a random number table; using a computer random number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.

**High risk of bias**

The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.

**Unclear**

Insufficient information about the sequence generation process is provided to permit judgement of low or high risk of bias.

2. Was the treatment allocation adequately concealed?

**Low risk of bias**

Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent method, was used to conceal allocation: central allocation (including telephone, web-based, and pharmacy-controlled randomisation); sequentially numbered drug containers of identical appearance; sequentially numbered, opaque, sealed envelopes.

**High risk of bias**

Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation based on: using an open random allocation schedule (e.g. a list of random numbers); assignment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or not sequentially numbered); alternation or rotation; date of birth; case record number; any other explicitly unconcealed procedure.

**Unclear**

Insufficient information to permit judgement of low or high risk of bias. This is usually the case if the method of concealment is not described or not described in sufficient detail to permit a definitive judgement, for example if the use of assignment envelopes is described, but it remains unclear whether envelopes were sequentially numbered, opaque, and sealed.

3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?

**Low risk of bias**

Any one of the following.

- No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by lack of blinding.
- Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
- Either participants or some key study personnel were not blinded, but outcome assessment was blinded, and the non-blinding of others was unlikely to introduce bias.

**High risk of bias**

Any one of the following.

- No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
- Blinding of key study participants and personnel attempted, but it is likely that the blinding could have been broken.
- Either participants or some key study personnel were not blinded, and the non-blinding of others was likely to introduce bias.
Unclear
Either of the following.

- Insufficient information is provided to permit judgement of low or high risk of bias.
- The study did not address this outcome.

4. Were incomplete outcome data adequately addressed?

**Low risk of bias**
Any one of the following.

- No missing outcome data.
- Reasons for missing outcome data are unlikely to be related to true outcome (for survival data, censoring is unlikely to be introducing bias).
- Missing outcome data are balanced in numbers across intervention groups, with similar reasons for missing data across groups.
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate.
- For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is not enough to have a clinically relevant impact on observed effect size.
- Missing data have been imputed using appropriate methods.

**High risk of bias**
Any one of the following.

- Reason for missing outcome data is likely to be related to true outcome, with either an imbalance in numbers or reasons for missing data across intervention groups.
- For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk is enough to induce clinically relevant bias in intervention effect estimate.
- For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is enough to induce clinically relevant bias in observed effect size.
- ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
- Potentially inappropriate application of simple imputation.

Unclear
Either of the following.

- Insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias (e.g. number randomised not stated, no reasons for missing data provided).
- The study did not address this outcome.

5. Are reports of the study free of the suggestion of selective outcome reporting?

**Low risk of bias**
Either of the following.

- The study protocol is available and all of the study’s prespecified (primary and secondary) outcomes that are of interest in the review have been reported in the prespecified way.
- The study protocol is not available, but it is clear that the published reports include all expected outcomes, including those that were prespecified (convincing text of this nature may be uncommon).

**High risk of bias**
Any one of the following.

- Not all of the study’s prespecified primary outcomes have been reported.
- One or more primary outcomes are reported using measurements, analysis methods, or subsets of the data (e.g. subscales) that were not prespecified.
- One or more reported primary outcomes were not prespecified (unless clear justification for their reporting is provided, such as an unexpected adverse effect).
- One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.

Unclear
Insufficient information is provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into this category.

6. Other sources of potential bias

Low risk of bias
The study appears to be free of other sources of bias.

High risk of bias
There is at least one important risk of bias. For example, the study:

• had a potential source of bias related to the specific study design used;
• had extreme baseline imbalance;
• has been claimed to have been fraudulent; or
• had some other problem.

Unclear
There may be a risk of bias, but there is either:

• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.

Appendix 4. Results of studies not included in pooled analyses
This appendix contains the results of studies which reported specified outcomes but could not be included in the pooled analyses we conducted; together with brief explanations of the methodological or reporting issues for this.

Primary outcomes

Mortality
There were no studies which reported mortality and could not be included in the pooled analysis.

SSI
Seven studies (Galiano 2018; Giannini 2018; Howell 2011; Kwon 2018; Pleger 2018; Sabat 2016; Schmid 2018; Stannard 2012) reported SSI data but could not be included in the pooled analysis.

One study in 100 people undergoing revision surgery on hip or knee prostheses (Giannini 2018) reported the ASEPSIS score (Wilson 1986). The authors reported that the mean score was 3.0 (SD 1.89) in the NPWT group compared with 5.1 (SD 3.89) in the standard dressing group; higher scores are indicative of a worse outcome. We could not analyse this data further, as the component elements of the score were not reported.

Several studies randomised or analysed wounds rather than individuals. Stannard 2012 reported results for this outcome including 249 participants who had sustained open fractures, requiring surgery for closure. Randomisation was by individual participant, but some participants had multiple wounds. Outcome data were collected and analysed by wound, not participant, so we have not carried out further analysis as clustering was not taken into account in this study. The investigators reported that there were 14/144 (9.7%) SSIs in the NPWT group compared with 23/122 (18.9%) SSIs in the standard dressing group. Pleger 2018 randomised 100 participants with 129 groin wounds, and outcome data were collected and analysed by groin wound. The investigators reported that there were 1/58 (1.7%) SSIs in the NPWT group compared with 10/71 (14.1%) SSIs in the standard dressing group. Sabat 2016 enrolled 49 people undergoing peripheral vascular surgery and randomised 63 wounds. The investigators reported 2/30 (6.7%) SSI in the NPWT compared with 7/33 in the standard dressing group (21.2%). Kwon 2018 used a design which combined a parallel group approach for most participants undergoing peripheral vascular surgery (75/99), with a split person design for 24 participants with bilateral surgeries, and then analysed all data at the level of the surgical incision. It is not clear how the combined design and different types of data (paired and unpaired) were accounted for in the analysis and the two were not reported separately, so we have not carried out further analysis. The investigators reported 6/59 (10.2%) SSIs in the NPWT group compared with 12/60 (20.0%) in the standard dressing group. Howell 2011 also included some participants with more than one wound (51 participants with 60 wounds) in knee arthroplasty; numbers of SSI were reported as 1/24 in the NPWT group compared with 1/36 in the standard dressing group.
Galiano 2018 used a split person design in women undergoing bilateral breast surgery. The reported results were 4/199 (2%) SSI in the NPWT and 6/199 (3%) in the standard dressing group. Schmid 2018 also used a split person design in inguinal lymph node removal. The reported results were 11/25 SSI in the NPWT group and 12/25 in the standard dressing group. In both studies, it was unclear whether the analysis accounted for paired data.

**Superficial SSI**

Kwon 2018, Howell 2011 and Pleger 2018 were not included in the analysis because of the use of wounds as the unit of analysis and/or randomisation (see above). We note the results reported for these studies as follows: Kwon 2018 3/59 compared with 5/60; Howell 2011 2/24 compared with 0/36 and Pleger 2018 5/58 compared with 28/71 superficial SSIs (incisions were the unit of analysis in each case).

**Deep SSI**

Kwon 2018, Howell 2011 and Pleger 2018 were not included in the analysis because of the use of wounds as the unit of analysis and/or randomisation (see above). We note the results reported for these studies as follows: Kwon 2018 3/59 versus 7/60; Howell 2011 1/24 compared with 0/36 and Pleger 2018 0/58 versus 0/24 deep SSIs (incisions were the unit of analysis in each case).

**Dehiscence**

Four studies (Galiano 2018; Pleger 2018; Stannard 2012; Tanaydin 2018) reported dehiscence data but could not be included in the pooled analysis.

Two studies reported dehiscence, but randomised wounds as opposed to individuals. Stannard 2012 assessed dehiscence in participants with an open fracture requiring surgical closure. Participants were randomised individually, but more than one wound per participant were included in the results. We did not have individual patient data, and the trial investigators did not account for clustering in their analysis, so further analysis was not undertaken (NPWT 12/139 (8.6%) versus standard dressing 20/122 (16.4%)). Pleger 2018 randomised 100 participants with 129 groin wounds, and outcome data were collected and analysed by groin wound. There were 3/58 (5.2%) superficial dehiscences in the NPWT group compared with 4/71 (5.6%) in the standard dressing group, and 1/58 (1.7%) deep wound dehiscences with fat necrosis in the NPWT group compared with 4/71 (5.6%) in the standard dressing group. Sabat randomised 63 wounds from 49 participants undergoing peripheral vascular surgery and reported 3/30 instances of dehiscence in the NPWT group compared with 8/33 in the standard dressing group.

Two studies in breast surgery reported dehiscence, but in each case they employed a split person design in women undergoing bilateral surgery (Galiano 2018; Tanaydin 2018); in neither study was it clear whether the analysis took the paired data into account. Although these studies were not included in the main pooled analysis, we were able to combine them separately. The two studies reported 37/231 dehiscences in the NPWT group compared with 62/231 in the standard dressing group. The pooled RR was 0.60 (95% CI 0.41 to 0.86; $I^2 = 0\%$).

**Secondary outcomes**

**Reoperation**

Two studies (Javed 2018; Kwon 2018) reported on reoperation but could not be included in the pooled analysis.

One trial reported data which allowed us to use only a generic inverse variance approach to calculate an RR. Javed 2018 enrolled 123 participants undergoing open pancreaticoduodenectomy and had a RR of 0.25 (95% CI 0.03 to 2.08) for reoperation.

One trial (Kwon 2018) used a mixed design involving both paired and unpaired data which we report but have not analysed further. The authors reported that there were 5/59 reoperations in the NPWT group compared with 11/60 with standard dressings.

**Readmission**

Two studies (Javed 2018; Kwon 2018) reported on readmission but could not be included in the pooled analysis.

One trial reported an RR but not the data used to calculate it. Javed 2018 enrolled 123 participants undergoing open pancreaticoduodenectomy and had a RR of 0.41 (95% CI 0.15 to 1.09) for all readmissions at 30 days. An RR for SSI-related readmission was also reported.

One trial (Kwon 2018) used a mixed design involving both paired and unpaired data which we report but have not analysed further. The authors reported that there were 4/59 (6.8%) readmissions in the NPWT group compared with 10/60 (16.7%) with standard dressings.

**Seroma**

Two studies (Galiano 2018; Pleger 2018) reported on seroma but could not be included in the pooled analysis.

Pleger 2018, randomising 100 participants with 129 groin wounds, reported 0/58 seromas in the NPWT group compared with 1/71 in the standard dressing group. Galiano 2018 used a split person design in breast surgery and reported zero events in the NPWT arm (0/199) and one (1/199) in the standard dressing arm.
Haematoma

Four studies (Bobkiewicz 2018; Galiano 2018; Kwon 2018; Pleger 2018) reported on haematoma but could not be included in the pooled analysis.

Pleger 2018, randomising 100 participants with 129 groin wounds, reported that there were 0/58 haematoma in the NPWT group compared with 8/71 in the standard dressing group. Kwon 2018 used a mixed design involving both paired and unpaired data which we report but have not analysed further. The authors reported that there were zero events (0/59) in the NPWT group compared with 1/60 with standard dressings. Galiano 2018 used a split person design in breast surgery and reported 2/199 events in the NPWT arm and 3/199 in the standard dressing arm. One trial Bobkiewicz 2018 enrolled 30 participants and reported narratively that “In the standard dressing group the incidence of hematoma was higher” but gave no further information.

Blisters

One study (Howell 2011) reported blisters and could not be included in the pooled analysis.

Howell 2011 included some participants with more than one wound (51 participants with 60 wounds) in knee arthroplasty; numbers of people with skin blistering were 15/24 versus 3/36.

Pain

There was no pooled analysis for pain so all studies are discussed in the main text.

QoL

There was no pooled analysis for pain; all studies are discussed in the main text.

Economic outcomes

We did not conduct pooled analyses of economic data; all studies are discussed in the main text and in Appendix 5.

Appendix 5. Cost effectiveness results used to inform relative cost effectiveness

There were five studies which used data from RCTs included in this review to assess measures of cost-effectiveness. Two of these looked at use of NPWT in obstetric surgery - obese women undergoing caesarean section (Heard 2017; Hyldig 2019b); these were based on the RCT of Chaboyer 2014 and Hyldig 2019a, respectively. Two evaluations considered people having orthopaedic surgery. The WHIST 2019b study was undertaken alongside the WHIST 2019a RCT in people having surgery for lower limb fractures. Nherera 2017 looked at NPWT in people having knee and hip arthroplasties and was based on Karlakki 2016. Finally, Nherera 2018 looked at people having CABG surgery and was based on Witt-Majchrzak 2015. Four studies included a formal cost-effectiveness analysis as part of their intervention (Chaboyer 2014; Hyldig 2019a; Karlakki 2016; WHIST 2019a) while another contributed data to a cost-effectiveness study (Witt-Majchrzak 2015; Nherera 2018). Three studies were pilot studies with small sample sizes but Hyldig 2019a and WHIST 2019a were large publicly funded trials with strong methodology and reporting.

In addition five studies which did not assess cost-effectiveness reported information on dressing costs or resource use (DiMuzio 2017; Gillespie 2015; Javed 2018; Kwon 2018; Manoharan 2016).

Dressing Costs

All five of the cost-effectiveness studies (Heard 2017; Hyldig 2019b; Nherera 2017; Nherera 2018; WHIST 2019b) and two additional RCTs (Gillespie 2015; Manoharan 2016) reported on dressing costs. In each case, NPWT was substantially more costly than the comparator treatment (Table 3). The studies reported dressing costs in different ways, with some summarising for the whole treatment period and others reporting costs per day or per dressing change; the largest trial WHIST 2019b reported a total treatment cost which incorporated the dressing cost but also the fracture cast, initial inpatient care, antibiotics and dressing changes. Cost data for dressings are reported in Table 3. All studies reported that NPWT represented a higher dressing cost than standard dressings.

Resource use

Resource use was costed for all the economic studies based on RCTs and costs related to resource use were also reported by three RCTs which did not undertake a cost-effectiveness analysis (DiMuzio 2017; Javed 2018; Kwon 2018). Data on costs are reported in Table 3. We focus on the information used, together with QALYs, to inform the analyses of cost-effectiveness.

Obstetric surgery: Caesarean sections in obese women

Chaboyer 2014 included obese women undergoing caesarean section (n = 70); Heard 2017, was based on Chaboyer 2014, and assessed resources in AUD at 2014 values. Data on costs were based on dressing costs, nursing time, length of hospital stay, and post-discharge costs (readmission, visits to healthcare professionals, and medications). Heard 2017 reported additional costs of AUD 133 for NPWT over standard dressings. Hyldig 2019a was a much larger trial which also enrolled obese women undergoing caesarean section (n = 876); Hyldig
2019b was based on this study and assessed resources in DK transformed into Euro; they found an additional cost difference of 47.29 Euro for NPWT over standard dressings.

Orthopaedic surgery: lower limb fracture surgery

Participants in WHIST 2019a were undergoing surgery for lower limb fracture; the cost-effectiveness analysis WHIST 2019b was based on this. Unit direct medical costs associated with the intervention were obtained from the NHS Supply Chain Catalogue 2018/2019. These included cost of standard dressing, the costs of orthotic cast, the cost associated with dressing change, the cost per working hour of the nurse (obtained from the Personal Social Service Research Unit (PSSRU) 2018). The cost of inpatient care was derived using NHS reference Costs 2017/18. Unit costs of additional medical items were also sourced from the NHS reference costs and medication costs were sourced from the British National Formulary (BNF). Unit costs for direct non-medical cost items were obtained from Personal Social Services Research Unit. Other costs were obtained from the NHS Supply Chain Catalogue, the patients and their next of kin and the Office for National Statistics. Cost data were derived from the key resource inputs of the WHIST 2019 trial and expressed in 2017/2018 GBP; a societal perspective was considered in a sensitivity analysis. Unit costs were adjusted to 2017/2018 prices using the NHS Hospital & Community Health Services (HCHS) index for health service resources. There was no discounting of costs applied due to a short-time horizon. The total costs up to six months taking an NHS and PSS perspective showed a mean difference of 770.00 GBP (95% CI 206.51 to 1333.49) more for NPWT compared with standard dressing. A societal perspective also showed a greater cost to NPWT but with much wider confidence intervals (MD 221.41 GBP, 95% CI -1334.37 to 1777.19).

Orthopaedic surgery: hip or knee arthroplasty

Participants in the Karlakki 2016 study were those scheduled for routine knee or hip arthroplasties (n = 220). Nherera 2017, was based on Karlakki 2016, and derived costs from standard cost references for the NPWT device from the UK National Drug Tariff and an assumption that each patient used two NPWT dressings. Inpatient care was based on the average of National Health Service reference costs for knee and hip arthroplasties, which, it was assumed, included the cost of the standard care dressing and nursing time. Costs associated with routine postdischarge care were not included because these costs would be similar across groups. Finally, for those who experienced a complication, an assumption was made that they had two general practitioner visits and received one prescription of antibiotics. Resource use was valued in GBP at 2015/16 values. Nherera 2017 reported cost savings of GBP 1132 for NPWT compared with standard dressings.

General surgery: CABG surgery

Participants in the Witt-Majchrzak 2015 trial (n = 80) underwent CABG surgery. They contributed clinical data to Nherera 2018 which drew both its utility and cost data from other sources. Nherera 2018 found a cost saving of 586 Euro with NPWT compared with standard dressings.

Quality-adjusted life year (QALY)

Each study took a different approach to the resource use and costs used to inform the model; details are provided in Characteristics of included studies. Three studies did not report SD for the QALY estimates for each group, one study reported 95% CIs for the mean difference in QALY. Given this, we have opted not to impute SD for the majority of studies which do not report them and instead to provide an overall narrative summary.

Across all studies, despite different methods of calculating QALY and the four different surgical indications represented, the differences in QALY between NPWT and standard dressings were uniformly extremely small.

Obstetric surgery: Caesarean sections in obese women

Heard 2017 calculated QALYs using the 12-item Short Form Health Survey (SF-12) version 2, scored with the UK preference-based algorithm (Brazier 2004). Hyldig 2019b calculated QALYs using the EQ-5D-3L utility scores. Hyldig 2019b reported QALY values of 0.863 in the NPWT group compared with 0.856 in the standard dressing group: mean difference 0.007 (95% CI -0.008 to 0.022). Heard 2017 reported QALY values of 0.067 (SD 0.01) in the NPWT group compared with 0.066 (SD 0.01) in the standard dressing group:mean difference 0.00 (-0.00 to 0.01).

Orthopaedic surgery: lower limb fracture surgery

WHIST 2019b calculated QALYs using the EQ-5D-3L utility scores. WHIST 2019b reported QALY values of 0.40 (0.22) for the NPWT group compared with 0.41 (SD 0.24) in the standard dressing group: mean difference -0.01 (95% CI -0.03 to 0.01).

Orthopaedic surgery: hip or knee arthroplasty

Nherera 2017 calculated QALYs using the 36-item Short Form Health Survey (SF-36) with a regression-based scoring algorithm developed from a sample of Jewish Israelis sampled between 1993 and 1994 (Shмуeli 1999). Nherera 2017 reported QALY values of 0.116 for the NPWT group compared with 0.115 in the standard dressing group; no SDs were reported.
**General surgery: CABG surgery**

Nherera 2018 calculated health state utilities to generate QALYs using published literature including a study looking at discharge from hospital with and without complications (Tuffaha 2015). QALY values were reported as 0.8904 in the NPWT group compared with 0.8593 in the standard dressing group.

Across all studies, despite different methods of calculating QALY and the four different surgical indications represented, the differences in QALYs between NPWT and standard dressings were uniformly extremely small.

**WHAT’S NEW**

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12 December 2019</td>
<td>New citation required and conclusions have changed</td>
<td>Updated. Conclusions changed.</td>
</tr>
<tr>
<td>12 December 2019</td>
<td>New search has been performed</td>
<td>Third update. New search. 15 new intervention studies and three new economic studies included. Three new co-authors added, En Lin Goh, Chunhu Shi and Adam Reid.</td>
</tr>
</tbody>
</table>

**HISTORY**

Protocol first published: Issue 8, 2011
Review first published: Issue 4, 2012

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 March 2019</td>
<td>New search has been performed</td>
<td>Second update: new citation; conclusions not changed. New search, 25 new studies included. 'Summary of findings' table added. Four new co-authors added, Gill Norman, Zhenmi Liu, Jo Dumville and Laura Chiverton.</td>
</tr>
<tr>
<td>27 August 2014</td>
<td>New search has been performed</td>
<td>First update, new search</td>
</tr>
<tr>
<td>27 August 2014</td>
<td>New citation required but conclusions have not changed</td>
<td>Four trials added (Crist 2014; Masden 2012; Petkar 2012; Standard 2012), no change to conclusions.</td>
</tr>
<tr>
<td>13 November 2013</td>
<td>Amended</td>
<td>Acknowledgement added to the funders.</td>
</tr>
<tr>
<td>16 May 2012</td>
<td>Amended</td>
<td>Adjustments to text</td>
</tr>
</tbody>
</table>

**CONTRIBUTIONS OF AUTHORS**

**Gill Norman**: designed the review update; coordinated the review update; extracted data; checked quality of data extraction; analysed or interpreted data; undertook quality assessment; checked quality assessment; performed statistical analysis; produced the first draft of the review update; contributed to writing or editing the review update; wrote to study authors/experts/companies; performed economic analysis; approved final review update prior to submission; is guarantor of the review update.

**En Lin Goh**: extracted data; checked quality of data extraction; analysed or interpreted data; undertook quality assessment; checked quality assessment; checked quality of statistical analysis; contributed to writing or editing the review update; advised on the review update; approved final review update prior to submission.

**Jo Dumville**: conceived the review; analysed or interpreted data; checked quality of statistical analysis; contributed to writing or editing the review update; advised on the review update; secured funding; approved final review update prior to submission.
Chunhu Shi: extracted data; checked quality of data extraction; analysed or interpreted data; undertook quality assessment; checked quality assessment; contributed to writing or editing the review update; performed economic analysis; approved final review update prior to submission.

Zhenmi Liu: extracted data; undertook quality assessment; contributed to writing or editing the review update; approved final review update prior to submission.

Laura Chiverton: extracted data; checked quality of data extraction; contributed to writing or editing the review update; approved final review update prior to submission.

Monica Stankiewicz: extracted data; undertook quality assessment; contributed to writing or editing the review update; approved final review update prior to submission.

Adam Reid: checked quality of data extraction; analysed or interpreted data; contributed to writing or editing the review update; advised on the review update; approved final review update prior to submission.

Contributions of editorial base
Nicky Cullum (Coordinating Editor): advised on methodology, interpretation, and content; edited and approved the review update prior to publication.

Gill Rizzello (Managing Editor): coordinated the editorial process; advised on interpretation, and content; edited the updated review.

Sophie Bishop (Information Specialist): edited the search methods section and search strategy and ran the search for this update.

Tom Patterson (Editorial Assistant): edited the plain language summary and reference sections for this update.

DECLARATIONS OF INTEREST
Gill Norman: my employment at the University of Manchester was funded by the National Institute for Health Research and focused on high-priority Cochrane Reviews in the prevention and treatment of wounds. My work on this review was supported by the NIHR Manchester Biomedical Research Centre.

En Lin Goh: none known.

Jo Dumville: I received research funding from the NIHR for the production of systematic reviews focusing on high-priority Cochrane reviews in the prevention and treatment of wounds. This research was co-funded by the NIHR Manchester Biomedical Research Centre and partly funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester.

Chunhu Shi: none known.

Zhenmi Liu: my employment at the University of Manchester was supported by a grant from the National Institute for Health Research (NIHR Systematic Review Fellowships).

Laura Chiverton: my work on this review was supported by the NIHR Manchester Biomedical Research Centre.

Monica Stankiewicz: none known.

Adam Reid: none known.

SOURCES OF SUPPORT
Internal sources

• Royal Brisbane and Women’s Hospital, Australia
  Time to conduct review
• Griffith University, Australia
  Time to conduct review
• Division of Nursing, Midwifery and Social Work, School of Health Sciences, Faculty of Biology, Medicine and Health, University of Manchester, UK

Copyright © 2020 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources

- The National Institute for Health Research (NIHR), UK

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure and Cochrane Programme Grant funding (NIHR Cochrane Programme Grant 13/89/08 – High Priority Cochrane Reviews in Wound Prevention and Treatment) to Cochrane Wounds. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.


- National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester Centre, UK

Jo Dumville was partly funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care (NIHR CLAHRC) Greater Manchester. The funder had no role in the design of the studies, data collection and analysis, decision to publish, or preparation of the manuscript. However, the review may be considered to be affiliated to the work of the NIHR CLAHRC Greater Manchester. The views expressed herein are those of the authors and not necessarily those of the NHS, NIHR or the Department of Health and Social Care.

- NIHR Manchester Biomedical Research Centre, UK

This review was co-funded by the NIHR Manchester Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.

Differences between protocol and review

Changes in the 2020 update

- We have excluded one study which was previously included in error; it did not report an eligible comparison.
- We have made some changes to the inclusion criteria; primarily to clarify that trials in wounds with pre-existing infections were excluded from the review. We have also removed the outcomes of dressing cost, resource use and QALY measures as independent outcomes. We have continued to record information on these and have presented it in additional tables and an appendix to the review but we have shifted the focus of the cost-effectiveness review to assessments of relative cost-effectiveness reported as ICERs.
- We have clarified that we extracted and reported data on adverse events such as seroma and haematoma only as the number of participants in each group with an event.
- We have altered the way in which we dealt with the likelihood of performance bias in included studies in order to better recognise the role this may play even in trials in which it is hard to avoid.
- We have undertaken some exploratory analyses of the primary outcome of SSI to see if there is the potential for additional research into the impact of NPWT on SSI classed as superficial or deep and we have also undertaken an additional sensitivity analysis to further explore the impact of risk of bias on the effect estimate and its confidence intervals for this outcome.
- We have somewhat revised our approach to GRADE assessments in terms of risk of bias and have only downgraded where high risk of bias was present and the potential impact of this was considered substantive. Previously we had downgraded where key domains had an unclear risk of bias. This new approach reflects the advice from GRADE working group.
- We have removed readmission to hospital from the ‘Summary of findings’ table in order to conform with MECIR guidance that this should include no more than seven outcomes.

Changes in the 2019 update

- We changed the title and the focus of the review. In previous versions, we included studies that investigated skin grafts and also those investigating surgical wounds expected to heal by primary intention. In the 2019 version of the review, we did not include studies of skin grafts. This decision was made after consultation with the Editorial base and was based on the following considerations: the healing mechanisms and outcome measures are different for graft sites and incisional wounds, so there was a clear, clinical reason for focusing on one type of wound; we also clarified that trials using NPWT following surgery that involved harvesting veins following flap elevation would also be excluded. Outcomes measures from these trials (such as flap necrosis, lymphorrhagia, and lymphoedema) also differed from primary closure surgery. In addition, the number of trials reporting outcomes following the application of NPWT has been growing exponentially, with the majority of these trials focusing on previously uninvestigated types of surgery using primary closure. Because of this, it seemed timely to focus this review only on ‘primary closure’ surgery.
- We modified the wording of the title from ‘primary intention’ to ‘primary closure’. The wording change was needed because closure by primary intention would mean the inclusion of grafts and flap surgery trials, whereas primary closure means the surgical edges are approximated and held together with sutures, glue, etc. Primary closure is the simplest closure technique and more accurately reflects the intention of the review.
- We removed the outcome ‘graft failure’ in line with the new focus of the review.
- We removed the outcome ‘time to complete healing’, as this outcome was deemed not to be appropriate for surgical wounds expected to heal by primary intention (it is difficult or impossible to determine or define the point of healing for a wound healing in this way).
For this reason, ‘proportion of surgical wounds healing by primary intention that completely heal’ was removed for the first update and ‘reoperation’ added (see also ‘Changes in previous versions’ below).

- We added one additional outcome: ‘readmission within 30 days for a wound-related complication’. We believe this outcome is important because, while readmission for repeat surgery is one of our current outcomes, the reason for readmission is not always stated in study reports.
- We split ‘adverse events’ into ‘surgical site infection’ and ‘dehiscence’.
- We removed the words ‘and including utility scores representing health-related quality of life’ from the outcome ‘healthcare costs’ and included it under the outcome ‘quality of life’.
- We split one of our secondary outcomes, ‘seroma/haematoma’, into two separate outcomes. This decision was based on differing definitions and aetiologies of the two conditions. A seroma is a collection of clear, serous fluid, which sometimes collects under a surgical wound, whereas a haematoma is a collection of blood outside a blood vessel.
- We changed the outcome ‘fracture blisters’ to ‘skin blisters’, as some blisters are associated with dressings that cover wounds from surgery that is not fracture surgery.
- We have split ‘cost’ into four separate outcomes: ‘dressing-related costs’, ‘resource use’, ‘incremental cost per quality-adjusted life year’, and ‘estimated incremental cost-effectiveness ratio’.
- We broke up costs into two categories. The first (‘dressing-related costs’) is a simple cost comparison from the intervention study reports, and the second (‘cost’) is a full economic analysis from the two cost-effectiveness studies. This analysis contains three outcomes: resource use, incremental cost per quality-adjusted life year, and estimated incremental cost-effectiveness ratio.
- We added three additional items of data extraction: ‘source of funding’, ‘prospective registration on a clinical trials registry’, and ‘economic data (healthcare costs)’. We made these additions to reflect the importance of prospective registration in the assessment of risk of bias in several domains, and in response to the insistence in many quality journals on prospectively registering clinical trials as a quality measure.
- We updated our search strategies, adding new terms for negative pressure wound therapy, and changed the term ‘surgical’ to ‘surgical site infection’ in the trial registries’ search.
- We included an additional (standard) sensitivity analysis with the following wording: “We performed a sensitivity analysis on the primary outcomes (surgical site infection) to assess the influence of removing studies classified as being at high risk of bias from the meta-analysis. We excluded studies that were assessed as having high or unclear risk of bias in the key domains of adequate generation of the randomisation sequence, adequate allocation concealment, and blinding of outcome assessor. We planned but were unable to undertake a similar analysis for the outcome of dehiscence.”
- We removed allocation concealment and type of randomisation from the sensitivity analyses; they are included in the new sensitivity analyses described above. We removed duration of follow-up from the sensitivity analyses.
- We changed one subgroup analysis from ‘type of surgery (traumatic wounds, reconstructive procedures, other post-surgical wounds; skin grafts)’ to ‘type of surgery’ without qualification.
- We removed one comparison (industry funded versus non-industry funded) following advice from the Editorial base. We removed one comparison (one negative pressure closure method compared with another), as the study providing data for this comparison, Dorafshar 2012, has now been excluded in line with the new focus of the review on surgical wounds healing by primary closure only.
- We updated the methods used to assess heterogeneity and taken this into account in our analyses; we changed methods of analysis as appropriate to the evidence that is now included in this updated version.
- We used the method for classifying economic evaluation described by Husereau and colleagues (Husereau 2013), rather than the evaluation described by Drummond 2005. This decision was based on the knowledge that the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist has become the standard for economic evaluations. The checklist was developed in collaboration with a range of organisations, and includes Drummond as a co-author.
- We added a ‘Summary of findings’ table to the review and used a GRADE assessment of the certainty of the evidence throughout.

Changes to previous versions

We added a comparison (one negative pressure closure method compared with another) to the previous version of this review, but this has now been removed (see comment above).

We expanded the list of extracted data from the protocol to include:

- study dates;
- number of participants per group;
- information about ethics approval, consent, and conflict of interest.

In trials of skin grafts, graft failure is an important outcome. We failed to include this as either a primary or secondary outcome in the protocol for the original review. We also failed to include length of hospital stay, which is important for any economic analysis. Consequently, we included graft failure and length of hospital stay as additional outcomes post hoc.
• In a previous update, we removed the primary outcome "proportion of surgical wounds healing by primary intention that completely heal (surgical wounds may include split skin grafts, full skin grafts, or any primary wound closure)". This decision was based on our experience conducting the first version of this review, where we noted that "it has become clear to us that this outcome is not appropriate for surgery that is expected to heal by primary intention; most clean surgical wounds will completely heal in a relatively short time. Moreover, determining when a surgical incision is 'completely healed' is difficult. Consequently, wound healing should not be included as a primary outcome for future updates".

• In the first version of the review, we considered any wound complications under the heading 'adverse events'. As many of these 'events' are qualitatively different and of varying levels of importance, we subsequently included only 'surgical site infection' and 'dehiscence' under the heading 'adverse events'. We moved other wound-related outcomes that were previously included under the primary outcome 'adverse events' (such as fracture blisters, seromas, etc.) to the secondary outcomes. We changed 'graft loss' to 'graft failure' and added it as a separate outcome because it is an important outcome for skin graft studies, and in our protocol we did not include any outcomes that were specific to skin grafts. We also added a new secondary outcome, 'reoperation', as this is an important outcome that indicates the severity of any wound dehiscence or graft loss.

• We changed the wording in the sections 'Unit of analysis issues' (we had not anticipated in the original version of the review that multiple wounds might be an issue) and 'Dealing with missing data' (to clarify what we intended to do).

INDEX TERMS

Medical Subject Headings (MeSH)

Bandages; Blister [epidemiology]; Hematoma [epidemiology]; Negative-Pressure Wound Therapy [economics] [instrumentation] [*methods] [mortality]; Orthopedic Procedures; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Reoperation [statistics & numerical data]; Seroma [epidemiology]; *Skin Transplantation; Surgical Procedures, Operative [mortality]; Surgical Wound Dehiscence [epidemiology] [*prevention & control]; Surgical Wound Infection [epidemiology] [*prevention & control]; *Wound Healing; Wounds and Injuries [surgery]

MeSH check words

Humans